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Whilst acute itch is a beneficial sensation that serves to remove irritants and potentially 
harmful agents from the skin by eliciting a scratch reflex, chronic itch is a debilitating 
condition associated with a reduction in quality of life and the development of skin lesions 
that risk becoming infected. Moreover, few effective treatments exist for chronic itch 
conditions, particularly those associated with skin diseases such as atopic dermatitis. 
 
Cathepsin S is a protease that has recently been demonstrated to be involved in pruritus. 
Preliminary work in our lab demonstrated that intradermal injection of Cathepsin S results in 
scratching behaviour in mice, while others have found that over-expression of Cathepsin S 
results in the development of atopic dermatitis-like conditions.  However, the source of 
Cathepsin S in itch conditions, whether Cathepsin S directly activates sensory neurons and 
the receptors on which it acts to mediate its effects, and whether it causes the release of 
neurotransmitters from primary afferent fibres had not been addressed. We thus sought to 
further investigate Cathepsin S-mediated itch. 
 
We found that skin keratinocytes are a potential source of Cathepsin S, expression of which 
is upregulated in inflammatory conditions similar to those found in atopic dermatitis. 
Furthermore, Cathepsin S can be released from these cells following stimulation of TRPV4, 
and propose that alterations in skin hydration and pH in conditions such as atopic dermatitis 
might result in increased activity of this channel and hence release of Cathepsin S. We 
established that Cathepsin S activates sensory neurons in vitro via protease activated 
receptor 2 (PAR2) and that Cathepsin S-responding neurons belonged to the TRPV1/TRPA1-
expressing subset of neurons. Finally, we found that intraplantar Cathepsin S injection 
results in activation of neurons in the outer laminae of the dorsal horn of the spinal cord, 
although we could not demonstrate the occurrence of release of neurotransmitters or 
neuropeptides from the central terminals of primary afferent neurons. 
 
In conclusion, we have identified a pathway for Cathepsin S-induced itch as release of this 
protease from keratinocytes activates TRPV1/TRPA1-expressing neurons via PAR2 
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Chapter 1  
General introduction 
 
Itch is defined as an unpleasant cutaneous sensation associated with the urge to scratch 
(Steinhoff et al., 2006). Itch signals are generated following activation of a subset of sensory 
neurons (pruriceptors) by itch causing agents (pruritogens). The purpose of itch is to protect 
from potentially harmful agents that may enter the skin, such as following an insect bite or 
plant sting (Hoon, 2015; Green and Dong, 2016; Ross, 2011). Such itch-causing agents are 
referred to as pruritogens. The scratching reflex that accompanies itch serves to remove the 
potentially dangerous substance from the skin and relieves the itching sensation, ensuring it 
is short-lived and preventing tissue damage that would otherwise result from excessive 
scratching. This type of itch is known as acute itch, typically lasts for several minutes, and is 
normally alleviated by scratching at the site of itch. However, in some cases such as found in 
atopic dermatitis and psoriasis, itch can persist for several weeks or months. Itch that lasts 
for 6 weeks or longer is defined as chronic itch (Ständer et al., 2007). Furthermore, rather 
than being relieved by scratching, excessive scratching in chronic itch damages the skin and 
causes localised inflammation that exacerbates itching, resulting in an itch-scratch cycle 
(Steinhoff et al., 2006).  
 
In both acute and chronic itch, transmission of itch signals via neurons can broadly be 
divided into a peripheral pathway, comprising primary sensory neurons of the peripheral 
nervous system (PNS) that detect pruritogens, and the central itch pathway, consisting of 
the central terminals of sensory neurons in the dorsal horn of the spinal cord that then relay 
the itch signal to interneurons and projection neurons in the central nervous system (CNS) 
where the sensation of itch is perceived and the behavioural scratching responses are 





Figure 1.1: Simplified schematic of the itch pathway 
Receptors on the endings of sensory neurons in the skin detect endogenous pruritogens 
released from cells in the skin such as keratinocytes or immune cells, or exogenous 
pruritogens from the environment. This results in the opening of ion channels, entry of 
cations into the neuron, culminating in propagation of action potentials and transmission of 
itch signals along the peripheral fibre, with the cell body located in the periphery in the 
dorsal root ganglia (DRG). Neurotransmitters and neuropeptides released in the dorsal horn 
of the spinal cord pass the signal to interneurons and eventually projection neurons which 
decussate and ascend along the spinothalamic tract to the thalamus of the brain, where the 
signal is relayed to higher brain centres. 
1.1 The skin as a source of pruritogens 
The free nerve endings of primary sensory neurons in the skin detect pruritogens. 
Pruritogens can be exogenous arising from the external environment, or they may come 
from our own cells and tissues, notably form the skin. Immune cells such as mast cells and 
basophils are known to release mediators that activate and sensitise pruriceptors especially 
during inflammation (Steinhoff et al., 2018). Skin keratinocytes are also known to release 






Overview of the skin 
The skin itself is comprised of three layers – an outer epidermis, an underlying dermis, and 
an inner hypodermis. All layers serve a protective barrier function against injury, infection, 
and loss of fluids, with disruption of normal skin function associated with several chronic 
itch conditions, such as atopic dermatitis (Baroni et al., 2012). The free nerve endings of 
peptidegc and non-peptidergic sensory neurons are found in both the epidermis and dermis, 
where they are responsible for transmission of sensory information from the skin (Gibbins 
et al., 1987; Reinisch and Tschachler, 2012; Schuttenhelm et al., 2015; Taylor et al., 2009; 
Tobin et al., 1992). The epidermis is the first line of defence against foreign pathogens. 
Keratinocytes make up 95% of the cells found in the epidermis of the skin, where they 
synthesise and express many structural proteins and lipids essential to the function of the 
skin (McGrath et al., 2004). The majority of the remaining cells of the epidermis are 
melanocytes and Langerhans cells (Wickett and Visscher, 2006). The dermis is separated 
from the epidermis by the basement membrane. It contains blood vessels required for 
thermoregulation and providing the skin with nutrients, and lymphatic vessels where 
immune cells leave the skin and migrate to the lymph nodes (Mueller et al., 2014; Valladeau 
and Saeland, 2005). The dermis of the skin contains many different types of immune cells 
that help to ensure this layer serves as an immunological barrier to potential pathogens 
(Mueller et al., 2014). This includes dendritic cells, involved in presenting antigens to 
resident cells in the lymph nodes (Nestle et al., 1994; Valladeau and Saeland, 2005; Zaba et 
al., 2007), and macrophages, which are involved in the recruitment of neutrophils from 
circulation during infection (Abtin et al., 2014). Several different types of lymphocytes have 
been described in the dermis, including CD90hi innate lymphoid cell-2 (ILC2) that interact 
with mast cells and produce IL-13 and NKp44+ ILC3 cells that increase in the skin of patients 
with psoriasis (Roediger et al., 2013; Villanova et al., 2014). The dermis also contains many T 
cells, particularly Th1-polarised T cells, even in healthy, non-inflamed skin (Clark et al., 
2006). These cells are thought to play a role in immune surveillance allowing a rapid 
response to antigens. The dermis additionally contains mast cells, which are more numerous 
at the junction with the epidermis and become less numerous deeper in the dermis (Cowen 
et al., 1979). As well as being involved in the release of histamine and inflammatory 
mediators following allergy, infection, and injury, mast cells may be important in the process 







The epidermis itself is comprised of four to five layers or strata of keratinocytes at different 
states of maturation and differentiation (Baroni et al., 2012; Wickett and Visscher, 2006) 
(Figure 1.2). As keratinocytes mature, they migrate up through the layers of the epidermis.  
 
 
Figure 1.2: Schematic of the layers of the skin (adapted from Wickett and Visscher, 2006) 
 
The stratum basale 
The deepest layer of the skin, the basal layer, or stratum basale, consists of continually 
dividing keratinocytes that serve to replenish the cells shed from the outer layers of the skin 
during the process of desquamation or lost following injury. Keratinocytes typically require 
two weeks to leave the basal layer and a further two weeks to migrate through to the 
outermost layer, although the rate of replication and migration can be altered during 
inflammation or injury (Fenner and Clark, 2016). Rather than being a homogeneous 
population of stem cell progenitors, it is thought that the keratinocytes of the basal layer 
comprise a heterogeneous population of cells of different sizes and varying growth 
capabilities. For instance, one group of cells, which have a high tissue growth and 
regeneration potential, are found to express low levels of transferrin (Trf) receptor and 
epidermal growth factor (EGF) receptor, and may comprise mainly stem cells. In contrast, 
another group of cells expressing high levels of Trf receptor and EGF receptor are thought to 
be more mature and have less regeneration potential, and are likely to be progenitors that 
will eventually give rise to fully differentiated keratinocytes. Accordingly, keratinocytes 
expressing lower levels of Trf receptor have been found to be more competent in DNA 
repair, which is essential for the long-term maintenance of genomic integrity required for 




When keratinocytes in the basal layer begin to migrate, intracellular expression of 
hemidesmosomal components increases as the hemidesmosomes connecting the 
keratinocytes to the basement membrane become internalised, allowing migration of these 
cells (Poumay et al., 1994). Integrin adhesion is reduced due to upregulation of RhoE, 
further allowing cells to migrate and become committed to differentiation (Liebig et al., 
2009). In addition, a number of transcription factors, such as Nkx2.5, C/EBP α and β, and 
MafB are upregulated in keratinocytes as they mature, and are proposed to control 
expression of a number of genes involved in differentiation of keratinocytes (Hwang et al., 
2009; Lopez et al., 2009; Miyai et al., 2017). A calcium and 1,25(OH)(2)D-3 (vitamin D 
metabolite) gradient may be important in keratinocyte differentiation, as cells leaving the 
basal layer become exposed to increasing concentrations of calcium and decreasing 
concentrations of 1,25(OH)(2)D-3 as they migrate and mature (Bikle, 2004; Menon et al., 
1985). Furthermore, expression of the extracellular calcium-sensing receptor on 
keratinocytes is required for differentiation, since transgenic mice lacking this receptor have 
an increase in the number of proliferating cells in the basal layer and a decrease in the 
expression of keratinocyte differentiation markers in the epidermis (Komuves et al., 2002). 
Temperature and the presence of epidermal growth factor may also affect keratinocyte 
differentiation (Ponec et al., 1997).  
 
The stratum spinosum 
Keratinocytes that have left the basal layer of the epidermis begin to differentiate in the 
spinous layer, or strata spinosum, where the process of keratinisation begins through 
expression of keratins 1 and 10 (Dai and Segre, 2004; Poumay and Pittelkow, 1995). The 
transcription factors Klf4, Dlx3, and Foxn1 are predominantly expressed in the spinous layer 
of the epidermis, where they serve to establish a functional permeability barrier and ensure 
proper transcription of terminal differentiation markers (Baxter and Brissette, 2002; Dai and 
Segre, 2004; Jaubert et al., 2003; Morasso et al., 1996; Segre et al., 1999).  
 
The stratum granulosum 
During the final stages of differentiation, keratinocytes migrate to the granular layer, or 
stratum granulosum, so-called because of the appearance of granules in the cells of this 
layer. The granules are of two types – keratohyalin granules which contain proteins, and 
lamellar granules which contain layered stacks of lipids (Landmann, 1986; Suzuki and 
Kurosumi, 1972; Wickett and Visscher, 2006). The proteins of the keratohyalin granules 
include filaggrin and loricrin (Steven et al., 1990; Wickett and Visscher, 2006). Filaggrin 
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serves to aggregate keratin filaments and is also broken down to produce Natural 
Moisturising Factor (NMF) (Rawlings et al., 1994; Rawlings and Matts, 2005; Scott and 
Harding, 1986), while loricrin cross-links with involucrin to result in the formation of an 
insoluble envelope (Steinert and Marekov, 1997) (Figure 1.3). The profilaggrin N-terminal 
domain has also been found to interact with loricrin in addition to keratin, and may be 
required for terminal differentiation of keratinocytes (Yoneda et al., 2012). Lamellar bodies 
comprise about 20% of the cell volume and are polarised towards the apical border (Menon 
et al., 2012). In the upper granular layer of the epidermis, the lipid contents of lamellar 
bodies are extruded into the intercellular space, resulting in the formation of lipid sheets 
that act as a type of glue or paste between the cells and cross-linked proteins (Landmann, 
1986; Nemes and Steinert, 1999).  
 
The stratum corneum 
Eventually the nucleus and organelles of the keratinocytes are digested and the cytoplasm 
disappears, leaving a flattened cell containing a dense network of proteins surrounded by 
covalently attached lipids that form a lipid envelope (Figure 1.3). These dead cells are known 
as corneocytes, and they comprise the outermost layer of the epidermis, known as the 
cornified layer or stratum corneum, forming a permeability barrier that prevents desiccation 
of the skin (Baroni et al., 2012; Wickett and Visscher, 2006). Lipids, including ceramides, 
cholesterol, and free fatty acids, comprise most of the intercellular space between 
corneocytes, and serve to prevent the loss of fluid from the skin (Feingold and Elias, 2014; 
Wertz and van den Bergh, 1998). The corneocytes themselves, which can be stacked up to 
20 layers of cells, are held tightly together by a modified desmosome known as the 
corneodesmosome (Ishida-Yamamoto and Kishibe, 2011; Menon et al., 2012). As 
corneocytes mature, the corneodesmosomes are broken down by and eventually the dead 
corneocytes are shed from the skin, to be replaced by new terminally differentiating 





Figure 1.3: Schematic of the corneocyte lipid envelope (adapted from Wickett and 
Visscher, 2006) 
 
The stratum lucidum 
In the epidermis in the palms of the hands and soles of the feet, an additional epidermal 
layer, the clear layer or stratum lucidum, is found (Wickett and Visscher, 2006). This layer is 
likely involved in providing additional mechanical support to the skin in these locations. In 
transgenic mice lacking a gene required for the hydrolysis of sphingolipids, the epidermal 
structure was found to be altered (Doering et al., 1999). The clear layer was found to be 
thickened, likely as a result of unprocessed sphingolipids such as glucosylceramides in this 
layer. In contrast, partial loss of the cornified layer was observed, proposed to be due to 
reduced mechanical stability resulting from the loss of fully processed lipids normally found 
in the corneocyte lipid envelope. 
 
Proteases in keratinocytes 
Keratinocytes contain numerous proteases that are required for the normal functioning of 
the skin (Table 1.1). Several of these proteases have been proposed to act as pruritogens in 










Table 1.1: Proteases found in skin kertainocytes 
Protease Function References 
Kallikrein 5 Degredation of skin corneodesmosomes 
Caubet et al., 2004; Levi et al., 
2008 
Kallikrein 7 Degredation of skin corneodesmosomes 
Caubet et al., 2004; Levi et al., 
2008 
Cathepsin V 
Degredation of skin corneodesmosomes 
and melanosomes 
Bernard et al., 2003; Homma 
et al., 2018 
Cathepsin D 
Degredation of skin corneodesmosomes; 
cross-linking involucrin and loricrin 
Egberts et al., 2004; Horikoshi 
et al., 1999; Igarashi et al., 
2004 
Cathepsin B 
Degradation of cell-cell contact in wound 
healing 
Buth et al., 2004 
Cathepsin S 
MHC class II-mediated antigen 
presentation 
Beers et al., 2005; Schonefuss 




Various types of T cells can be found in the epidermis and dermis of the skin, particularly 
during and after infection, injury, and inflammation where they may provide protection 
against reinfection (Gebhardt et al., 2009). During infection, CD4+ and CD8+ T cells migrate 
to the dermis and epidermis of the skin to fight the infection, although CD4+ T cells 
eventually migrate back into circulation, while CD8+ T cells remain in the epidermis, with 
some becoming tissue-resident memory αβ T cells (TRM) (Gebhardt et al., 2011). After 
infection, TRM cells predominate in the epidermis, while fewer numbers of γδ T cells (DETC) 
are also to be found (Foster et al., 1990; Spetz et al., 1996). Indeed, TRM cells and DETCs 
appear to compete with one another, with TRM cells replacing DETCs over time (Zaid et al., 
2014). Differentiation of CD8+ T cells to TRM cells in the epidermis requires chemokine 
receptor signals such as CXCR3 and cytokines such as IL-15 and TGF-β released from 
keratinocytes or Langerhans cells in the epidermis (Mackay et al., 2013; Mackay et al., 
2015).  
 
CD4+ T cells are usually present in low numbers in the epidermis of the skin, although their 
numbers are reported to increase in atopic dermatitis and psoriasis (Bos et al., 1989; 
Bovenschen et al., 2006; Schon et al., 1997; Sinke et al., 1997). Following antigen recognition 
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in response to infection, allergens, or autoimmunity, CD4+ T cells undergo clonal expansion 
to differentiate into T helper (Th) cells that secrete cytokines thought to be specific to each 
Th subset (Bettelli et al., 2007; Clark and Schlapbach, 2017; Fujita, 2013; McGeachy, 2013; 
Nakayama and Yamashita, 2008; Plank et al., 2017; Raphael et al., 2015; Stockinger et al., 
2004). Most of these cells undergo apoptosis when the antigen has been cleared, but a few 
become memory cells capable of lasting a long time and ready to respond following re-
exposure specific to antigens. It is hypothesised that in skin conditions such as atopic 
dermatitis and psoriasis, there is an increase in the number and activity of these T helper 
cells and alteration in their balance in the skin, resulting in an increased production and 
release of cytokines that damages the structure of the skin, compromising its ability to serve 
as a physical barrier and prevent fluid loss and contributing to the release of pruritogens or 
sensitisation of neurons responsible for enhanced pruritus. Some cytokines involved in skin 
conditions characterised by chromic itch may act directly as pruritogens or cause the release 
of pruritogens from other cells (Table 1.2). 
 
Table 1.2: Cytokines in skin conditions characterised by chronic itch 





Barker et al., 1991; Bjerke et al., 1983; Bockelmann et 
al., 2005; Grewe et al., 1994; Nattkemper et al., 2018; 
Schlaak et al., 1994; Zhu et al., 2010 
IL-4 Atopic dermatitis Pedrosa et al., 2017; Smits et al., 2017 
IL-5 Atopic dermatitis Simon et al., 2004 
IL-12 Atopic dermatitis Aral et al., 2006; Yoshizawa et al., 2002 
IL-13 Atopic dermatitis Smits et al., 2017 
IL-17 Psoriasis Kagami et al., 2010; Lowes et al., 2008; Ma et al., 2008 
IL-18 Atopic dermatitis Aral et al., 2006; Yoshizawa et al., 2002 
IL-22 Psoriasis Kagami et al., 2010; Ma et al., 2008 
IL-31 Atopic dermatitis 
Kato et al., 2014; Neis et al., 2006; Pitake et al., 2018; 
Raap et al., 2008; Raap et al., 2012; Sonkoly et al., 
2006; Szegedi et al., 2012 
TNFα Psoriasis Nattkemper et al., 2018; Portugal-Cohen et al., 2012 







Th1 cells are characterised by the production of IL-2, granulocyte-macrophage colony-
stimulating factor (GM-CSF), interferon gamma (IFNγ), and tumour necrosis factor alpha 
(TNFα) (Raphael et al., 2015). These cells are involved in immunity to intracellular pathogens 
and cell-mediated immune responses, and IFNγ has also been implicated in autoimmune 
diseases including psoriasis (Barker et al., 1991; Bjerke et al., 1983; Bockelmann et al., 2005; 
Schlaak et al., 1994; Zhu et al., 2010). Polarisation of Th cells to Th1 cells and expression of 
IFNγ in these cells is proposed to be under the control of the transcription factor T-bet 
(Szabo et al., 2000). T-bet induces ectopic expression of IFNγ in a mouse thyomal cell line 
that does not normally express this cytokine. Furthermore, T-bet can repress production of 
the Th2 cytokines IL-4 and IL-5 in Th2 cells and polarise these cells to Th1 cells capable of 
producing IFNγ and TNFα. Increased expression of T-bet might thus be responsible for the 
increase in Th1 cells characteristic of psoriasis and the subsequent increased production of 
IFNγ in this condition (Schlaak et al., 1994). In support of this, expression of T-bet mRNA in 
peripheral blood mononuclear cells is increased in patients with psoriasis compared with 
healthy controls. The number of T-bet positive cells in psoriatic lesions is also increased 
compared with healthy skin (Zhu et al., 2010).  
 
TNFα is additionally involved in psoriasis. Increased levels of TNFα are reported in the skin of 
patients with psoriasis compared with atopic dermatitis or in healthy skin (Nattkemper et 
al., 2018; Portugal-Cohen et al., 2012). Inhibitors for this cytokine have been shown to 
improve symptoms of psoriasis (Mease et al., 2000). A more recent study found that a 
psoriasis patient treated with anti-TNFα showed a decrease in disease severity and a 
decrease in the number of innate lymphoid cell-3 (ILC3) that may be involved in TNFα-
mediated symptoms of this disease (Villanova et al., 2014). However, these ILC3 are not 
known to produce TNFα, but instead have been reported to secrete IL-17 and IL-22 (Bernink 
et al., 2013). IL-17, a Th17 cytokine, and IL-22, a cytokine secreted by Th17 and Th22 cells, 
are both implicated in psoriasis (Kagami et al., 2010; Lowes et al., 2008; Ma et al., 2008). 
Thus, TNFα might be involved in the production of ILC3, contributing to the involvement of 
Th17 and Th22 cell types to psoriasis.  
 
Stimulation of human skin cell lines and primary keratinocytes with the Th1 cytokines IFNγ, 
TNFα, and IL-1α is reported to cause thickening of the corneal layer of these cultures, in a 
manner similar to that observed in psoriasis (Smits et al., 2017). Stimulation of these cells 
with these cytokines also resulted in increased expression of the psoriasis-related host 
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defence genes, peptidase inhibitor 3 (PI3) and defensin beta-4 (DEFB4), which encode for 
skin-derived antileukoprotease (SKALP)/elafin and human beta-defensin 2 (hBD2). 
SKALP/elafin is an elastase inhibitor reported to be present in the suprabasal layer of the 
skin in patients with psoriasis, but not in normal skin (Schalkwijk et al., 1993). SKALP/elafin 
mRNA is also upregulated in psoriatic skin compared with controls (Guttman-Yassky et al., 
2008). Upregulation of this inhibitor following stimulation with Th1 cytokines suggests 
protection of elastin proteins from proteolytic cleavage in psoriasis. In a skin auto-
fluorescence assay of patients with psoriasis and healthy controls, a small increase in the 
fluorescence spectra for elastin was observed in psoriatic lesional and non-lesional skin 
compared with the skin of healthy controls, however this difference was not significant, 
suggesting a lack of major changes in elastin cross-links in psoriasis (Portugal-Cohen et al., 
2012). hBD2 is an antimicrobial peptide purified from psoriatic scales and may help to 
explain why patients with psoriasis present with a low incidence of skin infections compared 
with other skin conditions (Harder et al., 1997; Henseler and Christophers, 1995). Expression 
of hBD2 in keratinocytes can be upregulated following incubation in TNFα and expression of 
hBD2 mRNA is increased in the skin of patients with psoriasis (Guttman-Yassky et al., 2008; 
Harder et al., 1997), supporting a role for this peptide in psoriasis. However, hBD2 is a 
product of Th17 cells rather than Th1 cells, suggesting the involvement of both Th1 and 
Th17 cells in this condition. 
 
Th2 cells 
Cytokines produced by Th2 cells in response to allergy and parasite infestation include IL-4, 
IL-5, IL-9, IL-10, IL-13, and IL-31 (Castellani et al., 2010; Raphael et al., 2015; Nakayama and 
Yamashita, 2008; Stott et al., 2013). However, the presence of some of these cytokines 
appears to be involved in development of Th2 responses, resulting in a positive feedback 
loop whereby the production of cytokines from Th2 cells results in the further development 
of more cytokine-producing Th2 cells from CD4+ cells. For instance, it was recently reported 
IL-4 was required for the development of IL-4 and IL-4/IL-13-expressing Th2 cells in mouse 
(Prout et al., 2018). IL-4 was not, however required for the development of IL-13-expressing 
Th2 cells, suggesting that subsets of Th2 cells are differentially regulated. Indeed, secretion 
of IL-13 has been shown to require the release of IL-33 from resident lymphoid cells and the 
presence of epidermal growth factor receptor (EGFR) and its ligand amphiregulin on Th2 
cells (Minutti et al., 2017). Thymic stromal lymphopoietin (TSLP), a cytokine released from 
keratinocytes (Wilson et al., 2013), may also be involved in the induction of IL-13-expressing 
Th2 cells. Ochiai et al. (2018) exposed naive CD4+ cells in culture to TSLP and observed the 
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development of a population of Th2 cells that expressed IL-13, IL-5, and IL-9, but not IL-4. In 
vivo, exposure of T cells in the lymph node to TSLP resulted in the development of two 
populations of Th2 cells, one expressing IL-13 but not IL-4, and the other population of Th2 
cells expressing both IL-13 and IL-4 (Ochiai et al., 2018). 
 
The acute phase of atopic dermatitis is characterised by a Th2 phenotype with T-cells that 
produce IL-4, IL-5, IL-13, and IL-31 cytokines (Mudde et al., 1992; Werfel, 2009). These 
cytokines have a variety of effects, particularly on immune cells and keratinocytes. IL-4 has 
been shown to induce apoptosis of eosinophils while enhancing survival of basophils 
(Reinhart and Kaufmann, 2018; Wedi et al., 1998). Apoptosis of eosinophils may serve to 
resolve chronic inflammation in atopic dermatitis. Basophils are a source of IL-4 and IL-13 
(Redrup et al., 1998). In contrast, IL-5 promotes survival of eosinophils (Simon et al., 2004; 
Wedi et al., 1998; Yamaguchi et al., 1988). Increased numbers of eosinophils and eosinohpil 
granule proteins are found in the skin and blood in patients with atopic dermatitis compared 
with healthy controls (Kiehl et al., 2001; Liu et al., 2011a; Simon et al., 2004; Schauer et al., 
1995). Eotaxin-3, or C-C motif chemokine ligand 26 (CCL26), is a chemoattractant of 
eosinophils (Griffithsjohnson et al., 1993; Ponath et al., 1996) and is elevated in the serum 
and skin of patients with atopic dermatitis, but not in patients with psoriasis or healthy skin 
(Kagami et al., 2003; Nattkemper et al., 2018). Together with IL-5, CCL26 might be 
responsible for the increased number of eosinophils observed in the skin in atopic 
dermatitis. IL-4 stimulates expression of CCL26 in cultured human keratinocytes (Nishi et al. 
2008), while IL-4 and IL-13 stimulate expression of CCL26 in HaCaTs (Bao et al. 2012, Bao et 
al., 2013, Kagami et al., 2005) and dermal fibroblasts (Banwell et al., 2002). Stimulation of 
primary keratinocytes and three-dimensional cultures of human skin equivalents with IL-4 
and IL-13 also results in an increase in CCL26 mRNA (Serezani et al., 2017; Smits et al. 2017). 
Thus, expression of CCL26 has been used as a marker of atopic dermatitis (Smits et al. 2017).  
 
Expression of carbonic anhydrase II (CA2) mRNA and protein is also upregulated in cultured 
human keratinocytes, N/TERT cells, and reconstructed human epidermis incubated with IL-4 
and IL-13 (Kamsteeg et al. 2007; Kamsteeg et al. 2011; Pedrosa et al., 2017; Serezani et al., 
2017; Smits et al. 2017). Similarly, expression of CA2 mRNA and protein is upregulated in the 
skin of patients with atopic and contact dermatitis (Kamsteeg et al. 2007; Kamsteeg et al. 
2010). Expression of CA2 is greater in patients with atopic dermatitis than in patients with 
psoriasis (Kamsteeg et al. 2007; Kamsteeg et al. 2010; Nomura et al., 2003). Taken together, 
these studies support a role for the involvement of IL-4 and IL-13 cytokines in the 
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upregulation of CA2 in atopic dermatitis. CA2 is a member of the metalloenzyme family that 
catalyses the conversion of carbon dioxide and water to carbonate and hydrogen ions 
(Tashian, 1989). As a consequence of this, CA2 is involved in the maintenance of intracellular 
pH and ion homeostasis. Blocking carbonic anhydrase activity in Xenopus oocytes slows 
down the intracellular rate of pH change in response to addition of CO2; conversely the rate 
of pH change is increased four-fold when oocytes are co-injected with CO2 and carbonic 
anhydrase (Nakhoul et al., 1998). Furthermore, pharmacological inhibition of carbonic 
anhydrase in retinal neural cells and rat choroid plexus results in an increase in intracellular 
pH (Johanson et al., 1992; Kniep et al., 2006; Reber et al., 2003). However, the effects of 
inhibition of carbonic anhydrase may vary between different cell types, since a reduction in 
pH is observed in corneal endothelial cells in the presence of carbonic anhydrase inhibitors 
(Bonanno et al., 1995). This effect may be due to differences in the resting intracellular pH 
of these cells and variations in the expression of ion transporters in different cell types. In 
atopic dermatitis, the skin surface pH is reported to be increased compared with non-atopic 
skin and is correlated with dryness and itchiness (Eberlein-Konig et al., 2000; Sparavigna et 
al., 1999). This change in skin pH could be the result of increased CA2 expression in the skin, 
ultimately due to enhanced secretion of IL-4 and IL-13. Because synthesis of barrier lipids 
and barrier regeneration require acidic pH (Rippke et al., 2002), the increased pH in the skin 
in atopic dermatitis could be responsible for the impaired barrier function observed in this 
condition.  
 
Neural epidermal growth factor-like 2 (NELL2), expressed in the developing and adult brain 
where it promotes the survival of neurons in the hippocampus and cerebral cortex (Aihara 
et al., 2003; Watanabe et al., 1996), is also implicated in the Th2 environment of atopic 
dermatitis. In addition to being expressed in neurons, expression of NELL2 has been 
reported in keratinocytes, where it could be responsible for post-natal survival of sensory 
neuron endings in the skin (Kamsteeg et al. 2011). Expression of NELL2 is increased in 
human skin equivalents following treatment with IL-4 or IL-13 and in the skin of patients 
with atopic dermatitis, but not contact dermatitis or psoriasis, supporting a role for IL-4 and 
IL-13 in increased expression of NELL2 specifically in atopic dermatitis (Kamsteeg et al. 2010; 
Kamsteeg et al. 2011; Pedrosa et al., 2017). It has been proposed that this increase in NELL2 
expression in atopic dermatitis could be responsible for the increase in density of free nerve 
endings characteristic of this condition (Tobin et al., 1992; Tominaga et al., 2009; Urashima 




In the skin keratinocytes of patients with atopic dermatitis, expression of filaggrin, loricrin, 
and involucrin mRNA and protein is reduced (Howell et al., 2007; Kim et al. 2008). Similarly, 
in primary keratinocytes, N/TERT cells, and Leiden epidermal models, expression of filaggrin, 
loricrin, and involucrin is down-regulated following incubation of cells in IL-4 and IL-13 
(Danso et al., 2014; Howell et al., 2007; Kim et al. 2008; Smits et al. 2017), suggesting that 
release of Th2 cytokines in atopic dermatitis is responsible for downregulation of these 
structural proteins and disruption of the epidermal barrier in this condition. Furthermore, 
because filaggrin is broken down to form Natural Moisturising Factor (NMF) (Rawlings et al., 
1994; Rawlings and Matts, 2005; Scott and Harding, 1986), and because extraction of NMF 
has been reported to increase the pH of the corneal layer of the skin (Nakagawa et al., 
2004), downregulation of filaggrin as a result of IL-4 and IL-13 and the subsequent loss of 
NMF could contribute to the increased pH of the skin in patients with atopic dermatitis 
(Eberlein-Konig et al., 2000; Sparavigna et al., 1999). 
 
IL-31 is another Th2 cytokine reported to be involved in atopic dermatitis. Expression of IL-
31 and cells expressing it is increased in skin biopsies from patients with atopic dermatitis 
compared with patients with psoriasis and healthy individuals and is correlated with disease 
severity (Kato et al., 2014; Neis et al., 2006; Raap et al., 2008; Raap et al., 2012; Sonkoly et 
al., 2006; Szegedi et al., 2012). In mice, injection of IL-31 into the dermis results in 
infiltration of inflammatory cells into the skin, thickening of the skin, and scratching 
behaviour, while administration of IL-31 via an osmotic pump resulted in scratching 
behaviour and hair loss that was not reported in mice that received saline (Andoh et al., 
2017; Arai et al., 2015; Cevikbas et al., 2014; Dillon et al., 2004; Pitake et al., 2018). 
Furthermore, transgenic mice over-expressing IL-31 developed severe pruritus, hair loss, 
increased infiltration of inflammatory cells and mast cells into the skin, and epidermal 
thickening (Dillon et al., 2004; Feld et al., 2016). Expression of IL-31 requires IL-4, since 
blocking IL-4 reduces the expression of IL-31 in Th2 clones and addition of IL-4 can induce 
expression of IL-31 in Th1 clones (Stott et al., 2013). The IL-31 receptor is expressed on 
several cell types, including keratinocytes, leucocytes, and neurons (Andoh et al., 2017; Arai 
et al., 2015; Cevikbas et al., 2014; Kato et al., 2014; Meng et al, 2018; Saleem et al., 2017; 
Zhang et al., 2008). The pruritic effects of IL-31 could thus be via direct action on neurons, or 
indirect via activation of cells that release pruritogens that then act on sensory neurons. 
Evidence for the direct activation of sensory neurons by IL-31 comes from the observation 
that application of IL-31 to cultured DRG neurons results in calcium fluxes and 
phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in these cells (Cevikbas 
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et al., 2014; Pitake et al., 2018). Furthermore, IL-31 promotes the growth of cutaneous 
nerve fibres in transgenic mice over-expressing IL-31 (Feld et al., 2016). This effect is likely to 
be the result of direct activation of IL-31 receptors on these neurons, since neurite 
outgrowth of cultured DRG neurons in response to IL-31 was reduced in neurons cultured 
from IL-31 receptor deficient transgenic mice (Feld et al., 2016). A mechanism by which IL-
31 might indirectly result in pruritus includes the release of the pruritogen leukotriene B4 
(LTB4) from keratinocytes following application of IL-31 (Andoh and Kuraishi, 1998; Andoh 
et al., 2001; Andoh et al., 2017). Activation of the histamine receptor H4R on Th2 cells also 
causes increased expression of IL-31, resulting in a situation whereby release of histamine, 
for example during an allergic reaction, results in activation of H4R on these T cells and the 
subsequent release of IL-31 and induction of pruritus (Gutzmer et al., 2009). 
 
The switch from Th2 to Th1 
While the acute phase of atopic dermatitis is characterised by a Th2 phenotype, the chronic 
phase is characterised by a Th1 phenotype during which the expression of Th1 cytokines, 
including IFNγ, are increased in the skin (Grewe et al., 1998). Skin biopsies of lesions from 
patients with atopic dermatitis show increased expression of IFNγ mRNA and protein in 
addition to IL-4, suggesting the involvement of Th1 cytokines in this condition (Grewe et al., 
1994; Nattkemper et al., 2018). In atopy patch tests, lesions from patients with atopic 
dermatitis show an increase in the production of IL-4 cytokines from T cells 24 hours after 
the patch test; however production of IFNγ from T cells dominates 48-72 hours after the 
patch test, suggesting the Th1 responses occur after onset of Th2 responses in this condition 
(Thepen et al., 1996). Whether this involves the conversion of Th2 cells already present in 
the lesions from a Th2 phenotype to a Th1 phenotype, or the infiltration of new Th1 cells 
into the lesions following signals released from Th2 cells, is not clear.  
 
Release of IL-12 and IL-18 from dendritic cells is believed to polarise naïve T cells towards a 
Th-1 phenotype by increasing production of IFNγ from these cells (Grewe et al., 1995; 
Grewe et al., 1998; Stoll et al., 1998; Yoshimoto et al., 1998). In support of the involvement 
of IL-12 and IL-18 cytokines in atopic dermatitis, disease severity correlates with serum 
levels of IL-12 and IL-18 in children with atopic dermatitis, and patients with atopic 
dermatitis have increased serum IL-18 (Aral et al., 2006; Yoshizawa et al., 2002).  
 
IFNγ upregulates expression of IL-4 receptor on keratinocytes, and pre-incubation of 
keratinocytes in IFNγ followed by IL-4 enhances the production of CCL26 (Nishi et al., 2008), 
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suggesting interactions between Th1 and Th2 responses in atopic dermatitis. Infiltration of 
IFNγ-releasing T cells in the dermis and epidermis in atopic dermatitis and allergic contact 
dermatitis results in upregulation of Fas receptors (CD95) on keratinocytes, causing them to 
be susceptible to apoptosis (Daehn et al., 2010; Trautmann et al., 2000; Trautmann et al., 
2001). This in turn causes disruption of the epidermal barrier and development of 
eczematous lesions. Fas-induced apoptosis of keratinocytes may also be involved in the 
switch from the Th2 phenotype characteristic of acute phase atopic dermatitis to the Th1 
phenotype characteristic of chronic-stage atopic dermatitis. Although Th1 cells can induce 
cell death in keratinocytes, Th2 cells are not able to induce apoptosis unless stimulated with 
IL-12, resulting in increased production of IFNγ from these cells (Trautmann et al., 2000). 
Furthermore, in a mouse model of atopic dermatitis in which mice lacked expression of Fas 
ligand or receptor, an increase in epidermal and dermal thickening, number of regulatory T 
cells, and mRNA expression of Th2 cytokines was observed compared with wild-type 
littermates, suggesting that Fas-induced apoptosis of keratinocytes is involved in the 
conversion of Th2 to Th1 phenotype in atopic dermatitis and lack of Fas-induced apoptosis 
results in worsening of atopic dermatitis symptoms including dermal thickening and Th2 
inflammation (Bien et al., 2017). 
1.2 Peripheral itch pathways 
Pruritogens released from keratinocytes and immune cells in the skin activate receptors on 
sensory neurons (pruriceptors) resulting in transmission of itch signals (Bautista et al., 2014). 
These sensory neurons belong to the C-fibre and Aδ-fibre classes (Johanek et al., 2008; 
Ringkamp et al., 2011; Schmelz et al., 1997). The cell bodies of these neurons are located in 
the dorsal root ganglia (DRG) or trigeminal ganglia (TG) (Akiyama and Carstens, 2013; Dhand 
and Aminoff, 2014), while the central terminals of these neurons are located in the CNS, 
where they release neurotransmitters and neuropeptides that then activate second-order 
interneurons in the dorsal horn of the spinal cord or spinal trigeminal nucleus in the 
medulla. 
 
Pruriceptors are thought to belong to a subset of nociceptors that also convey noxious 
stimuli. In healthy volunteers, the cutaneous endings of sensory neurons that respond to 
application of pruritogens also respond to algogens, suggesting that the same sensory 
neurons are responsible for the transmission of both stimuli (Schmelz et al., 2003). Itch and 
pain signals may be conveyed by neurons that express the capsaicin receptor transient 
receptor potential vanilloid 1 (TRPV1), since ablation of TRPV1-expressing neurons results in 
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the abolition of both sensations (Imamachi et al., 2009). Furthermore, exposure to algogens 
and pruritogens does not always give the expected pain and itch responses, respectively, 
suggesting a degree of cross-talk during transmission of nociceptive and pruritic stimuli by 
sensory neurons, or during their perception in the cortex, allowing for noxious stimuli to be 
perceived as itch and pruritic stimuli to be perceived as painful. Alternatively, both stimuli 
are detected and conveyed by the same neurons but abnormalities in their perception in the 
brain result is these unexpected sensations. Although capsaicin, the pungent ingredient of 
chilli peppers is an algogen, punctate application of capsaicin via spicules to the skin of 
healthy volunteers results in itch sensations (Sikand et al., 2009). Moreover, noxious 
stimulation of the skin by electrical stimulation and injection of acidic solution in patients 
with atopic dermatitis evokes itch instead of pain (Ikoma et al., 2004; Vogelsang et al., 
1995). In contrast, injection of histamine into the skin of patients with neuropathic pain is 
perceived as pain rather than itch (Baron et al., 2001). Thus, one possibility is that itch and 
pain stimuli are detected by the same sensory neurons and conveyed along the same 
spinothalamic tract neurons, with the distinction between itch and pain sensations 
occurring in the brain and the distinct scratching and withdrawal reflexes characteristic of 
itch and pain, respectively, occurring in the spinal cord (Davidson et al., 2007; Davidson et 
al., 2009; Davidson et al., 2012; Hachisuka et al., 2018; LaMotte et al., 2014). In this 
scenario, however, because the sensory neurons that detect and convey noxious and 
pruritic stimuli are the same, the abnormal perception of pruritic stimuli as painful or 
noxious stimuli as itch is the result of damage or abnormal activity in the spinal cord or 
brain, rather than the sensory neurons themselves. This would suggest that at least some 
itch and pain pathologies are the result of damage to the spinal cord or brain, rather than 
the pruriceptors or an increase in the exposure to pruritogens. However, because several 
chronic itch conditions arise due to pathologies in the skin, it is likely some other peripheral 
mechanism exists that distinguishes itch and pain sensations.  
 
If itch and pain signals are mediated by the same group of sensory neurons, then the 
obvious question is how are they distinguished from one another? One hypothesis is that 
dedicated subsets of nociceptors act as pruriceptors that only respond to pruritogens and 
specifically convey information that is perceived as itch. In support of this, a number of 
studies have shown the existence of sensory neurons that are specifically involved in itch. A 
subset of TRPV1 neurons that express the Mas-related G-protein coupled receptor A3 
(MrgprA3) has been shown to mediate itch and not pain. Ablation of these neurons in mice 
results in significant reduction of scratching behaviour in response to injection of 
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pruritogens, including histamine, chloroquine, and SLIGRL, although nocifensive behaviours 
in response to capsaicin are not affected (Han et al., 2013). Neurons that express MrgprA3 
show reduced excitability and firing of action potentials compared with neurons that 
innervate the skin that do not express MrgprA3, likely due to the enhanced voltage-gated 
potassium current in MrgprA3-expressing neurons, suggesting these itch-specific neurons 
are less likely to fire than neurons that do not express MrgprA3 (Tang et al., 2016). In an 
animal model of allergic contact dermatitis, MrgprA3-expressing neurons had increased 
excitability and firing of action potentials, which may explain the increase in pruritus 
experienced in chronic itch conditions (Qu et al., 2014). Although neurons specific for itch 
have been described, it cannot be assumed that all itch stimuli are detected by neurons 
dedicated to transmission of only itch signals. Furthermore, itch sensations are sometimes 
accompanied by other sensations, particularly pain (Ross, 2011).  
 
Models of itch coding 
Several models have been proposed to explain how itch sensations may be conveyed, either 
via dedicated neurons specific for itch or neurons that can transmit both itch and pain 
signals (Bautista et al., 2014; LaMotte et al., 2014) (Figure 1.4).  
 
One of the earliest models to explain the coding of stimuli to distinguish pruritic stimuli from 
noxious stimuli is intensity coding of the signals. This model proposes that the same 
polymodal neurons convey both itch and pain, and that it is the intensity of the stimulus 
which determines the sensation felt. Specifically, itch sensations occur when these neurons 
are weakly activated, while pain results from increased firing of action potentials in the 
same neurons in response to strong activation of these neurons. In support of this, using 
spicules to apply of low doses of capsaicin to the skin of healthy volunteers resulted in itch 
sensations, while injection of high doses of capsaicin resulted in pain (Sikand et al., 2011b). 
However, in this study, similar sensations of itch and pain were reported following 
application of histamine whether injected or applied via spicules. It is likely that the itch 
sensations experienced following punctate application of capsaicin were due to activation of 
receptors on the terminals of sensory neurons in the outer epidermis of the skin, while 
activation of receptors of nociceptive-specific neurons located deeper within the dermis 
following injection of capsaicin resulted in pain. In contrast, because itch is only experienced 
at the body surface where scratching can occur (McMahon and Koltzenburg, 1992), 
activation of receptors on sensory neurons in the epidermis by pruritogens could be 
sufficient for itch sensation. Indeed, in healthy volunteers, transcutaneous electrical 
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stimulation of the skin was found to cause itch sensations, although, increasing the intensity 
of the stimulus did not result in pain, but instead resulted in increasing the intensity of the 
itch sensation (Ikoma et al., 2005; Tuckett, 1982). Thus, at the surface of the skin, activation 
of sensory neurons may elicit itch sensations only, regardless of the intensity of the stimulus 
used. This suggests the neurons for itch and pain respond to both pruritic and noxious 
stimuli but that activation of the receptors on nerve endings in the outer epidermis results 
in itch sensation, while activation of receptors deeper in the dermis causes pain.  
 
It has also been proposed that punctate application of substances in the epidermis which 
results in the activation of one or a few nociceptors surrounded by inactivated nociceptors 
causes itch sensations (spatial-contrast coding), while simultaneous activation of a large 
number of pruriceptive and non-pruriceptive nociceptors in the skin following, for example, 
injection of an algogen, causes pain by inhibiting neurons conveying itch signals (population 
or selectivity coding) (Bautista et al., 2014; LaMotte et al., 2014). 
 
The pattern or frequency coding model proposes that sensory neurons conveying itch are 
polymodal, rather than being specific for itch. In this model, itch is thought to arise from 
polymodal sensory capable of detecting a range of stimuli, but it is the temporal pattern or 
frequency discharge which determines whether itch is the sensation that arises (Bautista et 
al., 2014). In support of this, pruritogens were found to elicit lower rates of discharge than 
algogens in peripheral sensory neurons (Davidson et al., 2012). However, this could also 
reflect the fact that in human volunteers, algogens such as capsaicin have been reported to 
be perceived as producing more intense sensations than pruritogens such as histamine 
(Sikand et al., 2011b). Thus, the frequency of coding could reflect the intensity of the 
stimulus rather than whether the stimulus is perceived as itch or pain.  
 
The labelled-line coding of itch, in contrast, proposes that the neurons responsible for itch 
are not polymodal, but instead specific for itch (Bautista et al., 2014; LaMotte et al., 2014). 
This would suggest that the itch and pain pathways are completely segregated and that 
activation of the neurons would result in a specific sensation, regardless as to the stimulus 
used. In support of this, a transgenic mouse model in which TRPV1 was expressed only in 
sensory neurons expressing MrgprA3 displayed scratching behaviour instead of nocifensive 
behaviour following injection of capsaicin, presumably because the nociceptive neurons that 
normally convey capsaicin-mediated pain had been effectively silenced and only the 




Figure 1.4: Schematic of proposed itch theories 
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this also agrees with the population or selectivity coding of itch, since simultaneous 
activation of both sets of neurons would have resulted in pain rather than itch.  
 
Thus, it is likely that the different models for coding of itch information each play a role in 
conveying itch information and distinguishing itch and pain sensations from one another, 
possibly depending on the stimulus type and the neurons that are activated. However, 
whether the neurons responsible for itch are polymodal or specific remains to be further 
investigated. 
 
Types of pruriceptors 
It is generally accepted that sensory neurons of the peripheral itch pathways are likely 
subsets of the peripheral neurons responsible for the transmission of pain. In many cases 
the same receptors, ion channels, neurotransmitters and neuropeptides are utilised by 
sensory neurons that transmit itch and pain signals (Ikoma et al., 2006; Liu and Ji, 2013; Luo 
et al., 2015; Ross 2011). However, the existence of different subtypes of pruriceptors has 
also been proposed, which are thought to convey itch elicited by various pruritogens.  
 
Itch is broadly subdivided into histaminergic or non-histaminergic itch, depending on 
whether pruritus is elicited following activation by histamine or other pruritogens. The 
existence of different types of itch might help to explain why the itch observed in chronic 
conditions, such as atopic dermatitis, is not treated by antihistamines, and that other 
pruritogens are likely to be involved in these types of itch (Klein and Clark, 1999; Rukwied et 
al., 2000; Wahlgren et al., 1990; Yarbrough et al., 2013). Distinct groups of pruriceptors are 
believed to be required for histaminergic and non-histaminergic itch, since most neurons 
respond to application of only one type of pruritogen (Roberson et al., 2013). Moreover, 
blocking one type of pruriceptor does not affect the itch responses observed following 
activation of other types of pruriceptors. This was recently demonstrated by Roberson et al. 
(2013) using the sodium channel blocker QX-314 to block specific subsets of neurons. 
Activation of G protein-coupled receptors (GPCRs) with a pruritogen results in the opening 
of large pore ion channel such as the transient receptor potential (TRP) channels, allowing 
the entry of sodium and calcium ions into the cell. However, when activated in the presence 
of QX-314, opening of the TRP channel allows the entry of QX-314 into the cell, where it 
then enters sodium channels in the cell membrane and blocks them, preventing further 
entry of sodium ions into the cells and hence activation of the cell (Figure 1.5).  Using this 
technique, calcium responses of sensory neurons to application of pruritogens were 
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inhibited, and in mice scratching behaviour following intradermal injection of pruritogens 
was reduced, confirming the ability of this technique to block itch signalling. Furthermore, 
blocking activity of histaminergic pruriceptors did not prevent scratching behaviour 
following injection of non-histaminergic pruritogens, and vice versa. Importantly, blocking 
activity of these pruriceptors did not prevent behavioural responses to noxious heat, cold, 
mechanical, or painful stimuli. This suggests pruriceptors, although comprising a subset of 
nociceptors, are not required for transmission of nociceptive stimuli and are therefore likely 
to comprise a distinct set of sensory neurons necessary for transmission of itch signals 
following activation by pruritogens. Thus, although pruriceptors tend to be studied as a 
subset of nociceptors, by knowing the properties of the neurons thought to be responsible 
mediating itch signals, we can begin to characterise the neurons that respond to application 
of pruritogens, determine whether substances applied to the cells are likely to be 
pruritogens, and hence whether itch is the sensation experienced following application of 
these substances. Neurons that respond to application of pruritogens can be further 
characterised as mediating histaminergic or non-histaminergic itch, and the receptors and 
ion channels involved and specific to those pathways can also be investigated. 
 
 
Figure 1.5: Schematic of targeted delivery of QX-314 following activation of neurons by a 
pruritogen (adapted from Roberson et al., 2013) 
The sodium channel blocker QX-314 is unable to pass through the cell membrane to enter 
the cell. Pruritogens acting on GPCRs cause opening of TRP channels in the cell membrane, 
allowing for entry of QX-314 into the cell. Once inside the cell, the pores of sodium channels 
in the cell membrane become blocked, preventing conduction of action potentials. 
1.2.1 Histaminergic itch and TRPV1 
The most well-studied of the itch pathways is the histaminergic itch pathway. In addition to 
causing itch sensations in healthy human volunteers, intradermal injection of histamine into 
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the skin results in the development of localised oedema known as a wheal, surrounded by 
an area of erythema known as a flare (Figure 1.6) (Simone et al., 1991). Histaminergic itch is 
thought to be conveyed by the histamine 1 receptor (H1R), a GPCR coupled to Gq (Gutowski 
et al., 1991). Antihistamines acting on H1R have long been used to treat itch, particularly in 
allergic conditions such as urticaria, where histamine thought to be released from mast cells 
and basophils acts on pruriceptors (Kaplan 2002; Schwartz, 1991; Simons, 2004).  
 
Histamine 1 receptor 
Histaminergic itch involves the coupling of H1R to TRPV1 by several different intracellular 
signalling pathways. Evidence for the coupling of H1R and TRPV1 comes from studies in 
which mechanically insensitive C fibres that responded to histamine were also found to 
respond to the TRPV1 agonist capsaicin (Schmelz et al., 1997). Furthermore, expression of 
both H1R and TRPV1 are required for histaminergic responses, as inward currents in 
response to application of histamine are reported only in HEK293 cells expressing both 
receptors (Shim et al., 2007). In DRGs, responses to histamine can be prevented by using an 
antagonist to TRPV1 (Kim et al., 2004; Shim et al., 2007), and histamine-induced scratching 
behaviours are reduced in TRPV1 KO mice (Imamachi et al., 2009; Shim et al., 2007), 
suggesting activation of TRPV1 is required for histamine-mediated responses.  
 
Figure 1.6: Characteristic wheal and flare response of skin following injection of histamine 
(adapted from Simone et al., 1991) 
Intradermal injection of 1 μg histamine dihydrochloride into the skin at site X causes 
formation of a wheal at the site of injection due to increased permeability of small blood 
vessels. Surrounding the wheal is an area of erythema (flare) caused by vasodilation of the 
blood vessels. The wheal and flare are encompassed in an area of alloknesis, or skin that is 
reported to be itchy when non-pruritic stimuli, such as gentle tactile stimuli, are applied. 
 
Phospholipase A2 signalling 
Histamine-mediated calcium responses in DRG neurons and HEK cells transfected with H1R 
and TRPV1 were reduced in the presence of inhibitors of phospholipase A2 (PLA2) and 12-
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lipoxygenase (12-LO), while intraperitoneal injection of these inhibitors prior to intradermal 
injection of histamine prevented histamine-induced scratching behaviour in mice, 
suggesting the involvement of these molecules in the coupling of H1R to TRPV1 (Kim et al., 
2004; Shim et al., 2007). It has been hypothesised that activation of H1R by histamine 
results in activation of PLA2, which cleaves membrane phospholipids resulting in the 
production of arachidonic acid (AA) (Leurs et al., 1994), which is then metabolised by 12-LO 
to form 12-hydroxyeicosatetraenoic acid (12-HPETE) (Figure 1.7). In support of this, 
histamine was found to cause a 2.5-fold increase in the production of 12-HPETE in sensory 
neurons (Shim et al., 2007). Furthermore, 12-HPETE has been found to have a three-
dimensional structure similar to that of capsaicin (Hwang et al., 2000) and to elicit scratching 
behaviour when intradermally injected into mice (Kim et al., 2007). It is thus plausible that 
12-HPETE, produced following H1R activity, could activate TRPV1 directly, allowing for entry 
of calcium and other cations into the cell.  
 
Similarly, LTB4, a product of AA metabolism by 5-LO, can also activate TRPV1-mediated 
currents (Hwang et al., 2000), while intradermal injection of LTB4 causes scratching 
behaviour in mice (Andoh and Kuraishi, 1998; Kim et al., 2007). However, whether activation 
of H1R results in production of LTB4 and itch sensations via activity at TRPV1 remains to be 
determined. Rather, it is more probable that LTB4 exerts its pruritic effects by acting on 
specific LTB4 receptors, since blocking these receptors with co-injection of antagonists 
reduces LTB4-mediated scratching behaviours in mice (Andoh and Kuraishi, 1998). 
Furthermore, keratinocytes are a potential source of LTB4, which could act on LTB4 
receptors on sensory neurons to result in itch sensations (Andoh et al., 2001; Andoh et al., 
2017).  
 
Phospholipase C signalling 
Activation of H1R additionally activates phospholipase C (PLC) and increases production of 
inositol 1,4,5-trisphosphate (IP3) in cells in both neuronal and non-neuronal cells, suggesting 
the existence of multiple signalling pathways by H1R (Leurs et al., 1994; Nicolson et al., 
2002). Inhibition of PLC reduced calcium responses to histamine and transgenic mice lacking 
the PLCβ3 isoform showed reduced scratching behaviour in response to injection of 
histamine, highlighting the importance of this particular isoform in histamine-induced itch 
(Han et al., 2006; Nicolson et al., 2002). In non-neuronal cells, activation of H1R and 
subsequent activation of PLC and production of IP3 causes calcium fluxes as a result of 
calcium released from intracellular stores, since the responses to histamine remained when 
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stimulated in a calcium-free medium (Leurs et al., 1994). However, in neuronal cells, 
responses to histamine are reduced when cells are stimulated in a calcium-free medium, 
suggesting extracellular calcium is required for histamine-induced responses in neurons 
(Kim et al., 2004; Nicolson et al., 2002). Because histamine-mediated calcium fluxes are 
absent in TRPV1 KO mice and can be blocked by a TRPV1 antagonist, entry of extracellular 
calcium ions and other cations through activated TRPV1 is the likely mechanism by which 
histamine binding to H1R results in calcium fluxes (Shim et al., 2007).  
Phosphatidylinositol 4,5-bisphosphate (PIP2) inhibits TRPV1 (Chuang et al., 2001), however 
hydrolysis of PIP2 to IP3 and diacylglycerol (DAG) by PLC removes this inhibition from TRPV1 
(Prescott and Julius, 2003), providing a mechanism by which activation of H1R could 
sensitise TRPV1 via PLC signalling. Furthermore, DAG and metabolites of DAG such as 2-
arachidonoylglycerol (2-AG) can behave as endogenous agonists of TRPV1 (Woo et al., 2008; 
Zygmunt et al., 2013). Another product of PLC signalling is protein kinase C (PKC), which 
sensitises and activates TRPV1, likely via phosphorylation of the receptor (Premkumar and 
Ahern, 2000). Responses to histamine, but not to other pruritogens or capsaicin, were 
reduced in DRGs cultured PKCδ KO mice, suggesting the role of this PKC isoform in 
histamine-mediated itch (Valtcheva et al., 2015a). PKCδ is dependent upon DAG, but not 
calcium, for its activation (Exton, 1996), and is phosphorylated in response to histamine 
(Hao et al., 2008; Mizuguchi et al., 2011). In mouse DRG cultures, histamine also potentiates 
TRPV1-mediated calcium responses and membrane depolarisation to acid, the effect of 
which can be reduced in the presence of inhibitors for PLC and PKC (Kajihara et al., 2010). 
This supports the notion that activation of the histamine receptor sensitises TRPV1-





Figure 1.7: Schematic of sensitisation of TRPV1 via histamine 
Activation of H1R by histamine activates PLA2 and PLCβ3 pathways to result in activation 
and sensitisation of TRPV1.  
 
Histamine 3 and 4 receptors 
The histamine 3 receptor (H3R) and histamine 4 receptor (H4R) have also been proposed to 
play a role in itch (Bell et al., 2004; Rossbach et al., 2011).  
 
Rossbach et al. (2011) reported that sensory neurons innervating that skin could be 
activated by agonists of H4R in addition to H1R agonists. Dunford et al. (2007) observed that 
administration of an agonist selective for H4R elicited scratching behaviour in mice that was 
significantly reduced in the presence of a H4R antagonist or in H4R knockout mice. In 
healthy human volunteers, a H4R antagonist was found to be effective in reducing 
histamine-induced pruritus (Kollmeier et al, 2014), and H4R antagonists were found to 
improve symptoms in a clinical trial of patients with atopic dermatitis (Murata et al., 2015). 
However, other studies have found that H4R antagonists were ineffective in animal models 
of atopic dermatitis (Bäumer et al., 2011; Kamo et al., 2014). The reasons for this 
discrepancy are unclear, although concerns have been raised about expression of H4R in 
neuronal cells, off-target effects of histamine receptor agonists and antagonists, and lack of 
reproducibility of results from other groups (Schneider and Seifert, 2016). The mechanisms 
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by which activation of H4R would mediate itch are not fully known, although TRPV1 may 
mediate downstream signalling of H4R via PLC activity (Jian et al., 2016).  
 
Expression of H3R has been detected in rodent DRGs, suggesting activity of this receptor on 
sensory neurons could be involved in transmission of itch signals (Cannon et al., 2007; Heron 
et al., 2001; Kajihara et al., 2010). However, Rossbach et al. (2011) reported that 
intradermal injection of an inverse agonist to H3R resulted in scratching behaviour in mice 
and increased calcium in cultured DRG cells, suggesting that activation of these receptors 
normally inhibits transmission of itch signals and may have a protective role in reducing itch.  
1.2.2 Non-histaminergic itch 
In addition to histamine, itch resulting from other pruritogens is known to occur via 
receptors other than the histaminergic receptors. Plant-derived proteases, such as papain 
from papaya, ficin from figs, bromelain from pineapples, and mucunain from cowhage, have 
all been reported to cause pruritus by acting on protease activated receptors (Papoiu et al., 
2011; Reddy and Lerner, 2010; Reddy et al., 2008). The antimalarial drug chloroquine and 
bovine adrenal medulla 8-22 peptide (BAM8-22), a cleaved produced of proenkephalin A, 
are also non-histaminergic pruritogens (Liu et al., 2009; Sikand et al., 2011a).  
 
MrgprA3 and MrgprC11-mediated itch 
Non-histaminergic itch is thought to be conveyed by pruriceptors expressing GPCRs such as 
MrgprA3, MrgprC11, and PAR2, as well as the ion channel transient receptor potential 
ankyrin 1 (TRPA1) in polymodal C-fibres (Johanek et al., 2008; Liu et al., 2009; Ross, 2011; Ru 
et al., 2017; Wilson et al., 2011). These fibres comprise a subset of TRPV1-positive neurons, 
since a subset of TRPV1 neurons that express MrgprC11 and MrgprA3 is reported to be 
activated by the pruritogens BAM8-22 and chloroquine, respectively (Liu et al., 2009). 
However, unlike with histaminergic itch, TRPV1 is not required for BAM8-22 and 
chloroquine signalling in neurons, as neurons from TRPV1 deficient animals demonstrate 
similar calcium activity and action potential firing in response to application of BAM8-22 or 
chloroquine as neurons from control wild-type littermates do (Wilson et al., 2011). Rather, 
TRPA1 is thought to be necessary for this type of itch (Figure 1.8), since scratching observed 
in wild type (WT) mice injected with BAM8-22 or chloroquine is significantly reduced in 
TRPA1-deficient mice (Wilson et al., 2011). Furthermore, in a neuroblastoma cell line 
transfected with MrgprA3 or TRPA1 alone, chloroquine failed to trigger calcium responses, 
instead requiring expression of both MrgprA3 and TRPA1 (Wilson et al., 2011). BAM8-22 did 
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result in calcium responses in cells transfected only with MrgprC11, although greater 
calcium responses occurred in cells transfected with both MrgprC11 and TRPA1 (Wilson et 
al., 2011). This suggests that expression of both GRPRs and TRPA1 is required for robust 
responses to pruritogens and that they are functionally coupled.  
 
Both MrgprA3 and MrgprC11 are coupled to the Gαq/11 signalling pathway where they can 
elicit calcium responses in transfected HEK cells (Han et al., 2002). These calcium responses 
were inhibited in the presence of a PLC inhibitor, suggesting activation of PLC downstream 
of Gαq/11 signalling and supporting a role for PLC in the coupling of MrgprA3 and MrgprC11 
to TRPA1. Similarly, Wilson et al. (2011) reported a reduction in the amplitude and 
percentage of mouse DRG neurons that responded to BAM8-22 in the presence of a PLC 
inhibitor, while Ru et al. (2017) found that neurons from transgenic mice lacking PLCβ3 
lacked action potential discharges following application of chloroquine. In contrast, Wilson 
et al. (2011) reported that neuronal chloroquine-mediated calcium responses were not 
reduced by the addition of a PLC inhibitor, and Imamachi et al. (2009) observed that 
chloroquine-mediated scratching behaviours were not altered in transgenic mice lacking 
PLCβ3, suggesting MrgprA3 couples to TRPA1 via an additional mechanism. Indeed, pre-
treatment of neurons with an inhibitor of the Gβγ subunits resulted in a decrease in both 
the amplitude of calcium responses and percentage of neurons that responded to 
chloroquine (Wilson et al., 2011). Gβγ has also been shown to be required for activation of 
TRPA1 via the GPCR bile acid receptor 1 (Lieu et al., 2014), suggesting that activation of 
TRPA1 by the Gβγ subunit of MrgprA3 as a plausible pathway. Gβγ subunits can bind to ion 
channels including inwardly-rectifying potassium channels and voltage-gated calcium 
channels and modulate their activity (Dascal, 2001), although whether direct binding of Gβγ 
subunits to TRPA1 is also responsible for their opening and the transmission of itch signals 
remains to be investigated. However, chloroquine-mediated activation of MrgprA3 can also 
result in sensitisation of TRPV1 via the PLC-PKC pathway, providing an additional mechanism 





Figure 1.8: Schematic of sensitisation of TRP channels via non-histaminergic pruritogens 
Activation of MrgprC11 and MrgprA3 by BAM8-22 and chloroquine, respectively, results in 
activation of TRPA1 via PLCβ3 and Gβγ signalling. MrgprA3 can additionally sensitise TRPV1 
via PLC signalling. 
 
Serotonergic itch 
As well as being a neurotransmitter, serotonin (5-hydroxytryptamine or 5-HT) can act as a 
pruritogen that causes scratching behaviour when injected intradermally in mice and rats 
(Akiyama et al., 2016b; Imamachi et al., 2009; Jinks and Carstens, 2002; Klein et al., 2011; 
Morita et al., 2015; Nojima and Carstens, 2003; Ostadhadi et al., 2015; Shim et al., 2007; 
Thomsen et al., 2001; Yamaguchi et al., 1999). Along with other pruritogens, serotonin can 
be released from resident immune cells and keratinocytes in the skin, where it acts on 
receptors expressed on sensory neurons (Green and Dong, 2016). Release of serotonin from 
platelets has also been proposed to be involved in a mouse model of dry skin itch and 
allergic itch (Luo et al., 2018).  
 
Serotonergic itch likely occurs via a different intracellular signalling pathway to 
histaminergic itch, as application of serotonin into the skin via iontophoresis of human 
volunteers does not result in the development of a localised wheal that is observed 
following application of histamine, and antihistamines do not significantly reduce serotonin-
induced itch sensations (Hosogi et al., 2006). However, serotonin is also not known to 
activate Mrgprs (Liu et al., 2009), suggesting serotonergic itch is mediated either by direct 
opening of ionotropic serotonergic receptors or via coupling of metabotropic serotonergic 
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receptors to second messenger signalling systems where they can interact with other 
receptors expressed by sensory neurons.  
 
5-HTR7 
Despite being transmitted by TRPV1-expressing neurons, serotonin-mediated scratching 
behaviour is not reduced in TRPV1 KO mice (Akiyama et al., 2016b; Imamachi et al., 2009; 
Shim et al., 2007). Moreover, the percentage of neurons that demonstrate calcium 
responses to agonists of the 5-HTR7 serotonergic receptor is not decreased in DRGs cultured 
from TRPV1 KO mice, suggesting TRPV1 is not required for itch mediated by this 
serotonergic receptor (Morita et al., 2015). In contrast, there is evidence suggesting TRPA1 
is required for serotonergic itch mediated by the 5-HTR7 receptor. In sensory neurons 
innervating the skin, expression of 5-HTR7 occurs in a subset of fibres that express TRPA1 
(Morita et al., 2015). Furthermore, TRPA1 KO mice spend less time scratching following 
injection of the 5-HTR7 agonist and DRGs cultured from these mice demonstrate fewer 
calcium responses to application of 5-HTR7 agonists than DRGs from wild-type mice (Morita 
et al., 2015). 5-HTR7 is thought to activate TRPA1 by Gβγ-mediated activation of adenylate 
cyclase and the production of cyclic adenosine monophosphate (cAMP), as inhibition of 
these pathways reduces serotonin-mediated calcium signals in cultured DRGs (Morita et al., 
2015). TRPA1 is not required for all serotonergic itch responses, however. For example, 
scratching behaviour is not reduced in TRPA1 KO mice injected with serotonin (Akiyama et 
al., 2016b), suggesting activation of additional serotonergic receptors not linked to TRPA1 is 
sufficient to induce scratching behaviour. Indeed, different types of itch have been 




The 5-HTR2 receptor is also involved in pruritus (Akiyama et al., 2016b; Imamachi et al., 
2009; Luo et al., 2018; Wilson et al., 2011; Yamaguchi et al., 1999). 5-HT-induced scratching 
behaviour is reduced in mice pre-treated with the 5-HT2R antagonist ketanserin (Akiyama et 
al., 2016b). Moreover, activation of 5-HTR2 by α-methyl 5-HT results in scratching behaviour 
in both wild-type mice (Yamaguchi et al., 1999) and TRPA1 KO mice (Wilson et al., 2011). 
PLCβ3 may be involved in mediating serotonergic itch through 5-HTR2, as scratching in 
response to injection of the 5-HTR2 agonist α-methyl 5-HT was also significantly reduced in 





The ionotropic 5-HTR3 serotonin receptor may additionally be involved in pruritus. In mice, 
scratching behaviour following intradermal injection of serotonin is reduced when mice are 
pre-treated with 5-HTR3 antagonists (Ostadhadi et al., 2015) and there are case studies of 5-
HTR3 antagonists being effective in treating cholestatic pruritus (Raderer et al., 1994; 
Schwörer and Ramadori, 1993). However, other studies did not report scratching behaviour 
in rodents following injection with a 5-HTR3 agonist, or a reduction of serotonin-mediated 
scratching when mice were treated with 5-HTR3 antagonists or in 5-HTR3 deficient mice 
(Imamachi et al., 2009; Yamaguchi et al., 1999). Thus, whether serotonin-mediated itch 
occurs through activation of 5-HTR3 is unresolved, although it is likely serotonin normally 
acts through more than one receptor to result in activation of pruriceptors. 
 
MrgprD-mediated itch 
Some forms of non-histaminergic appear to be mediated by pruriceptors that do not express 
TRPA1 or MrgprA3, but instead express MrgprD. Despite belonging to a subpopulation of 
nociceptive neurons, these pruriceptors do not express TRPV1 or produce neuropeptides, 
but instead belong to the IB4-expressing subpopulation of nociceptors (Zylka et al., 2005). 
They respond to β-alanine, a supplement used for muscle building that often induces itch 
and tingling sensations (Décombaz et al., 2012; Liu et al., 2012), and increased sensitivty to 
heat and mechanical noxious stimuli, suggesting that these neurons can function as both 
pruriceptors and nociceptors, although they do not respond to all pruritogens (Imamachi et 
al,. 2009; Liu et al., 2012). Indeed, it was observed in MrgprD knockout mice that scratching 
behaviour in response to oral administration of β-alanine was abolished, while scratching 
behaviour in response to administration of histamine was unaffected (Liu et al., 2012). The 
mechanism of itch via MrgprD receptors has not yet been fully elucidated but may involve 
calcium-activated chloride channels and PLC-mediated cleavage of PIP2 to form IP3, as 
inhibitors to calcium-activated chloride channels and PLC inhibitors both reduced β-alanine-
induced currents in MrgprD-expressing Xenopus oocytes (Zhuo et al., 2014). 
1.2.3 Peripheral sensitisation of itch 
The phenomena of alloknesis (ithe perception of itch in response to non-pruritic stimuli) and 
hyperknesis (enhanced pruritus following applcation of a pruritic stimulus) during chronic 
itch suggest the existence of sensitisation mechanisms that result in overall enhanced 
pruritus (Schmelz, 2010). In the periphery, sensitisation may result from increased sprouting 
of nerve endings following enhanced expression of neurotrophins such as NGF and artemin 
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in the skin, as has been reported in atopic dermatitis conditions (Murota et al., 2012; 
Urashima and Mihara, 1998). This increased sprouting of nerve endings would increase the 
likelihood of a pruriceptor encountering a pruritogen and subsequent transmission of an 
itch signal. Moreover, NGF causes sensitisation of TRPV1 channels in neurons, proposed to 
occur following removal of inhibitory PIP2 signalling when NGF binds to TrkA receptors and 
PLC signalling is initiated (Chuang et al., 2001). Increased expression of TRPA1 in sensory 
neurons is also reported due to NGF-mediated activation of p38 MAPK signalling (Diogenes 
et al., 2007). Although sensitisation of TRPV1 and TRPA1 could play a role in peripheral 
sensitisation of itch signals, it does not explain why pruritus, and not pain, is increased in 
response to NGF in chronic itch conditions. It could be speculated that a specific subset of 
nociceptors that respond to pruritogens is sensitised by NGF in chronic itch conditions, 
although the mechanisms that would result in this are not clear. Alternatively, a 
combination of peripheral sensitisation that serves to enhance overall activity in the 
periphery, as well as altered signalling centrally such that pain signals and other non-
pruriceptive sensations are reduced, could be responsible for increased pruriception in 
chronic conditions. 
1.3 Central itch pathways 
Sensory neurons that respond to pruritogens in the skin release neurotransmitters and 
neuropeptides at their central terminals in lamina I and II of the dorsal horn of the spinal 
cord or the corresponding area of the trigeminal nucleus. The signal then passes through a 
series of interneurons in the spinal cord to projection neurons that transmit the signal to 
higher centres. Unlike nociceptive signalling in which there may be direct input of primary 
afferent fibres to projection neurons in the dorsal horn, pruriceptive signals are passed 
through a series of interneurons before reaching the projection neurons, where the signals 
may be modulated, interacting with nociceptive signals where transmission of pruriceptive 
signals may be prevented, or become enhanced by loss of inhibitory inputs.  
 
The most generally accepted pathway of itch transmission (Figure 1.9) is that, following 
activation of pruriceptos, neurotransmitters such as glutamate and neuromodulators such 
as substance P, calcitonin gene related peptide (CGRP), and natriuretic polypeptide B (NPPB) 
are released from the terminals of primary sensory neurons in the spinal cord. These bind to 
their respective receptors on interneurons in lamina I and II of the dorsal horn of the spinal 
cord, which release gastrin releasing peptide (GRP) from their terminals. GRP then binds to 
its receptor found on another group of interneurons in the spinal cord, and these neurons 
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are proposed to signal to projection neurons in lamina I responsible for transmitting the itch 
signal to higher areas in the CNS (Bautista et al., 2014; Braz et al., 2014b; Green and Dong, 
2016; LaMotte et al., 2014). A separate population of neuromedin B (NMB)-expressing 
neurons are proposed to signal to GRP receptor-expressing interneurons (Wan et al., 2017; 
Zhao et al., 2014). Itch signals may be inhibited by inhibitory interneurons that release 
gamma-aminobutyric acid (GABA), glycine, somatostatin, and/or dynorphin (Akiyama et al., 
2011; Braz et al., 2014b; Huang et al., 2018; Ross, 2011). These interneurons are proposed 
to be activated by noxious stimuli or other sensory modalities and may serve to inhibit 
transmission of itch signals, for example, as a result of scratching the affected area.  
 
 
Figure 1.9: Overview of itch circuitry in the dorsal horn 
Neuropeptides such as NPPB and NMB released from the terminals of pruriceptors bind to 
receptors expressed on interneurons in the dorsal horn, which in turn signal to NK1-
expressing projection neurons in lamina I. Inhibitory circuits originating from nociceptors 
prevent transmission of itch signals in the spinal cord. 
 
A population of interneurons in the dorsal horn that express the basic helix loop helix b5 
(Bhlhb5) are known to be belong to the itch circuitry. Transgenic mice lacking expression of 
Bhlhb5 display a loss of these neurons and development of spontaneous scratching 
behaviour and skin lesions. Compared with wild-type littermates, scratching behaviour in 
these transgenic mice is increased following intradermal injection of the mast cell 
degranulator compound 48/80 (Ross et al., 2010). Bhlhb5-expressing interneurons include a 
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population of excitatory glutamatergic neurons as well as inhibitory populations, known as 
B5-I neurons, expressing GABA, glycine, and dynorphin (Kardon et al., 2014; Ross et al., 
2010; Sardella et al., 2011). To investigate whether loss of excitatory or inhibitory 
interneurons was responsible for increased scratching behaviour in mice, Bhlhb5 KO mice 
were crossed with Tlx3-cre mice, thereby abolishing the development of excitatory Bhlhb5 
interneurons. Loss of Bhlhb5 inhibitory interneurons, but not excitatory interneurons 
expressing glutamate, increased compound 48/80-induced pruritus (Ross et al., 2010). This 
suggests a role for B5-I neurons in modulating scratching behaviour in acute and chronic 
itch. The roles of some of these neurotransmitters and neuropeptides in itch circuitry in the 
spinal cord is described in more detail below and in Table 1.3. 
 
Transmission of the signals continues via projection neurons, which decussate the spinal 
cord and continue along the contralateral spinothalamic tract to the thalamus and 
parabrachial nucleus (Dong and Dong, 2018). Many of these projection neurons express the 
neurokinin-1 receptor (NK1R) (Carstens et al., 2010) and tracing experiments have shown 
that some of them do project to the brain (Akiyama et al., 2015). It has been observed that 
ascending spinothalamic tract neurons that respond to pruritogens such as histamine or 
cowhage also respond to noxious stimuli such as capsaicin, suggesting these two sensations 
share some common pathways to the brain (Davidson et al., 2007; Davidson et al., 2009; 
Davidson et al., 2012). Furthermore, different types of itch appear to be mostly mediated by 
different populations of spinothalamic tract neurons (Davidson et al., 2007; Davidson et al., 
2012). Spinothalamic tract neurons terminate in the ventrobasal and posterior thalamus 
(Akiyama et al., 2015; Davidson et al., 2007; Davidson et al., 2009; Davidson et al., 2012; 
Moser and Giesler, 2014). Recent studies in anesthetised rats have found a population of 
neurons in the thalamus, extending from the posterior triangular nucleus to the ventral 
posterior medial nucleus, that respond to intradermal injection of pruritogens including 
histamine, chloroquine, serotonin, and beta-alanine (Lipshetz et al., 2018). About half of the 
neurons in the thalamus were found to have mechanically defined receptive fields that 









Table 1.3: Summary of neurotransmitters and neuropeptides in spinal cord itch circuitry 
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From the thalamus, transmission of the itch signal is relayed to various other areas of the 
brain. Several imaging studies in healthy volunteers experiencing a pruritic stimulus have 
revealed activation of the primary somatosensory cortex corresponding to the location of 
the itch (Darsow et al., 2000; Drzezga et al., 2001; Herde et al., 2007; Ishiuji et al., 2009; 
Papoiu et al., 2012; Schneider et al., 2008). Some studies have reported activation of 
secondary somatosensory cortex following an itch stimulus (Herde et al., 2007; Mochizuki et 
al., 2009; Papoiu et al., 2012), while others failed to detect activation of this area (Drzezga et 
al., 2001; Mochizuki et al., 2003), although differences in dosing and administration of 
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pruritogens as well as differences in imaging techniques could explain this discrepancy. 
Other areas of the brain that undergo changes during itch include areas involved with 
emotional processing and reward, such as the cingulate and prefrontal cortex, amygdala, 
and limbic systems, the insular cortex, which is involved in evaluation and self-awareness, 
and areas such as the motor, premotor, and supplementary motor cortex, which are 
involved in initiation of scratching behaviour (Darsow et al., 2000; Drzezga et al., 2001; 
Ishiuji et al., 2009; Leknes et al., 2007; Mochizuki et al., 2003; Mochizuki et al., 2009; Papoiu 
et al., 2012; Schneider et al., 2008; Valet et al., 2008). Different types of itch also appear to 
activate different regions of the brain. Compared with histamine-induced itch, itch induced 
by cowhage results in greater activation of the insular cortex, claustrum, and basal ganglia 
(Papoiu et al., 2012). Differences in regions of brain activity have also been observed in 
atopic itch compared with histamine-induced itch (Ishiuji et al., 2009; Leknes et al., 2007; 
Schneider et al., 2008). 
 
1.3.1 Glutamate and itch 
Glutamate is a neurotransmitter that is found in high concentration in the axons of neurons, 
where it is locally synthesised and packaged into vesicular glutamate transporters (VGLUTs) 
(Featherstone, 2010). VGLUT2 in particular is involved in transmission of itch and pain 
signals (Aresh et al., 2017; Lagerstrom et al., 2010; Liu et al., 2010; Scherrer et al., 2010). 
Different receptors for glutamate exist, which can be classified as fast-acting ionotropic ion 
channel receptors or G protein-coupled metabotropic receptors that are proposed to be 
involved in longer-term modulation of transmission of signals (Featherstone, 2010). The 
main ionotropic glutamate receptors are AMPA, NMDA, and kainate receptors. Both 
ionotropic and metabotropic types of receptors are located both on primary afferent 
neurons (Willcockson and Valtschanoff, 2008) and both pre- and post-synaptically in the 
dorsal horn of the spinal cord (Bardoni, 2013; Yung, 1998). The GluR2/4 subunits of the 
AMPA receptor and several kainate receptor subunits are pre-synaptically expressed on the 
terminals of GABAergic interneurons in the dorsal horn, where they are thought to be 
involved in the modulation of nociceptive signals, potentially by increasing the release of 
GABA from these interneurons thereby reducing transmission of nociceptive signals (Lu et 
al., 2005). 
 
Histaminergic itch is mediated by glutamate, since firing of dorsal horn neurons in response 
to microinjection of histamine into the hindpaw is reduced when spinal cord sections are 
superfused with the AMPA/kainate receptor antagonist, CNQX, and scratching behaviour in 
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mice following intradermal injection of histamine in the skin is abolished when histamine 
was administered five minutes after injection of CNQX via lumbar puncture (Akiyama et al., 
2014). Furthermore, around 80% of DRG cells that show calcium fluxes in response to 
histamine are positive for the VGLUT2 marker for glutamatergic neurons. Chloroquine-
mediated scratching behaviour may also be mediated by glutamate, as chloroquine-
mediated itch following intradermal injection of the pruritogen is partially reduced by CNQX 
injected into the cerebrospinal fluid, although antagonists of other receptors such as the 
NK1 and gastrin releasing peptide receptors are additionally required for complete 
inhibition of chloroquine-mediated itch (Akiyama et al., 2014). 
 
As well as mediating pruriceptive signals, VGLUT2-expressing neurons have also been found 
to be involved in mediating nociceptive information. In conditional KO mice lacking 
expression of VGLUT2 in nearly all C fibres (peptidergic and non-peptidergic) and most Aδ 
fibres, decreased firing of neurons in lamina I of the spinal cord to noxious mechanical and 
thermal stimuli was observed in compared with neurons from WT mice, suggesting noxious 
input to superficial dorsal horn lamina I neurons depends on glutamate release from 
VGLUT2-expressing nociceptors (Scherrer et al., 2010). These transgenic mice also displayed 
decreased nocifensive behaviour in response to noxious heat and injection of capsaicin, 
displaying longer response latencies, as well as increased mechanical pain threshold as 
measured using von Frey filaments (Scherrer et al., 2010). Furthermore, specific ablation of 
VGLUT2 in Nav1.8-expressing (Liu et al., 2010) or TRPV1-expressing (Lagerstrom et al., 2010) 
nociceptors results in reduced responsiveness to nociceptive stimuli but increased 
spontaneous scratching behaviours, suggesting these VGLUT2 nociceptors are also involved 
in the regulation of itch responses in the opposite direction to the regulation of nociception. 
A pathway is proposed in which activation of nociceptors, for example as a result of 
scratching, results in the release of glutamate from the central terminals of VGLU2-
expressing nociceptors, which in turn excites interneurons in the spinal cord that inhibit 
signalling along the itch pathway. Thus, when glutamate transmission is prevented in 
nociceptors, this inhibitory input to pruriceptive signalling is removed, causing activity of 
this pathway even in the presence of nociceptive stimuli that would otherwise normally 






1.3.2 Neuropeptides in itch 
 
Gastrin releasing peptide 
GRP is a 27-amino acid peptide that, although considered a gastrointestinal peptide, is also 
found in neuronal tissues (Weber, 2015). It is the mammalian homologue of the amphibian 
peptide bombesin, with similarities to other so-called gastrointestinal peptides including 
neuromedin B. The receptor for GRP, the gastrin releasing peptide receptor (GRPR) 
(sometimes known as BB2) is a GPCR expressed in many tissues including the the spinal cord 
and all brain regions, with highest expression reported in the hippocampus, hypothalamus, 
amygdala, and pons (Jensen et al., 2008). Activation of this receptor results in activation of 
PLC and the breakdown of phosphoinositides to generate DAG, resulting in the mobilisation 
of calcium and activation of PKC (Jensen et al., 2008). Serum GRP is correlated with disease 
severity in patients with atopic dermatitis, while an increase in GRP-expressing nerve fibres 
is reported in primates with chronic itch, suggesting a role for this neuropeptide in itch 
(Kagami et al., 2013; Nattkemper et al., 2013; Tirado-Sanchez et al., 2015). Using antibody 
staining, Kagami et al. also reported an increase in the number of GRP-positive fibres in the 
skin of patients with atopic dermatitis. Moreover, GRP peptide and mRNA is reported to be 
increased in DRG neurons a mouse model of dry skin itch (Barry et al., 2016). Intrathecal 
injection of GRP in rats, mice, and primates results in scratching behaviour, suggesting GRP 
acts centrally to mediate itch signals (Lee and Ko, 2015; Su and Ko, 2011; Sukhtankar and Ko, 
2013). 
 
GRP is reported to be expressed in approximately 8% of cells in the DRG which are likely to 
be neurons as expression of GRP peptide has been reported to co-localise with the neuronal 
marker NeuN in mouse DRG (Barry et al., 2016; Kiguchi et al., 2016). These neurons are 
proposed to belong to a subset of nociceptors since co-localisation with TRPV1 and 
neuropeptides including CGRP and substance P is reported (Barry et al., 2016; Sun and Chen, 
2007). These neurons are also believed to be pruriceptors, since isolated GRP-expressing 
neurons in show calcium responses following application of pruritogens. Akiyama et al. 
(2013) found that 20-40% of DRG cells that exhibited calcium fluxes in response to 
pruritogens including histamine, chloroquine, and SLIGRL stained positively for GRP peptide. 
Expression of GRP peptide has also been reported in the dorsal horn, where it overlaps with 




Howver, conflicting evidence exists as to whether GRP is expressed in the central terminals 
of primary afferent neurons or in interneurons in the dorsal horn. Barry et al. (2016) could 
not find evidence of GRP-expressing cells in dissociated dorsal horn neurons but did find a 
reduction in GRP-expressing fibres in the dorsal horn following dorsal root rhizotomy. Sun 
and Chen (2006) did not find GRP mRNA in the dorsal horn and also found a significant 
reduction in GRP peptide in the dorsal horn following dorsal rhizotomy, suggesting GRP 
synthesised by the DRG was unable to be transported to the central terminals of primary 
afferents following rhizotomy. These studies suggest GRP is mostly synthesised by primary 
sensory neurons where it is subsequently transported to their terminals in the dorsal horn. 
In contrast, other studies have found that GRP peptide in the dorsal horn is mostly restricted 
to cell bodies and is likely to be synthesised locally. Indeed, while dorsal root transection 
results in a small reduction in the amount of GRP immunoreactivity in the dorsal horn, likely 
due to a reduction in the transport of GRP from a few cell bodies in the DRG to the dorsal 
horn, overall most of the GRP immunoreactivity remains as before rhizotomy, suggesting 
that a significant amount of GRP is synthesised and expressed locally by cells in the dorsal 
horn, allowing for most of the immunoreactivity to be retained. In contrast, compared with 
GRP, immunoreactivity of CGRP is more greatly reduced following dorsal root transection, as 
transport of CGRP from the DRG cell bodies to the terminals in the dorsal horn is impeded 
(Fleming et al., 2012).  
 
Studies have also found expression of GRP mRNA in mouse spinal cord using in-situ 
hybridisation (Wang et al., 2013). The number of cells expressing GRP mRNA decreased 
more than 76% in conditional KO mice with selective deletion of testicular orphan nuclear 
receptor 4 in the CNS by crossing with Nestin-Cre mice, resulting in a reduction in the 
number of excitatory interneurons in the dorsal horn and a reduction in pain behaviours to 
the hotplate, von Frey test of mechanical pain, and capsaicin-induced licking and flinching 
behaviours. Scratching behaviours following intradermal injection of histamine, chloroquine, 
and serotonin are also reduced in these mice, supporting a role for GRP in pruritus (Wang et 
al., 2013).  
 
GRP-expressing cells in the dorsal horn are mainly located in lamina II, with a small 
population found in lamina I, where they likely comprise interneurons rather than 
projection neurons. Transgenic mice in which GRP-expressing neurons were labelled with 
enhanced green fluorescent protein (EGFP) did not show co-localisation of GRP with the 
vesicular GABA transporter VGAT or Pax2, markers for inhibitory interneurons; however, 
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colocalisation with the vesicular glutamate transporter 2 (VGLUT2) was observed, 
suggesting many of the cells are excitatory neurons (Gutierrez-Mecinas et al., 2014). EGFP-
positive cells were mostly restricted to lamina I and II of the dorsal horn, and fewer cells in 
deeper layers. Additionally, using retrograde tracers injected into the lateral parabrachial 
nucleus, Solorzano et al. (2015) were unable to observe double labelling of GRP with the 
tracer, in the spinal cord, suggesting these cells are likely to be interneurons rather than 
projection neurons.  
 
Bell et al., (2016) observed that only 3-7% of GRP-expressing cells in the spinal cord were 
positive for Fos or phospho-ERK following injection of chloroquine in mice, while the 
majority of activated neurons in the dorsal horn did not express GRP, suggesting GRP is not 
critical for chloroquine-mediated itch, although it may be required for other types of itch. 
However, chloroquine-mediated scratching behaviour is found to be reduced following 
systemic or intrathecal administration of a GRP receptor antagonist (Akiyama et al., 2013). 
Furthermore, Wan et al. (2017) and Zhao et al. (2014c) found that scratching behaviour was 
reduced in GRP KO mice when injected with chloroquine, SLIGRL-NH2, or BAM8-22. In 
contrast, no difference in scratching behaviour was observed following injection of 
compound 48/80 or histamine in GRP KO mice compared with wild-type mice. This suggests 
that GRP is not involved in histaminergic itch. However, both Sun and Chen (2007) and Zhao 
et al. (2014c) reported a small decrease in itch mediated by compound 48/80 in their GRPR 
KO mice, suggesting the GRP receptor may play a role in itch mediated by histamine 
released from mast cells. Sun et al. (2017) also reported a decrease in histamine and 
chloroquine-mediated scratching behaviours in mice following ablation of GRP-expressing 
neurons. Thus, the precise contribution of GRP signalling to histaminergic and non-
histaminergic itch remains unclear, though it appears to at least contribute to transmission 
both types of itch signal.  
 
GRP may also be involved in transmission of pain signals. Wan et al. (2017) reported that 
GRP KO mice had normal sensitivity to noxious mechanical, thermal, and chemical stimuli, 
suggesting GRP is not required for pain responses. In contrast, Sun et al. (2017) found that 
ablation of more than 95% of GRP-expressing neurons in transgenic mice expressing 
diphtheria toxin receptors in GRP-expressing neurons resulted in increased wiping 
behaviour following injection of capsaicin into the cheek and increased licking and flinching 
was noted following intraplantar injection of capsaicin into the hindpaw, while responses to 
tail immersion in hot water, hot plate, and Hargreaves were also increased. However, these 
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mice did not show increased sensitivity to von Frey, suggesting no change in mechanical 
sensitivity and that loss of GRP-expressing neurons enhances chemical and thermal pain 
only. This difference in response to noxious stimuli may be due to the different approaches 
used in these two studies (transgenic mice lacking expression of GRP versus ablation of GRP-
expressing neurons), which may have off-target effects and differing degrees of 
compensation as a result of loss of GRP activity. Sun et al. (2017) also reported that GRP-
expressing neurons received input from primary sensory neurons conveying both itch and 
pain information, with pruritogens and algogens capable of triggering action potentials in 
GRP-expressing neurons. Moreover, coding of pain by GRP-expressing neurons was 
intensity-dependent, with weak and strong activation of GRP-expressing neurons producing 
little nocifensive behaviour, and medium activation of GRP-expressing neurons producing 
greatest nocifensive behaviour. This intensity-dependence of activation of GRP-expressing 
neurons could explain why some studies have reported that GRP signalling is not involved in 
nociception, while other studies report a role for GRP in transmitting pain information. 
However, while the role of GRP in pain responses is unclear, expression of GRP in DRG 
neurons likely increases following injury. Peripheral nerve injury was reported to increase 
expression of GRP mRNA in DRGs by about 20-fold, while no change in GRP expression in 
the dorsal horn was observed (Solorzano et al., 2015). A quarter of these DRG neurons that 
expressed GRP following injury were positive for TRPV1, while a quarter were positive for 
the NF-200 marker of myelinated axons, suggesting that GRP is not restricted to pruriceptive 
or small diameter nociceptive neurons, and may have additional roles in the transmission of 
pruritic or nociceptive signals in chronic states following injury by upregulation or de novo 
expression in larger diameter cells. 
 
Concerns about the GRP antibody have been raised, casting doubt on the interpretations of 
earlier studies investigating the expression and function of GRP signalling in neurons. Some 
studies use a GRP antibody raised against bombesin, which has a high affinity for the GRP 
receptor as well as the neuromedin B receptor (Jensen et al., 2008), and GRP antibodies may 
be able to cross react with neuromedin B and substance P (Goswami et al., 2014). Thus, 
studies examining the staining of GRP protein could potentially be looking at expression of 
neuropeptides other than GRP. Some studies have reported cross-reaction of GRP 
antibodies with other peptides (Gutierrez-Mecinas et al., 2014), while others have not found 
any cross-reactivity (Fleming et al., 2012). However, Solorzano et al. (2015) reported that 
the GRP antibody when used at low dilutions was non-specific, staining many DRG cells and 
terminals in the spinal cord in tissue sections from GRP KO mice. Staining of DRG cells and 
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terminals from GRP KO mice was prevented only when the antibody was used at 1:4000 
dilution. However, at this dilution, cells in the DRG from WT mice did not stain for GRP, and 
only a few GRP-positive cells were observed in the dorsal horn. Rather than binding to GRP, 
it was reported that the GRP antibody could cross-react with substance P when used at 
higher concentrations, which could explain the presence of GRP-positive cells in DRG tissues 
and in the terminals of the dorsal horn reported in other studies using antibody staining. 
The GRP staining protocol has also been found to affect the outcome of GRP staining. Barry 
et al. (2016) reported that tissue sections mounted on slides prior to antibody staining 
resulted in a widespread staining pattern for GRP, while staining of free-floating sections 
resulted in a more specific pattern of staining with fewer numbers of cells stained. Such 
differences in staining protocol may also explain why some groups have reported expression 
of GRP in a substantial percentage of DRG cells, while other groups report only occasional 
numbers of GRP-positive cells in the DRG. Of the few cells that do appear to be positive for 
GRP, co-localisation with CGRP is reported, suggesting these cells belong to a subset of 
peptidergic sensory neurons (Fleming et al., 2012). 
 
Expression of GRP mRNA has sometimes been reported in the DRG and spinal cord, 
although at very low levels. Using qPCR, expression of GRP mRNA has been reported to be 
very low in the mouse DRG (Fleming et al., 2012; Liu et al., 2014b; Mishra and Hoon, 2013; 
Solorzano et al., 2015), and Barry et al. (2016) reported that at least 32 cycles were required 
before GRP mRNA could be detected in the DRG using this technique. Using RNA-seq, Barry 
et al. (2016) detected low expression of GRP in murine DRGs, while Goswami et al. (2014) 
were unable to detect GRP in the DRG or TG in mouse, rat, or human, although expression 
of GRP in the spinal cord of all three species was confirmed. Solorzano et al. (2015) and 
Fleming et al. (2012) did not report expression of GRP mRNA in the DRG using in-situ 
hybridisation, while Barry et al. (2016) and Liu et al. (2014b) were able to successfully stain 
for GRP mRNA in DRG tissue sections. However, Barry et al. (2016) also found that GRP 
mRNA could be detected in DRG tissue sections only after several hours of incubation in 
substrate, likely reflecting the low copy number of GRP in these cells. This could also explain 
why some groups have been unable to find expression of GRP mRNA in the DRG using in-situ 
hybridisation. The low expression of GRP mRNA in the DRG makes it difficult to detect 
expression of this neuropeptide using certain methods, while more sensitive methods, such 
as qPCR, have been more successful in detecting the presence of GRP mRNA in tissues. 
However, expression of GRP mRNA can be increased under certain conditions. For instance, 
in a dry skin model of itch, Barry et al. (2016) detected an 8-fold increase in GRP mRNA in 
59 
 
the DRG using qPCR. GRP mRNA as well as peptide has been detected in spinal cord dorsal 
horn tissues, with expression being greater than that observed in DRG tissues (Fleming et 
al., 2012; Goswami et al., 2014; Mishra and Hoon, 2013; Zhao et al., 2013). As more GRP 
mRNA is detected in the spinal cord than in the DRGs, GRP mRNA is likely to be synthesised 
locally by cells in the dorsal horn rather than synthesised in the DRG cell body and 
transported to terminals the dorsal horn. This is also reflected in the difference in 
expression of GRP peptide in these tissues (Fleming et al., 2012; Solorzano et al., 2015).  
 
The receptor for GRP, GRPR, is expressed in the outer laminae of spinal cord dorsal horn 
tissues (Aresh et al., 2017; Fleming et al., 2012; Nattkemper et al., 2013; Sun and Chen, 
2007; Zhao et al., 2013; Zhao et al., 2014c). These GRPR-expressing neurons in the dorsal 
horn are likely to be excitatory interneurons, as they express VGLUT2 (Aresh et al., 2017; 
Zhao et al., 2014c). Expression of GRPR mRNA and protein is increased in a mouse model of 
chronic itch in which a constitutively active form of the serine/threonine kinase, BRAF, is 
expressed in Nav1.8 neurons, suggesting a role for GRP-GRPR signalling in chronic itch 
conditions (Zhao et al., 2013). In these transgenic mice, constitutively active BRAF in Nav 1.8 
neurons enhanced signalling of the RAF/MEK/ERK cascade, as demonstrated by an increase 
in the phosphorylation of MEK and ERK in the DRGs, particularly in TRPV1-positive DRG 
neurons. Expression of BRAF and activation of the RAF/MEK/ERK signalling cascade is 
presumed to be involved in the development and projection of normal neuronal circuitry, as 
aberrant expansion of CGRP-expressing fibres deeper into the dorsal horn into lamina IIi and 
invasion of IB4-positive fibres into the outer parts of lamina II and lamina I is observed in 
these mice. Conversely, axon outgrowth is reduced in neurons from BRAF-deficient mice 
(Zhong et al., 2007). However, only pruritus appears to be affected in mice expressing 
constitutively active BRAF, as responses to noxious stimuli and motor behaviours are normal 
in these mice and comparable to those of WT littermates (Zhao et al., 2013). Furthermore, 
scratching behaviour following injection of pruritogens including compound 48/80, SLIGRL-
NH2, and chloroquine is significantly reduced in mice lacking the GRP receptor compared 
with wild-type littermates (Sun and Chen, 2007).  
 
Neuromedin B 
Like GRP, neuromedin B (NMB) is a bombesin-like peptide associated with itch. NMB 
injected intrathecally in rats or mice results in scratching behaviour, suggesting NMB has a 
role in transmission of itch signals in the CNS (Su and Ko, 2011; Sukhtankar and Ko, 2013). 
Wan et al. (2017) reported that, compared with wild-type mice, scratching behaviour was 
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reduced in NMB KO mice following injection of histamine, serotonin, chloroquine, SLIGRL-
NH2, or BAM8-22, suggesting NMB is involved in both histaminergic and non-histaminergic 
itch. Although mice lacking the NMB receptor do not display reduced scratching behaviour 
in response to injection of pruritogens, double KO mice lacking both NMB and GRP 
receptors show significant reduction of scratching behaviours to injection of histaminergic 
pruritogens that is not observed when only one of the receptors is missing (Zhao et al., 
2014c). This suggests the NMB receptor acts synergistically with the GRP receptor to 
mediate transmission of histaminergic itch, and that some compensation may occur when 
signalling via one of the receptors is prevented. In support of this, GRP has been found to 
weakly activate the NMB receptor, and may account for the scratching behaviour observed 
in mice that lack functional NMB receptors (Zhao et al., 2014c). NMB is not required for pain 
behaviours, since NMB KO mice displayed normal sensitivity to noxious mechanical and 
thermal stimuli. However, injection of NMB has been reported to induce oedema and 
thermal and mechanical hypersensitivity, suggesting a role for NMB in nociception (Mishra 
et al., 2012). 
 
Expression of NMB in DRG tissues has been reported using RNA-seq, qPCR, and in-situ 
hybridisation, where it is reported to be expressed in 50% of DRG neurons (Barry et al., 
2016; Fleming et al., 2012; Goswami et al., 2014; Mishra et al., 2012; Zhao et al., 2014c). 
Most NMB-expressing neurons are small diameter, unmyelinated or thinly myelinated 
neurons of both peptidergic and non-peptidergic subsets (Fleming et al., 2012; Zhao et al., 
2014c). These neurons are likely to be pruriceptive neurons, as many NMB-expressing 
neurons co-express TRPV1 and MrgprA3 (Fleming et al., 2012; Mishra et al., 2012). Co-
expression of NMB and GRP has also been reported (Zhao et al., 2014c). The NMB receptor 
is expressed in cells in the dorsal horn of the spinal cord (Goswami et al., 2014; Zhao et al., 
2014c). Most NMBR-positive cells are located in lamina I and II of the superficial dorsal horn, 
with a few cells found in the deeper layers (Zhao et al., 2014c). NMBR-positive cells do not 
express NK1 receptor, suggesting thee cells are not projection neurons and are likely to be 
excitatory interneurons that form part of the spinal cord itch circuitry. Only 10% of NMBR-
expressing neurons also expressed GRPR, suggesting NMBR and GRPR cells likely comprise 
distinct cell populations. Moreover, patch clamping experiments in spinal cord slice 
preparations have revealed that GRPR-expressing neurons in the spinal cord receive 
excitatory input from NMBR-expressing cells (Wan et al., 2017). Thus, although likely 
comprising distinct cell populations transmitting itch information from primary afferents, 
NMB and GRP signalling is also interconnected, with NMBR neurons relaying itch 
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information to GRPR neurons, and could help to explain the significant reduction in 
scratching behaviour in response to injection of histaminergic pruritogens that is observed 
only in mice that are lacking both receptors (Zhao et al., 2014c). 
 
Natriuretic polypeptide B 
The natriuretic peptides A, B, and C are a family of structurally related peptides containing 
the conserved sequence CFGXXXDRIXXXXGLGC, where X is any amino acid (Potter et al., 
2006). Expression of natriuretic peptides was first described in heart tissues, but they have 
since been found to be expressed in other tissues, including the brain and sensory ganglia, 
where they have tissue-specific functions. They are synthesised in a pro-form that is 
subsequently proteolytically cleaved by corin and furin to form the mature peptides (Hall, 
2004; Potter et al., 2006). Three receptors are known to exist for the natriuretic peptides. 
Natriuretic peptide receptor A (NPRA) is the receptor for both NPPA and NPPB, while 
natriuretic peptide receptor B (NPRB) is the receptor for NPPC (Potter et al., 2006). Both 
NPRA and NPRB are guanylyl cyclase linked receptors that results in the production of cyclic 
GMP when activated. The third receptor, natriuretic peptide receptor C (NPRC), in contrast, 
does not have guanylyl cyclase activity, and it thought to be involved in the clearance of 
natriuretic peptides through receptor-mediated internalisation and degradation (Potter et 
al., 2006). 
 
Expression of NPPB is increased 3.5-fold in the sensory ganglia of a mouse model of atopic 
dermatitis (Meng et al., 2018). NPPB evokes scratching behaviour when injected into mice, 
which is reduced following ablation of NPPB-expressing cells or in the presence of 
antagonists to the NPPB or GRP receptors (Kiguchi et al., 2016; Mishra and Hoon, 2013). 
NPPB is also required for itch mediated by other pruritogens, since scratching behaviour 
following injection of histamine is reduced following ablation of neurons expressing the 
NPPB receptor via intrathecal injection of NPPB-saporin (resulting in death of NPRA-
expressing cells) and scratching behaviour in response to injection of pruritogens including 
histamine, serotonin, chloroquine, and SLIGRL-NH2 is reduced in NPPB KO mice compared 
with wild-type littermates (Mishra and Hoon, 2013). NPPB-induced scratching behaviour is 
also reduced in the presence of a GRP antagonist or following ablation of GRPR-expressing 
neurons by injection of GRP-saporin, suggesting NPPB is required for GRP-mediated 
scratching behaviours (Mishra and Hoon, 2013). NPPB is also likely to be required for IL-31-
induced itch, since release of NPPB peptides from cultured mouse DRG cells is reported 
following stimulation with IL-31 (Pitake et al., 2018). In contrast, NPPB is not required for 
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responses to thermal and mechanical stimuli, as these responses were unaltered in NPPB 
KO mice, and nocifensive behaviours in inflammatory conditions are not affected in NPPB 
KO mice (Mishra and Hoon, 2013; Pitake et al., 2017), although Liu et al. (2014b) reported 
that in mice pain responses following intraplantar injection of capsaicin and the phase II 
response of formalin-evoked nocifensive behaviour were reduced when NPPB was 
administered intrathecally. Moreover, NPPB has been found to have reduced formalin-
induced flinching behaviour in rats (Zhang et al., 2010). This suggests NPPB signally may 
additionally have a role in inhibition of nocifensive behaviours. 
 
Expression of NPPB mRNA in cells of the DRG has been detected using in-situ hybridisation 
and qPCR (Li et al., 2016c; Mishra and Hoon, 2013; Pitake et al., 2017; Pitake et al., 2018; 
Solorzano et al., 2015). RNA-seq revealed that NPPB is highly expressed in mouse DRG, but 
to a lesser extent in rat and human sensory ganglia, suggesting species variation may exist in 
the expression of neuropeptides in these tissues (Goswami et al., 2014). Expression of NPPB 
was found to occur in a subset of neurons expressing TRPV1, suggesting these cells comprise 
a subset of nociceptors (Mishra and Hoon, 2013). All cells that were positive for NPPB mRNA 
were also positive for MrgprA, and MgrprC11, receptors for pruritogens such as 
chloroquine, and BAM8-22 and SLIGRL-NH2, respectively (Mishra and Hoon, 2013). In 
contrast to NPPB mRNA, NPPB protein has been reported to be expressed in non-neuronal 
cells in mouse DRG and TG, using several different NPPB antibodies (Liu et al., 2014b; Vilotti 
et al., 2013). However, none of these studies verified the specificity of their antibodies in 
NPPB KO mice or by co-staining for NPPB mRNA. Furthermore, Zhang et al. (2010) and Li et 
al. (2016) both reported the presence of NPPB protein in small neurons in the rat DRG using 
antibody staining. NPPB was expressed in CGRP-positive and some IB4-positive cells, and 
expression in the DRG was increased following intraplantar injection of Complete Freund's 
Adjuvant and two days after injection of BmK I, a sodium channel modulator from the 
venom of Chinese scorpion (Li et al., 2016c; Zhang et al., 2010). Expression of NPPB peptide 
has also been reported in murine DRG cells in at least one study, where it co-localises with 
the neuronal marker NeuN (Kiguchi et al., 2016).  As well as being expressed in the DRG, 
NPPB peptide is reported to be expressed in the outer laminae of the dorsal horn of the 
spinal cord, where it overlaps with CGRP-expressing fibres (Abdelalim et al., 2016; Kiguchi et 
al., 2016). Some NPPB-expressing cells are also found in the ventral horn of the spinal cord 
in rat, in what appear to be motor spinal neurons expressing choline acetyltransferase 




Expression of the NPPB receptor natriuretic peptide receptor A (NPRA) has been reported in 
the dorsal horn of the spinal cord and overlaps with expression of cells positive for CGRP 
and GRP, suggesting GRP acts downstream of NPPB (Goswami et al., 2014; Kiguchi et al., 
2016; Mishra and Hoon, 2013; Pitake et al., 2017; Zhang et al., 2010). Liu et al. (2014b) also 
observed expression of NPRA in the dorsal horn, although the staining patterns were 
different depending on the antibody used, sometimes appearing to stain individual cells 
throughout the entire dorsal horn and other times staining fibres restricted to the outer 
laminae, casting doubt on the actual distribution of NPRA-expressing cells and fibres in the 
spinal cord. Furthermore, NRPA-positive cells have also been reported in the DRG (Goswami 
et al., 2014; Li et al., 2016c; Liu et al., 2014b; Zhang et al., 2010).  
 
Activation of primary sensory neurons by pruritogens is proposed to result in release of 
NPPB from the terminals of these neurons in the spinal cord dorsal horn. The released NPPB 
then binds to its receptor, NPRA, located on the dendrites of interneurons located mostly in 
lamina II of the dorsal horn. These interneurons, in turn, release GRP from their terminals, 
which binds to its receptor on additional interneurons or on projection neurons that 
transmit the itch signal to higher centres in the CNS. However, whether NPPB is upstream of 
GRP signalling in itch is disputed. Liu et al. (2014b) and Kiguchi et al. (2016) found that 
injection of NPPB did result in scratching behaviour in mice, but with a different timecourse 
to that observed following injection of GRP. Injection of GRP caused robust scratching 
behaviour shortly after injection, returning to baseline 40 minutes after injection. In 
contrast, injection of NPPB elicited very mild scratching behaviour that gradually increased 
over time, peaking at 40-50 minutes after injection. Furthermore, in contrast to Mishra and 
Hoon, 2013, scratching behaviour in response to injection of NPPB was not abolished in the 
presence of a GRP blocker (Liu et al., 2014b). Scratching responses were also unaffected in 
GRP KO mice and in GRPR KO mice (Liu et al., 2014b). If GRP signalling is downstream of 
NPPB, then it would be expected that preventing signalling of GRP would at least reduce 
scratching behaviour following injection of NPPB. One possible explanation for this is that 
some signalling of GRP occurs downstream of NPPB, but some signalling of GRP and NPPB 
also occurs independently of each other, and compensatory mechanisms may exist such 
that blocking of one pathway results in enhanced activity of another pathway, preserving 
transmission of the itch signal and the subsequent scratching behaviour. However, this does 
not explain the differences in scratching behaviour following injection of NPPB in the 




1.3.3 Central sensitisation of itch 
In addition to being involved in peripheral sensitisation, NGF may also play a role in central 
sensitisation of pruriceptors via upregulation of neuropeptides such as CGRP and substance 
P, resulting in their increased release from the central terminals of primary afferents in the 
spinal cord dorsal horn in response to pruritogens from the periphery (Verge et al., 1995). 
NGF may similarly increase expression of itch-related neuropeptides, such as NPPB and GRP. 
Increased release of neurotransmitters such as glutamate may further contribute to 
sensitisation via phosphorylation of the GluN2B subunit on post-synaptic NDMA receptors, 
resulting in enhanced activity of neurons in the dorsal horn circuitry (Inoue et al., 2016). 
Activation of glial cells and the subsequent release of inflammatory mediators such as TNF 
and IL-1β in the spinal cord is known to be involved in central sensitisation in chronic pain, 
and may similarly do so for chronic itch (Ji, 2015). However, as for several of the proposed 
mechanisms of peripheral sensitisation in itch, the factors that determine sensitisation of 
itch signals over pain signals in the spinal cord remain to be further investigated. 
1.4 Pathology of itch and the role of Cathepsin S in chronic itch 
Although acute itch is a beneficial sensation, chronic itch is a detrimental condition that 
severely negatively impacts the quality of life of the sufferer (Erturk et al., 2012; Kini et al., 
2011; Yosipovitch et al., 2000; Yosipovitch et al., 2001; Yosipovitch et al., 2002). Disorders of 
itch are classified into four different categories (Twycross et al., 2003): 
• Pruritoceptive itch – Itch that originates in the skin, usually as a result of 
inflammation or damage to the skin. This type of itch is also a feature of conditions 
such as atopic dermatitis and psoriasis. Some forms of urticaria are also examples of 
pruritoceptive itch due to the release of histamine from cells in the skin. 
• Neurogenic itch – Itch that originates in the CNS but without evidence of neuronal 
pathology. This type of itch is typically observed in liver disease with cholestasis and 
chronic kidney failure. 
• Neuropathic itch – Itch due to disease or lesions of the afferent fibres, for example, 
as observed in postherpetic neuralgia, notalgia paraesthetica, and multiple sclerosis. 




Atopic dermatitis is described as an inflammatory skin condition that usually develops 
during early childhood and is believed to affect up to 20% of the population (Bieber, 2010; 
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Leung and Soter, 2001). Pruritus is characteristic of atopic dermatitis and is used as a 
diagnostic criterion for this condition (Hong et al., 2011). Other features of atopic dermatitis 
include increased serum IgE and infiltration of mast cells and basophils (Ito et al., 2011; 
Leung and Soter, 2001; Sugiura et al., 1992) into the skin. Infiltration of T-cells, particularly 
of the Th2 phenotype, is also observed in the skin during the acute phase atopic dermatitis 
(Mudde et al., 1992; Werfel, 2009), although these appear to be replaced by Th1 cells that 
release interferon-γ (IFNγ) during the chronic phase of the disease (Grewe et al., 1998).  
 
Increased infiltration of immune cells in this condition likely results in heightened 
inflammation in the skin and an increase in the release of mediators that could serve as 
pruritogens by acting directly on sensory neurons. For example, IL-31, a cytokine released by 
Th2 cells, causes scratching behaviour when injected into mice and was recently 
demonstrated to directly activate pruriceptors (Pitake et al., 2018). Alternatively, cytokines 
released from these cells may cause the release of pruritogens from other cells in the skin, 
such as keratinocytes. Increased inflammation is likely to be the cause of itch in atopic 
dermatitis, via the release of histamine and other pruritogens from mast cells and 
keratinocytes, rather than being a symptom of itch (Costa et al., 2008; Malaviya et al., 1996; 
Shimizu et al., 2015; Terakawa et al., 2008). However, the excessive scratching that 
accompanies chronic itch is likely to exacerbate inflammation, resulting in an itch-scratch 
cycle whereby scratching damages the skin and further worsens inflammation, resulting in 
the release of more pruritogens and continuation of the cycle.  
 
As well as in increase in potential sources of pruritogens, the density of sensory nerve 
endings is increased in the skin of patients with atopic dermatitis, where they are more 
likely to come into contact with pruritogens (Horiuchi et al., 2005; Takano et al., 2005; Tobin 
et al., 1992). Sprouting of nerve fibres is likely to be due to NGF, which has been reported to 
be increased in atopic dermatitis conditions and correlates with disease severity (Horiuchi et 
al., 2005; Takano et al., 2005; Toyoda et al., 2002; Yamaguchi et al., 2009). NGF does not 
appear to sensitise neurons to histamine, suggesting the enhanced pruritus characteristic of 
atopic dermatitis is not caused by sensitisation of neurons to this pruritogen (Rukwied et al., 
2013). However, NGF was found to sensitise neurons to other pruritogens, such as cowhage, 
providing a mechanism by which enhanced itch sensations could occur. Increased 
expression of receptors on sensory neurons, such as the receptor for cowhage, as well as 




Another interesting feature of this condition is that punctate application of pruritogens into 
lesioned skin results in much stronger pruritus than is reported by healthy controls 
(Andersen et al., 2017; Ikoma et al., 2003), and stimuli that would normally be felt as pain in 
healthy volunteers are felt as itch when applied to the lesioned skin of patients with atopic 
dermatitis, which is suggestive of sensitisation (Hosogi et al., 2006; Ikoma et al., 2004). 
Although histamine may play a role in scratching in atopic dermatitis, antihistamines have 
been shown to be ineffective in treating itch in this condition, suggesting other pruritogens 
are likely to be involved (Klein and Clark, 1999; Rukwied et al., 2000; Wahlgren et al., 1990; 
Yarbrough et al., 2013). Furthermore, in the lesioned skin of patients with atopic dermatitis, 
sensitisation to pruritogens is greater for non-histaminergic pruritogens such as cowhage 
than to histamine, further supporting a role for non-histaminergic pruritogens in this 
condition (Andersen et al., 2017).  
 
Changes in the skin are also observed in patients with atopic dermatitis. In addition to the 
development of skin lesions, dry skin with increased transepidermal water loss is reported in 
this condition, suggestive of dysfunction of the epidermal barrier (Bieber, 2010; Leung and 
Soter, 2001). This dysfunction may be the result of loss of structural proteins in 
keratinocytes which contribute to barrier function. For instance, expression of filaggrin, 
loricrin, and involucrin proteins is reported to be reduced in the skin in atopic dermatitis and 
mutations in the filaggrin gene are often reported in patients with atopic dermatitis (Howell 
et al., 2007; Kim et al. 2008; Palmer et al., 2006). Increased skin pH is also found in atopic 
dermatitis, where it may contribute to barrier dysfunction by altering lipid organisation and 
metabolism and contribute to growth of bacteria in the skin (Rippke et al., 2004). This loss of 
integrity of the epidermal barrier and subsequent increase in bacterial colonisation of the 
skin may be responsible for the increased infiltration of immune cells into the skin of atopic 
dermatitis patients and the subsequent release of pruritogens, although at least some cases 
of atopic dermatitis are proposed to result from IgE-mediated autoimmunity (Bieber, 2010). 
 
Oral administration of the μ-opioid receptor antagonist naltrexone has been found to be 
effective in reducing pruritus in atopic dermatitis, although topical administration of opioid 
antagonists does not relieve pruritus, suggesting centrally acting opioids can inhibit 
transmission of itch signals in this condition while pruritus in atopic dermatitis is unlikely to 
be mediated by peripheral opioid receptors (Herzog et al., 2011; Heyer et al., 2002; 
Malekzad et al., 2009). Nevertheless, expression of the μ-opioid receptor has been 
confirmed on sensory nerve fibres in the epidermis and dermis, and expression of both μ 
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and κ opioid receptors has been reported in skin keratinocytes, with greater expression of κ 
opioid receptors in the skin of patients with atopic dermatitis compared with healthy 
controls (Stander et al., 2002; Tominaga et al., 2007). Furthermore, in addition to improving 
skin symptoms in patients with atopic dermatitis, psoralen-ultraviolet A treatment also 
decreased expression of μ-opioid receptor in the skin (Tominaga et al., 2007). This suggests 
peripheral opioidergic activity may be responsible for some of the symptoms of atopic 
dermatitis, although not necessarily pruritus. Nevertheless, an indirect role of opioids acting 
on receptors on keratinocytes and sensory nerve endings in the skin may contribute to 
pruritus in this condition. 
 
Cathepsin S 
Cathepsin S (CatS) is a lysosomal protease that belongs to the cysteine family of proteases, 
and closely resembles Cathepsins K and L (Kirschke and Wiederanders, 1994; McGrath, 
1999). The proteolytic functions of CatS have been well documented. CatS is expressed in 
the lysosomes of professional bone marrow-derived antigen presenting cells such as 
macrophages, microglia, B lymphocytes, and dendritic cells, as well as non-professional 
antigen presenting cells such as epithelial cells, where it is involved in major 
histocompatibility complex (MHC) class Ii-mediated antigen presentation by degradation of 
the invariant chain Ii and peptide loading (Bender et al., 2015; Chapmanm, 2006; Chapman 
et al., 1997; Clark et al., 2007; Clark et al., 2010; Hsing and Rudensky, 2005; Liuzzo et al., 
1999; Petanceska et al., 1996; Shi et al., 1992; van Kasteren and Overkleeft, 2014). CatS can 
also cleave laminin, fibronectin, collagens I and IV, and chondroitin sulfate and heparan 
sulfate proteoglycans at both acidic and neutral pH, supporting a role for this protease in 
the degradation of extracellular matrix tissue remodelling following injury (Liuzzo et al., 
1999; Petanceska et al., 1996). Moreover, endothelial cells from CatS KO mice have reduced 
proteolytic activity and impaired invasion into Matrigel and collagen gel, while development 
of microvessels during wound repair is defective in these mice (Shi et al., 2003). The CatS 
inhibitory antibody Fsn0503 also impaired the ability of endothelial cells to degrade 
extracellular matrix and blocked the development of tumour blood vessels in mice that 
received transplants of the HCT116 human colon cancer cell line (Ward et al., 2010). These 
findings suggest a role for CatS released from endothelial cells in angiogenesis following 
injury and in tumourigenesis. 
 
Like the other cysteine proteases, CatS is synthesised as an inactive pre-pro-enzyme. Under 
reducing conditions and at acidic pH, inactive pre-pro-CatS synthesised in yeast and E. coli is 
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activated by self-cleavage, suggesting some CatS must exist in an active form (Bromme et 
al., 1993; Kopitar et al., 1996). CatS can also be activated following the addition of the non-
specific serine protease subtilisin (Bromme et al., 1993), but not the aspartic protease 
Cathepsin D (Kopitar et al., 1996). In contrast, pro-CatS can be degraded by Cathepsin L 
(Maubach et al., 1997). Thus, other proteases may modulate activation of CatS, although 
whether they do so under physiological conditions remains to be determined. Activation of 
pro-CatS is accelerated by negatively-charged molecules such as glycosaminoglycans, 
chondroitin sulfates, dermatan sulfate, and dextran sulfate. Furthermore, while auto-
activation of pro-CatS is greatest at acidic pH and decreases when the pH increases above 6, 
significant levels of auto-activation of pro-CatS can occur at neutral and mildly alkaline pH 
when in the presence of dextran sulfate (Vasiljeva et al., 2005). Auto-activation of CatS at 
neutral pH is affected by ionic strength, with increasing ionic strength resulting in a decrease 
in activation, suggesting negatively-charged glycosaminoglycans and polysaccharides 
interact with CatS via electrostatic interactions to accelerate auto-activation of this 
protease. The presence of a large number of positively-charged residues on pro-CatS 
supports this notion. The synthesis of lysosomal cathepsins as inactive zymogens that 
require activation serves two purposes. First, the N-terminal of the pro-peptide is required 
for correct folding of the peptide targeting to the lysosomal compartment (Turk et al., 
2012). Second, production of cysteine proteases in an inactive pre-form, as well as peak 
activation at acidic pH, serves to protect in the event of accidental release or mistargeted 
release of proteases. However, because CatS can activate itself and has proteolytic activity 
at neutral pH, its release into the cytosol or extracellularly could potentially result in 
unwanted cleavage of proteins and tissue damage by the degradation of healthy tissues. 
Moreover, CatS can activate other cathepsins, such as Cathepsin C (Dahl et al., 2001). 
However, CatS is also regulated by the endogenous protein inhibitor, cystatin C, which 
reversibly binds to CatS and has been shown to regulate activity of CatS during maturation 
of dendritic cells (Bromme et al., 1991; Pierre and Mellman, 1998).  
 
Cathepsin S in itch conditions 
In addition to its proposed role in antigen presentation and degradation of extracellular 
matrix, CatS in the skin has been demonstrated to be involved in itch. Transgenic mice over-
expressing CatS have increased expression of CatS in the skin and demonstrate spontaneous 
scratching behaviours, resulting in the formation of lesions, infiltration of mast cells, and 
thickening of the skin (Kim et al., 2012). CatS released from skin cells may be responsible for 
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pruritus by cleaving receptors on primary sensory neuron endings, or may result in pruritus 
via indirect mechanisms such as causing release of pruritogens from other cell types. 
 
In a mouse model of atopic dermatitis in which transgenic mice over-expressed CatS, mRNA 
and protein expression of Th2 cytokines, including IL-4 and IL-10 was increased in the skin 
(Kim et al., 2012). Interestingly, however, compared with expression of Th2 cytokines, 
expression of Th1 cytokines, such as IL-2, IFNγ, and TNFα was even greater in transgenic 
mice compared with wild-type mice. This could reflect the development of chronic lesions in 
these mice, which were 16 weeks old at the time of the experiments, rather than the acute 
lesions associated with Th2 cytokines. However, because no time course was performed 
comparing the age of the mice, the development of lesions, and the cytokine profile, it is not 
possible to confirm whether younger mice with acute lesions would have had a dominant 
Th2 phenotype, or whether older mice with more advanced lesions would have had a 
complete Th1 phenotype. In a canine model of acute atopic dermatitis, gene expression of 
CatS, along with Th2 cytokines, was upregulated over 48 hours, supporting a role for CatS in 
the acute stage of this disease (Olivry et al., 2016).  
 
CatS is also associated with itch conditions other than atopic dermatitis. Expression of CatS 
protein is increased in the lesions of patients with seborrhoeic dermatitis compared with 
healthy subjects (Viode et al., 2014). Moreover, Ainscough et al., (2017) and Schonefuss et 
al., (2010) both reported that CatS protein was upregulated in keratinocytes from patients 
with psoriasis. Furthermore, in HaCaT cultures, expression and release of CatS protein can 
be increased following incubation with Th1 cytokines, such as IFNγ and TNFα, while IFNγ 
upregulates expression of CatS in primary keratinocytes, further supporting a role for CatS in 
psoriasis (Ainscough et al., 2017; Schonefuss et al., 2010; Schwarz et al., 2002). In addition, a 
mechanism by which CatS activates IL-36γ to mediate inflammation in psoriasis has been 
proposed (Ainscough et al., 2017). IL-36γ is expressed in psoriatic lesions and serum levels 
are correlated with disease severity (D'Erme et al., 2015). However, IL-36γ is expressed as an 
inactive precursor that must be cleaved in order to be active (Towne et al., 2011). CatS 
released from keratinocytes and fibroblasts or applied exogenously cleaves IL-36γ at S18, 
resulting in secretion of IL-8 from keratinocytes (Ainscough et al., 2017). It is therefore likely 
that CatS is involved in both Th1 and Th2-mediated chronic itch conditions. 
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1.5 Animal models of itch 
In order to study the mechanisms of itch, animal models are frequently employed. Mouse 
models in particular are often used due to the ease of handling and genetic manipulation, 
although rats, guinea pigs, dogs, and primates are also used. However, because pruritic 
stimuli elicit two responses – acknowledgement of the sensation and site directed 
scratching toward the stimulus site, the use of animal models to study itch is limited in that 
we can only measure scratching behaviour in animals (LaMotte et al., 2011). In contrast, 
studies in human volunteers typically use verbal reports acknowledging the onset, duration, 
and intensity of itch, and volunteers may be asked not to scratch. Scratching results in the 
generation of pain signals which can affect transmission of itch signals, potentially inhibiting 
it in the case of acute itch or exacerbating it in chronic and inflammatory itch, thereby 
affecting the duration and severity of itch that is being measured. However, animals are 
allowed to scratch in most models of itch, although their nails may be clipped to reduce skin 
damage and nociceptive effects. Elizabethan collars may be used to prevent scratching 
behaviour altogether, ensuring only pruriception and not nociception is being investigated, 
although this prevents the experimenter from determining the pruritic effects of the 
stimulus. Thus, when using animal models, there is a compromise between determining 
pruritinogicity of stimuli and examining pruritus without influence of nociception caused by 
scratching behaviour. Whether or not the animal is allowed to scratch is thus determined by 
the questions that are being addressed by the study. 
 
Models of chronic itch 
Because itch, like pain, exists in both acute and chronic forms, models for both acute and 
chronic itch have been developed. Animal models of chronic itch are usually based on 
clinical observations of diseases in which pruritus is a defining feature of the condition. 
Spontaneous scratching behaviour, often accompanied by the development of lesions on 
the skin, is characteristic of these models. Several animal models of chronic itch conditions 
exist, the most common being those that resemble atopic dermatitis, contact dermatitis, 
and psoriasis. There are also mouse models in which chronic itch develops due to defects in 
the central itch circuitry, which are thought to be applicable to most, if not all, cases of itch, 
rather than specific chronic itch conditions. 
 
The NC/Nga inbred mouse strain is a spontaneous model of atopic dermatitis first described 
by Matsuda et al. (1997). When housed in conventional (non-sterile) conditions, these mice 
develop atopic dermatitis-like conditions, including chronic scratching behaviour, the 
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development of skin lesions, increased plasma IgE, infiltration of mast cells and eosinophils, 
thickening of the epidermis, and impaired skin barrier function (Aioi et al., 2001; Matsuda et 
al., 1997; Matsumoto et al., 1999). In contrast, NC/Nga mice kept in specific pathogen-free 
conditions do not develop these symptoms. Immunohistochemical analysis of the skin of 
these mice demonstrated the production of Th2 cytokines such as IL-4 and IL-5 from T cells 
and mast cells infiltrating the skin (Matsuda et al., 1997), a feature which is characteristic in 
the acute lesions of patients with atopic dermatitis and is thought to contribute to the 
pathogenesis of this disease by increasing production of IgE from B cells (Mudde et al., 1992; 
Werfel, 2009). Indeed, NC/Nga mice have a mutation resulting in constitutively active JAK3 
on B cells, resulting in greater activity of these cells in response to IL-4 released from T cells, 
mast cells, and basophils (Matsumoto et al., 1999). Interestingly, constitutive activity of 
JAK3 is also observed from B cells from patients with atopic dermatitis, suggesting this 
mouse model mimics the disease in humans (Matsumoto et al., 1999). However, in signal 
transducer and activator of transcription 6 (STAT6)-deficient NC/Nga mice in which IL-4-
mediated immune responses and production of IgE are prevented, atopic dermatitis-like 
conditions occur at a similar frequency, age of onset, and severity as reported in normal 
NC/Nga littermates (Yagi et al., 2002). This suggests that IL-4-mediated production of IgE via 
the STAT6 transcription factor is not required for the development of atopic dermatitis-like 
symptoms in these mice and that they are a symptom of disease progression, although 
whether this is also the case in humans with atopic dermatitis remains to be investigated. 
Nevertheless, STAT6 polymorphisms have been found to be associated with risk of 
developing atopic dermatitis, and synthetic double-stranded oligodeoxynucleotides which 
inhibit binding of STAT6 to its promoter regions have been demonstrated to improve 
pruritus and inflammation in patients with atopic dermatitis (Casaca et al., 2013; Igawa et 
al., 2009; Lee et al., 2015). Thus, IL-4-mediated production of IgE via STAT6 may be one of 
several means by which symptoms of atopic dermatitis develop, although other pathways 
may exist that can function independently of STAT6. 
 
Other models of atopic dermatitis involve genetic manipulation of mediators known or 
proposed to be involved in this disease. For example, to investigate the involvement of CatS 
in atopic dermatitis, Kim et al. (2012) developed a transgenic mouse line in which CatS was 
over-expressed, and found that these mice displayed scratching behaviour and developed 
skin lesions, infiltration of mast cells into the skin, serum IgE levels, and increased 
proliferation of keratinocytes. However, the source of CatS responsible for these symptoms 
and whether CatS acts as a pruritogen or an inflammatory mediator was not addressed in 
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this study. Mice over-expressing Th-2 cytokines such as IL-4, IL-13, or IL-31 also develop 
atopic dermatitis-like symptoms, further supporting the role of these cytokines in the 
disease (Chan et al., 2001; Dillon et al., 2004; Zheng et al., 2009). However, the observation 
that increased expression of any one of these cytokines can result in atopic dermatitis-like 
symptoms suggests individual mediators can elicit these symptoms, although it is likely that 
clinically these mediators act together to result in the observed symptoms. Indeed, each 
mediator might contribute to different symptoms of the disease and work with other 
mediators to give the full range of symptoms. In support of this, transgenic mice over-
expressing IL-4 or IL-13 in the skin have increased IgE serum, as is often reported in patients 
with atopic dermatitis; however, transgenic mice over-expressing IL-31 do not have 
increased serum IgE, suggesting this cytokine mediates other symptoms of the disease 
(Dillon et al., 2004). Another cytokine that is proposed to be involved in atopic dermatitis is 
TSLP, which is expressed in and released from keratinocytes (Wilson et al., 2013). Over-
expression of this cytokine in the skin of mice also results in atopic dermatitis-like 
symptoms, supporting the role of TSLP in this disease (Yoo et al., 2005). However, when 
these mice were crossed with mice that lacked T cells, atopic dermatitis-like symptoms, 
including epidermal thickening and infiltration of mast cells and eosinophils into the skin, 
were still observed in these mice, although IgE levels were not increased compared with 
TSLP over-expressing mice that had T cells. This suggests T cells are not required for the 
development of skin inflammation in atopic dermatitis, although they do play a role in the 
production of IgE. Moreover, this supports the notion that increased IgE may be a symptom 
of atopic dermatitis but is not required for development or progression of the disease. 
 
Some transgenic mouse lines also show spontaneous, chronic scratching behaviour without 
being linked to any specific disease. In these mice, signalling of itch is disrupted due to 
alterations in the activity of primary afferent neurons or neurons in the spinal cord circuitry. 
They are therefore applicable to itch in general and are useful for delineating itch 
transmission in the spinal cord. Such models include expression of constitutively active BRAF 
in sensory neurons, knocking out expression of VGLUT2 in Nav1.8-positive sensory neurons 
or TRPV1-positive neurons, and knocking out expression of the Bhlhb5 transcription factor 
in interneurons in the spinal cord (Lagerstrom et al., 2010; Liu et al., 2010; Ross et al., 2010; 
Zhao et al., 2013).  
 
Not all animal models of chronic itch involve specific strains of mice that display 
spontaneous development of the disease or transgenic mice. Several models of atopic 
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dermatitis have been established in wild-type mice following repeated application of 
sensitisers including ovalbumin, house dust mite allergens, acetone/diethyl ether mixture, 
and haptens (Huang et al., 2003; Man et al., 2008; Miyamoto et al., 2002; Spergel et al., 
1998), although it could be argued these more closely resemble contact dermatitis rather 
than atopic dermatitis. Nevertheless, these models are useful for studying many features of 
chronic itch associated with skin inflammation, without the need for acquiring specific 
breeds of mice. Moreover, these models can be applied to different areas of the animal, 
including the cheek, back of the neck, or hindpaw, and have additionally been performed in 
rats and dogs (Andoh et al., 2018; Olivry et al., 2016; Schuttenhelm et al., 2015; Valtcheva et 
al., 2015b). Similarly, psoriasis-like dermatitis can be induced in mice following daily topical 
application of the TLR7/8 ligand and immune activator, imiquimod, resulting in the 
development of psoriatic plaques and increased expression of IL-17 and IL-23 (van der Fits et 
al., 2009). 
 
Transplantation models have been established to study chronic itch conditions. These 
models have been particularly well established for psoriasis, but not for other chronic itch 
conditions as of yet. In these models, donor skin from patients with psoriasis is transplanted 
onto immunodeficient mouse strains such as nude, SCID, or AGR129 mice to prevent 
rejection of the grafts (Boyman et al., 2004; Krueger et al., 1981; Villadsen et al., 2003). 
Importantly, transplantation from non-lesional and lesional skin can be used to study the 
development of psoriasis and established psoriasis, respectively. Although technically 
challenging to perform and requiring large amounts of donor tissue for the grafts, this 
model is believed to most closely resemble the disease, demonstrating the requirement of T 
cells and TNFα for the development of psoriasis in recipient mice and has been useful in 
validating drug targets, such as vitamin D and cyclosporin A (Boyman et al., 2004; Dam et al., 
1999). 
 
A table summarising different models of chronic itch is provided below. Each model has its 
own merits and limitations, which will affect the choice of model used. For instance, some 
models may mimic a disease state better than others but may also be more difficult to 
obtain or generate. The choice of model will also depend on whether a specific disease or 
more general features of pruritus are being investigated. Another important factor to 
consider is how accurately the model reflects the clinical observations. For instance, the IL-
31 KO mouse, although displaying many symptoms of atopic dermatitis, does not have 
increased serum IgE, which is a feature of atopic dermatitis (Dillon et al., 2004). However, it  
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Table 1.4: Summary of animal models of chronic itch 
Model Disease Reference 
NC/Nga strain Atopic dermatitis Matsuda et al., 1997 
DS-Nh strain Atopic dermatitis Hikita et al., 2002 
Cathepsin S over-expression Atopic dermatitis Kim et al., 2012 
IL-4 over-expression Atopic dermatitis Chan et al., 2001 
IL-13 over-expression Atopic dermatitis Zheng et al., 2009 
IL-18 over-expression Atopic dermatitis Konishi et al., 2002 
IL-31 over-expression Atopic dermatitis Dillon et al., 2004 
TSLP over-expression Atopic dermatitis Yoo et al., 2005 
Caspase over-expression Atopic dermatitis Konishi et al., 2002 
TRPV3 over-expression Atopic dermatitis Yoshioka et al., 2009 
STAT3 over-expression Psoriasis Sano et al., 2005 
TGFβ over-expression Psoriasis Li et al., 2004 
Β1-integrin expression in 
epidermal suprabasal layers 
Psoriasis Carroll et al., 1995 
Amphiregulin expression in 
epidermal basal layer 
Psoriasis Cook et al., 1997 
BRAF over-expression in 
sensory neurons 
General itch Zhao et al., 2013 
“Flaky tail” filaggrin knock-out Atopic dermatitis Oyoshi et al., 2009 
Cathepsin E knock-out Atopic dermatitis Tsukuba et al., 2003 
Serine palmitoyltransferase 
knock-out 
Psoriasis Nakajima et al., 2013 
Interleukin-1 receptor 
antagonist-deficient 
Psoriasis Shepherd et al., 2004 
VGLUT2 knock-out in sensory 
neurons 
General itch 
Lagerstrom et al., 2010; Liu 
et al., 2010 
Bhlhb5 knock-out General itch Ross et al., 2010 
Ovalbumin-induced Atopic/Contact dermatitis Spergel et al., 1998 
House dust mite-induced Atopic/Contact dermatitis Huang et al., 2003 
Acetone/diethyl ether 
mixture-induced 
Atopic/Contact dermatitis Miyamoto et al., 2002 
Hapten-induced Atopic/Contact dermatitis Man et al., 2008 
Trimellitic anhydride-induced Urticaria/Contact dermatitis Lauerma et al., 1997 
Imiquimod-induced Psoriasis van der Fits et al., 2009 
Delivery of VEGF to skin Psoriasis Xia et al., 2003 
Xenotransplantation Psoriasis 
Boyman et al., 2004;  Krueger 




has also been reported that not all patients with atopic dermatitis have elevated IgE (Novak 
and Bieber, 2003). Thus, whether this model really reflects atopic dermatitis, or whether IL-
31 is involved in other symptoms of the disease and this model is therefore more akin to 
atopic dermatitis as observed in a subset of patients, requires further investigation. 
 
Models of acute itch 
Models of acute itch tend to investigate the short-term effects of specific pruritogens or 
neurotransmitters of the itch pathway. Acute itch is typically induced following single 
injection of a pruritogen into the animal, and site-directed behaviour is measured usually as 
the amount of time spent scratching or the number of scratching bouts. Scratching 
behaviour is typically observed following intradermal or subcutaneous injection of 
pruritogens into the nape of the neck or the cheek, although site-directed biting and licking 
of the calf or hindpaw is observed following injection of pruritogens into these sites (Hoeck 
et al., 2016; LaMotte et al., 2011). Pruritogens may also be injected intrathecally to 
investigate the role of spinal neurotransmitters and neuropeptides in itch signalling (Hoeck 
et al., 2016). 
 
For a long time, the Kuraishi model of subcutaneous injection of substances into the nape of 
the neck and observation of site-directed scratching behaviour as an indication of acute 
pruritus was used (Kuraishi et al., 1995). Both the number of scratching bouts and the total 
time spent scratching can be recorded, with stronger pruritogens resulting in increased 
scratching behaviour. However, injection of algogens such as capsaicin in this way also 
results in scratching behaviour, presumably as scratching is the only site-directed behaviour 
available at this site regardless of whether the stimulus is a pruritogen or algogen (Shimada 
and LaMotte, 2008). 
 
The gold standard for measuring acute pruritus in mice is currently the “cheek model” 
developed by Shimada and LaMotte (2008), in which substances are injected intradermal 
into the cheek and two site-directed behaviours are observed – if the substance is a 
pruritogen, scratching with the hindpaw is observed, while wiping with the forepaw occurs if 
the substance is an algogen. Importantly, many substances act as both pruritogens and 
algogens and cause both scratching and wiping behaviours when injected into the cheek. 
Indeed, many TG neurons (the equivalent of DRG that innervates the cheek) that show 
calcium responses following application of pruritogens also respond to algogens (Akiyama et 
al., 2010b), although this may be due to the fact that pruriceptors comprise a subset of 
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nociceptors that also respond to algogens, and not necessarily be involved in the 
transmission of nociceptive signals or be felt as pain. Such differences in the activation of 
individual neurons in vitro and behavioural responses in vivo highlight the ongoing need for 
suitable animal models to study itch. The main drawback with the “cheek model” for 
investigating pruritus is that it is difficult to study the central effects of the pruritogen. 
Although the cheek is innervated by sensory neurons with cell bodies in sensory ganglia and 
central terminals in the spinal trigeminal nucleus, a structure in the medulla that is 
analogous to the dorsal horn where the terminals of sensory neurons innervating the skin in 
areas other than the face are located, the TG and nucleus have been less studied and are 
less well defined than their counterparts in the rest of the body. The spinal trigeminal 
nucleus is a continuation of the substantia gelatinosa and Lissauer tract of the spinal cord, 
and is rich in opioid receptors (Kam and Tan, 1996), although whether the itch circuitry in 
the spinal trigeminal nucleus is similar to that in the dorsal horn of the spinal cord has not 
yet been investigated. Furthermore, the sensory neurons innervating the skin of the cheek 
and face may be different to those innervating skin in other parts of the body. In healthy 
human volunteers, itch induced by histamine iontophoresis is stronger in the arm than in 
the face, while mechanically-evoked itch is observed in facial skin but not the arm when 
stimulated using a probe attached to a piezoelectric actuator (Fukuoka et al., 2013). This 
suggests there is less innervation of polymodal C fibre afferents in the skin of the cheek than 
in other body areas, while sensory neurons conveying mechanically-evoked itch signals may 
be more numerous in the face. Thus, this model of itch may not be completely 
representative of itch in other areas of the body, although it likely shares many similarities. 
 
Pruritogens may also be injected into the skin of the calf or hindpaw, where biting and 
licking behaviours are used as indications of itch and pain, respectively (LaMotte et al., 
2011). This allows for the effects of peripherally applied pruritogens to be investigated in 
the more familiar lumbar spinal cord. However, discrimination of biting and licking 
behaviours is difficult to perform, and in the case of injection into the hind limb, 
spontaneous behaviours are frequently reported. 
1.5.1 Cathepsin S-induced itch 
As well as belonging to the cysteine family of proteases, CatS also belongs to the papain 
superfamily of cysteine proteases (Turk et al., 2012). Papain is a plant cysteine protease 
found in papayas and was the first described protease of the superfamily which is called 
after it, although several papain-like proteases are now known to exist in many life forms 
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including protozoans, fungi, and animals (McGrath, 1999). Several members of the papain 
superfamily, including papain itself, elicit itch sensations in human volunteers when applied 
to the skin via a spicule (Arthur and Shelley, 1955). More recently it has been shown that 
these cysteine proteases activate protease activated receptors (PARs) expressed on HeLa 
cells and it has been proposed that activation of these receptors on sensory neurons is 
responsible for the initiation of itch signals (Reddy et al., 2008; Reddy and Lerner, 2010). 
Furthermore, application of CatS to the skin via spicules also results in itch sensations in 
humans, and HeLa cells expressing PARs 2 and 4 similarly respond to CatS (Reddy et al., 
2010). These observations support a role for CatS in pruritus by activation of PARs expressed 
on sensory neurons, although this had not been demonstrated when the work in this thesis 
was begun. 
 
To investigate whether CatS acts as a pruritogen in vivo and establish an animal model of 
CatS -induced acute itch, initial studies were conducted by our lab in which hr-CatS (Medivir, 
Sweden) was injected intradermal into the cheek of C57BL/6 mice as for Shimada and 
LaMotte (2008) and both wiping and scratching behaviours were observed. Injection of 4 
µg/10 µl hr-CatS resulted in only minimal scratching and wiping behaviours. In contrast, 
injection of 20 µg/10 µl hr-CatS caused substantial scratching behaviour which persisted for 
about 20 minutes and some wiping behaviour which occurred within the first few minutes 
after injection before rapidly decreasing (Figure 1.10). 
 








































Figure 1.10: Behaviour observed following injection of hr-CatS into the cheek 
Intradermal injection of 20 μg/10 μl hr-CatS into the cheek resulted in significant scratching 
behaviour and some wiping behaviour over a 20 minute observation period. Timecourse of 
scratching and wiping behaviours in 5 minute bins (A). Total time spent scratching and 




To investigate the roles of the TRP channels in CatS -induced scratching behaviour, hr-CatS 
was injected intradermal in transgenic mice lacking expression of TRP channels (Table 1.5). 
In TRPV1 KO mice, scratching behaviour was reduced, suggesting TRPV1 is required for CatS-
mediated scratching behaviour. A slight reduction in scratching behaviour was observed 
following injection of CatS in TRPA1 KO mice, although this was not significantly different 
compared with the amount of time wild-type mice spent scratching. In TRPV1/TRPA1 double 
KO mice, scratching behaviour following injection of CatS was reduced similar to that 
observed in TRPV1 KO mice. No reduction in scratching behaviour was observed in 
transgenic mice lacking expression of TRPV4. 
 
Injection of the PAR2 agonist SLIGRL-NH2 (50 µg/10 µl) also causes scratching behaviour in a 
dose-dependent manner. Importantly, scratching induced by both SLIGRL-NH2 and CatS can 
be inhibited with the PAR2 antagonist FSLLRY-NH2 (Pitcher et al., 2014). This suggests that 
CatS-induced scratching behaviour occurs via activation of PAR2. However, in contrast to 
CatS, SLIGRL-induced scratching behaviour was significantly reduced in TRPA1 KO mice, but 
not TRPV1 KO mice. In TRPV1/TRPA1 double KO mice, scratching behaviour was reduced as 
for TRPA1 KO mice. This suggests TRP channels contribute differently to itch elicited by 
different types of pruritogens, and also suggests CatS does not signal entirely via activation 
of PAR2. An alternative explanation is that activation of PAR2 by CatS is different to that by 
SLIGRL-NH2, resulting in activation of different TRP channels and their involvement in 
transmission of itch signals and scratching behaviour. Indeed, PAR2 can be cleaved at 
different sites by various agonists as well as being activated by short synthetic ligands such 
as SLIGRL-NH2 to result in activation of different downstream signalling pathways in a 
phenomenon known as biased agonism, which will be discussed in more detail later. 
 
Table 1.5: Cathepsin S-induced scratching behaviour in transgenic mice 
Data from Thomas Pitcher. NS = not significant. 
 
% Scratching Reduction 
hr-CatS SLIGRL-NH2 
TRPV1 KO 50% NS 
TRPA1 KO NS 80% 
TRPV1/TRPA1 KO 50% 80% 




These in vivo studies demonstrate that CatS is a pruritogen that causes scratching behaviour 
in mice, and also an algogen that causes some wiping behaviour. Scratching behaviour is 
mediated by the PAR2 receptor, as scratching is reduced following administration of a PAR2 
antagonist. CatS-induced scratching requires expression of functional TRPV1, while TRPA1 
appears to be dispensable, suggesting TRPV1, but not TRPA1, is required for CatS-mediated 
signalling of itch. Alternatively compensation may occur in TRPA1 KO mice such that 
signalling via other TRP channels, such as TRPV1, is sufficient to allow CatS -induced 
scratching behaviour to occur. The observation that scratching behaviour is not further 
reduced in TRPV1/TRPA1 double KO mice compared with TRPV1 KO mice also suggests that 
expression of TRPV1 is critical for CatS-induced scratching and that signalling via TRPA1, if it 
does occur, does not contribute additionally to this response. TRPV4 also is not required for 
CatS-induced scratching behaviour in these mice, as scratching behaviour is not reduced in 
TRPV4 KO animals. Although the expression of functional TRPV4 channels on sensory 
neurons in non-inflammatory pain has been questioned (Alexander et al., 2013), TRPV4-
expressing sensory neurons are known to mediate nociceptive responses to hypotonic 
stimuli as well as inflammatory hyperalgesia (White et al., 2016). TRPV4 may also be 
involved in itch in inflammatory conditions, although it does not appear to be necessary for 
CatS-induced acute itch. 
1.6 Protease activated receptors 
Several proteases have been implicated in pruritus, particularly non-histaminergic itch and 
chronic itch, most of which act via the protease-activated receptors (PARs) (Briot et al., 
2009; Reddy and Lerner, 2010; Reddy et al., 2008; Stefansson et al., 2008; Zhu et al., 2009; 
Zhu et al., 2015). In addition to their involvement in itch and inflammatory skin conditions, 
PARs have been reported to be involved in conditions including neurodegenerative diseases 
such as Alzheimer's disease and Parkinson's disease, respiratory diseases such as asthma, 
diseases of the gastrointestinal tract, and cancer (Amadesi and Bunnett, 2004; Ebrahimi et 
al., 2017; Kawabata and Kawao, 2005; Kularathna et al., 2014; Luo et al., 2007). Thus, PARs 
are involved in a range of physiological processes and diseases, which is made possible by 
the unique properties of these receptors. 
 
The PAR family consists of four members – PAR1, PAR2, PAR3, and PAR4 (Macfarlane et al., 
2001; Ossovskaya and Bunnett, 2004; Ramachandran and Hollenberg, 2008). There are two 
potential mechanisms by which PARs can be activated. The first and most physiologically 
relevant is following cleavage of the receptor extracellular domain by a protease, revealing a 
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tethered ligand at one end that then activates the receptor by binding on one of the 
extracellular loops (Macfarlane et al., 2001; Ossovskaya and Bunnett, 2004; Ramachandran 
and Hollenberg, 2008) (Figure 1.11). The second way PARs can be activated is by short 
synthetic peptide sequences that are derived from the sequences of the tethered ligand, 
such as the peptide SLIGRL-NH2 which is derived from the trypsin cleavage site of mouse 
PAR2 (Nystedt et al., 1994). The human equivalent of this peptide is SLIGKV. 
 
 
Figure 1.11: Mechanism of PAR activation (adapted from Ramachandran and Hollenberg, 
2008) 
PARs are activated when a protease cleaves the extracellular domain, revealing a tethered 
ligand. Synthetic ligands derived from the tethered ligand sequences (underlined in blue) can 
also activate the receptor. 
 
The PARs are seven-transmembrane-spanning receptors coupled to G proteins, at the third 
intracellular loop and carboxyl terminus (Covic et al., 2002; Ramachandran et al., 2012). 
Both PAR1 and PAR2 couple with Gαi, Gαq, and Gα12/13 proteins (Coughlin, 2005; 
Macfarlane et al., 2001; Ossovskaya and Bunnett, 2004; Russo et al., 2009; Steinhoff et al., 
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2005). PAR3 is not known to signal via G proteins. PAR4 receptors activate calcium signalling 
via Gq and G12/13 (Coughlin, 2005; Russo et al., 2009). In addition to G proteins, PARs are 
also coupled to β-arrestins, increasing the number of downstream signalling pathways 
following activation of PARs (Ramachandran et al., 2012). β-arrestin-1 and 2 are involved in 
desensitisation but not internalisation of PAR1, while β-arrestin-1 and 2 are required for 
both desensitisation and internalisation of PAR2 (Dery et al., 1999; Kumar et al., 2007; Paing 
et al., 2002; Stalheim et al., 2005). β-arrestins are also involved in PAR2 intracellular 
targeting of activated ERK1/2 and chemotaxis (DeFea et al., 2000; Ge et al., 2003; Ge et al., 
2003; Ge et al., 2004; Stalheim et al., 2005; Zoudilova et al., 2010). 
 
PARs are expressed on many cell types, which in part may explain their different effects. 
They were first discovered on platelets as receptors for thrombin where they result in 
platelet activation and aggregation (Zhao et al., 2014b). PAR1 and PAR2 are expressed on 
the endothelium of blood vessels, where their activation results in nitric oxide-mediated 
vasodilation (Hamilton et al., 1998; Kawabata et al., 2004; Roy et al., 1998). In contrast, in 
the absence of functional endothelium, activation of PAR1 and PAR2 on vascular smooth 
muscle results in vasoconstriction (Laniyonu and Hollenberg, 1995; Moffatt and Cocks, 
1998). PAR4 is not normally expressed in the vasculature in humans, but has been reported 
to be expressed during inflammation (Hamilton et al., 2001). PARs are also expressed on the 
epithelial and smooth muscle cells of the airways (Abey et al., 2006; Chambers et al., 2001; 
Kawabata and Kawao, 2005; Knight et al., 2001; Miotto et al., 2002). Activation of PARs in 
the epithelium results in the production of TSLP and development of Th2-type airway 
inflammation (Kouzaki et al., 2009). Expression of PARs on cells of the gastrointestinal 
system is thought to regulate neurotransmission, secretion, motility, mucosal permeability, 
and recruitment of immune cells (Amadesi and Bunnett, 2004). PARs are additionally 
expressed on primary sensory neurons and spinal cord, where they are proposed to be 
responsible for the sensations of itch and pain (Chen et al., 2015; Mrozkova et al., 2016a, b; 
Vellani et al., 2010; Zhu et al., 2005). 
 
Responses of protease-activated receptors 
PARs can be activated following cleavage by several proteases, resulting in different 
responses depending on the cell type and the receptor involved. For example, in platelets, 
activation of PAR1 and PAR4 by thrombin results in aggregation (Anderson et al., 1999; 
Hollenberg and Saifeddine, 2001; Hung et al., 1992). In human airway epithelial cells and 
astrocytoma cells, thrombin cleaves PAR3 to induce release of IL-8 (Ostrowska and Reiser, 
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2008). In vascular endothelial cells, trypsin is thought to cleave PAR2 resulting in 
hypotension (Cicala et al., 1999), while in a murine keratinocyte cell line trypsin cleaves 
PAR2 to cause inflammation and expression of chemokines (Meyer-Hoffert et al., 2004). In 
the pleural cavity of mice, trypsin cleaves PAR4 expressed on neutrophils and endothelial 
cells to mediate infiltration of neutrophils (Gomides et al., 2012). In human pulmonary 
epithelial cells, cleavage of PAR2 by neutrophil Cathepsin G (a serine protease) results in 
disarming of PAR2, such that the receptor can no longer be cleaved by trypsin (Dulon et al., 
2003). In contrast, cleavage of PAR4 by Cathepsin G results in activation and aggregation of 
platelets (Sambrano et al., 2000).  
 
Canonical signalling of protease-activated receptors 
Canonical signalling of the PARs involves cleavage of the N-terminus of the receptor at 
defined sites by proteases, revealing tethered ligands that bind to a region in the second 
extracellular loop of the cleaved receptor, resulting in activation of the receptor and 
initiation of downstream signals (Zhao et al., 2014b). In the case of PAR1, canonical 
signalling occurs following cleavage of PAR1 at position R41/S42 by thrombin to reveal the 
tethered ligand SFLLRN (Vu et al., 1991). This results in the activation of Gαq and Gα12/13 
proteins, allowing for increased mobilisation of calcium via PLC signalling, and changes in 
endothelial cell barrier permeability and cell shape via Rho signalling, respectively (Barr et 
al., 1997; McLaughlin et al., 2005; Ossovskaya and Bunnett, 2004). Once thrombin has 
cleaved PAR1, it may remain bound to the receptor, where it facilitates the formation of 
PAR1 and PAR4 heterodimers and cleavage of PAR4 (Arachiche et al., 2013; Leger et al., 
2006). The 41 amino acid peptide that is cleaved from the receptor, known as parstatin, has 
been reported to penetrate cells of the cardiovascular system and is an inhibitor of 
angiogenesis (Zania et al., 2009). Thus, canonical cleavage of PAR1 might result in numerous 
effects in addition to the effects mediated by activation of G proteins. 
 
Canonical signalling of PAR2 involves cleavage of the receptor by trypsin at position R36/S37 
(Figure 1.12 A), after which the ligand remains tethered to the receptor and interacts with 
the second extracellular loop of the receptor to exert its effects (Al-Ani and Hollenberg, 
2003; Al-Ani et al., 1999; Al-Ani et al., 2002b). A number of pathways are activated following 
canonical activation of PAR2 (Figure 1.12 B, C), including Gαq-mediated mobilisation of 
intracellular calcium via PLC and PIP2 signalling, Gαs-mediated elevation of cAMP, Gα12/13-
mediated activation of Rho, and recruitment of β-arrestins resulting in receptor endocytosis 
and activation of ERK 1/2 (Böhm et al., 1996a, b ; DeFea et al., 2000; Dery et al., 1999; Ricks 
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and Trejo, 2009; Scott et al., 2003; Stalheim et al., 2005; Zhao et al., 2014a). Other serine 
proteases, including tryptase, acrosin, and membrane-type serine protease 1 also cleave 
PAR2 at the canonical site, although the potencies and kinetics of cleavage vary compared 
with trypsin (Molino et al., 1997; Smith et al., 2000; Takeuchi et al., 2000). For instance, the 
reduced potency of tryptase for PAR2 is thought to be due to a second cleavage site for 
tryptase at R41/S42, which prevents cleavage of the receptor at the canonical R36/S37 site 
(Molino et al., 1997). Following canonical activation of PAR2, calcium signalling is terminated 
by PKC acting on calcium release activated channels, and the receptor is internalised and 
degraded by lysosomes (Böhm et al., 1996a). 
 
Thrombin may cleave PAR3 at K38/T39, resulting in hydrolysis of PIP2 and generation of 
calcium (Ishihara et al., 1997). However, other groups have failed to observe thrombin 
signalling of PAR3 (Nakanishi-Matsui et al., 2000). Rather than being directly involved in cell 
signalling, PAR3 is thought to be a co-factor for the activation of other PARs, such as PAR1 
and PAR4 (McLaughlin et al., 2007; Nakanishi-Matsui et al., 2000). 
 
PAR4 is cleaved by both thrombin and trypsin at position R47/G48, although the EC50 is much 
greater than for cleavage of PAR1 and PAR3 by thrombin (Xu et al., 1998). Cleavage of PAR4 
at the canonical site results in activation of Gαq and signalling via PLC, hydrolysis of PIP2, and 
increase in calcium (Bao et al., 2015; Xu et al., 1998). Following activation of PAR4, 
internalisation of the receptor occurs independently of β-arrestins and instead occurs via 
clathrin-mediated endocytosis (Smith et al., 2016). 
 
Biased agonism of protease-activated receptors 
In addition to the canonical signalling pathways, PARs can also be cleaved by proteases that 
act at sites other than the canonical sites cleaved by thrombin and trypsin. This 
phenomenon is known as biased agonism (or biased signalling) and has been proposed as a 
reason why cleavage of PARs can result in a variety of different responses. A consequence of 
biased agonism is that different agonists or ligands acting on the same receptor can elicit 
different effects that may be different to the canonical signalling pathways (Geppetti et al., 
2015; Urban et al., 2007).  
 
Several biased agonists have been identified for PAR1, which cleave the receptor at sites 
distinct from the canonical thrombin site. Activated protein C (APC) cleaves PAR1 both at 
the canonical R41/S42 site and a non-canonical R46/N47 site, resulting in activation of Rac1 
84 
 
mediated by β-arrestin, independent of G protein activity (Soh and Trejo, 2011). The 
neutrophil proteases elastase and proteinase-3 are also biased agonists of PAR1, cleaving at 
sites L45/R46 and A36/T37, respectively (Mihara et al., 2013). Rather than activation of Gαq and 
Gα12/13 as would be observed following canonical activation of PAR1, cleavage of PAR1 by 
neutrophil proteases results in Gαi-mediated activation of mitogen-activated protein kinase 
(MAPK) (Mihara et al., 2013).  
 
Similarly, proteases cleaving at the non-canonical site of PAR2 can activate different 
signalling pathways to that observed following canonical cleavage of PAR2 by trypsin. For 
instance, while cleavage of PAR2 by trypsin results in Gαs-mediated elevation of cAMP and 
increase in intracellular calcium (Böhm et al., 1996a, b; Scott et al., 2003; Zhao et al., 2014a), 
CatS, which cleaves PAR2 at E56/T57 (Figure 1.12 A), results in Gαs-mediated formation of 
cAMP but not Gαq-mediated mobilisation of intracellular calcium (Zhao et al., 2014a) (Figure 
1.12 C). Activation of PAR2 is reported to sensitize TRPV4, resulting in inflammation and 
hyperexcitability of nociceptors. However, the mechanism by which PAR2 sensitises 
neuronal TRPV4 depends on the protease used to cleave PAR2. In the case of trypsin, PKC, 
PKA, and tyrosine kinases are reported to result in sensitisation of TRPV4 (Grace et al., 2014; 
Grant et al., 2007; Poole et al., 2013), while CatS -mediated activation of PAR2 causes 
sensitisation of TRPV4 mainly via the adenylyl cyclase/cAMP/PKA pathway (Zhao et al., 
2014a). A further difference that occurs following canonical and non-canonical activation of 
PAR2 is that β-arrestins are recruited and PAR2 is endocytosed following cleavage with 
trypsin (DeFea et al., 2000; Dery et al., 1999; Ricks and Trejo, 2009; Zhao et al., 2014a), 
whereas no recruitment of β-arrestins is observed following cleavage of PAR2 with CatS and 
the receptor is not endocytosed, but instead remains on the surface of the cell (Zhao et al., 
2014a). However, despite the different cleavage sites by CatS and trypsin, injection of both 
of these proteases results in similar scratching behaviours in mice and itch sensations in 
humans (Costa et al., 2008; Pereira et al., 2011; Reddy et al., 2010; Thomsen et al., 2002). 
This suggests a convergence of signalling in the sensory neurons following activation of 
PAR2 by several proteases, or that cleavage of additional receptors by both proteases is 





Figure 1.12: Canonical and biased agonism of PAR2 by various proteases (adapted from 
Geppetti et al., 2015; Zhao et al., 2014a and Zhao et al., 2014b) 
The N-terminus of human PAR2 consists of 84 amino acids and can be cleaved by several 
proteases at the sites indicated (A). The green residues denote the canonical tethered ligand 
that is revealed following cleavage of the receptor by trypsin or tryptase; the blue residues 
show the tethered ligand revealed following cleavage by Cathepsin S. Canonical activation of 
PAR2 by trypsin (B) and non-canonical activation by CatS (C) result in activation of different 
downstream pathways and cell responses. 
 
Unlike the other PARs, PAR3 and PAR4 do not appear to undergo biased agonism. Apart 
from thrombin, the only other protease to show activity at PAR3 is APC, which requires the 
formation of heterodimers with PAR1 (in mice) or PAR2 (in humans) (Burnier and Mosnier, 
2013; Madhusudhan et al., 2012). APC cleaves PAR3 at the non-canonical R41/G42 site 
(Burnier and Mosnier, 2013). To date, no other proteases have been observed to cleave 
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PAR3. In addition to thrombin and trypsin, other proteases such as Cathepsin G and plasmin 
cleave PAR4 (Quinton et al., 2004; Sambrano et al., 2000). However, these appear to cleave 
PAR4 at the canonical site. Mannose-binding lectin-associated serine protease-1 has also 
been shown to cleave PAR4, but the exact cleavage site remains to be determined (Megyeri 
et al., 2009). 
 
Disarming of protease-activated receptors 
One of the consequences of biased agonism is that the canonical cleavage site for the PAR 
may be removed from the N-terminal if cleavage of the receptor occurs further from the N-
terminal than the canonical site (Ramachandran et al., 2012; Zhao et al., 2014b). Thus, the 
receptor can no longer be cleaved at the canonical site. In this sense, proteases that disarm 
PARs can also be thought of as antagonists to the canonical signalling pathway, even if they 
are agonists for other non-canonical signalling pathways (Ramachandran et al., 2012). 
Because CatS cleaves the N-terminal of PAR2 further from the N-terminal than the canonical 
site for trypsin (Figure 1.12), CatS can be considered to disarm the receptor for trypsin. In 
support of this, CatS has been reported to prevent trypsin-induced activation of PAR2. Zhao 
et al. (2014a) demonstrated that HEK cells pre-incubated with CatS showed reduced calcium 
activity in response to trypsin compared with cells that had been pre-incubated with vehicle, 
likely as a result of reduced trypsin-induced calcium signalling following disarming PAR2 by 
CatS. The neutrophil proteases Cathepsin G, which cleaves PAR2 at position P65/S66, elastase, 
which cleaves PAR2 at position S68/V69, and proteinase-3, which cleaves PAR2 at V62/D63, are 
also biased agonists of PAR2 that disarm the canonical cleavage site (Ramachandran et al., 
2011; Zhao et al., 2014b) (Figure 1.12 A). 
 
Post-translational modifications of protease-activated receptors 
The activity of PARs can be affected by post-translational modifications, such as 
phosphorylation, ubiquitination, and glycosylation (Grimsey et al., 2011). It has been 
observed that, following activation of PAR1 by thrombin, PAR1 is phosphorylated by G-
protein receptor kinases and subsequently inactivated (Ishii et al., 1994). Likewise, PAR2 is 
also phosphorylated following its activation. Phosphorylation of PAR2, resulting in 
uncoupling of the receptor with G-protein signalling, causes endocytosis of the receptor in a 
β-arrestin independent manner (Ricks and Trejo, 2009). Ubiquitination of PAR1 appears to 
prevent its internalisation (Paing et al., 2004; Wolfe et al., 2007), whereas it has been 
reported to be involved in internalisation and trafficking of PAR2 to the lysosome for 
degradation (Hasdemir et al., 2009; Jacob et al., 2005). Glycosylation is necessary for the 
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expression of PAR1 at the cell surface, and PAR1 mutants that are unable to be fully 
glycosylated show enhanced signalling compared with fully glycosylated PAR2, possibly as a 
result of conformational changes in the receptor (Soto and Trejo, 2010; Tordai et al., 1995). 
In contrast, glycosylation of PAR2 is not necessary for the expression of PAR2 at the cell 
surface, but does appear to be necessary for tryptase to activate the receptor (Compton et 
al., 2001; Compton, 2003). This suggests that glycosylation could play a role in protease 
specificity for PARs, adding to the signalling complexity of these receptors. 
 
Synthetic and endogenous ligands of protease-activated receptors 
In addition to proteases, the PARs can also be activated by short synthetic ligands 
(sometimes referred to as activating peptides) that correspond to the tethered ligands 
exposed following cleavage of the receptor by a protease, although these are unlikely to 
occur physiologically and are mostly of interest in experimental conditions (Ramachandran 
et al., 2012; Zhao et al., 2014b). Interestingly, the responses elicited following activation of a 
PAR by a synthetic ligand are not always the same as the responses following cleavage by a 
protease (Al-Ani et al., 2002b; Jiang et al., 2017b). This is another potential source of 
different responses following activation of PARs. For example, despite activating the same 
part of the receptor, activation of PAR1 by thrombin results in signalling via Gαq and 
Gα12/13, while activation of PAR1 by the synthetic ligand SFLLRN favours Gαq over 
Gα12/13 signalling (McLaughlin et al., 2005). The hexapeptides SLIGRL-NH2 and SLIGKV-NH2 
correspond to the mouse and human tethered ligands that are exposed following cleavage 
of PAR2 by trypsin, although they have been reported to have a relatively low potency 
compared with trypsin (Al-Ani et al., 2002b; Bohm et al., 1996; Nystedt et al., 1994). As with 
cleavage of PAR2 by trypsin, they have been reported to induce Gαq-mediated increase in 
intracellular calcium and activation of ERK (Ramachandran et al., 2009; Sriwai et al., 2013; 
Stalheim et al., 2005). However, while cleavage of PAR2 by trypsin results in elevation of 
cAMP, activation of PAR2 by SLIGRL-NH2 has been reported to result in an increase in cAMP 
on some occasions (Amadesi et al., 2006; Scott et al., 2003), but not in others (Sriwai et al., 
2013), which may be dependent on the cell type being activated.  
 
Activating peptides corresponding to the tethered ligands generated following non-
canonical cleavage of PAR2 can also be used to activate the receptor. Zhao et al. (2014a) 
used the CatS activating peptide TVFSVDEFSA in HEK cells and observed a similar effect of 
Gas signalling and lack of receptor endocytosis as found following activation with CatS. The 
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CatS activating peptide acting on PAR2 was also able to sensitise TRPV4 in a similar manner 
to CatS in Xenopus laevis oocytes expressing TRPV4 and PAR2.  
 
Interestingly, the synthetic peptide for PAR3 does not activate its receptor, although it can 
activate PAR1 and PAR2 (Hansen et al., 2004; Ishihara et al., 1997). This could be due to the 
fact that PAR3 on its own is unlikely to be involved in signalling (Nakanishi-Matsui et al., 
2000). However, it does add further complexity to PAR signalling, since agonists could 
potentially activate more than one PAR on the same cell, resulting in complex responses 
that would not be detected following activation of just a single receptor. Furthermore, these 
synthetic peptides for PARs have been reported to act on receptors distinct from PARs (Liu 
et al., 2011b; McGuire et al., 2002). 
 
Sensitisation of neurons by protease-activated receptors 
The protease activated receptors have been reported to mediate several of their effects via 
sensitisation of TRP channels expressed on neurons, resulting in enhanced signalling, which 
is proposed to be responsible for sustained sensations of pain and hyperalgesia during 
inflammatory conditions (Amadesi et al., 2004; Amadesi et al., 2006; Chen et al., 2011; Dai 
et al., 2004; Dai et al., 2007; Geppetti et al., 2015; Grace et al., 2014; Grant et al., 2007; Lieu 
et al., 2016; Mrozkova et al., 2016b; Poole et al., 2013). Activation of PAR2 is known to 
cause sensitisation of TRPA1 via PLC and PIP2 signalling (but not PKC) (Dai et al., 2007), 
TRPV1 via Gaq-mediated PKC and PKA phosphorylation of TRPV1 (Amadesi et al., 2004; 
Amadesi et al., 2006; Dai et al., 2004), and TRPV4 via PKC and tyrosine phosphorylation of 
TRPV4 (Grace et al., 2014; Grant et al., 2007; Poole et al., 2013). In a similar manner, 
activation of PAR2 by various pruritogens could also sensitise these channels to contribute 
to itch sensations (Davidson and Giesler, 2010). Indeed, co-application of trypsin, which 
cleaves PAR2, was found to potentiate responses to histamine and serotonin in calcium 
imaging experiments in human submucous plexus preparations (Ostertag et al., 2017). In 
mice, scratching behaviour in response to injection of chloroquine or BAM8-22 was 
increased if the mice were pre-treated with the PAR2 agonist SLIGRL-NH2 first, and pre-
treatment of DRG cells with SLIGRL-NH2 resulted in an increase in the peak calcium response 
of cells to chloroquine and BAM8-22, suggesting cross-sensitisation had occurred, and 
possibly reflecting sensitisation of pruriceptors that convey non-histaminergic itch (Akiyama 
et al., 2012). Furthermore, in a rat model of liver disease, potentiation of TRPV1 by PAR2 
was found to be responsible for enhanced scratching behaviour and increased responses of 
TRPV1 in calcium imaging experiments (Belghiti et al., 2013). 
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1.6.1 Protease activated receptors and itch 
All of the PARs, apart from PAR3, are involved in itch (Tsujii et al., 2008; Akiyama et al., 
2009b). There are many mechanisms by which activation of PARs could result in itch. For 
instance, direct activation of PARs expressed on sensory neurons might be responsible for 
the generation of action potentials, initiation of second messenger signalling and 
mobilisation of calcium, and the transmission of itch signals. Sensitisation of sensory 
neurons via PAR signalling could also be a mechanism by which stimuli, which would 
otherwise not normally activate the neuron, result in transmission of itch signals. 
Alternatively, indirect signalling via activation of PARs on other cell types, which release 
mediators that then act on neurons, could be responsible for itch sensations. In support of 
this, activation of PAR2 on keratinocytes has been found to cause the release of TSLP, an 
itch-related cytokine that acts on neurons (Wilson et al., 2013). Similarly, activation of PAR2 
on mast cells in the skin could result in their degranulation and release of histamine and 
proteases, resulting in itch sensations (Sakai et al., 2016; Ui et al., 2006). 
 
Protease-activated receptor 1 and itch 
Injection of the synthetic ligand TFLLR-NH2, which activates PAR1, has causes scratching 
behaviour in mice (Tsujii et al., 2008). This may be in part due to histamine release from 
cutaneous mast cells that express PAR1 (Moormann et al., 2006), and also due to direct 
activation of sensory neurons that express PAR1 (de Garavilla et al., 2001). Activation of 
PAR1 in corneal stromal cells with this synthetic ligand has also releases the itch-related 
cytokine TSLP and may be responsible for itch sensations in the cornea (Yin et al., 2017). 
TSLP is also released from keratinocytes where it causes itch sensations (Wilson et al., 2013). 
Whether release of TSLP from keratinocytes is also mediated by PAR1 remains to be 
elucidated. 
 
Protease-activated receptor 2 and itch 
Of the involvement of all the PARs in itch, most research has been carried out on PAR2. 
PAR2 is expressed in many cell types, including sensory neurons, keratinocytes, and mast 
cells (Steinhoff et al., 1999; Steinhoff et al., 2000; Steinhoff et al., 2003). Expression of PAR2 
is increased in the nerve fibres and mast cells of patients with atopic dermatitis, and 
injection of the PAR2 agonist SLIGKV induces itch which is greatly enhanced when injected 
into the skin of patients with atopic dermatitis compared to control subjects (Steinhoff et 
al., 1999; Steinhoff et al., 2003). Moreover, mucunain, a protease which is the active 
ingredient of cowhage, produces itch in humans by acting on PAR2 (Reddy et al., 2008). 
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PAR2-mediated pruritus has also been reproduced in mice, in which injection of the PAR2 
agonist SLIGRL-NH2 causes scratching behaviour and activation of neurons in the superficial 
dorsal horn of the spinal cord in a histamine-independent manner (Akiyama et al., 2009a, b; 
Shimada et al., 2006; Tsujii et al., 2008). In addition to the numerous exogenous proteases 
and ligands for PAR2 that have been reported to cause itch sensations, several endogenous 
ligands that act on PAR2 to cause itch have been proposed. Tryptase and chymase, released 
from mast cells, have been reported to cause itch (Gordins et al., 2004; Tsujii et al., 2009), 
and may do so via activation of PAR2 (Ui et al., 2006). The kallikreins, a family of trypsin-like 
serine proteases that are expressed in the skin, are also potential candidates as endogenous 
agonists of PAR2 that cause itch (Komatsu et al., 2003; Komatsu et al., 2005). In support of 
this, kallikrein-5 and kallikrein-14 have been found to activate PAR2 (Oikonomopoulou et al., 
2006; Stefansson et al., 2008), while expression of kallikrein-14 is increased in the skin in 
inflammatory skin conditions such as atopic dermatitis (Stefansson et al., 2008). 
Exogenously applied CatS has also been reported to cause itch via cleavage of PAR2 (Reddy 
et al., 2010), although the endogenous source of CatS that directly cleaves PAR2 to cause 
itch sensations was not known and is a topic of investigation for this project. Furthermore, 
whether activation of neuronal PAR2 by pruritogens or release of pruritogens following 
activation of PAR2 on non-neuronal cells was responsible for itch was not determined.  
 
Although there is much evidence for the involvement of PAR2 in itch, there remains 
controversy as to whether or not this receptor is responsible for itch sensations or whether 
it plays a role in pain. Activation of PAR2 by proteases such as CatS and the synthetic 
peptide SLIGRL-NH2 has been reported to cause pain (Amadesi et al., 2004; Barclay  et al., 
2007; Vergnolle et al., 2001). Other studies found that the PAR2 agonist SLIGRL-NH2 does 
evoke scratching behaviour, but that it is not abolished in PAR2 knockout mice, suggesting 
that PAR2 is not required for scratching behaviour (Liu et al., 2011b). Indeed, the role of 
SLIGRL-NH2 in PAR2-mediated itch has been questioned. Liu et al. (2011b) reported that 





Figure 1.13: Overview of hypothesised roles of MrgprC11 and PAR2 in itch and 
hyperalgesia (adapted from Liu et al., 2011b). 
SLIGRL activates both MrgprC11 to cause itch and PAR2 to cause hyperalgesia. The 
shortened peptide, SLIGR, is reported to only activate PAR2, causing hyperalgesia. 
 
Protease-activated receptor 4 and itch 
Whether PAR2 is involved in itch and whether it does so via SLIGRL remains controversial 
(Liu et al., 2011b; Reddy et al., 2015; Reddy et al., 2018). However, one possibility is that 
cleavage of PAR2 by other proteases results in itch, as a consequence of the effects of 
biased agonism. Another possibility is that activation of other receptors, such as PAR4, is 
also required for itch. Indeed, in humans, injection of mucunain acts on PAR4 as well as 
PAR2 to cause itch, and application of CatS elicits itch via PAR4 and results in calcium 
transients in HeLa cells expressing PAR2 or PAR4 (Reddy et al., 2010; Reddy et al., 2018). 
Alternatively, activation of PAR4 alone might be sufficient for itch. In support of this, 
injection of just PAR4 agonists in mice also elicits scratching behaviour and activation of 
neurons in the superficial dorsal horn of the spinal cord in a TRPV1/TRPA1-dependent 
manner (Akiyama et al., 2009b; Patricio et al., 2015).  
 
Itch induced by PAR4 may or may not be dependent on histamine. Because PAR4 is 
expressed on mast cells as well as neurons and injection of a PAR4 agonist causes 
degranulation of mast cells, one hypothesis is that activation of PAR4 on mast cells might 
result in the release of histamine (Han et al., 2012; Patricio et al., 2015; Russell et al., 2011). 
In support of this, Tsuji et al. (2008) reported that scratching behaviour in mice following 
injection of a PAR4 agonist was partially but significantly attenuated by the H1R antagonist 
terfenadine, suggesting that this itch is at least partially dependent on histamine. However, 
Patricio et al. (2015) reported that PAR4 mediated itch is independent of histamine, as 
injection of a PAR4 agonist still induced scratching behaviour in mice treated with the mast 
cell stabiliser cromolyn and in mast cell-deficient mice. Because these studies used different 
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methods to investigate the contribution of histamine to PAR4 mediated itch, one 
explanation is that PAR4 mediated itch is partially dependent on histamine, which may or 
may not be observed, depending on the method used in the study. 
1.6.2 Protease activated receptor 2 and Cathepsin S 
CatS is a likely candidate for being involved in at least some instances of itch mediated by 
PAR2. First, the active site of CatS shares sequence homology with mucunain, the active 
component of cowhage, and both induce itch (Reddy et al., 2010). Furthermore, mucunain 
and CatS cleave PAR2 in transfected cells (Reddy et al., 2008; Reddy et al., 2010; Reddy and 
Lerner 2010). Second, CatS is expressed in keratinocytes and is upregulated under 
conditions of inflammation, especially in inflammatory skin conditions associated with 
chronic itch, such as seborrhoeic dermatitis, atopic dermatitis, and psoriasis, suggesting the 
involvement of CatS in chronic itch conditions (Ainscough et al., 2017; Olivry et al., 2016; 
Schönefuß et al., 2009; Schwarz et al. 2002; Viodé et al., 2014). Furthermore, transgenic 
mice over-expressing CatS develop a skin disorder similar to atopic dermatitis, characterised 
by chronic skin inflammation and increased scratching behaviour (Kim et al., 2012).  
 
However, while there is some evidence supporting the involvement of CatS and PAR2 in itch, 
there remain a number of discrepancies. Although CatS does cleave PAR2, at E56/T67 (Figure 
1.12 A), rather than mediating itch sensations, this appears to be involved in 
hyperexcitability of nociceptors and pain sensations (Zhao et al., 2014a). It is possible that 
cleavage of PAR2 at different sites is responsible for different sensations. An additional 
cleavage site for CatS on PAR2, G41/K42, has also been identified (Elmariah et al., 2014), but 
whether or not this is involved in itch is not known. Furthermore, SLIGRL and CatS still cause 
activation of sensory neurons and elicit scratching behaviour in PAR2 KO mice, suggesting 
that this pathway might not be involved in itch (Liu et al., 2011b; Reddy et al., 2015). 
However, it cannot be ruled out that a compensatory mechanism, such as enhanced 
signalling via PAR4 (Reddy et al., 2010) or MrgprC11 (MrgprX in humans) (Reddy et al., 2015; 
Reddy et al., 2018), is responsible for SLIGRL and CatS-mediated responses and scratching 
behaviour in these animals.  
 
The role of PAR2 in CatS-mediated itch has recently been questioned. As with the recent 
reports that SLIGRL activates Mrgprs in addition to PAR2, (Figure 1.13), it has similarly been 
reported that CatS and mucunain also activate Mrgprs in addition to PARs (Reddy et al., 
2015; Reddy et al., 2018). Sensory neurons from PAR2 KO mice were found to respond to 
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application of CatS or mucunain, and scratching behaviour was observed in PAR2 KO mice 
following injection of CatS or mucunain. As with PARs, proteases can activate Mrgprs by 
cleavage at the N-terminal. CatS has been reported to cleave MrgprC11 at site N16/E17 
(Reddy et al., 2015). However, unlike the PARs, tethered or diffusible ligands of the cleaved 
region do not activate the receptor. Instead, it is proposed that cleavage of Mrgprs by 
proteases just results in a conformational change that causes activation of G-proteins and 
allows signalling to occur, likely via coupling to Gq and mobilisation of calcium, as has been 
reported for other agonists of these receptors (Robas et al., 2003; Subramanian et al., 2011; 
Subramanian et al., 2013). As well as activating mouse MrgprC11, CatS was also found to 
activate the human analogue MrgprX2, but not human MrgprX1 (Reddy et al., 2015). The 
role of Mrgprs in CatS-mediated itch would likely involve TRPA1-expressing neurons (Ross, 
2011; Wilson et al., 2011). However, preliminary studies from our group found that 
scratching behaviour following injection of CatS was not significantly reduced in TRPA1 KO 
mice. While it is possible that compensatory mechanisms exist in transgenic animals that 
prevent overt changes in behaviour, another possibility is that CatS signals via several 
receptors, including PAR2 and Mrgprs, and potentially others that have yet to be discovered, 
and that activation of a number of different receptor types is required to induce itch. 
Knocking out one of the receptors may result in a small but unnoticeable reduction in 
scratching behaviour, which could be compensated for by increased expression of or activity 
at other receptors. 
1.7 Thesis aims 
The overall aim of the work in this thesis is to investigate the mechanisms underlying CatS -
induced itch, from the periphery where CatS is released and itch signals are initiated in the 
endings of sensory neurons to the dorsal horn of the spinal cord where it becomes 
integrated with the spinal cord circuitry.  
 
Chapter two concerns the source of CatS in itch; specifically we investigate whether skin 
keratinocytes are a potential source of endogenous CatS and the conditions under which 
they might release CatS. We proposed that the skin is an endogenous source of CatS, 
released from keratinocytes in inflammatory conditions, and that CatS may act on its own or 
in addition with other endogenous proteases to cause itch.  
 
Given the observation that CatS may be involved in chronic itch conditions such as atopic 
dermatitis, we investigate whether CatS acts as a pruritogen by acting directly on primary 
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sensory neurons and whether they do so via PAR2, and we begin to characterise these 
neurons and whether they belong to the subset of TRPV1 and/or TRPA1 sensory neurons 
proposed to be involved in pruriception. This is addressed in chapter three.  
 
The aim of chapter four is to determine whether peripherally applied CatS causes activation 
of neurons in the spinal cord dorsal horn via the release of neuropeptides from the central 
terminals primary afferent fibres.  
 
By utilising in vivo and in vitro techniques including behavioural testing, release assays, 
immunohistochemical techniques, calcium imaging, and quantitative polymerase chain 
reactions, this work examines the hypothesis that in the skin endogenously-released CatS 
acting on PAR2 expressed on neurons is responsible for transduction of itch signals to the 




















Chapter 2  
Cathepsin S in keratinocytes – intracellular expression & extracellular activity 
2.1 Introduction 
 
The HaCaT cell line as a keratinocyte model 
To investigate the role of keratinocytes in releasing pruritogens such as CatS in atopic 
dermatitis-like conditions, we used the HaCaT (human adult low calcium high temperature) 
cell line (so-called after their origin and initial growth conditions, Boukamp et al., 1988) as 
an in vitro model system. This cell line is a spontaneously immortalised keratinocyte cell line 
that expresses keratins 1 and 10 as well as structural proteins such as filaggrin, loricrin, and 
involucrin (Boukamp et al., 1988; Seo et al., 2012). Importantly, HaCaTs also contain CatS, 
which is located primarily in the lysosomes, as is also reported in normal human 
keratinocyte cultures (Schonefuss et al., 2010; Schwarz et al., 2002). As a result of being 
immortalised, the cell line does not need to be replaced over time, reducing the variability 
that occurs with conventional primary keratinocyte cultures from multiple donors. from 
multiple donors. Thus, unlike primary keratinocyte cell lines which have a short window 
during which experiments must be performed (Choi and Lee, 2015; Lichti et al., 2008), 
experiments can be performed with immortalised cell lines such as HaCaTs for a longer 
period of time. Furthermore, unlike primary keratinocytes, HaCaTs do not require the use of 
a feeder layer to grow, which would add a further level of complexity to the system under 
investigation (Boukamp et al., 1988). Moreover, the use HaCaTs offers the advantage of a 
single cell type and avoids the risk of fibroblast contamination sometimes observed with 
primary keratinocyte cultures (Guo and Jahoda, 2009).  
 
However, compared with normal human primary keratinocytes, the transcriptional profile of 
proteins such as filaggrin, loricrin, involucrin, and keratin-10 is abnormal (Seo et al., 2012). 
In addition, karyotyping of the cell line shows it is aneuploid, containing 72-88 chromosomes 
(Boukamp et al., 1988), although it has been suggested that aneuploidy may be necessary 
for the development of immortalised cell lines and cancerous cells from primary cells 
(Duesberg et al., 2001).  
 
A low calcium concentration is used to maintain both primary keratinocytes and HaCaTs in a 
basal state in vitro (Boyce and Ham, 1983; Deyrieux and Wilson, 2007; Hennings et al., 1980; 
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Li et al., 2017). Increasing the calcium concentration inhibits cell growth and synthesis of 
DNA and induces differentiation of keratinocytes (Boyce and Ham, 1983; Colombo et al., 
2017; Deyrieux and Wilson, 2007; Hennings et al., 1980; Li et al., 2017; Sakaguchi et al., 
2003). This reflects the situation in the epidermis in vivo, whereby the calcium 
concentration increases towards the surface of the skin, apart from the corneal layer, which 
is almost completely devoid of calcium (Bikle, 2004; Menon et al., 1985). However, unlike 
primary keratinocytes which undergo irreversible terminal differentiation in the presence of 
increased calcium concentrations, HaCaTs are capable of reverting from a differentiated 
state back to an undifferentiated state then the calcium concentration is decreased 
(Deyrieux and Wilson, 2007). Furthermore, cell confluence affects the differentiation of 
keratinocytes including HaCaTs, with cells showing signs of differentiation when grown at 
high confluency, even in the presence of low calcium (Colombo et al., 2017; Deyrieux and 
Wilson, 2007; Lee et al., 1998). Cell density-mediated differentiation of normal human 
keratinocytes and HaCaTs is mediated by PKC, since blocking PKC activity decreases 
expression of filaggrin, involucrin, and loricrin in keratinocytes (Lee et al., 1998; Papp et al., 
2003). Because the release of cytokines from HaCaTs maintained in low calcium and sub-
confluent conditions is similar to that of normal keratinocytes (Colombo et al., 2017), we 
cultured our keratinocytes in defined keratinocyte serum-free medium (DK-SFM) which 
contains less than 0.1 mM calcium, and performed experiments before the cells reached full 
confluence.  
 
Although typically grown in a basal-like, undifferentiated state as a monolayer in culture, 
HaCaTs can be made to differentiate and grow as a multilayered epithelium, for example, 
following transplantation onto nude mice or when grown at an air-liquid interface on 
collagen gels containing fibroblasts (Boelsma et al., 1999; Boukamp et al., 1988; Schoop et 
al., 1999). However, these cells do not undergo complete terminal differentiation and have 
a disorganised appearance, lacking a granular and cornified layer, and unable to synthesise 
lipids necessary for proper barrier formation (Boelsma et al., 1999). This could explain why 
HaCaTs, unlike normal keratinocytes, are able to revert back to a basal-like state after 
differentiation. Furthermore, additional keratins that are not normally expressed in the skin 
were found to be expressed in multilayered HaCaTs (Boelsma et al., 1999; Schoop et al., 
1999). For these reasons, experiments were performed in HaCaTs that were cultured in a 





Release of Cathepsin S from antigen presenting cells 
CatS released from cells in the skin could be responsible for pruritus. In addition to being 
expressed in skin keratinocytes, CatS is also expressed from immune cells, including 
microglia and monocytes/macrophages (Clark et al., 2007; Clark et al., 2010; Liuzzo et al., 
1999; Petanceska et al., 1996), as well as vascular and cervical smooth muscle cells (Fonovic 
et al., 2013; Watari et al., 2000). Although not involved in itch, the mechanisms of release of 
CatS from these cells has been elucidated and likely share at least some similarities with the 
release of CatS from skin keratinocytes. 
 
The expression and release of CatS from microglia in the spinal cord and its role in 
neuropathic pain has been well documented. CatS protein is expressed in microglia in the 
spinal cord of the rat, with the number of CatS -positive microglia increasing in the dorsal 
horn following peripheral nerve injury (Clark et al., 2007). CatS mRNA and protein is also 
expressed in primary microglia cultured from rat brain and spinal cord and in the N-13 
microglia-like cell line (Clark et al., 2010; Liuzzo et al., 1999; Petanceska et al., 1996). 
Incubation of microglia-like cells in IFNγ for 5 hours does not increase release of CatS from 
these cells (Petanceska et al., 1996); in contrast, incubation in IFNγ for 24 hours increases 
release of CatS (Liuzzo et al., 1999), suggesting that IFNγ-mediated release of CatS from 
these cells requires a long incubation time. Furthermore, incubation of N-13 cells with TNFα 
for 24 hours was induces the release of CatS (Liuzzo et al., 1999), suggesting that these cells 
can release CatS under inflammatory conditions, for example, following injury, and could be 
similar to the release of CatS from HaCaTs that is reported following 24-72 hours incubation 
with IFNγ and TNFα (Schonefuss et al., 2010; Schwarz et al., 2002). However, the 
mechanisms by which IFNγ and TNFα result in the release of CatS from cells is not yet 
understood.  
 
Although Liuzzo et al., (1999) and Petanceska et al., (1996) observed release of CatS from N-
13 cells following incubation in lipopolysaccharide (LPS), an activator of Toll-like receptor 4 
(TLR4), incubation of primary microglia from rats with LPS alone did not result in the release 
of CatS from these cells (Clark et al., 2010). However, primary microglia cells incubated with 
LPS underwent morphological changes, and small increases in the intracellular expression of 
pre and mature forms of CatS protein were observed, suggesting microglia were primed by 
LPS. Following priming with LPS and stimulation with high concentration adenosine 
triphosphate (ATP) to activate the P2X7 receptor, an increase in the release of CatS from 
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these microglia was observed. In contrast, ATP on its own was unable to induce release of 
CatS, indicating the requirement for LPS priming of these cells for CatS to be released.  
 
ATP-induced release of CatS from primed microglia required the presence of extracellular 
calcium ions, since the release of CatS is halved when the cells are stimulated in the 
presence of a calcium-free buffer. Entry of extracellular calcium could be through P2X7 
channels, which allow conductance of calcium ions when expressed in gonadotropin-
releasing hormone-secreting neurons (Koshimizu et al., 2000). Calcium release from 
intracellular stores also appears to be required for the release of CatS from microglia, since 
release of CatS is completely abolished when stimulated in the presence of dantrolene, an 
inhibitor of calcium release from stores in the sarcoplasmic reticulum (Clark et al., 2010). 
The increase in intracellular calcium ions promotes the trafficking of lysosomes to the cell 
membrane and release of lysosome contents, which would thus allow release of CatS from 
these cells (Andrews, 2002; Blott and Griffiths, 2002; Li et al., 2013).  
 
As well as entry of calcium ions, potassium ions also appear to be involved in the release of 
CatS from microglia, since release of CatS is reduced in the presence of a high potassium 
buffer and increased in a potassium-free buffer (Clark et al., 2010). Activation of P2X7 by ATP 
induces rapid efflux of potassium ions from the cell, possibly through P2X7 channels 
themselves, which are permeable to potassium ions as well as calcium ions (Di Virgilio et al., 
2001; Yaron et al., 2015). Thus, increasing the extracellular potassium concentration should 
reduce the efflux of potassium ions from the cell by reducing the potassium gradient across 
the cell; conversely reducing the extracellular potassium concentration would facilitate 
potassium efflux. Potassium efflux is upstream of calcium influx and may be required for the 
entry of extracellular calcium ions, since calcium chelation suppresses calcium fluxes 
without affecting ATP-induced potassium fluxes, while preventing efflux of potassium ions 
also prevents entry of extracellular calcium ions into the cell (Yaron et al., 2015).  
 
Exocytosis of lysosomes also requires activity of PLC and calcium-dependent PLA2. Inhibitors 
of either PLC or PLA2 can prevent the lysosomal release of IL-1β and caspase-1 from 
monocytes as well as the release of CatS from microglia following stimulation with ATP 
(Andrei et al., 2004; Clark et al., 2010). Activation of PLC is proposed to be required for the 
increase in intracellular calcium that follows activation of P2X7 by ATP, since ATP-induced 
calcium fluxes are prevented by PLC inhibitors (Andrei et al., 2004). In contrast, ATP-induced 
calcium fluxes are not prevented by PLA inhibitors, suggesting PLA is downstream of PLC 
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activation or part of a parallel signalling pathway (Figure 2.1). Activation of PLC, which 
cleaves PIP2 to form IP3, would result in the release of calcium from intracellular stores, 
thereby contributing to calcium-mediated exocytosis from cells. Furthermore, cleavage of 
PIP2 by PLC to generate DAG has been shown to be required for exocytosis from mast cells 
(Hammond et al., 2006). This supports a role for PLC in the release of vesicles from cells, and 
may also apply to the exocytosis of lysosomes in other cell types. PLA2 has previously been 
shown to prime vesicles for fusion to plasma membranes (Karli et al., 1990), although 
whether PLA2 primes lysosomes in a similar manner for subsequent exocytosis remains to 
be investigated. Activation of PLC is thought to result in phosphorylation of MAPK, which in 
turn phosphorylates PLA2 (Figure 2.1), since incubation of microglia in LPS and ATP 
increases the presence of phosphorylated p38 MAPK in cultured microglia and inhibition of 
p38 MAPK prevents release of CatS from these cells (Clark et al., 2010). 
 
 
Figure 2.1: Schematic of proposed mechanism of lysosomal Cathepsin S release from cells 
(adapted from Clark et al., 2010) 
 
We hypothesised that, similar to what has been reported in microglia, priming of HaCaT 
keratinocytes with LPS followed by stimulation with ATP could be a potential mechanism of 
CatS release from these cells. Although injured neurons might be a source of ATP for 
activation of microglia and subsequent release of CatS (Fields and Burnstock, 2006; Masuda 
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et al., 2016), keratinocytes themselves could be the source of ATP in skin inflammation 
(Mizumoto et al., 2003). Priming of keratinocytes for release of CatS could be due to LPS 
secreted by bacteria on the skin, although other inflammatory mediators present in the skin 
could also have a role in priming keratinocytes for release. Furthermore, the LPS receptor 
TLR4 is also expressed in neurons, and LPS has been found to enhance histamine-induced 
scratching behaviours in mice and the calcium responses of DRGs to histamine (Ji et al., 
2018; Min et al., 2014). These support a role for LPS in the sensitisation of neurons to 
pruritogens as well as the release of CatS as a pruritogen from keratinocytes. 
 
TRPV4-mediated release of Cathepsin S 
An additional mechanism for the release of CatS from cells could be via activation of TRPV4 
channels. TRPV4 is expressed in skin keratinocytes, where it is involved in barrier formation 
and recovery, cell-volume regulation, and UVB-induced pain (Becker et al., 2005; Denda et 
al., 2007; Kida et al., 2012; Moore et al., 2013). Furthermore, a role for TRPV4 in itch has 
been proposed, since injection of the TRPV4 agonist GSK1016790A (GSK101) results in 
scratching behaviours in mice (Chen et al., 2016). Importantly, this scratching behaviour is 
reduced in transgenic mice in which expression of TRPV4 was absent in keratinocytes, 
supporting a role for TRPV4 on keratinocytes in itch. TRPV4 appears to be involved in 
mediating histaminergic itch, as scratching behaviours in response to intradermal injection 
of histamine and histaminergic pruritogens is reduced in TRPV4 KO mice or when injected in 
wild-type mice in the presence of a TRPV4 antagonist (Chen et al., 2016). In contrast, 
compared with behaviours in wild-type mice, chloroquine-induced scratching behaviour is 
not altered in TRPV4 KO mice or in the presence of a TRPV4 antagonist. Furthermore, 
calcium fluxes in both murine and human keratinocytes in response to application of H1R, 
H3R, and H4R agonists were abolished when in the presence of TRPV4 inhibitors, suggesting 
TPRV4 mediates all forms of histaminergic itch signalling (Chen et al., 2016). TRPV4 may also 
be involved in chronic itch conditions, as expression of TRPV4 is increased in the skin in 
mouse models of dry skin and inflammatory itch and scratching behaviour is reduced when 
mice are given a TRPV4 antagonist (Luo et al., 2018). 
 
Application of GSK101, exposure to warm temperatures (33°C), UVB, or swelling, all result in 
calcium transients in keratinocytes, suggesting involvement of calcium signalling in TRPV4-
mediated responses (Becker et al., 2005; Kida et al., 2012; Moore et al., 2013). When 
activated, TRPV4 allows the entry of several cations, including calcium ions, into the cell 
(Nilius et al., 2003). Chen et al. (2016) reported that ERK signalling was downstream of 
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TRPV4-mediated calcium responses in skin keratinocytes, since phosphorylation of ERK was 
increased in both cultured keratinocytes and skin tissue in response to application of 
histaminergic pruritogens, and was reduced in the presence of a TRPV4 antagonist. 
Scratching behaviours in mice following injection of histaminergic pruritogens was also 
reduced following topical administration of an inhibitor of ERK, providing a role for ERK in in 
the skin in histaminergic scratching behaviours, likely mediated by TRPV4 in keratinocytes. 
However, the signalling pathway downstream of ERK phosphorylation in keratinocytes that 
is responsible for transmission of the itch signal remains to be elucidated. We propose that 
activation of TRPV4 on keratinocytes culminates in the release of CatS from these cells, 
which then acts as a pruritogen on the endings of sensory neurons in the skin.  
 
A recent study has reported that exposure of HaCaT cells and a melanoma cell line to the 
TRPV4 agonist GSK101 resulted in changes in cell morphology resembling apoptosis, 
detachment of cells, and cell death (Olivan-Viguera et al., 2018). Apoptosis was apparent as 
soon as after one hour incubation in GSK101 (10 nM). Co-incubation of cells with GSK101 
and a TRPV4 antagonist reduced the morphological changes but the number of dead cells 
was not significantly reduced. The authors attributed these morphological changes and cell 
death to excessive entry of calcium and sodium into the cells following stimulation of 
TRPV4. However, a study by Fusi et al. (2014) reported that overnight incubation of HaCaTs 
in GSK101 (5 μM), or other TRPV4 agonists, did not affect the viability of cells, despite using 
a greater concentration of GSK101. The reason for this discrepancy is not clear, although 
GSK101 has not been reported to affect cell viability in a number of cell types, including a 




There is much evidence supporting the involvement of CatS in numerous skin conditions 
characterised by chronic itch. However, whether release of CatS from cells in the skin is 
directly responsible for signalling of itch by acting on receptors on the endings of sensory 
neurons in the skin, or whether CatS causes itch by indirect means, is not clear and is one of 
the questions addressed in this thesis. Furthermore, the mechanisms by which CatS is 
released from skin cells, particularly keratinocytes, in chronic skin conditions, is not fully 




Using the HaCaT keratinocyte cell line as a model system of the skin, the aims of this chapter 
were to investigate the expression of CatS in this cell line and to investigate the conditions 
under which CatS would be released. In particular, we wanted to determine whether these 
keratinocytes would release CatS following incubation in LPS and stimulation with ATP, as 
has been observed in microglia, and whether incubation with Th2 cytokines resulted in or 
modulated the release of CatS from these cells. Finally, we investigated whether stimulation 
of TRPV4 would cause release of CatS from HaCaT cells, establishing whether TRPV4 could 
potentially mediate its pruritic effects via the release of CatS. 
2.2 Methods 
2.2.1 HaCaT cell line culture 
The immortalised HaCaT keratinocyte cell line, originally established by Dr Boukamp and Dr 
Fusenig (Boukamp et al., 1988) was supplied from Anthony Young. HaCaTs were grown in 
Defined Keratinocyte Serum-free Medium (DK-SFM) (Gibco, Life Technologies, UK) 
containing a growth supplement comprising bovine pituitary extract (BPE) (0.2% v/v), 
recombinant human insulin-like growth factor-1 (1μg/ml), hydrocortisone (0.18μg/ml), 
bovine transferrin (5μg/ml), and human epidermal growth factor (0.2 ng/mL), as well as 
penicillin-streptomycin (1%) (Gibco, Life Technologies, UK) and incubated in a humidified 
atmosphere of 5% CO2 at 37˚C. The culture medium was refreshed every 2-4 days. These 
adherent cells stick to the plastic on which they are cultured and so do not require a 
substrate on which to grow. When HaCaTs were between 80-100% confluent 
(approximately 8.4 x 106 cells per T75 tissue culture flask), they were split and sub-cultured 
to maintain optimal cell growth to plate for performing experiments. HaCaTs were split by 
removing DK-SFM from the flask and replacing with trypsin-EDTA containing 0.5 g/L porcine 
trypsin and 0.2 g/L EDTA•4Na (Sigma, UK). Once most of the cells had dislodged from the 
flask, trypsin was inactivated by addition of DMEM containing 10% serum. The cell 
suspension was then centrifuged, forming a pellet of cells. The liquid was aspirated and the 
pellet re-suspended in DK-SFM and added to a T75 tissue culture flask to maintain the 
culture, or plated onto 6-well tissue culture plates (35 mm diameter, Nunc, UK) or 24-well 
tissue culture plates (15.6 mm diameter, Nunc, UK) for use in experiments.  
2.2.2 Immunocytochemistry and image acquisition 
HaCaTs were seeded onto sterilised uncoated 13 mm diameter glass coverslips at 50,000 
cells per coverslip and cultured in 5% CO2 at 37˚C until 50-60% confluent. Cells were fixed in 
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4% PFA (VWR, UK) for 30 minutes at 4˚C. Cells were then washed 3 times with phosphate 
buffered saline (PBS). Single staining using antibodies from Wako or Abcam could be 
achieved without using the antigen retrieval method. However, preliminary experiments 
performed using antibodies from SantaCruz without using the antigen retrieval method did 
not produce reliable staining. Thus, for all co-staining experiments, the antigen retrieval 
method was used, followed by blocking in 2% milk, following a protocol adapted from Jio et 
al. (1999). Antigen retrieval was performed using citrate antigen unmasking solution (Vector 
Laboratories, USA) diluted 1:100 in H2O, in which the cells were incubated at 80˚C for 30 
minutes. The cells were then left to cool at room temperature followed by blocking in 2% 
milk for 30 minutes and 3 washes with PBS. Primary antibodies (Table 2.1) were prepared in 
blocking buffer and cells were incubated in primary antibody dilutions for at least 2 hours at 
room temperature. This was followed by a further 3 washes in PBS and incubation in 
appropriate secondary antibodies diluted in blocking buffer (Table 2.1) for 2 hours at room 
temperature in the dark. Finally, cells were washed 3 times in PBS and mounted on a 25 mm 
x 75 mm x 1 mm glass slide in Vectashield mounting medium with DAPI (Vector 
Laboratories, USA). 
 
The antibodies for CatS were also tested on mouse dorsal spinal cord. Mice were terminally 
anaesthetised with an overdose of sodium pentobarbital (Euthanol, 150 mg/kg body weight) 
and were transcardially perfused with 0.9% saline followed by 4% PFA. Spinal cords were 
removed and post-fixed in 4% PFA for 2 hours followed by dehydration and cryoprotection 
in 20% sucrose for 72 hours at 4˚C, before being snap frozen and embedded in Optimum 
Cutting Temperature embedding medium (OCT) (VWR, UK). Transverse sections were cut to 
20 μm thickness using a cryostat (Bright Instruments, UK) and sections were mounted on 25 
mm x 75 mm x 1 mm microscopic glass slides (VWR, UK) and stored at -20˚C. Before 
staining, sections were rehydrated in PBS for 10 minutes. Sections then underwent antigen 
retrieval, blocking, and incubation in primary and secondary antibodies as for above. All 
images were taken using a Zeiss Axioplan 2 fluorescent microscope and Axiovision version 









Table 2.1: List of primary and secondary antibodies used for immunocytochemistry 
Primary Concentration Secondary Concentration 
Goat anti-cathepsin S, M-
19 (Santa Cruz 
Biotechnology Inc, UK) 
1:100 – 1:500 
Donkey-anti-goat IgG-
conjugated AlexaFluor 546 
or 488 (Molecular Probes, 
USA) 
1:500 
Mouse anti-cathepsin S, 
E-3 (Santa Cruz 
Biotechnology Inc, UK) 
1:100 – 1:500 
Goat-anti-mouse IgG-
conjugated AlexaFluor 488 
(Molecular Probes, USA) 
1:500 
Rabbit anti-Iba1, ab18207 




conjugated AlexaFluor 546 
(Molecular Probes, USA) 
1:500 




conjugated AlexaFluor 488 
(Molecular Probes, USA) 
1:500 
 
2.2.3 Western blotting 
HaCaTs were cultured in 35 mm diameter wells until confluent. Cells were lysed by the 
addition of lysis buffer (TRIS-HCl pH7.5, 20 mM, Sigma, UK; NaF, 10 mM, Sigma, UK; NaCl, 
150 mM, VWR, UK; NP-40, 1%, Sigma, UK; PMSF, 1 mM, Sigma, UK; Na3VO4, 1 mM, Sigma, 
UK) containing Complete Mini Cocktail Protease Inhibitor (Roche, UK) to each well. Cells 
were removed from the wells using a cell scraper, agitated at 12 rpm for 40 minutes, and 
centrifuged at 11,000 rpm for 15 minutes. The supernatant was then collected and stored at 
-20˚C.  
 
Protein concentration was determined using a Bradford assay and BSA standards. Samples 
were diluted 1:40 in water and loaded in duplicate into the wells of a clear-walled and clear-
bottom 96-well plate. BSA standards (Sigma, UK) from 2 mg/ml to 15.625 μg/ml were also 
diluted 1:40 in water and loaded in duplicate. Bradford protein assay dye reagent (BioRad, 
UK) was added to the diluted samples and standards at 1:5 dilution, such that the final 
concentration of the samples and standards was at 1:50 dilution. Samples were read using a 
SpectraMax 340 PC platereader (Molecular Devices, USA) at 595 nm wavelength. A standard 
curve was generated using the BSA standards and from this the concentration of protein in 
the samples was calculated.  
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Samples were diluted in Laemmli sample buffer (BioRad, UK) to give an equal concentration 
of protein in each sample and incubated at 95˚C for 5 minutes before loading into the gel. 
The gels for running the samples comprised of a 10% resolving gel (TRIS-HCl pH 8.8, 375 
mM, Sigma, UK; acrylamide, 10%, BioRad, UK; SDS, 0.1%, Sigma, UK; ammonium persulfate 
(APS), 0.1%, Sigma, UK; N,N,N’,N’-tetramethylethyldiamine (TEMED), 0.04%, Sigma, UK) with 
a stacking gel on top (TRIS-HCl pH 6.8, 125 mM, Sigma, UK; acrylamide, 5%, BioRad, UK; SDS, 
0.1%, Sigma, UK; APS, 0.1%, Sigma, UK; TEMED, 0.01%, Sigma, UK). Gels were made at 1.5 
mm thickness using BioRad (UK) moulds. Once the gels had set, they were placed inside an 
electrophorator (tank) filled with 1x SDS-PAGE running buffer (TRIS-base, 25 mM, Sigma, UK; 
glycine, 200 mM, Sigma, UK; SDS 10%, Sigma, UK). Precision Plus Protein Kaleidoscope 
ladder (BioRad, UK) was loaded onto each side of the gel, and the appropriate volumes of 
protein samples were loaded into the remaining wells of the gel. The electrophorator was 
run at 90V using a PowerPac200 (BioRad, UK) until the samples had run to the end of the 
stacking gel, and then run at 100V until the samples reached the end of the resolving gel.  
 
The gels were cut to size and placed in a tray of ice-cold 1x TRIS-glycine transfer buffer (TRIS-
base, 20 mM, Sigma, UK; glycine, 200 mM, Sigma, UK; methanol, 20% v/v, VWR, UK). For 
each gel, a cassette containing 0.2µm pore size nitrocellulose membrane (Amersham, GE 
Healthcare) was assembled and placed in the transfer chamber, which was run at 80V for 1 
hour, or until the samples in the gel had transferred to the membrane. The membrane was 
then washed in 1x TBS-T at pH7.6 (TRIS-HCl, 50 mM, Sigma, UK; NaCl, 150 nM, VWR, UK; 
Tween-20, 0.1%, Sigma) and the presence of proteins was confirmed using a Ponceau red 
stain.  
 
The membrane was washed twice in 1x TBS-T before being blocked in 5% milk prepared in 
1x TBS-T for 45 minutes on a shaker. The membrane was then washed twice more in 1x TBS-
T and cut according to the expected band size of interest. The primary antibody for CatS (M-
19, goat, Santa Cruz, USA, and E-3, mouse, Santa Cruz, USA) was diluted 1:200 in 5% milk in 
1x TBS-T, and the primary antibody for β-actin (rabbit, CST, USA) was diluted 1:1000 in 3% 
BSA in 1x TBS-T. The membrane was incubated in primary antibody solution overnight at 4˚C 
on a shaker. The following day, the membranes were washed 3 times in 1x TBS-T. The 
secondary antibody for CatS, HRP-conjugated rabbit anti-goat (Dako, UK) for M-19 or goat-
anti-mouse (Dako, UK) for E-3, was diluted 1:2000 in 5% milk TBS-T. The secondary antibody 
for β-actin, HRP-conjugated goat-anti-rabbit (Dako, UK), was diluted in 1:2000 dilution in 5% 
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milk TBS-T. The membrane was incubated in the secondary antibody solution for 1 hour at 
room temperature on a shaker, followed by 3 washes in 1x TBS-T.  
 
To reveal the membrane, the membrane was covered in Luminata Forte Western HRP 
Substrate (Millipore) and agitated for 3 minutes on a shaker. The membrane was visualised 
using a BioSpectrum Imaging System (UVP, USA) and images were acquired using 
VisionWorks LS software (UVP, USA). Imagine acquisition times varied from 1 minute to 10 
minutes exposure for CatS and from 10 seconds to 20 seconds exposure for actin. 
2.2.4 Quantitative polymerase chain reaction (qPCR) 
HaCaTs were cultured in 35 mm diameter wells until confluent. Total RNA was extracted 
from the cells using the RNeasy Mini Kit (Qiagen), according to the manufacturer's protocol. 
The total concentration of RNA was measured using the NanoDrop spectrometer. 1000 ng 
RNA was used to synthesise first strand DNA using the Superscript VILO cDNA Synthesis Kit 
(Invitrogen, UK) according to the manufacturer’s protocol. Expression levels of CA2, CCL26, 
NELL2, CatS, PAR2, TLR4, and TRPV4 were analysed, with 18S rRNA used as a reference 
transcript. Amplification was performed with a LightCycler 480 (Roche, UK) using SYBR 
Green I Master (Roche, UK). The primers used are given in Table 2.2. The instrument was 
programmed as follows: 95˚C for 5 minutes and 45 cycles of 3 steps of 10 seconds each, 
including denaturing at 95˚C, annealing at 60˚C, and primer extension at 72˚C. Samples were 
run as duplicates, with 18S as the housekeeping gene. Samples in which the melting curve 
had more than one peak were excluded from analysis. Data was analysed using LightCycler 
480 software (version 1.5.1). The relative gene expression level was calculated according to 
the 2-ΔCt method and 2-ΔΔCt, where Ct represents the threshold cycle. The efficiency of the 
primers was confirmed using standard curves with cDNA concentrations of 15 ng/µl, 5 ng µl, 
1.6 ng µl, 0.55 ng µl, and 0.185 ng µl. Efficiencies were required for be between 1.8 and 2.2. 
The qPCR products were added to 6x blue/orange loading dye (Promega, UK) and run on a 
2% agarose gel containing ethidium bromide (0.01%, Sigma, UK) in TBE at 100V for one hour 
to confirm the presence of a single primer product. A 1 kb DNA ladder (Promega, UK) was 
run alongside to allow estimation of the band sizes, and band sizes obtained were compared 







Table 2.2: Primers used for CA2, CCL26, NELL2, CatS, PAR2, TLR4, TRPV4 and 18S in qPCR 
Gene Forward Sequence Reverse Sequence Reference 
CA2 AACAATGGTCATGCTTTCAACG TGTCCATCAAGTGAACCCCAG 
Kamsteeg 
et al., 2010; 














et al., 2010 
CatS GCCTGATTCTGTGGACTGG GATGTACTGGAAAGCCGTTGT 
Fan et al., 
2012, Wang 
et al., 2015 
TLR4 CGATTCCATTGCTTCTTG GCTCAGGTCCAGGTTCTT 
Pivarsci et 
al., 2004 
TRPV4 CTACGCTTCAGCCCTGGTCTC GCAGTTGGTCTGGTCCTCATTG 
Spinsanti et 
al., 2008 
18 S GCTGGAATTACCGCGGCT CGGCTACCACATCCAAGGAA 
Denning et 
al., 2008 
2.2.5 Cathepsin S activity assays 
HaCaTs were cultured in 15.6 mm or 35 mm diameter wells until confluent. Cells were 
stimulated according to several different paradigms. In all situations, the supernatant was 
transferred to 1.5 ml microfuge tubes (Starlab, UK) and snap frozen in liquid nitrogen and 
stored at -80˚C, or used straight away to measure CatS activity.  
 
To begin with, the culture media was removed from 15.6 mm diameter wells and replaced 
with warmed HEPES buffer at pH7.4 (HEPES, 10 mM, Sigma, UK; NaCl, 150 mM, Sigma, UK; 
KCl, 5 mM, Sigma, UK; MgCl2, 1 mM, G Biosciences, USA; CaCl2, 1 mM, Fisher Scientific, UK; 
glucose, 5.55 mM, Sigma, UK). Cells were incubated in HEPES with or without 1 μg/ml 
lipopolysaccharide (LPS) (E. coli 011:B4, Sigma, UK) for 3, 6, or 12 hours, followed by 
incubation with either 50 μM or 1 mM ATP (Sigma) or HEPES for 20 minutes. The rest of the 
incubations and stimulations were performed in HaCaTs cultured in 35 mm diameter wells. 
HaCaTs were incubated with the Th2 cytokines, IL-4 and IL-13, to investigate whether this 
would affect CatS activity. The culture media was replaced with fresh DK-SFM containing IL-
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4 (50 ng/ml, BioLegend, UK) and IL-13 (50 ng/ml, Shenandoah, USA) or without any 
cytokines added, and incubated for 48 hours followed by collection of the media. To 
investigate whether additional stimulation was required for the release of CatS from these 
cells following incubation in Th2 cytokines, HaCaTs were also stimulated in IL-4 and IL-13 for 
48 hours, followed by removal of the culture media and incubation in warmed HEPES 
containing LPS (1 μg/ml) for 6 hours and ATP (1 mM, ATP, SIgma) for 20 minutes. To 
determine whether stimulation of the TRPV4 channel could cause the release of CatS from 
HaCaTs, the culture media was replaced with warmed HEPES buffer, and cells were 
stimulated for 20 minutes with the TRPV4 agonist GSK1016790A (GSK101) (10 nM or 100 
nM, Sigma) or with DMSO (0.001 %). To examine whether Th2 cytokines could enhance the 
release of CatS following stimulation of HaCaTs with GSK101, cells were stimulated in IL-4 
and IL-13 for 48 hours, followed by removal of the culture media and incubation in warmed 
HEPES buffer containing GSK101 or DMSO for 20 minutes. To investigate the involvement of 
extracellular calcium in TRPV4-mediated release of CatS, the culture media was removed 
and replaced with standard warmed HEPES buffer or warmed HEPES buffer without any 
calcium ions added to it (HEPES, 10 mM, Sigma, UK; NaCl, 150 mM, Sigma, UK; KCl, 5 mM, 
Sigma, UK; MgCl2, 1 mM, G Biosciences, USA; glucose, 5.55 mM, Sigma, UK), in which cells 
were stimulated with GSK101 (100 nM) or DMSO (0.001%) for 20 minutes. Samples were 
collected and the activity assay was then performed in standard HEPES buffer for the 
samples that had been incubated in standard HEPES buffer, while those that were incubated 
in HEPES buffer without any calcium ions added to it were had the activity assay performed 
in HEPES buffer containing double the concentration of calcium ions (HEPES, 10 mM, Sigma, 
UK; NaCl, 150 mM, Sigma, UK; KCl, 5 mM, Sigma, UK; MgCl2, 1 mM, G Biosciences, USA; 
CaCl2, 2 mM, Fisher Scientific, UK; glucose, 5.55 mM, Sigma, UK), such that the final 
concentration of calcium following the addition of the samples to the activity assay buffer 
was the same across all experiments to account for any effects that varying the calcium 
concentration may have had on CatS activity. 
 
To investigate the activity of intracellular CatS in HaCaTs, total protein was extracted on ice 
as follows. The culture media was aspirated and cells were washed twice in cold, sterile PBS. 
An extraction buffer comprising sucrose (250 nM, Sigma, UK) in TRIS (10 mM, Sigma, UK) at 
pH7.2 was added to the cells, and using a cell scraper, cells were removed from the wells 
and transferred to 1.5 ml Eppendorf tubes. The samples were homogenised and agitated at 
12 rpm at 4˚C for 30 minutes. Finally, the samples were centrifuged at 11,000 rpm at 4˚C for 
15 minutes, and the top layer of supernatant was transferred to a new 1.5 ml Eppendorf 
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tube and snap frozen in liquid nitrogen and stored at -80˚C or used straight away to 
measure CatS activity. 
 
CatS is unique in that, unlike the other cathepsins, it retains activity at neutral pH, allowing it 
to function outside the acidic environment of lysosomes (Bromme et al., 1993; Shi et al., 
1992; Vasiljeva et al., 2005). Thus, to examine whether the activity observed in the activity 
assay was due to the activity of CatS or due to other cathepsins and proteases, protein 
extraction and the activity assay were both performed at pH5 and pH7, using extraction 
buffers at pH5 and pH7 and HEPES buffer at pH5 and pH7, respectively. For some 
experiments, the activity of all proteases in the HaCaT cell lysates was inhibited by 
performing the protein extraction in a lysis buffer containing protease inhibitors (TRIS-HCl 
pH7.5, 20 mM, Sigma, UK; NaF, 10 mM, Sigma, UK; NaCl, 150 mM, VWR, UK; NP-40, 1%, 
Sigma, UK; PMSF, 1 mM, Sigma, UK; Na3VO4, 1 mM, Sigma, UK; Complete Mini Cocktail 
Protease Inhibitor, Roche, UK). 
 
Samples that had been frozen were defrosted on ice; otherwise freshly prepared samples 
were used in the activity assays. The samples were added in duplicate to the wells of a 
black-walled and clear-bottom 96-well plate. To activate CatS, samples were incubated with 
dithiothreitol (DTT) (0.5 mM) at 37˚C for 10 minutes. The Z-Val-Val-Arg-MCA substrate (50 
μM in 0.01 potassium phosphate buffer and 5 mM disodium EDTA at pH7.5, Peptide 
Institute, Japan) was added to the samples. Fluorescence following cleavage of the Z-Val-
Val-Arg-MCA substrate and liberation of 7-amino-4-methylcoumarin (Kirschke and 
Wiederanders, 1994) was measured using a FlexStation platereader (Molecular Devices, 
USA) at 360 nm excitation wavelength and 460 nm emission wavelength, and SOFTmax Pro 
software (Molecular Devices, USA). The assay was run for 2 hours in all conditions, with 
readings taken at 10-minute intervals. To investigate whether the increase in fluorescence 
was due to CatS or other cathepsins, extraction of the proteins and the activity assay were 
performed at pH5 and pH7. Proteins that had been extracted using an extraction buffer at 
pH5 underwent the activity assay in HEPES buffer at pH5, while those that had been 
extracted at pH7 underwent the activity assay at pH7. To further confirm that the increase 
in fluorescence was due to CatS activity, the activity assay was performed in the presence of 
the CatS inhibitor, MDV-590 ((S)-N-(1-((1-(2-amino-2-oxoacetyl)cyclobutyl)amino)-3-(1-
fluorocyclopentyl)-1-oxopropan-2-yl)-3,3,3-trifluoro-2,2-dimethylpropanamide) (Medivir UK 
Ltd (2011), New Cathepsin S protease inhibitors, useful in the treatment of e.g. autoimmune 
disorders, allergy and chronic pain conditions. International Patent Application 
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WO2011/158197). HaCaT cell lysates that had been extracted as for above were loaded in 
duplicate in a 96-well plate and incubated with DTT (0.5 mM) at 37˚C for 10 minutes. The Z-
Val-Val-Arg-MCA substrate was then added, along with MDV-590 (10 μM) or DMSO (0.01%). 
The samples were incubated for a further 10 minutes in the dark prior to beginning the 
assay. Some HaCaTs were stimulated in GSK101 (100 nM) or DMSO (0.001%) in a HEPES 
buffer containing calcium ions (1 mM); others were stimulated in GSK101 or DMSO in a 
HEPES buffer without calcium ions added. However, for all activity assays, the final 
concentration of calcium in the supernatant and substrate mixture was 1 mM. 
2.2.6 Statistical Analysis 
Data were analysed and graphs generated using GraphPad Prism 5 (Graphpad Software Inc., 
USA). For qPCR experiments, data were analysed using one-way ANOVA followed by 
Bonferroni’s multiple comparison tests when comparing multiple groups with each other or 
one-way ANOVA followed by Dunnett’s multiple comparison test when comparing multiple 
groups against one control group. For the CatS activity assays, the kinetic time course data 
were analysed using two-way ANOVA followed by Bonferroni post hoc tests, while the 
changes in fluorescence were analysed using Student’s t-tests when comparing just two 
groups, one-way ANOVA followed by Bonferroni’s multiple comparison tests when 
comparing multiple groups with each other, or one-way ANOVA followed by Dunnett’s 
multiple comparison test when comparing multiple groups against one control group. The n 
numbers are displayed within the figure legends of the results section. Data are presented 
as mean ± standard error of the mean (SEM). P≤0.05 was set as the level of statistical 
significance. 
2.3 Results 
To investigate whether the skin is a likely source of endogenous CatS, we first wanted to 
establish whether CatS is expressed in skin keratinocytes and if this CatS can be released 
from these cells. We then sought to investigate the mechanisms of CatS release from 
keratinocytes. 
2.3.1 Expression of Cathepsin S protein and mRNA 
To begin with, we wanted to establish whether the HaCaT keratinocyte cell line expressed 
CatS. This was investigated using qPCR for the expression of CatS mRNA, and antibody 
staining and Western blotting for the presence of CatS protein. We attempted to stain 
HaCaTs cells for CatS using two different antibodies against CatS. However, no positive 
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staining for was detected at any dilution used (Figure 2.2 A and B), although the lysosomal 
marker, LAMP-1, was expressed (Figure 2.2 C). However, as one of the antibodies to CatS 
(M-19) was able to detect the presence of CatS in mouse spinal cord, where it co-localised 
with Iba1 staining for microglia (Figure 2.2 D), suggesting that the antibody can detect 
protein and that perhaps insufficient CatS was expressed in HaCaTs to be able to detect 
using this method. Alternatively, the antibody does not recognise the CatS conformation in 
these cells.  
 
 
Figure 2.2: Expression of Cathepsin S peptide and LAMP-1 
No expression of CatS in HaCaTs using M-19 (A) or E-3 (B) anti-CatS at 1:100 dilution. 
Staining for the lysosomal marker LAMP-1 in HaCaTs at 1:100 dilution (green) (C). Staining 
for CatS in mouse dorsal horn spinal cord using 1:100 M-19 anti- CatS (green) and 1:1000 
Iba1 antibody (red) (D). Nuclei are stained blue using DAPI stain. Scalebar represents 50 μm. 
 
Using the same antibodies for CatS, we were unable to confirm expression of CatS protein in 
HaCaT cells using Western blotting (Figure 2.3 A), although actin could be detected (Figure 
2.3 B). In the THP-1 cell line, which is also reported to express CatS (Pawar et al., 2016) we 
were unable to show expression of CatS in our Western blots. However, samples of active 
human recombinant CatS provided from Medivir run in a Western blot did produce a band 
at about 25 kDa (Figure 2.3 A), as well as the presence of a few smaller fragments. The 





Figure 2.3: Western blots for Cathepsin S and actin 
No bands for CatS in HaCaT or THP-1 samples were found. A band was observed for purified 
activated human recombinant CatS at about 25 kDa (A).  Actin bands were observed in 
HaCaT samples at about 45 kDa, while the predicted size of actin is 42 kDa (B). 
 
Although we could not detect expression of CatS protein in our HaCaTs, expression of CatS 
protein might not have been sufficient to be detected using this method. Using qPCR, 
however, we found expression of CatS mRNA in our cells. The qPCR products were also run 
on an agarose gel, which gave a band of about 250 base pairs, while the predicted band size 
was 232 base pairs for the primers for CatS that were used (Figure 2.4). 
 
 
Figure 2.4: qPCR products of mRNA extracted from HaCaT cells 
Image cropped from a gel containing several samples. 
 
LPS has been reported to increase expression of CatS in cervical smooth muscle cells (Watari 
et al., 2000) and microglia (Tam et al., 2016). We thus hypothesised that LPS could also 
cause upregulation of CatS in skin keratinocytes. The receptor for LPS, TLR4, has been 




al., 2003; Pivarcsi et al., 2004; Song et al., 2002). We first confirmed the expression of TLR-4 
on our HaCaT cell cultures using qPCR. Running the qPCR products on a gel gave a band of 
about 150 base pairs, while the predicted band size for this product was 137 base pairs 
based on the primers that were used (Figure 2.4). It has previously been reported that 
incubation of HaCaTs in LPS causes upregulation of TLR4 mRNA in these cells (Kollisch et al., 
2005). We too observed an increase in the expression of TLR4 following 6 hours incubation 
in LPS (Figure 2.4 A). Although changes in the expression of TLR4 were found following 
incubation with LPS, we were mainly interested in investigating whether expression of CatS 
in these cells was also affected by incubation with LPS. Incubating HaCaTs in LPS for 6 hours 
resulted in an increase in the expression of CatS, compared with cells that had been 
incubated in buffer for the same length of time (Figure 2.5 B). No changes were reported 
after 3 hours incubation in LPS or buffer. 
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Figure 2.5: Toll-like receptor-4 and Cathepsin S mRNA expression in HaCaTs is increased 
following incubation in LPS 
Incubation of HaCaTs in 1 μg/ml LPS for 6 hours resulted in an increase in the expression of 
TLR4 (A) and CatS (B) mRNA in these cells compared with incubation in buffer. n = 3; 2 
replicates per sample, data are mean ± SEM. **p ≤ 0.01, One-way ANOVA followed by 
Bonferroni’s multiple comparison test vs HEPES incubations.  
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Table 2.3: Ct values for qPCR performed on HaCaTs following 3 or 6 hours incubation in 
vehicle (buffer) or LPS 
Average Ct values of samples run as duplicates. 
  18S TLR4 CatS 
    Vehicle LPS Vehicle LPS Vehicle LPS 
3 hours Sample 1 10.58 9.05 28.94 28.28 34.08 27.46 
3 hours Sample 2 14.63 7.135 32.895 27.235 36.95 27.595 
3 hours Sample 3 7.9 7.275 32.895 30.315 29.89 28.255 
6 hours Sample 1 7.085 8.835 35.105 26.295 28.395 27.335 
6 hours Sample 2 8.125 7.51 28.5 26.755 33.62 27.92 
6 hours Sample 3 8.365 7.635 30.85 25.585 35.49 27.665 
 
IL-4 and IL-13 are proposed to be involved in the pathogenesis of atopic dermatitis (Danso et 
al., 2014; Kamsteeg et al., 2011; Smits et al., 2017; Werfel, 2009), and so we hypothesised 
they might do so by upregulating expression of CatS in keratinocytes. Incubation of HaCaTs 
in IL-4 and IL-13 (50 ng/ml) for 48 hours resulted in a two-fold increase in CatS mRNA (Figure 
2.6 A). Similarly, the expression of CA2, CCL26, and NELL2 have been reported to be 
increased in the skin of patients with atopic dermatitis (Kagami et al., 2003; Kamsteeg et al., 
2007; Kamsteeg et al., 2010), as well as following stimulation of keratinocytes with Th2 
cytokines such as IL-4 and IL-13 (Kamsteeg et al., 2011; Smits et al., 2017). We therefore 
investigated whether our HaCaTs had similar changes in the expression of these genes 
following incubation with IL-4 and IL-13, and hence whether we were able to model an 
atopic dermatitis-like condition in our cells. Although we were able to confirm expression of 
CA2, CCL26, and NELL2 in our HaCaTs, no significant changes in their expression were 











































































































































Figure 2.6: Cathepsin S mRNA expression in HaCaTs is increased following incubation in IL-
4 and IL-13 
mRNA expression of CatS (A), CA2 (B), CCL26 (C), and NELL2 (D) for HaCaTs incubated in 50 
ng/ml IL-4 and 50 ng/ml IL-13 for up to 48 hours. n = 3, 4; 2 replicates per sample, data are 
mean ± SEM. *p ≤ 0.05, One-way ANOVA followed by Dunnett’s multiple comparison test vs 
no IL-4/IL-13.  
 
Table 2.4: Ct values for qPCR performed on HaCaTs following 0, 24, 0r 48 hours incubation 
in Il-4 and IL-13 
Average Ct values of samples run as duplicates. X denotes missing data. 
  18S CatS CA2 CCL26 NELL2 
0 hours Sample 1 7.695 28.32 25.1025 X 31.36 
0 hours Sample 2 7.9425 31.0425 23.245 35.43 X 
0 hours Sample 3 6.8425 29.12 23.3825 34.61 31.5025 
0 hours Sample 4 7.3025 28.0725 24.3175 34.91 29.9625 
24 hours Sample 1 9.015 34.1275 23.0225 32.815 30.0725 
24 hours Sample 2 8.9 29.745 24.7925 36.9625 X 
24 hours Sample 3 8.745 28.18 23.2275 33.25 29.14 
24 hours Sample 4 7.2875 27.845 21.96 33.475 29.94 
48 hours Sample 1 10.0475 28.37 21.735 34.195 28.98 
48 hours Sample 2 X X X X X 
48 hours Sample 3 7.0825 26.6025 24.2975 34.475 29.635 




2.3.2 Intracellular Cathepsin S activity 
Although we were unable to detect CatS peptide expression, mRNA expression suggested 
that the enzyme is present in HaCaT cells. Thus, we next investigated whether CatS activity 
could be detected in these cells, either in cell media or in cell lysates, incubated with a Z-Val-
Val-Arg-MCA substrate that fluoresces following the liberation of 7-amino-4-
methylcoumarin cleaved when by CatS (Kirschke and Wiederanders, 1994). Because the Z-
Val-Val-Arg-MCA substrate can potentially be cleaved by cathepsin L and other cysteine 
lysosomal proteases, and because CatS, unlike other cathepsins, retains its activity at 
physiological pH, this assay was performed at both pH5 and pH7 to determine if the activity 
that was observed was due to CatS and not other proteases (Bromme et al., 1993; Kirschke 
and Wiederanders, 1994; Shi et al., 1992). High levels of fluorescence were detected in 
HaCaT cell lysates at both pH5 and pH7. Although the fluorescence level at pH7 was less 
than that at pH5, it was still significantly greater than the fluorescence in assay buffer alone 
without protein samples (Figure 2.7 A and B). Thus, most fluorescence changes observed in 
this assay at pH7 can be attributed to the cleavage of the Z-Val-Val-Arg-MCA substrate by 
CatS. 
 
To further confirm that the fluorescence changes observed in HaCaT cell lysates, the activity 
assay was performed in the presence of a buffer containing protease inhibitors including 
PMSF and E-64. This resulted in almost a complete reduction of fluorescence and hence 
protease activity in the assay (Figure 2.7 A and B). To test more specifically for the activity of 
CatS, the assay was also performed at pH7 in the presence of the CatS inhibitor MDV-590. 
Pre-incubating the HaCaT cell lysate in MDV-590 for 10 minutes before performing the assay 
resulted in a significant decrease in fluorescence (Figure 2.8), suggesting much of the 
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Figure 2.7: Cathepsin S activity is detected in HaCaT cell lysates and occurs at both acidic 
and neutral pH 
A. Time course of fluorescence changes over a 2 hour period when HaCaT cell lysates were 
incubated with the Z-Val-Val-Arg-MCA substrate at both pH5 and pH7 or in the presence of a 
lysis buffer containing protease inhibitors at pH7. n = 3; 2 replicates per sample, data are 
mean ± SEM. ***p ≤ 0.001, Two-way ANOVA followed by Bonferroni post hoc test.  
B. Quantification of changes in fluorescence at time point 120 minutes (t120) minus the 
initial reading at time point 0 (t0). n = 3; 2 replicates per sample, data are mean ± SEM. ***p 








































Figure 2.8: Cathepsin S activity in HaCaT cell lysates is reduced by the Cathepsin S inhibitor 
MDV-590 
A. Time course of fluorescence changes from HaCaT cell lysates incubated with the Z-Val-Val-
Arg-MCA substrate in the presence of MDV-590 (10 μM). n = 4; 2 replicates per sample, data 
are mean ± SEM. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001, Two-way ANOVA followed by 
Bonferroni post hoc test.  
B. Quantification of changes in fluorescence. n = 4; 2 replicates per sample, data are mean ± 
SEM. *p ≤ 0.05, Student’s t-test. 
2.3.3 Extracellular Cathepsin S activity 
In addition to intracellular CatS activity of HaCaTs, we also wanted to demonstrate that 
HaCaTs could be made to release CatS. It has previously been shown that incubation of 
microglia with LPS and ATP results in the maturation and release of CatS from these cells 
(Clark et al., 2010). We therefore investigated whether stimulation of HaCaTs with LPS and 
ATP could also result in maturation and release of CatS. We first confirmed expression of 
TLR4 and P2X7, the receptors for LPS and ATP, respectively, using qPCR (Figure 2.4). HaCaTs 
were then incubated with LPS (1 µg/ml) for 3 hours and stimulated with ATP (1 mM) for 20 
minutes, and the culture medium was collected to test for CatS activity. However, no 
changes in fluorescence were observed, suggesting no release of CatS from these cells 
(Figure 2.9 A and B). To reduce the possibility that sub-optimal stimulation conditions was  
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Figure 2.9: LPS and ATP do not induce release of Cathepsin S from HaCaTs 
A, B. Time course and quantification of fluorescence changes of supernatant following 
incubation of HaCaTs in LPS (1 µg/ml) for 3 hours and stimulation in ATP (1 mM) for 20 
minutes. n = 4; 6 replicates per sample, data are mean ± SEM. No significance, Two-way 
ANOVA followed by Bonferroni post hoc test (A) and One-way ANOVA followed by Dunnett’s 
multiple comparison test vs HEPES (B). 
C, D. Time course and quantification of fluorescence changes of supernatant following 
incubation of HaCaTs in LPS (1 µg/ml) for up to 12 hours. n = 3, 4; 4 replicates per sample, 
data are mean ± SEM. No significance, Two-way ANOVA followed by Bonferroni post hoc test 
(C) and Two-way ANOVA followed by Bonferroni’s multiple comparison tests (D). 
E, F. Time course and quantification of fluorescence changes of supernatant following 
incubation of HaCaTs in LPS (1 µg/ml) for 6 hours and stimulation in ATP (50 µM or 1 mM) 
for 20 minutes. n = 3, 4; 4 replicates per sample, data are mean ± SEM. No significance, Two-
way ANOVA followed by Bonferroni post hoc test (E) and Two-way ANOVA followed by 





responsible for the lack of CatS activity observed, HaCaTs were also incubated in LPS for up 
to 12 hours (Figure 2.9 C and D), and underwent stimulation with ATP (50 µM or 1 mM) for 
20 minutes following 6 hours incubation in LPS (Figure 2.9 E and F), although in all 
conditions no significant differences in fluorescence, and hence activity of extracellular CatS, 
were observed, suggesting that LPS and ATP do not play a role in the release of CatS from 
HaCaTs. 
 
Because IL-4 and IL-13 have been proposed to be involved in the pathogenesis of atopic 
dermatitis, and because CatS is reported to be upregulated in the skin in atopic dermatitis 
conditions (Danso et al., 2014; Kamsteeg et al., 2011; Kim et al., 2012; Smits et al., 2017; 
Werfel, 2009), we hypothesised that these cytokines might regulate CatS expression in 
keratinocytes. Indeed, as 48 hours incubation with IL-4 and IL-13 resulted in an increase in 
CatS mRNA in our HaCaTs (Figure 2.6 A), we investigated whether this resulted in an 
increase in CatS protein as well, which would subsequently be released from the cells. A 
preliminary study was performed in which HaCaTs were incubated with IL-4 and IL-13 for 48 
hours and release of CatS was measured. However, no changes in fluorescence, and hence 
CatS activity were observed (Figure 2.10 A and B), suggesting that IL-4 and IL-13 on their 
own are not involved in the release of CatS from HaCaTs. To exclude the possibility that IL-4 
and IL-13 increased intracellular CatS without affecting release of CatS from the cells, CatS 
activity was also measured in the cell lysates. However, no significant changes were found in 
CatS activity of HaCaT cell lysates following stimulation with IL-4 and IL-13, (Figure 2.10 C 




























































Figure 2.10: IL-4 and IL-13 did not induce release of Cathepsin S from HaCaTs 
Preliminary data of time course of fluorescence changes in extracellular (A) and intracellular 
(C) solution of HaCaTs following incubation in IL-4 and IL-13 (50 ng/ml) for up to 48 hours. 
Quantification of changes in fluorescence from extracellular (B) and intracellular (D) 
samples. n = 2; 2 replicates per sample, data are mean. No statistics performed. 
 
Since preliminary data suggested that IL-4 and IL-13 are not capable of causing release of 
CatS from these cells on their own, we tested the possibility that incubation with IL-4 and IL-
13 along with LPS and ATP could cause release of CatS from these cells. HaCaTs were 
incubated with IL-4 and IL-13 for 48 hours, followed by incubation with LPS for 6 hours and 
ATP for 20 minutes. However, no significant differences in fluorescence from the 
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Figure 2.11: Combined IL-4 and IL-13 treatment with LPS and ATP does not induce release 
of Cathepsin S from HaCaTs 
Time course of fluorescence changes in extracellular (A) and intracellular (C) solution of 
HaCaTs following incubation in IL-4 and IL-13 (50 ng/ml) for 48 hours, LPS (1 µg/ml) for 3 
hours, and stimulation in ATP (1 mM) for 20 minutes. n = 4; 2 replicates per sample, data are 
mean ± SEM. No significance. Two-way ANOVA followed by Bonferroni post hoc test. 
Quantification of changes in fluorescence from extracellular (B) and intracellular (D) 
samples. n = 4; 2 replicates per sample, data are mean ± SEM. No significance, One-way 












Activation of TRPV4 on keratinocytes has been reported to cause itch sensations (Chen et 
al., 2016). We first confirmed expression of TRPV4 in our HaCaT cells using qPCR (Figure 2.4). 
Running the qPCR products on a gel gave a band of about 100 base pairs, while the 
predicted band size for this product was 76 base pairs based on the primers that were used. 
HaCaTs were incubated in the TRPV4 agonist GSK101 at 10 nM and 100 nM concentrations 
for 20 minutes and CatS activity was measured in supernatant and cell lysates. 100 nM 
GSK101 caused an increase in fluorescence, and hence CatS activity (Figure 2.12 A and B). 
No significant changes in intracellular CatS activity were observed following stimulation with 
GSK101 (Figure 2.12 C and D). To investigate if IL-4 and IL-13 could enhance TRPV4-
mediated release of CatS, HaCaT were stimulated with GSK101 (10 nM and 100 nM) for 20 
minutes following pre-incubation in IL-4 and IL-13 for 48 hours. Although a significant 
increase in fluorescence was observed following stimulation with 100 nM GSK101 compared 
with stimulation of 10 nM GSK101 or DMSO (Figure 2.12 E and F), it was not significantly 
enhanced compared with the activity observed following stimulation with 100 nM GSK101 
in the absence of pre-incubation with IL-4 and IL-13. Furthermore, no significant increase in 
CatS activity was observed following stimulation of HaCaTs with 10 nM GSK101 in the 
presence of IL-4 and IL-13, suggesting no sensitisation of these cells to release CatS in 
response to these cytokines. No significant changes in intracellular CatS activity were 
observed following stimulation with GSK101 with pre-incubation in IL-4 and IL-13 (Figure 
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Figure 2.12: TRPV4 activation induces the release of Cathepsin S from HaCaTs 
Time course of fluorescence changes in extracellular (A) or intracellular (C) solution of 
HaCaTs following 20 minute incubation in 0.001% DMSO (vehicle) or GSK101 (10 nM or 100 
nM). Time course of fluorescence changes in extracellular (E) or intracellular (G) solution of 
HaCaTs following 48 hour incubation in IL-4 and IL-13 (50 ng/ml) and 20 minute incubation 
in DMSO or GSK101. n = 6, 7; 2 replicates per sample, data are mean ± SEM. **p ≤ 0.01; 
***p ≤ 0.001, Two-way ANOVA followed by Bonferroni post hoc test. Quantification of 
changes in fluorescence from extracellular (B, F) and intracellular (D, H) samples. n = 6, 7; 2 
replicates per sample, data are mean ± SEM. *p ≤ 0.05; **p ≤ 0.01, One-way ANOVA 




Entry of calcium into keratinocytes, fibroblasts and epithelial cells induces exocytosis of 
lysosomes (Jans et al., 2004; Rodriguez et al., 1997). Since CatS is a lysosomal protease, we 
hypothesised that entry of calcium into HaCaTs might be responsible for the release of CatS. 
Furthermore, because TRPV4 channels allow for the entry of cations such as calcium ions 
into the cell (Nilius et al., 2003; Voets et al., 2002), we further hypothesised that the entry of 
extracellular calcium though these channels might be the mechanism by which CatS is 
released. We therefore incubated HaCaTs in GSK101 (100 nM) or DMSO in the presence of a 
buffer with 1 mM calcium and a buffer without calcium ions added to it. When it came to 
performing the activity assay, the supernatant from cells incubated in GSK101 or DMSO in 
buffer without calcium added to it had assay buffer containing 2 mM calcium, such that the 
final concentration of calcium was 1 mM, the same for all experiments, as initial 
experiments suggested that CatS activity may be affected by the concentration of calcium 
ions in the assay buffer. We observed that incubation of cells in GSK101 in the buffer 
containing 1 mM calcium resulted in significant CatS activity, while the activity from cells 
incubated in DMSO or GSK101 in the buffer without calcium ions added to it did not show 
any significant CatS activity (Figure 2.13 A and B), suggesting extracellular calcium ions are 













































Figure 2.13: Extracellular calcium is required for TRPV4-mediated release of Cathepsin S 
from HaCaTs 
A. Time course of fluorescence changes from the supernatant of HaCaT cells incubated with 
the Z-Val-Val-Arg-MCA substrate following stimulation with 100 nM GSK101 for 20 minutes 
prior to the assay being performed. n = 5, 6; 2 replicates per sample, data are mean ± SEM. 
*p ≤ 0.05, Two-way ANOVA followed by Bonferroni post hoc test.  
B. Quantification of changes in fluorescence. n = 5, 6; 2 replicates per sample, data are mean 
± SEM. *p ≤ 0.05, One-way ANOVA followed by Bonferroni’s multiple comparison test. 
2.4 Discussion 
Several findings relating to expression and release of CatS from skin keratinocytes were 
made in this chapter. We confirmed expression of CatS mRNA in the HaCaT cell line, and 
that incubation of these cells in LPS or IL-4 and IL-13 cytokines results in an increase in CatS 
mRNA. Furthermore, we demonstrated that HaCaTs contain intracellular active CatS 
protease that can cleave a substrate, emitting a fluorescent signal that can be measured as a 
proxy for CatS activity, and that stimulation of HaCaTs with the TRPV4 agonist GSK101 
results in the release of CatS from these cells. This TRPV4-mediated release of CatS is 
dependent on the presence of extracellular calcium ions. 
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Although we could confirm expression of CatS mRNA in HaCaT cells using qPCR, we were 
unable to detect expression of CatS protein in our cells using either antibody staining of 
fixed cells or Western blotting. Staining of HaCaTs using the lysosomal marker LAMP-1 
revealed punctate staining around the nucleus of the cell, similar to previous reports by 
other groups using primary human keratinocyte cell cultures (Jans et al., 2004; Sarafian et 
al., 2006). In primary microglia cultures, CatS protein is co-localised with LAMP-1 and can be 
visualised in cells stained with antibodies (Clark et al., 2010). However, we were unable to 
detect expression of CatS protein in our cells, despite using two different antibodies for 
CatS. Nevertheless, one of the antibodies used detected expression of CatS in mouse spinal 
cord tissue, which co-localised with Iba1, suggesting the antibody is able to detect CatS 
expressed in murine spinal cord microglia, but not in human keratinocytes. Although the 
antibody claims to be able to detect human CatS in addition to murine CatS, we were unable 
to detect staining for CatS in our human cell line. However, the same antibody for Western 
blotting detected bands for purified human recombinant CatS. The band sizes were at about 
25 kDa, while mature CatS is predicted to be 24 kDa in size (Wiederanders et al., 1992). At 
least two faint bands of smaller sizes were detected in the purified CatS sample, although it 
is not known whether these are fragments of CatS protein in the sample or whether some 
non-specific staining has occurred. No bands of larger sizes were detected, suggesting the 
antibody does not detect unprocessed CatS or that insufficient quantities of unprocessed 
CatS were in our samples to be detected using this method. The same antibody for CatS 
used in other experiments was able to detect the presence of both pre-pro and pro-forms of 
CatS, as well as the mature form (Clark et al., 2010). This suggests the pre-pro and pro forms 
of CatS are also undetected in our samples. Despite the ability of the antibody to detect 
purified CatS, no bands were observed in either HaCaT or THP-1 positive control. It cannot 
be ruled out that HaCaTs do not normally express much CatS protein, as THP-1 cells, which 
are reported to express CatS (Pawar et al., 2016), also failed to show bands for CatS. 
Furthermore, bands for actin could be detected in our HaCaT samples, suggesting the 
presence of adequate concentrations of protein for Western blotting. Thus, it is likely that 
insufficient quantity of CatS protein is expressed in these cells to be detected using antibody 
staining and Western blotting techniques, while the activity assay may be sensitive enough 
for the low levels of CatS in our cells. Indeed, this is in agreement with other studies in 
which CatS protein was undetectable in healthy skin keratinocytes (Schonefuss et al., 2010). 
However, under certain conditions, such as those found in atopic dermatitis, keratinocytes 
may increase expression of CatS. Thus, to establish whether upregulation of CatS is required 
for its detection using antibody staining and Western blotting, future experiments should be 
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performed in which HaCaTs are incubated with LPS or IL-4 and IL-13 to determine if 
increased CatS mRNA corresponds with detection of CatS protein using these methods. 
 
Despite being unable to detect expression of CatS protein in HaCaTs, HaCaT cell lysates 
demonstrated protease activity with the ability to cleave the Z-Val-Val-Arg-MCA substrate. 
This substrate can be cleaved by Cathepsins B and L as well as CatS, however most activity is 
reported with CatS compared with other cathepsins, and the activity of other cathepsins on 
this substrate is abolished at pH7 while CatS maintains 60-70% of its activity at this pH 
(Kirschke and Wiederanders, 1994). Thus, at pH7, this substrate is most specific for CatS. We 
observed that HaCaT cell lysates could cleave the Z-Val-Val-Arg-MCA substrate, resulting in a 
fluorescent signal that is taken as a readout of protease activity. Activity was observed at 
pH5 and pH7, although fluorescence at pH7 was about half that observed at pH5, which is 
less than what has previously been reported. Nevertheless, substantial fluorescence 
readouts were obtained at pH7 compared with buffer, suggesting the presence of active 
CatS in the HaCaT cell lysate. When the cells were lysed using a lysis buffer containing 
protease inhibitors, fluorescent readout was low, likely due to prevention of cleavage of the 
substrate by CatS. To further confirm that the fluorescence changes observed were due to 
the activity of CatS on the Z-Val-Val-Arg-MCA substrate, the assay was repeated in the 
presence of the CatS inhibitor MDV-590, resulting in a modest reduction in fluorescence 
readout. Cell lysates were incubated in MDV-590 for 10 minutes prior to the assay being 
performed, which may not have allowed sufficient time for maximal inhibition of CatS 
activity in the samples. Furthermore, the concentration of MDV-590 used may not have 
been enough to allow for complete inhibition of CatS activity. The concentration of MDV-
590 used was based on the upper ranges of the preferable concentration for inhibition of 
physiological proteases (Medivir UK Ltd (2011), New Cathepsin S protease inhibitors, useful 
in the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions. 
International Patent Application WO2011/158197). Furthermore, because MDV-590 is 
dissolved in DMSO, increasing the concentration of MDV-590 would have also increased the 
concentration of DMSO used in the assay, which could have resulted in unwanted effects. 
Addition of MDV-590 to the samples at earlier time points could also have been performed, 
but would have resulted in the samples being left on ice for long periods of time, potentially 
resulting in premature CatS activity, which could have affected overall CatS activity and 
prevented comparison of these results with other activity assays using cell lysate samples. 
Thus, further optimisation of the assay is still required to completely block the effects of 
CatS activity using MDV-590. 
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Incubating HaCaTs in LPS for 6 hours resulted in a 50-fold increase in the expression of TLR4, 
the receptor for LPS. Expression of TLR4 in HaCaTs and primary keratinocytes has previously 
been confirmed, with increasing expression as cells undergo differentiation and following 
incubation with LPS or LPS and IFNγ (Iotzova-Weiss et al., 2017; Kollisch et al., 2005; Pivarcsi 
et al., 2003; Pivarcsi et al., 2004; Song et al., 2002). Using 100 ng/ml LPS, Kollisch et al. 
(2005) found that TLR4 mRNA was maximal after 8 hours incubation in LPS and began to 
decline at 24 hours incubation in LPS, although TLR4 mRNA was still much greater than that 
from untreated cells. They also found that 2 hours incubation in LPS did not have any 
significant effects on TLR4 mRNA levels, which is similar to the lack of effect of 3 hours LPS 
incubation that we observed. Increased expression of TLR4 following incubation of cells in 
LPS would potentially result in a positive feedback loop, whereby cells become more 
responsive to LPS and further increase expression of TLR4. However, as expression of TLR4 
mRNA was shown to decrease by 24 hours incubation in LPS, this likely acts as a mechanism 
to prevent excessive expression of TLR4 on keratinocytes and potential damage to cells in 
response to long-term exposure to LPS. TLR4 also suppresses proliferation of keratinocytes, 
with increased proliferation observed in HaCaTs in which TLR4 expression is knocked down, 
and decreased proliferation in a squamous cell carcinoma line over-expressing TLR4 
(Iotzova-Weiss et al., 2017). In healthy skin, this could serve to prevent proliferation of 
differentiating cells that leave the basal layer, as expression of TLR4 increases. 
 
Expression of CatS mRNA in HaCaTs was increased 40-fold following 6 hours incubation in 
LPS, compared with incubation in buffer. No increase in CatS mRNA was observed after 3 
hours incubation in LPS. Incubation of human cervical smooth muscle cells in LPS for 12 
hours has previously been shown to increase expression of CatS mRNA by 12.5-fold (Watari 
et al., 2000). Although we obtained a greater increase in CatS mRNA than Watari et al., 
despite the shorter incubation time in LPS, we also used a greater concentration of LPS (1 
μg/ml) than that used by Watari et al. (100 ng/ml). The LPS serotype that was used also 
differed, as we used serotype O11:B4 LPS, while serotype O55:B5 LPS was used by Watari et 
al. Furthermore, we detected changes in mRNA expression using qPCR, while Watari et al. 
detected mRNA changes using Northern blotting, which is less sensitive than qPCR. Finally, 
the difference in cell type (HaCaT versus cervical smooth muscle cell) could explain the 
observed differences in CatS mRNA changes in response to LPS. LPS has also been reported 
to result in upregulation of CatS mRNA in bipolar/rodshaped microglia that have been 
transformed into amoeboid microglia, as detected using qPCR (Tam et al., 2016). 
Upregulation of CatS in these experiments was much lower, at about 1.3-fold. However, as 
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with Watari et al., a different concentration (10 μg/ml) and serotype (O127:B8) of LPS was 
used by Tam et al. It is interesting to note that, despite using a greater concentration of LPS 
than in our experiments and incubating cells for the same length of time in LPS, Tam et al. 
reported a lower increase in CatS mRNA in their microglia than we did in HaCaTs. One 
possibility is that excessive LPS is suboptimal and impairs the upregulation of CatS mRNA 
following incubation in LPS. In support of this, Watari et al. found that incubating cervical 
smooth muscle cells in LPS for 48 hours resulted in a reduced upregulation of CatS mRNA, 
compared with incubation in LPS for 12 or 24 hours. Similarly, a reduction in the 
upregulation of CatS mRNA was observed when cervical smooth muscle were incubated in 1 
μg/ml LPS compared with incubation in 100 ng/ml LPS. 
 
LPS has previously been demonstrated to prime microglia to release CatS, causing slight 
increases in the expression of pre and mature forms of CatS protein (Clark et al., 2010). 
However, we did not observe an increase in CatS activity from HaCaT cell supernatant 
following incubation with LPS for up to 12 hours, suggesting LPS only upregulates the 
expression of CatS mRNA, and may or may not affect translation of CatS mRNA or processing 
of CatS into its mature form in our cell line. Although LPS was required for priming microglia 
to release CatS, release of CatS from these cells was observed only when followed by 
stimulation with high concentration ATP (Clark et al., 2010). Furthermore, significant 
increases in the expression of the pre- and mature forms of CatS protein were reported 
following treatment of microglia with both LPS and ATP (Clark et al., 2010). Thus, while LPS 
might increase the expression of LPS mRNA, ATP might be required for this to result in an 
increase in the release of active CatS from cells. However, in contrast to Clark et al., (2010), 
we were unable to observe any changes in CatS activity following stimulation of HaCaTs with 
high concentration ATP. To exclude the possibility that ATP activity might be modulated by 
P2X4 activity on keratinocytes rather than P2X7, HaCaTs were also stimulated with a lower 
concentration of ATP (50 μM). However, this also did not affect the release of CatS from 
these cells, even when primed with LPS prior to stimulation. This suggests that, in contrast 
to microglia, keratinocytes do not release CatS in response to LPS and ATP. 
 
If LPS and ATP do not cause the release of CatS from HaCaTs, then what are the mediators 
that might enable the release of CatS from these cells? Following incubation of HaCaTs in 
the Th1 cytokines IFNγ and TNFα, the release of CatS has been reported (Schonefuss et al., 
2010). In these experiments, CatS was detected in the supernatant of the cells following 
cytokine treatment. This suggests the release of CatS from keratinocytes in psoriasis and 
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other skin diseases characterised by Th1 cytokines. However, whether CatS is released from 
keratinocytes in other skin diseases, such as those mediated by Th2 cytokines, was one of 
the questions we aimed to address in this chapter. Expression of the Th2 cytokines IL-4 and 
IL-13 is reported to be increased in the skin of patients with atopic dermatitis, supporting a 
role for these cytokines in itch (Werfel, 2009). We hypothesised that release of these 
cytokines from T cells could result in increased expression and release of CatS from 
keratinocytes, which would be responsible for activating sensory neurons and transmission 
of itch signals in atopic dermatitis. To address this question, we first determined whether 
expression of CatS would be increased following incubation in the Th2 cytokines IL-4 and IL-
13. Incubation of HaCaTs in these cytokines for 48 hours resulted in a 2.5-fold increase in 
CatS mRNA compared with untreated cells. However, expression of CA2, CCL26, and NELL2 
was not significantly altered following incubation of cells in IL-4 and IL-13. CA2, CCL26, and 
NELL2 have all previously been used as in vitro markers for atopic dermatitis and have been 
reported to be increased in the skin of patients with this condition. Stimulation of primary 
keratinocytes, N/TERT keratinocytes, and HaCaTs with these cytokines has previously been 
shown to result in increased expression of CA2 and CCL26 (Bao et al. 2012, Bao et al., 2013, 
Kagami et al., 2005; Smits et al. 2017). This suggests we were unable to fully mimic atopic 
dermatitis conditions in vitro, although we were still able to observe upregulation of CatS. 
Compared with incubation in LPS, the increased expression of CatS mRNA following 
incubation in IL-4 and IL-13 is much lower, suggesting a much smaller effect with these 
cytokines. Thus, one possibility is that the cells have not been optimally treated to release 
CatS and express markers of atopic dermatitis in Th2 conditions. For example, Kagami et al. 
(2005) reported that incubation of HaCaTs with IL-4 and TNFα resulted in an increase in 
CCL26 that was larger than when either cytokines were used alone, suggesting they can act 
synergistically. This should not be so surprising, given that chronic atopic dermatitis lesions 
are associated with an increase in Th1 cytokines in addition to Th2 cytokines. Thus, a more 
accurate atopic dermatitis model in vitro might involve the presence of Th1 cytokines in 
addition to Th2 cytokines, and might be required for both upregulation ond release of CatS 
and potentially other pruritogens from keratinocytes. 
 
Since incubation of HaCaTs in IL-4 and IL-13 for 48 hours increased expression of CatS mRNA 
in HaCaTs, we investigated whether these cytokines would also affect the release of CatS. 
However, because incubation for 48 hours was required, the cells needed to be maintained 
in their culture medium to prevent cell death and other changes due to being outside of 
their normal growth conditions for long periods of time. This resulted in the protocol being 
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unsuitable for the assay for measuring CatS activity, as the HaCaT culture media contains 
phenol red, with no suitable phenol red-free alternative existing, and the activity assay 
measures changes in fluorescence that could be interfered with by the phenol red in the 
culture media. A preliminary trial measuring CatS activity in the supernatant of HaCaTs 
stimulated with IL-4 and IL-13 in their culture media yielded negative results, suggesting IL-4 
and IL-13 do not cause the release of CatS from these cells, but it cannot be excluded that 
the presence of phenol red in the samples interfered with the fluorescence readings. As an 
alternative, we investigated whether incubation of HaCaTs with IL-4 and IL-13 would result 
in LPS and ATP-mediated release of CatS from these cells. However, IL-4 and IL-13 did not 
affect the release of CatS, with or without the addition of LPS and ATP. Furthermore, no 
differences in intracellular CatS were observed. We thus conclude that IL-4 and IL-13, on 
their own or in combination with LPS and ATP, do not affect the intracellular activity of CatS 
or the release of CatS from HaCaTs, despite increasing the expression of CatS mRNA. 
Nevertheless, it cannot be excluded that IL-4 and IL-13 are not involved in the release of 
CatS from keratinocytes in atopic dermatitis and other skin conditions. Since others have 
reported increased expression of markers of atopic dermatitis following incubation of cells 
with IL-4 and IL-13, and since we did not observe an increase in these markers in our 
experiments, it is possible that optimal conditions would allow for increased expression of 
these markers and even greater increase in the expression of CatS mRNA, as well as the 
release of CatS from cells and/or increased intracellular activity of CatS. 
 
Treatment of HaCaTs with the TRPV4 agonist GSK101, on the other hand, resulted in a 
significant increase in extracellular CatS activity, indicative of an increase in the release of 
CatS following activation of TRPV4 on these cells. Incubation of keratinocytes with GSK101 
has previously been shown to result in calcium transients (Moore et al., 2013). In 
keratinocytes, entry of calcium induces exocytosis of lysosomes. Jans et al., (2004) found 
that treating keratinocytes with ionomycin to raise intracellular calcium levels increased the 
appearance of LAMP-1 and LAMP-2 lysosomal markers at the surface of the cell. Thus, entry 
of calcium into the cell following activation of TRPV4 could also mediate exocytosis of 
lysosomes from the cell, resulting in the release of CatS. In support of this, we demonstrated 
that extracellular calcium was required for TRPV4-mediated release of CatS. This is also in 
agreement with the observations of Moore et al. (2013), who found that extracellular 
calcium was required for GSK101-mediated calcium transients in cultured keratinocytes. 
Similarly, extracellular calcium has been shown to be required for LPS and ATP-mediated 
release of CatS from microglia (Clark et al., 2010). However, the downstream mechanisms of 
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TRPV4-mediated release of CatS have yet to be explored. Release of calcium from 
intracellular stores may also be involved, as was reported for microglia by Clark et al. (2010), 
and should be addressed in future experiments to determine if release of calcium from 
intracellular stores can further enhance TRPV4-mediated release of CatS from keratinocytes. 
 
Specificity of the action of GSK101 on the TRPV4 receptor should also be addressed in future 
experiments, for example, by stimulating release of CatS from cells in the presence of a 
TRPV4 antagonist such as HC067047. The specificity of molecules commonly used as TRPV4 
agonists, such as 4αPDD, has been questioned and it is reported to have off-target effects 
(Alexander et al., 2013). Likewise, GSK101 may have offtarget effects that should be 
addressed. Stimulation of TRPV4-mediated CatS release from keratinocytes could 
additionally be performed using other TRPV4 agonists, such as bisandrographolide A, a 
plant-based molecule reported to exclusively target TRPV4 (White et al., 2016). 
 
It has recently been reported that GSK101 results in morphological changes and subsequent 
cell death of several different cell types, including HaCaT cells (Olivan-Viguera et al., 2018). 
This raises the possibility that the death of cells following treatment with GSK101 causes 
them to release their contents, and this could result in the increased CatS activity observed 
in our assay. However, no significant changes in intracellular CatS activity were observed 
following incubation with GSK101, suggesting the cells had not undergone apoptosis and 
had retained most of their intracellular contents during treatment. This is similar to other 
reports that incubation of HaCaTs and other cell lines in GSK101 for several hours does not 
affect cell viability (Fang et al., 2018; Fusi et al., 2014; Thoppil et al., 2015). Moreover, 
incubation of hepatic stellate cells with TRPV4 agonists results in a decrease in apoptosis in 
these cells, suggesting activation of TRPV4 prevents against apoptosis (Zhan et al., 2015). 
 
To conclude, we have demonstrated that the HaCaT keratinocyte cell line express CatS 
mRNA, and although we were unable to detect CatS protein in our cells, it is likely that 
healthy keratinocytes do not normally express large quantities of CatS in any event. 
Furthermore, lysed HaCaT samples demonstrated protease activity at pH7, at which the 
activity of all other cathepsins is diminished, and could be reduced in the presence of a CatS 
inhibitor, suggesting these cells do contain active CatS, although at levels that cannot be 
detected using antibody staining of fixed cells or Western blotting techniques. Incubation of 
HaCaTs with Th2 cytokines did increase the expression of CatS mRNA, but did not result in 
the release of CatS from these cells, although additional cytokines may be required for 
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release, reflecting the complex nature of cytokine signalling during skin diseases such as 
atopic dermatitis. Further experiments should be performed to determine whether 
conditions which result in increased CatS mRNA in HaCaTs also results in increased 
expression of the protease that can be detected using antibody and Western blotting 
methods. Finally, activation of TRPV4 channels results in the release of CatS from HaCaTs, 
although whether this mechanism of CatS release from skin keratinocytes plays a role in 

























Chapter 3  
Activation of cultured sensory neurons by Cathepsin S 
3.1 Introduction 
CatS is a pruritogen that causes itching sensations in healthy human subjects and scratching 
behaviour when injected into mice (Reddy et al., 2010). There are two main mechanisms by 
which CatS -mediated pruritus may be achieved. The first is direct activation of sensory 
neurons following cleavage of receptors such as PAR2. Alternatively, CatS may result in 
pruritus by activating receptors on non-neuronal cells, causing them to release pruritogens 
such as histamine that then activates sensory neurons or mediators that sensitise neurons 
and make them more likely to respond to pruritogens. 
 
The similarity of the peptide sequences between human and mouse CatS and PAR2 
underlies their importance throughout evolution and suggests the human analogue of the 
protease may be able to interact with receptors from the mouse and vice versa. Indeed, 
using NCBI Protein BLAST (National Center for Biotechnology Information, Bethesda, MD, 
USA) to compare human and mouse CatS protein sequences (GenBank accession numbers 
AAC37592.1 and BAE29827.1 respectively) and PAR2 sequences (GenBank accession 
numbers AAP97012.1 and NP_032000.3 respectively) revealed more than 70% similarity 
between proteins from the two species (Figure 3.1). It has also been previously published 
that the protein sequence of the PAR2 receptor for CatS is more than 80% similar between 
human and mouse (Böhm et al., 1996b). Furthermore, the use of human CatS on cells 
derrived from mice has already been previously observed (Zhao et al., 2014a). Since human 
recombinant CatS was provided from Medivir as a purified and activated enzyme, unlike 
commercially supplied CatS which must first be actiated and so contains DTT and EDTA, we 
therefore decided to investigate the effects of this human CatS on cells cultured from mouse 






Figure 3.1: Comparison of human and mouse CatS (A) and PAR2 (B) peptide sequences 
Human and mouse CatS protein sequences were determined from GenBank accession 
numbers AAC37592.1 and BAE29827.1, respectively, and PAR2 sequences from GenBank 
accession numbers AAP97012.1 and NP_032000.3, respectively. 
 
Chapter objectives 
Pruriceptors can be regarded as a subset of nociceptors, as determined by their response to 
the TRPV1 agonist capsaicin and other algogens, and are considered as being pruriceptors if 
they also respond to application of a pruritogen. In this regard, we assume for the purposes 
of this chapter that pruriceptors are polymodal, capable of responding to both algogens and 
pruritogens, but as to whether the sensation that would be experienced would be itch or 
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pain following activation of these neurons is beyond the scope of this chapter. Instead, we 
aimed to characterise the neurons that would respond to pruritogen CatS that likely 
underlie the itching and scratching behaviour observed in vivo. 
 
The primary aim of this chapter therefore was to determine if sensory neurons could 
respond to direct application of CatS, and hence whether CatS itself can directly act as a 
pruritogen, rather than acting via an indirect mechanism. To investigate whether sensory 
neurons could respond directly to application of CatS and characterise these neurons, 
isolated mouse DRGs were exposed to human CatS and various other compounds in both 
patch clamping and calcium imaging experiments. 
3.2 Methods 
3.2.1 Production of human recombinant Cathepsin S in baculovirus 
Human recombinant CatS was provided by our industrial collaborators at Medivir, produced 
using the methods detailed below, and was used in all subsequent experiments in this 
chapter and in chapter 4. 
 
Human pro-CatS, with a hexa-histidine tag, was expressed in the Sf9 insect cell line using a 
FlashBAC One recombinant baculovirus (Oxford Expression Technologies, UK). Sf9 cells were 
grown in Insect-Xpres protein-free culture medium (Lonza, Switzerland) without antibiotics, 
incubated at 28˚C and agitated at 100 rotations per minute. Cells were seeded at a density 
of 0.5 x106 cell/ml and split every 3-4 days to maintain optimal growth conditions. Virus 
stock was maintained by infecting a culture of Sf9 cells at a density of 1 x 106 cells/ml, and 
was harvested after a few days in culture. An expression culture was established in a culture 
of Sf9 cells seeded at a density of 1 x 106 cells/ml and allowed to grow for 24 hours before 
addition of virus stock at a ratio of 1 part virus to 5 parts cell culture. Cells were counted and 
visually inspected every 24 hours to confirm infection of the cells by the virus, as indicated 
by a decrease in the rate of cell growth and the appearance of swollen and dead cells. 
Supernatant was collected 72 hours after infection and protein was harvested by 
centrifugation at 3,000 g for 10 minutes. 
 
Harvested proteins were purified using immobilised metal ion affinity chromatography 
(IMAC) over a Ni Sepharose 6 Fast Flow column (GE Healthcare, USA). All steps were 
performed at 4˚C. The nickel beads were equilibrated in a wash buffer (1x PBS at pH7.4–7.5, 
138 
 
containing NaCl, 0.36 M; glycerol, 10%; imidazole, 50 mM; PMSF, 0.2 mM) before use. The 
harvested supernatant containing proteins was then added to the equilibrated nickel beads, 
to which NiSO4 (1 mM) was added. The suspension was mixed for 90 minutes at 70-80 rpm 
to prevent the nickel beads from sinking to the bottom and allow binding of the histidine-
tagged proteins to the beads. The bead suspension was poured through a No.2 Pyrex filter 
and the beads were recovered and packed into an Econo-pac chromatographic column (Bio-
Rad, USA). The beads were washed with wash buffer to remove any proteins that bound 
weakly to the beads. CatS was eluted using elution buffer (1x PBS at pH7.4–7.5, containing 
NaCl, 0.36 M; glycerol, 10%; imidazole, 250 mM; PMSF, 0.2 mM), the higher concentration 
of imidazole in this buffer displacing the histidine-tagged CatS from the beads, and a 
minimum of 10 fractions were collected. The purity of the collected fractions was checked 
by running an SDS-PAGE gel. Following purification, CatS was dialysed overnight to remove 
imidazole and EDTA was added for sequestering ions such as calcium, magnesium, and 
nickel that may be added during the purification process or derive from the culture medium. 
The purest fractions of CatS protein were pooled together and the concentration of protein 
was measured using a spectrophotometer. Dialysis was performed at 4˚C using dialysis 
tubing cellulose membrane with a 14,000 Da cut-off (Sigma, UK). The pooled fractions of 
CatS protein were poured into the tubing and placed overnight in a beaker containing 
dialysis buffer (PBS at pH7.4–7.5, containing NaCl, 0.36 M; glycerol, 10%; EDTA, 2 mM; 
PMSF, 0.2 mM). Protein concentration was again checked the following day using dialysis 
buffer as a blank. The purified CatS is required to be concentrated to about 20 mg/ml, as 
this is the optimum concentration for activating it. This was performed by centrifuging the 
protein through an Amicon Ultra-15 centrifuge filter with a cut-off of 10,000 Da (Merck 
Millipore, UK) at 3,300 g for 25 minutes at 4˚C. The concentration and purity of the 
concentrated CatS was then remeasured using a spectrophotometer and by running another 
SDS-PAGE gel to ensure successful concentration. 
 
Because CatS was secreted from the cells in its pro-form, it is required to be activated 
before it can be used in experiments. However, before it can be activated, the activation 
time course of the pro-CatS needs to be measured to determine the optimal incubation time 
for activation of CatS. This assay requires 11 μM DTT to be made up in activation buffer (Na 
acetate, 1.1 M; NaCl 1.1 M; EDTA, 55 mM, at pH 4.5), and 1 part of this DTT to be added to 5 
parts of the purified, concentrated pro-CatS. The CatS/DTT mixture is then placed on a 
heatblock at 37˚C. Every 5 minutes, 1 μl of this mixture is diluted 1:10 in assay buffer (ADA, 
100 mM; NaCl, 100 mM; PEG4000, 0.1%, at pH 6.5), after which 1 μl is then further diluted 
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1:250 in substrate buffer (ADA, 100 mM; NaCl, 100 mM; PEG4000, 0.1%; DTT, 1 mM; boc-
val-leu-lys-AMC, 100 μM, Bachem, Switzerland, at pH 6.5) in a white polystyrene round-
bottom 96-well plate (Corning, UK). The plate was read using a CLARIOstar 
Spectrophotometer (BMG Labtech, UK) at excitation wavelengths of 360 – 390 nm and 
emission wavelengths of 450 – 470 nm every second for 10 seconds. Readings were taken 
after each 5-minute incubation period until the activity started to decrease. The peak of the 
time course, which represents optimum CatS activity where the pro form of CatS has been 
cleaved but non-specific cleavage that deactivates the protease has not yet occurred, is 
usually reached within 20 – 90 minutes. To activate CatS, 10 μl of activation buffer is added 
for every 100 μl of purified pro-CatS there is. Upon addition of the activation buffer, the pH 
will be reduced, allowing partial unfolding of CatS to open up the cleavage site for 
activation. The CatS and activation buffer mixture is then placed on a heat block at 37˚C for 
the length of time that was required to reach peak activity during the activation time 
course. After heating, the mixture is centrifuged at 14,000 rpm for 5 minutes to remove any 
precipitates that may form during heating, and the CatS is transferred to a new microfuge 
tube kept on ice. 
 
Activated CatS was buffer exchanged into 1x PBS (pH7.4) using an Econo-Pac 10DG column 
(Bio-Rad, USA). The column was first equilibrated with 1x PBS and the flow-through 
discarded. To ensure the highest concentrations of activated CatS were collected, the 
protein was passed through the column followed by 1x PBS, and the drops that came out of 
the column were collected one at a time into a UV-transparent 96-well plate (UVStar, 
Greiner Bio-One, Austria). The plate was centrifuged at 500 g for 30 seconds and the 
absorbance was measured at 280 nm wavelength using a CLARIOstar Spectrophotometer. 
The protein in the wells which contained the highest absorbance values was collected and 
pooled into a new microfuge tube on ice. 
 
The active site concentration of CatS was determined by titration with cysteine protease 
inhibitor E-64. E-64 was diluted in DMSO to give 100 μM stocks. The activated and desalted 
CatS was diluted 1:400 in assay buffer, to which DTT (1 mM) was added. 200 μl of this CatS 
mixture was added to the first well in one row of a polystyrene 96-well plate, while 100 μl 
was added to the remaining wells in that row. 2 μl of the diluted E-64 was then added to the 
first well in the row (final E-64 concentration 1 μM) and mixed. 100 μl was then transferred 
from this first well to the next well in the row, resulting in “double dilution”, in which the 
concentration of E-64 was halved. This double dilution was carried out across the row of the 
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plate, discarding the last 100 μl. The plate was then sealed and incubated at room 
temperature for at least one hour. Into each well of one of the roes of a new white 96-well 
plate, 100 μl of substrate buffer was added. 1 μl from each well of the first polystyrene plate 
was added to the corresponding wells of this new plate containing substrate buffer (i.e. 1 μl 
from the well in row 1 of the first plate was added to the contents of the well in row 1 of 
this plate, etc.). The plate was then read at excitation wavelengths of 360 – 390 nm and 
emission wavelengths of 450 – 470 nm every 30 seconds for 31 to 61 cycles (i.e. for 15 to 30 
minutes). The rate of activity was plotted against the E-64 concentration and linear 
regression of non-zero rates was performed. The concentration of active sites in the CatS 
was determined by multiplying the x-intercept by 400 (i.e. the amount by which the CatS 
was diluted for performing this assay). From this assay, the concentration of activated CatS 
stock in mg/ml was obtained. From this, CatS stocks were diluted to 2 mg/ml concentrations 
in 1x PBS and aliquoted at 50 μl in cryovials. The aliquots were labelled with the batch 
number, concentration, volume, and dates, and stored at -80˚C. 
 
Before measuring the substrate kinetics of activated CatS, an initial dilution experiment is 
performed to find the optimal dilution of CatS to use for the kinetics assays. The initial 
dilution is performed by adding 200 μl of substrate buffer to the first well in one row of a 
white 96-well plate and 100 μl to the rest of the wells in that row. A 1:10 dilution of the 
activated CatS is made before starting the assay by diluting in assay buffer. 2 μl of this 
diluted CatS was then added to the substrate buffer in the first well in the row of the plate. 
The contents of the well were mixed, and 100 μl of this was transferred to the next well of 
the plate. This double dilution was performed across all wells in the row, such that the 
concentration of CatS in each well was halved each time, and the last 100 μl was discarded 
to ensure the volume in all wells was the same. The plate was then read at excitation 
wavelengths of 360 – 390 nm and emission wavelengths of 450 – 470 nm every 30 seconds 
for 61 cycles. The well in which most CatS activity can be observed indicates the factor by 
which the activated CatS needs to be diluted for use in the kinetics assay.  
 
The substrate kinetics of CatS were measured by adding 100 μl of DMSO (12.5%, diluted in 
assay buffer) to wells 2 – 8 across one row of a polypropylene 96-well plate. A mixture of 
179 μl of assay buffer and 25 μl of substrate buffer was mixed in the first well of the row, 
and 100 μl was transferred to the second well containing DMSO. This double dilution was 
performed across all well in the row that contained DMSO, such that the concentration of 
substrate in each well was halved. 20 μl of the contents of each well was then transferred to 
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three rows in a new 96-well plate, such that the reaction could be performed in triplicate to 
obtain an average value. To each of the wells in the new assay plate, 80 μl of CatS, diluted in 
assay buffer and DTT (1 mM) to the concentration determined in the initial dilution 
experiment, was added. The plate was then read at excitation wavelengths of 360 – 390 nm 
and emission wavelengths of 450 – 470 nm every 30 seconds for 61 cycles. The rate is fitted 
by linear regression, plotted against substrate concentration and fitted to the Michaelis-
Menten equation. The specific activity of CatS can be calculated using the formula (Vmax x 
assay dilution) / (enzyme concentration x 155 x 25), where 155 is the fluorescence of 1 μM 
AMC and 25 is the MW of CatS in kDa.  
 
Inhibitor kinetics were determined as follows. The CatS substrate boc-val-leu-lys-AMC 
(Bachem, Switzerland) was diluted in assay buffer to 1 mM, of which 20 μl was added to the 
first wells in two rows of a 96-well plate, while 10 μl was added to the wells 2 – 8 in these 
two rows of the plate. The CatS inhibitor MVO78590 was diluted in DMSO to 10 μM, and 2 
μl was added to the first well in the top row, while 2 μl of DMSO only was added to the first 
well in the other row (as a control for the activity of uninhibited CatS). To each well in the 
assay plate, CatS, diluted in assay buffer and DTT (1 mM) to the concentration determined in 
the initial dilution experiment, was added. 190 μl of diluted CatS was added to the first well 
in both rows, while 80 μl was added to the remaining wells. A double dilution was then 
performed by transferring 100 μl of the contents of the first wells to the next wells in that 
row of the plate, discarding the last 100 μl. The plate was read in a spectrophotometer at 
excitation wavelengths of 360 – 390 nm and emission wavelengths of 450 – 470 nm every 
30 seconds for 61 cycles. The rates were fitted by linear regression, plotted against 
log(inhibitor concentration) and fitted to the competitive inhibition equation (IC50). 
3.2.2 Isolation and culture of mouse dorsal root ganglia 
All experiments were performed in accordance with the United Kingdom Home Office 
Regulations (Scientific Procedures Act, 1986). Experiments were carried out on 6-18 weeks 
old adult male and female C57/BL6 mice obtained from Charles River. Animals were housed 
in the Biological Services Unit, King’s College London in groups of 8 per cage, on a 12 hour 
day/night cycle with ad libitum access to water and food. 
 
Mice were humanely killed either by terminal anaesthesia with an overdose of sodium 
pentobarbital (Euthanol, 200 mg/kg body weight) or by concussion of the brain by striking 
the cranium followed by decapitation. The spinal column from the base of the skull to the 
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level of the hips was removed and cut in half along the dorsal and ventral midpoints. Using 
forceps, the spinal cord was removed and discarded (Figure 3.2). By gently tugging on the 
axon bundles of the DRGs with the forceps, the DRGs could be removed from the crevices 
along the length of the spinal column. The roots were trimmed from the DRGs and the DRGs 
were placed in a dish containing 2 ml of Ham's DMEM F-12 (Sigma, UK). Up to 30 DRGs were 





Figure 3.2: Dissection of DRGs from the spinal cord (adapted from Sleigh et al., 2016) 
The spinal column was removed from the mouse and cut in half along the dorsal and ventral 
midpoints to expose the spinal cord (A). The spinal cord was removed, revealing the DRGs 
which were located within crevices along the length of the spinal column (black arrows) (B). 
Axon bundles could also be observed (black arrowheads). Scale bar = 0.5 cm. 
 
Isolation and culture of mouse DRGs was performed following a protocol adapted from 
Malin et al., (2007) and Simeoli et al. (2017). In brief, 5% w/v type-4 collagenase 
(Worthington, Lorne Laboratories, UK) was added to the culture dish containing the 
dissected DRGs (final collagenase concentration 0.125% w/v) and incubated at 37°C 5% CO2 
for 60 to 120 minutes. Following digestion, cells were triturated using either flame-polished 
glass Pasteur pipettes or P1000 pipette tips with 5 mm cut off from the tips. Ham's DMEM F-
12 (Sigma, UK) containing 10% FBS (Sigma, UK) was then added to the cells to neutralise the 
collagenase. The cells were centrifuged at 600 rpm for 5 minutes and the media was 
aspirated from the pellet of cells. Cells were resuspended in Ham's DMEM F-12 
supplemented with 10% FBS, 1% penicillin/streptomycin (Thermo Fisher Scientific, UK) and 
10 ng/ml 7S murine NGF (Promega, UK). Cells were plated on glass coverslips (13 mm 
diameter) pre-coated with 100 µg/ml poly-L-ornithine (Sigma, UK) and 50 µg/ml collagen 
type-1 (Ibidi, Germany or Sigma, UK) at a volume of 5 – 20 μl/well, yielding about 1,500 – 
6,000 cells per coverslip, and flooded with 500 μl of Ham's DMEM F-12 after at least 30 
minutes of incubation. DRGs were cultured at 37°C 5% CO2 until ready to use. 
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3.2.3 Patch clamping 
Patch clamping experiments were performed on isolated mouse DRGs that had been in 
culture for 1 – 3 days, measuring changes in membrane current following application of 
various substances. All recordings were made at room temperature. Recordings were 
performed using an Axopatch 200B amplifier (Molecular Devices, USA) and command 
voltages were generated with a Digidata 1320A interface (Molecular Devices, USA). Neurons 
were held at -60 mV or -90 mV for KCl (Sigma, UK) application and -60 mV for all other 
applications. Data were digitised and analysed using Clampex 9.2 and Clampfit 9.2 
(Molecular Devices, USA). Cells were viewed using a Nikon Diaphot 300 microscope at x200 
magnification. During patch clamping, cells were maintained in a HEPES buffer (HEPES, 5 
mM, Sigma, UK; NaCl, 130 mM, Sigma, UK; glucose, 5 mM, Sigma, UK; KCl, 3 mM, Sigma, UK; 
MgCl2, 1 mM, G Biosciences, USA; CaCl2, 1 mM, Fisher Scientific, UK; pH7.4 adjusted with 
NaOH), similar in composition to extracellular solution, with a flow rate of 2 ml/minute. Cells 
were patched using a microelectrode pipette made from a 1.5 mm outside diameter 
borosilicate glass capillary with filament (World Precision Instruments, UK) pulled using a 
Model P-97 Flaming/Brown Micropipette Puller (Sutter Instrument Company, USA). The 
microelectrode tip was heat polished and then backfilled with a HEPES buffer similar in 
composition to intracellular solution and passed through a 0.2 μM syringe filter (HEPES, 10 
mM, Sigma, UK; KCl, 120 mM, Sigma, UK; MgCl2, 1 mM, G Biosciences, USA; CaCl2, 1 mM, 
Fisher Scientific, UK; EGTA, 10 mM, Sigma, UK; pH7.4 adjusted with NaOH). The filled 
microelectrode tip was placed on a thin silver chloride wire attached to an Axon Instruments 
CV 203BU Headstage. To patch the neurons, the tip of the microelectrode was placed over a 
cell and lowered until a small “bight dent” appeared on the surface of the cell. Recordings 
were made using whole cell parameters. The “VC Seal” protocol was run, which involved 
stepping the holding potential from -90 mV to 0 mV for 30 ms, and then back to -90 mV, 
during which gentle suction was applied to the micropipette in order to form a patch onto 
to the cell. Once the cell had been patched, the “VC Seal” protocol showed a characteristic 
trace in which the step to and from 0 mV was characterised by upward and downward 
peaks in the trace (Figure 3.3 A). The pipette offset was adjusted until the trace was at 0 nA 
when the command potential was at 0 mV. To improve the quality of the clamp, the “VC 
Cap” protocol was run, during which the holding potential was stepped from -90 mV to -100 
mV for 30 ms, and then back to -90 mV. Whole cell capacitance and series resistance 
parameters were adjusted until the peaks in the trace during the steps to and from -100 mV 
were as flat as possible (Figure 3.3 B). Cells that had a holding current of less than -0.3 nA 
were not used in experiments. Finally, to disrupt the patch and allow access of the 
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microelectrode in to the cell interior (i.e. to establish a “whole cell recording”), increased 
suction was applied to the microelectrode or a brief oscillation of the command potential 
was carried out. Changes in the membrane current of cells were recorded in response to 
substances applied using either the bath perfusion method or the pressure puffer method. 
 
 
Figure 3.3: Example current traces during patching of the neurons 
The “VC Seal” protocol involved stepping the holding potential from -90 mV to 0 mV for 30 
ms and then back to -90 mV, characterised by upward and downward peaks during the steps 
(A). The “VC Cap” protocol involved stepping the holding protocol from -90 mV to -100 mV 
for 30 ms and then back to -90 mV (B). 
 
HEPES buffer was applied to the cells using bath perfusion at a rate of about 2 ml/minute. 
Substances were applied directly onto the cells using a thin glass pipette attached to a 
PV830 Pneumatic PicoPump (World Precision Instruments, UK) located only a few 
micrometres away from the patched cell. This resulted in the application of the substance 
directly onto the cell over a period of 5 seconds at about 5 psi with 600 – 800 nl/puff. 
Patched cells were voltage clamped at -60 mV and substances were applied 3 times with a 
50 second interval between applications. Because application of substances in this way was 
local and did not affect cells located further away in the chamber, this method could be 
used on several cells on the same coverslip. Furthermore, because the glass pipette held 
only a few microliters of solution, this method of application was suitable for applying CatS, 
which was available to us in only small volumes. KCl (12 mM), extracellular buffer (control 
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for KCl), capsaicin (1 µM) in 0.01% DMSO, 0.01% DMSO (control for capsaicin), and DPBS 
with 1 µM Ca2+ and Mg2+ (control for CatS) were also applied using the pressure puffer. 
3.2.4 Calcium imaging 
Calcium imaging experiments were performed on DRG cultures that had been plated on 
coverslips 24 hours beforehand. Experiments were carried out and analysed using either PTI 
Image Master software or PTI Easy Ratio Pro software (version 1.2.1.87). Cells were 
incubated in Fura-2-AM (2 µM; Teflabs, Cambridge Bioscience, UK) for 1 hour prior to 
experiments being conducted. Coverslips were placed cell-side-down on a chamber and 
sealed in place with a ring of Vaseline to prevent leakage. The chambers were filled with 1 x 
HBSS (Gibco, UK) with 10 mM HEPES (Sigma, UK) at pH7.4) and secured onto the microscope 
stage. Recordings were made at room temperature. Fluorescence of calcium in cells was 
measured at 340 nm and 380 nm excitation and 510 nm emission wavelengths. Results are 
expressed as a 340/380 nm emission ratio. Substances were applied directly into the 
chambers using mostly bath perfusions, although attempts were made to apply directly to 
the chamber using a pipette or injected into the chamber using a syringe. Application of 
substances using bath perfusion involved setting up reservoits above the chamber with 
tubing connecting to one side of the chamber on the microscope. The rate of perfusion was 
4 ml/minute. For calcium imaging experiments, most substances were applied into the 
bathing solution surrounding the cells (the so-called bath perfusion). For this, the 
substances to be applied were contained in reservoirs located above the chamber, and 
connected into one end of the chamber via a tube, where they entered the chamber at a 
rate of 4 ml/minute. HEPES calcium buffer, capsaicin (10 nM – 1 µM; Sigma, UK), mustard oil 
(1 µM – 100 µM; Sigma, UK), CatS (400 nM; Medivir, Sweden), SLIGRL-NH2 (1 µM – 50 µM; 
Insight Biotechnology, UK), the CatS inhibitor MDV-590 (0.5 µM – 5 µM; Medivir, Sweden), 
the PAR2 antagonist FSLLRY-NH2 (1 µM – 10 µM; Sigma, UK) (Al-Ani et al., 2002a), and KCl 
(50 mM, Sigma, UK) were all applied using this method. Substances were applied for 2 
minutes, with responses observed 1-2 minutes after application. In the case of CatS 
application, CatS was applied to the cells for 2 minutes, after which the flow was switched 
off and the cells were left to incubate in CatS for 2, 10, or 20 minutes, before resuming the 
flow and application of other substances (Figure 3.4 A). In the case of the CatS inhibitor 
MDV-590 and the PAR2 antagonist FSLLRY-NH2, cells were left to incubate in either of these 
substances for 10 minutes and then incubated in CatS in the presence of either of these 
substances for a further 20 minutes (Figure 3.4 B). At the end of each experiment, KCl (50 




Figure 3.4: Schematic of drug application and incubation protocol for calcium imaging 
experiments 
Isolated DRGs in culture were exposed to most substances for 2 minutes, except for CatS (A), 
the CatS inhibitor MDV-590, and the PAR2 antagonist FSLLRY-NH2 (B), to which the cells 
were exposed to for up to 20 minutes. 
 
The main drawback of applying CatS to the cells using the bath application was the volume 
of CatS that was required. Because CatS was provided to us in aliquots of 80 µM in 50 µl 
buffer, we were restricted in the concentration and volume that could be applied to our 
cells in our experiments. To apply CatS using the bath method of application, CatS was 
diluted to give the minimum volume required to be able to apply using this method, i.e. 
approximately 5 ml of 400 nM CatS. Additional methods of applying CatS to the cells were 
also tested, although each of these had their own limitations too and were ultimately not 
used in further experiments. In order to apply concentrated CatS to the cells, 50 µl of CatS 
(40 µM to 500 nM) was carefully pipetted directly into the chambers during calcium imaging 
experiments. However, it was not possible to accurately determine the volume of fluid in 
the chamber, and hence the final concentration of CatS in the chamber. In addition, it was 
not possible to determine whether the CatS applied in this way mixed with the solution in 
the chamber, and hence whether cells being imaged had been exposed to CatS. To ensure 
all cells in the chamber were exposed to CatS, CatS stocks were diluted to give 500 µl of 1 
µM CatS. The diluted CatS was loaded into a 1 ml syringe and attached to a 23G needle and 
connected to an inlet into the chamber by a short length of 0.86 mm ID/1.27 mm OD tubing. 
To avoid bubbles in the tube, the tubing and syringe were backfilled with CatS. CatS was 
injected slowly and gently into the chamber, displacing the buffer already present in the 
chamber and replacing it with the CatS solution. Typically it took about 1 minute to empty 
the contents of the syringe into the chamber. However, this method of application caused 
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cells to move, creating artefact responses presumably as a result of mechanical stimulation 
of the cells due to fluid being forced into the chamber, and making it difficult to track cells 
during analysis of the experiment. Thus, bath perfusion for application of substances was 
used in all calcium imaging experiments. 
3.2.5 Quantitative Polymerase Cain Reaction (qPCR) 
Total RNA was extracted from mouse DRG cultures that had been plated on 13 mm 
diameter coverslips (4 coverslips per mouse) 48 hours beforehand using the PureLink RNA 
Mini Kit (Invitrogen, UK), according to the manufacturer’s protocol. The total concentration 
of extracted RNA was measured using a NanoDrop spectrometer. Total RNA (1 μg) was used 
to synthesise first strand cDNA using the Superscript VILO cDNA Synthesis Kit (Invitrogen, 
UK) according to the manufacturer’s protocol. Expression levels of protease activated 
receptor-2 (PAR2) were analysed, with 18S rRNA used as a reference transcript. 
Amplification was performed with a LightCycler 480 (Roche, UK) using SYBR Green I Master 
(Roche, UK). The primers used are given in Table 3.1. The instrument was programmed as 
follows: 95˚C for 5 minutes and 45 cycles of 3 steps of 10 seconds each, including denaturing 
at 95˚C, annealing at 60˚C, and primer extension at 72˚C. All samples were run as duplicates, 
with 18S as the housekeeping gene. Samples in which the melting curve had more than one 
peak were excluded from analysis. Data was analysed using LightCycler 480 software 
(version 1.5.1). The relative gene expression level was calculated according to the 2-ΔCt 
method, where Ct represents the threshold cycle. 
 
Table 3.1: Primers used for PAR2 and 18S in qPCR 
Genes Forward Sequence Reverse Sequence Reference 
PAR2 GGACCGAGAACCTTGCAC GAACCCCTTTCCCAGTGATT 
Touw et al., 2012;  
Li et al., 2016a 
18S GCTGGAATTACCGCGGCT CGGCTACCACATCCAAGGAA 
Denning et al., 
2008 
3.2.6 Data analysis and statistics 
For patch clamping experiments, recordings were analysed using Clampfit 9.2 software. 
Data were lowpass filtered at 3 Hz (-3 dB, 8-pole Bessel filter) and sampled at 100 Hz. The 
baseline was adjusted by subtracting the slope between time-points at 0 seconds and at 10 
or more seconds of the recording (which ever was more stable) prior to drug application. 
The peak polarity at the most negative-going points during drug application was then 
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obtained. A cell was considered to have responded to application of a substance if the 
holding was less than -0.3 nA and the magnitude of the response was greater than the 
control responses ± 2 standard deviations. 
 
Once the recordings had been made for calcium imaging experiments, cells were circled 
using the PTI Image Master or PTI Easy Ratio Pro software and non-responders to KCl or 
other substances were removed. A cell was considered to have responded to application of 
a substance if the response to that substance was at least 20% of the size of the response of 
the same cell to application of KCl. Traces of responders were individually analysed for drifts 
in the baseline that might otherwise be considered to be responses, and such “responses” 
were subsequently classed as false positives and removed from analysis. 
 
Data were analysed and graphs generated using GraphPad Prism 5 (Graphpad Software Inc., 
USA) using unpaired Student’s t-tests when comparing just two groups (application of a 
substance compared with its control), or one-way ANOVA when comparing more than two 
groups. One-way ANOVA was followed by Dunnet’s multiple comparison test when 
comparing multiple groups against one control group, while Bonferroni’s multiple 
comparison tests were used when comparing multiple groups with each other. Two-way 
ANOVA was used when comparing the percentages of cells that responded to various 
concentrations of capsaicin or mustard oil following pre-incubation in buffer or CatS. Chi-
squared tests (Fisher's exact tests) were used to compare the number of cells that 
responded to application of capsaicin or mustard oil following pre-incubation in buffer or 
CatS. The n numbers are displayed within the figure legends of the results section. Data are 
presented as mean ± standard error of the mean (SEM). P≤0.05 was set as the level of 
statistical significance. 
3.3 Results 
To investigate whether sensory neurons could respond directly to application of CatS and 
characterise these neurons, isolated mouse DRGs were exposed to CatS and various other 
compounds in both patch clamping and calcium imaging experiments. 
3.3.1 Cathepsin S induces inward current in dorsal root ganglia 
74 out of 121 cells (61.2%) responded to application of one or more of the agonists applied 
to them using pressure puffer application method. It is proposed that itch-sensitive neurons 
comprise a subpopulation of the TRPV1-expressing nociceptors (Han et al., 2013; Imamachi 
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et al., 2009; Shim et al., 2007). We first wanted to determine whether the neurons in our 
culture were viable for patch clamping and whether they expressed TRPV1 cells by testing if 
they could respond to TRPV1 agonists such as capsaicin. Isolated mouse DRGs were voltage-
clamped and exposed to capsaicin (1 µM) or KCl (12 mM), or their respective controls, 
DMSO (0.01%) or HEPES buffer. Significant increases in membrane currents were observed 
when cells were exposed to capsaicin or KCl, but not to their respective controls (DMSO or 
buffer) (Figure 3.5). 56% of cells responded to capsaicin and 67% responses to KCl applied in 
this way. Our cells were therefore also able to respond to substances applied directly to 
them using this method. 
 
CatS was supplied to us as 80 µM buffer exchanged into Dulbecco’s PBS without calcium or 
magnesium. Application of this concentration of CatS directly to the cells using a pressure 
puffer resulted in an initial large inward current response, followed by responses of much 
smaller magnitude upon subsequent application of CatS. However, because the buffer which 
the CatS was supplied contained no calcium or magnesium ions, and because low 
extracellular Ca2+ can cause hyperexcitability of the cell, we could not be sure that the 
response we were observing was due to application of CatS, and not due to low extracellular 
calcium (Hille, 2001). To overcome this, 80 µM stocks of CatS were diluted in 1 x DPBS 
containing 2 mM Ca2+ and Mg2+ making a final concentration of 40 µM CatS stock in buffer 
containing 1 mM Ca2+ and Mg2+. Application of this Cathepsin S resulted in a large inward 
current, which was severely reduced in magnitude following subsequent applications of 
Cathepsin S to the same cell 50 seconds after the previous application (Figure 3.6), 
suggesting desensitisation of the cell to further applications of Cathepsin S. 13% of the cells 














































































Figure 3.5: Inward currents in neurons following direct application of capsaicin or KCl 
Representative traces of changes in membrane current following puffer application of 
capsaicin and DMSO vehicle (A), or KCl and buffer vehicle (B). Quantification of changes in 
membrane current (C-D). n = 9, 10, data are mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, unpaired 
Student’s t-test. 
 
Table 3.2: Data for Figure 3.5 
Data in nA. 
DMSO Capsaicin Buffer KCl 
0.001288 -0.044903 -0.014726 -0.192489 
-0.009065 -0.259192 -0.015522 -0.342306 
-0.00149055 -0.059744 -0.007274 -0.387971 
-0.00416846 -0.629548 -0.003006 -0.101497 
-0.005175 -0.0683356 -0.006363 -0.057037 
-0.023099 -0.776179 -0.000788 -0.0905533 
-0.011752 -0.586358 -0.011477 -0.0424436 
0.001425 -0.033194 -0.021058 -0.194678 
-0.003576 -0.022551 -0.003769 -0.097612 

















































Figure 3.6: Inward currents in neurons following direct application of Cathepsin S 
Representative trace of changes in membrane current following puffer application of hr-CatS 
(A). Solid lines at the top of the trace indicate duration of CatS application. Quantification of 
changes in membrane current (B). n = 5 - 18, data are mean ± SEM. *p ≤ 0.05, One-way 
ANOVA followed by Dunnett’s multiple comparison test vs CatS first response. 
 
Table 3.3: Data for Figure 3.6 
Data in nA. 
CatS First Response CatS Second Response CatS Third Response DPBS 
-0.143236 -0.005988 -0.021298 -0.005477 
-0.060741 -0.070957 -0.013383 -0.004115 
-0.214871 -0.011885 -0.001582 -0.008405 
-0.134273 -0.012808 -0.001448 -0.009399 





3.3.2 Cathepsin S-mediated calcium influx in dorsal root ganglia 
Patch clamping experiments were initially performed with the intention of characterising 
the neurons that responded to CatS applied directly to the cells. However, we were unable 
to obtain robust responses following application of agonists to the bath, and hence were 
unable to characterise the cells that responded to CatS applied directly using the pressure 
puffer. We decided therefore to use calcium imaging to investigate CatS responses in 
sensory neurons and to further characterise cells that responded to CatS. For calcium 
imaging experiments, the ratiometric dye Fura-2-AM was used to measure the calcium 
responses of cells following application of various substances. Excitation of cells at 340 nm 
and 380 nm allowed for changes in calcium levels to be detected as changes in fluorescence 
and expressed as a ratio (i.e. the F340/F380 ratio). The use of a ratiometric dye over other 
types of calcium indicators was essential to reduce the effects of photobleaching and 
leakage during the long incubation times with CatS. 
 
As with patch clamping, we first applied capsaicin to determine whether the neurons were 
viable for calcium imaging and whether any of them belonged to the TRPV1-expressing 
subpopulation. Isolated mouse DRGs were exposed to capsaicin (10 nM – 50 nM) for 2 
minutes followed by 2-minute washes between applications. A delay of about 1 to 2 
minutes was observed between application of substances and the cells responding, 
presumably reflecting the time taken for the substance solution to reach the cells and 
equilibrate in the bath as a result of the length of tubing used and/or the application system. 
31% of cells responded to 10 nM capsaicin, 38% to 20 nM capsaicin, and 54% to 50 nM 
capsaicin (Figure 3.7 A, C). Similarly, DRGs were also exposed to mustard oil to test whether 
any belonged to the TRPA1-expressing subpopulation of neurons. Mustard oil (1 μM – 100 
μM) was applied for 2 minutes, with a 2-minute wash between applications. 2.7% of cells 
responded to application of 1 µM mustard oil and 5.8% responded to 10 µM mustard oil. 




































































































Figure 3.7: Calcium increase in neurons following bath application of capsaicin and 
mustard oil 
Representative traces to application of capsaicin. The solid grey line shows the trace of a cell 
responding to application of 50 nM capsaicin only. The dotted and dashed black lines are 
Representative traces to application of capsaicin (A) or mustard oil (B). Solid lines at the top 
of the graph indicate application of agonists. Analysis showing the percentage of cells 
responding to application of capsaicin (C), from 144 cells, n = 5; 1 - 3 coverslips per mouse, 
data are mean ± SEM. No significance, One-way ANOVA followed by Bonferroni’s multiple 
comparison test. Analysis showing the percentage of cells responding to application of 
mustard oil (D), from 83 cells, n = 4; 1 coverslip per mouse, data are mean ± SEM. **p ≤ 0.01, 












Table 3.4: Data for Figure 3.7 
Data as the percentage of cells in each experiment that responded to application of agonist. 
Capsaicin 
10 nM 20 nM 50 nM 
56.590910 16.363640 28.409090 
15.625000 25.000000 43.750000 
14.714720 18.318320 44.894890 
37.500000 75.000000 87.500000 
33.333330 55.555560 66.666660 
Mustard Oil 
1 M 10 M 100 M 
5.555555 0.000000 27.777780 
0.000000 5.263158 42.105260 
5.263158 10.526320 68.421050 
0.000000 7.407407 66.666660 
 
Because CatS was supplied to us in very small volumes (50 µl), and because application of 
substances to the bath in this way requires millilitres of the substance, we were limited in 
the amount and concentration of CatS that could be applied using this method. The most 
concentrated CatS in the minimum volume required to apply to the bath using this method 
was 400 nM, which was the concentration subsequently used in all further calcium imaging 
experiments. CatS (400 nM) was applied to the cells for 2 minutes, until a stable CatS 
concentration was achieved, and the flow was stopped and the cells were left to incubate in 
CatS for up to 20 minutes. Some cells responded to application of CatS, with the number of 
responders increasing as the incubation time with CatS increased. The percentage of cells 
that responded to 20 minutes exposure to CatS (15.3 %) was significantly greater than the 
percentage that responded to 20 minutes exposure to buffer (5.9 %). In contrast, there was 
no significant difference in the percentage of cells that responded to 2 or 10 minutes 
exposure to CatS and 20 minutes exposure to buffer (Figure 3.8). Thus, cells can respond to 
CatS applied to the bath, although unlike the fast current changes observed following direct 
application of high concentration CatS to the cells in patch clamping, these calcium 
responses to lower concentration CatS take some time to occur. 20 minutes incubation in 






















































Figure 3.8: Calcium increase in neurons following bath application of Cathepsin S 
Representative traces; the dashed gold line shows traces of a cell that responded to CatS, 
while the dotted black line shows the traces of a cell that did not respond to application of 
CatS, but did respond to KCl (50 nM) (A). Analysis of the percentage of cells that responded 
to application and incubation of CatS (B). From 461 cells, n = 4 - 5, 1 coverslip per mouse, 
data are mean ± SEM. *p ≤ 0.05, One-way ANOVA followed by Dunnett's multiple 
comparison test, vs 20 minutes buffer incubation. 
 
Table 3.5: Data for Figure 3.8 
Data as the percentage of cells in each experiment that responded to application of CatS. 
Buffer (20 minutes) CatS (2 minutes) CatS (10 minutes) CatS (20 minutes) 
9.090909 7.692307 11.428570 26.666670 
3.571429 14.285710 10.526320 7.692307 
5.000000 3.636364 10.000000 14.545450 
5.882353 11.764710 10.714290 12.500000 
6.451613 X X X 
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Cathepsin S acts via PAR2 to cause calcium fluxes in dorsal root ganglia 
To confirm that the observed calcium responses were due to CatS activity, cells were pre-
incubated with the CatS inhibitor, MDV-590. Because MDV-590 was dissolved in DMSO, we 
tested for the optimal concentration to use that would not interfere with the calcium 
imaging assay. Incubation in MDV-590 (0.5 µM) for 10 minutes resulted in calcium 
responses in 1.7% of cells, while incubating in 1 µM MDV-590 resulted in calcium responses 
in 7.6% of cells (Figure 3.9 A). We therefore used MDV-590 at 0.5 µM concentration for our 
experiments, as this was the concentration that appeared to interfere least with the assay. 
Pre-incubation of cells for 10 minutes in 0.5 µM MDV-590 and application of 400 nM CatS 
for 20 minutes in the presence of MDV-590 resulted in a reduction of cells responding to 
CatS, with percent inhibition at 51%. Calcium responses were noted only in 8.9% of cells 
following 10 minutes pre-incubation with MDV-590 and 20 minutes application of buffer in 
the presence of MDV-590, and was comparable to that of the percentage of cells that 
responded to buffer alone (Figure 3.9 C). Therefore, MDV-590 reduces the percentage of 
cells responding to CatS, suggesting the calcium responses detected are due activity of CatS. 
 
It has previously been suggested that CatS might exert its effects via activation of the PAR2 
receptor (Reddy et al., 2010). We therefore tested the possibility that the calcium responses 
observed following application and incubation of cells in CatS were due to enzymatic 
activation at the PAR2 receptor by using the PAR2 antagonist, FSLLRY-NH2. To test for the 
optimal concentration of FSLLRY-NH2 that would not interfere with the assay, cells were 
exposed to 1 µM, 5 µM, and 10 µM FSLLRY-NH2 for 10 minutes. Incubation of cells in 1 µM 
FSLLRY-NH2 resulted in calcium responses in 1% of cells, while incubation in 5 µM resulted in 
calcium responses in 4.6% of cells, and incubating in 10 µM FSLLRY-NH2 resulted in calcium 
responses in 11.7% of cells (Figure 3.9 B). We thus chose to use 5 µM FSLLRY-NH2 for our 
experiments as this concentration did not appear to interfere significantly with the assay, in 
that the percentage of cell that showed calcium responses was similar to that observed 
following incubation in buffer. Pre-incubation of cells for 10 minutes in 5 µM FSLLRY-NH2 
followed by application of 400 nM CatS for 20 minutes in the presence of FSLLRY-NH2 
resulted in a reduction in the percentage of cells responding to CatS by 48.5%. Calcium 
responses were detected in only 8.4% of cells following 10 minutes pre-incubation with 
FSLLRY-NH2 and 20 minutes application of buffer in the presence of FSLLRY-NH2 (Figure 3.9 
C). Because pre-incubating the cells with FSLLRY-NH2 resulted in a significant decrease in the 
percentage of cells that responded to CatS, we propose that the CatS-induced calcium fluxes 
were mediated via PAR2. 
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Figure 3.9: Calcium increase in neurons following application of Cathepsin S (400 nM) in 
the presence of the Cathepsin S inhibitor MDV-590 or the PAR2 antagonist FSLLRY-NH2 
DRGs were incubated in different concentrations of MDV-590 (A) or FSLLRY-NH2 (B) for 10 
minutes. From 82, 83 cells; n = 2, 1 coverslip per mouse, data are mean. Analysis of the 
percentage of cells that responded to application and incubation of CatS in the presence of 
the CatS inhibitor MDV-590 or the PAR2 antagonist FSLLRY-NH2 (C). From 663 cells, n = 3, 4 ; 
1 coverslip per mouse, data are mean ± SEM. *p ≤ 0.05, One-way ANOVA followed by 













Table 3.6: Data for Figure 3.9 A and B 
Data as the percentage of cells in each experiment that responded to application of the CatS 
inhibitor MDV-590 or the PAR2 antagonist FSLLRY-NH2. 
MDV-590 




1 M 5 M 10 M 
0.000000 2.857143 8.571428 
2.127660 6.382979 14.893620 
 
Table 3.7: Data for Figure 3.11 C 
Data as the percentage of cells in each experiment that responded to application of the CatS 
in the presence or absence of MDV-590 or FSLLRY-NH2. 
Buffer MDV-590 FSLLRY 
Vehicle CatS Vehicle CatS Vehicle CatS 
9.677420 10.344830 9.090909 5.681818 8.333333 8.333333 
3.030303 32.432430 8.108109 8.108109 9.090909 13.636360 
3.278688 12.962960 8.888889 17.777780 4.545455 4.545455 
9.090909  X 9.523809 4.761905 11.764710 11.764710 
 
Because the PAR2 antagonist FSLLRY-NH2 significantly reduced the percentage of cells 
responding to CatS, we wondered whether activation of the PAR2 receptor directly would 
result in calcium responses in our cells. We first confirmed the expression of PAR2 mRNA in 
our cell cultures using qPCR (Table 3.8). Expression of PAR2 relative to 18S was 0.003. 
 
Table 3.8: Ct values for PAR2 expression 
Average Ct values of samples run as duplicates. 
  18S PAR2 
Sample 1 14.905 26.64 






After confirming expression of PAR2 in our cultures, we tested whether calcium responses 
could be detected in our cells following exposure to the PAR2 agonist, SLIGRL-NH2. The 
percentage of cells that responded to buffer or any concentration of SLIGRL-NH2 tested did 
not differ (Figure 3.10), suggesting that application of this PAR2 receptor agonist at these 




















Figure 3.10: No calcium responses following application of the PAR2 agonist SLIGRL-NH2 
Application of SLIGRL-NH2 for 10 minutes did not cause calcium responses in cells. From 213 
cells, n = 3 – 6; 1 coverslip per mouse, data are mean ± SE. No significance, One-way ANOVA 
followed by Dunnett's multiple comparison test, vs 20 minutes buffer incubation. 
 
Table 3.9: Data for Figure 3.10 
Data as the percentage of cells in each experiment that responded to application of SLIGRL-
NH2. 
Buffer 1 mM SLIGRL-NH2 10 mM SLIGRL-NH2 50 mM SLIGRL-NH2 
6.250000 0.000000 10.714290 7.692307 
7.142857 0.000000 8.333333 4.000000 
0.000000 0.000000 5.555555 9.090909 
0.000000 0.000000 X 6.896552 
16.000000 11.538460 X 13.043480 
X 0.000000 X X 
 
Calcium influx following to application and incubation of Cathepsin S is decreased in 
cultures from TRPV1 knock-out mice and TRPA1 knock-out mice 
Itch neurons are thought to belong to a subset of TRPV1 nociceptors (Han et al., 2013; 
Imamachi et al., 2009; Shim et al., 2007). Indeed, we previously observed that scratching 
behaviour in response to injection of CatS was significantly reduced in TRPV1 KO mice. Some 
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pruriceptors (mainly those responsible for non-histaminergic itch) are also proposed to 
express TRPA1 (Wilson et al., 2011). We therefore investigated whether calcium responses 
to application of CatS were altered in DRGs cultured from TRPV1 KO mice. In DRGs cultured 
from TRPV1 KO mice, the percentage of cells that showed calcium responses following 
application of CatS decreased from 15.7% to 7.5% (Figure 3.11). DRGs cultured from TRPA1 
KO mice were also exposed to CatS, and it was found that the percentage of cells that 
responded decreased from 15.7% to 5.9% (Figure 3.11). As expected, DRGs cultured from 
TRPV1 KO mice and TRPA1 KO mice also showed a reduction in the percentage that 
responded to capsaicin or mustard oil, respectively.  
 




















Figure 3.11: Reduction in response to Cathepsin S in TRPV1 KO and TRPA1 KO DRGs 
compared with WT controls 
The percentage of responders to CatS in DRG cultures from TRPV1 or TRPA1 KO mice, from 
373 cells, n = 3 – 5; 1 coverslip per mouse, data are mean ± SEM. *p ≤ 0.05, One-way ANOVA 
followed by Dunnett's multiple comparison test, vs 20 minutes buffer incubation.  
 
Table 3.10: Data for Figure 3.11 
Data as the percentage of cells in each experiment that responded to application of CatS. 
Buffer CatS 
WT  WT TRPV1 KO TRPA1 KO 
2.222222 12.500000 10.526320 6.250000 
7.692307 14.285710 5.555555 7.317073 
11.764710 20.588240 5.000000 7.407407 
11.111110  X 9.090909 0.000000 




Because the percentage of cells that responded to CatS was significantly reduced in DRG 
cultures from TRPV1 and TRPA1 KO mice, this suggests that the neurons which respond to 
CatS belong to the TRPV1 and TRPA1 subpopulation of nociceptors. Indeed, most of the cells 
that responded to CatS also responded to capsaicin (10 nM or greater) or mustard oil (10 
µM or greater) applied after CatS (Figure 3.12). 
 
 
Figure 3.12: Most of the cells that responded to Cathepsin S also responded to capsaicin or 
mustard oil 
Following application of CatS to DRG neurons in culture, cells were subsequently exposed to 
capsaicin (10 nM – 1 µM) or mustard oil (10 µM or 100 µM). For capsaicin at 10 nM 
concentration or greater, more than 80% of the cells that responded to CatS also responded 
to capsaicin. More than 70% of the cells that responded to CatS also responded to mustard 
oil. n = 3, 4; 111 cells in total for 1 nM capsaicin; 63 cells in total for 10 nM capsaicin; 111 
cells in total for 100 nM capsaicin; 63 cells in total for 1 µM capsaicin; 108 cells in total for 10 
µM capsaicin; 108 cells in total for 100 µM capsaicin. 
 
Pre-application of Cathepsin S increases the number of cells that respond to capsaicin or 
mustard oil 
One observation we made was that the percentage of cells responding to capsaicin and 
mustard oil following application of CatS was greater than the percentage of DRG cells that 
typically respond to application of these agonists in calcium imaging experiments. For 
example, Kwan et al. (2006) reported that approximately 31% of their DRGs from WT mice 
responded to application of 3 µM capsaicin and that 23% responded to application of 10 µM 
mustard oil. Wilson et al. (2011) observed that about 55% of cultured sensory neurons 
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responded to 1 µM capsaicin in calcium imaging experiments. We therefore wondered 
whether CatS could be sensitising cells to respond to agonists such as capsaicin and mustard 
oil. To test this, we applied capsaicin (10 nM – 1 µM) or mustard oil (10 µM or 100 µM) to 
cells following application of CatS or buffer. The number and percentage of cells that 
responded to capsaicin increased when cells were first exposed to CatS before application of 
capsaicin, compared with when they were first exposed to buffer before application of 
capsaicin (Table 3.11; Figure 3.13 A). Similarly, the number and percentage of cells that 
responded to mustard oil also increased when cells were first exposed to CatS (Table 3.11; 
Figure 3.13 B). This suggests that CatS could be sensitising the TRP channels on these cells, 
making them more likely to respond to application of their agonists. As activation of PAR2 
has previously been reported to sensitise TRPV1 and TRPA1 channels, cleavage of PAR2 by 
CatS could be responsible for the sensitisation we observed (Amadesi et al., 2004; Amadesi 
et al., 2006; Dai et al., 2004; Dai et al., 2007). 
 
Table 3.11: Increase in the number of cells that responded to capsaicin or mustard oil 
following pre-incubation with Cathepsin S 
 Buffer Cathepsin S P value 
Capsaicin (1 nM) 3 of 115 33 of 114 *** P≤0.001 
Capsaicin (10 nM) 33 of 109 35 of 63 ** P≤0.01 
Capsaicin (100 nM) 51 of 115 74 of 114 ** P≤0.01 
Capsaicin (1 μM) 67 of 109 48 of 63 No significance 
Mustard oil (10 μM) 11 of 132 41 of 108 *** P≤0.001 
Mustard oil (100 μM) 83 of 132 88 of 108 ** P≤0.01 

















































Figure 3.13: Pre-application of Cathepsin S resulted in an increase in the percentage of 
cells that responded to either capsaicin or mustard oil 
The percentage of cells that responded to each concentration of capsaicin (A) or mustard oil 
(B) tested following application of CatS tended to be greater than the percentage that 
responded to capsaicin or mustard oil following application of buffer. Data are mean. n = 3 – 
5, * P≤0.01; *** P≤0.001, Two-way ANOVA followed by Bonferroni post hoc test. 
3.4 Discussion 
 
The main finding of this chapter is that application of CatS to sensory neurons in culture 
resulted in both inward currents in the membrane and calcium increases in the cell, 
suggesting neurons can respond directly to CatS. 13% of patched cells responded to CatS 
applied directly to the cell, and in calcium imaging experiments 10-15% of cells responded 
following incubation in CatS for up to 20 minutes. The percentage of cells that responded 
with calcium fluxes to CatS is similar to what has previously been reported at 8-10% (Reddy 
et al., 2015). In calcium imaging experiments, the effect of CatS was prevented by the CatS 
inhibitor, MDV-590, confirming the calcium fluxes observed were due to the enzymatic 
activity of CatS. The effect of CatS was also prevented by the PAR2 antagonist FSLLRY-NH2, 
suggesting that PAR2 mediated the effects of CatS. However, the percentage of cells that 
responded to CatS is lower than the percentage of sensory neurons found to express PAR2, 
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reported by others to be around 60% in rat DRG sections, using both antibody staining and 
in situ hybridisation (Russell et al., 2012; Steinhoff et al., 2000). This suggests activation of 
additional receptors or channels could be involved in CatS -mediated responses. 
Alternatively, species differences and differences in the tissue stained could also explain the 
difference in the percentage of DRGs reported to express PAR2 compared to the percentage 
of responders to application of CatS as a PAR2 agonist. Indeed, Vellani et al., (2010) 
reported that 21.5% of their mouse DRGs in culture were positive for PAR2 using in-situ 
hybridisation, which is closer in agreement with the percentage of cells we observed to 
respond to application of CatS. 
 
Although CatS-mediated calcium fluxes could be reduced in the presence of the PAR2 
antagonist, FSLLRY-NH2, suggesting the involvement of PAR2 in these responses, we were 
unable to observe significant responses in our cells to application of the PAR2 agonist, 
SLIGRL-NH2. This is unlikely to be due to lack of expression of PAR2 on the DRG neurons, as 
qPCR revealed the presence of PAR2 mRNA in our cells and expression of PAR2 on sensory 
neurons has previously been described by others. One possibility is that the concentration 
of SLIGRL-NH2 used in our experiments was not sufficient to elicit a significant percentage of 
cells to respond compared with the percentage that responded following application of 
buffer. Indeed, Liu et al. (2011b) used 100 µM SLIGRL-NH2 in their calcium imaging 
experiments and observed calcium fluxes in about 3% of their DRG cultures. Furthermore, 
the variance in the percentage of cells that responded was quite high, especially for the 
responders to buffer, which may have masked any potential increase in the percentages of 
cells responding to SLIGRL-NH2, particularly if only a small percentage of cells would respond 
to application of SLIGRL-NH2.  
 
Previous studies in KNRK (Kirsten Murine Sarcoma Virus transformed rat kidney epithelial) 
cells expressing PAR2 reported that cleavage of PAR2 by CatS results in coupling to Gαs and 
the activation of adenylyl cyclase, resulting in the formation of cAMP (Zhao et al., 2014a). 
Mobilisation of calcium was not reported, suggesting that cleavage of PAR2 by CatS is not 
coupled to Gαq, at least in this cell line. How then, might the calcium fluxes observed 
following incubation with CatS be explained? Calcium fluxes following application of CatS 
have been observed in other cell lines and DRGs, suggesting, in line with our observations, 
that CatS can cause either influx of extracellular calcium or mobilisation of intracellular 
calcium in cells (Elmariah et al., 2014; Lieu et al., 2016; Reddy et al., 2010; Reddy et al., 
2015; Zhao et al., 2014a). One possible explanation is that CatS can exert its effects not only 
165 
 
by acting on PAR2, but also by acting on other receptors. When Zhao et al. used HEK293 and 
KNRK cell lines transfected with PAR2 in their experiments, calcium responses to CatS were 
not observed. However, when they used mouse DRGs (which express a wide variety of 
different receptors in addition to PAR2), calcium transients occurred, suggesting the 
requirement of additional receptors or channels for CatS-mediated calcium fluxes. Similarly, 
our experiments were performed in mouse DRGs expressing many different types of 
receptors and channels. In additional to non-canonical cleavage of PAR2 and activation of 
the receptor by a tethered ligand, CatS has also been reported to activate PAR4 (Reddy et 
al., 2010), as well as Mrgprs by a change in conformation of the receptor (Reddy et al., 
2015). Various agonists at PAR4 and MrgprC11 are reported to result in calcium fluxes, and 
so CatS activity at these receptors could also result in calcium fluxes (de la Fuente et al., 
2012; Han et al., 2002; Megyeri et al., 2009; Wilson et al., 2011). Indeed, increasing evidence 
suggests CatS is likely to act at receptors other than or in addition to PAR2. For example, 
Reddy et al., (2015) reported that DRGs from PAR2 KO mice still showed calcium fluxes 
following treatment with CatS, while no calcium fluxes were observed in DRGs from Mrgpr 
KO mice. Future experiments in which PAR4 and MrgprC11 are blocked or inhibited are 
required to further elucidate the mechanisms by which CatS activates its receptors and 
results in calcium fluxes. However, if this is the case, then it does not explain the reduction 
in calcium responses we observed when CatS was applied in the presence of a PAR2 
antagonist, unless the antagonist is capable of blocking activity at other receptors, including 
PAR4 and/or MrgprC11, which has not yet been reported.  
 
Our finding that CatS-mediated calcium transients can be reduced in the presence of a PAR2 
antagonist does not appear to be in agreement with the reports of Reddy et al., (2015) that 
CatS-mediated calcium fluxes are not abolished in DRG cultures from PAR2 KO mice. We 
found that the PAR2 antagonist could significantly reduce the percentage of cells responding 
to CatS to that of the control level (i.e. the percentage that responded to buffer), although it 
cannot be ruled out from our results that some DRGs can be additionally activated by CatS 
at receptors other than PAR2. Furthermore, in their calcium imaging experiments, Reddy et 
al. used CatS at 2 μM concentration while we performed our calcium imaging experiments 
using CatS at a much lower concentration of 400 nM. It cannot be excluded that CatS when 
used at higher concentrations can activate additional receptors, such as Mrgprs, while lower 
concentrations of CatS mostly cleave PAR2. This could also explain some of the delay 
required for calcium responses to occur in our calcium imaging experiments, reflecting the 
time taken for an indirect effect of calcium entry into the cell following cleavage of PAR2 by 
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CatS, while activation of other receptors by higher concentration CatS could result in 
immediate entry of calcium into the cells, as observed by Reddy et al. The observed calcium 
responses to CatS may also be explained by the existence of additional cleavage sites on 
PAR2 for CatS. Elmariah et al. (2014) reported the existence a cleavage site for CatS on PAR2 
different than the site reported by Zhao et al. (2014a), which, when cleaved, resulted in 
calcium fluxes. The synthetic peptide agonist for this cleavage site, KVDGTS, was also able to 
generate calcium responses (albeit with slightly different kinetics than when activated by 
CatS). Future experiments which prevent cleavage of PAR2 at this site will be required to 
address this issue. The factors that determine which of the sites on PAR2 is cleaved by CatS 
also remain to be investigated. Variations in pH, cell type, concentration of CatS, the 
number of PAR2 receptors, the presence of other receptors, and dimerisation of PAR2 with 
other receptors could all potentially affect the cleavage site for CatS. 
 
Finally, there is the possibility that the calcium responses observed are not due to direct 
activation of the cell by CatS acting on PAR2, but instead are due to indirect effects of CatS 
acting on the cell. Activation of PAR2 sensitises TRPV1 and TRPA1, to the point where TRPV1 
channels become activated at a temperature about 10°C lower than usual (Amadesi et al., 
2004; Amadesi et al., 2006; Dai et al., 2004; Dai et al., 2007). Thus, rather than directly 
resulting in calcium fluxes in neurons, the calcium transients could be due to spontaneous 
activity more likely to occur as a result of sensitisation of channels such as TRP channels 
following activation of neuronal PAR2, resulting in increased opening of these channels and 
subsequent entry of cations into the cell. Alternatively, because mixed DRG cultures were 
used for our experiments, activation of PAR2 on other non-neuronal cells could result in the 
release of mediators that in turn activate neurons in close proximity, which could explain 
the delay observed between application of CatS and the time taken for calcium fluxes to 
occur. Cultured fibroblasts have been observed to express PAR2 (Gruber et al., 2004). 
Activation of PAR2 expressed on human lung fibroblasts by trypsin has been reported to 
result in the release of IL-6, IL-8, and prostaglandin E2 (PGE2) (Asokananthan et al., 2015). 
Expression of the IL-6 receptor has been reported in rodent neuronal DRG cell bodies and 
can be upregulated following injury (Brazda et al., 2013; Gadient and Otten, 1996; Thier et 
al., 1999). However, neuronal activation by IL-6 is unlikely to result in calcium transients, as 
this cytokine signals via JAK/STAT, ERK, and PI3 kinase (Erta et al., 2012; Rothaug et al., 
2016). IL-8 is not expressed in rodents, so involvement of this cytokine can be excluded 
(Guenet, 2005). PGE2 signalling through the EP1 receptor can cause calcium transients in 
cultured human myometrial cells and Chinese hamster ovary cells (Asbóth et al., 1996; 
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Watabe et al., 1993), and expression of EP1 on DRGs is reported to be increased following 
nerve injury (Durrenberger et al., 2006). However, whether EP1 is expressed on cultured 
DRGs and results in calcium transients has not been thoroughly investigated. Indeed, in 
sensory neurons EP1 has been reported to signal via PKC to cause sensitisation of TRPV1, 
although activation of TRPV1 could in turn cause in neuronal calcium transients (Moriyama 
et al., 2005). However, whether cleavage of PAR2 expressed on murine fibroblasts by CatS 
would result in a similar release of cytokines and mediators and cause calcium transients in 
DRG cells is not clear. Nevertheless, activation of PAR2 or other receptors that can be 
cleaved by CatS on other cell types in close proximity to DRG neurons is a potential 
mechanism by which neurons might be caused to respond. 
 
PAR2 has also been reported to sensitise TRPV4 (Grace et al., 2014; Grant et al., 2007; Poole 
et al., 2013; Zhao et al., 2014a). It has been proposed that CatS cleaves PAR2 on sensory 
neurons, which in turn sensitises neuronal TRPV4 via the adenylyl cyclase/cAMP/PKA 
pathway, resulting in an influx of calcium ions from the extracellular space, rather than 
mobilisation of calcium from internal stores, and that this is responsible for the calcium 
transients observed in DRGs during calcium imaging experiments with CatS (Zhao et al., 
2014a). Importantly, this CatS-mediated influx of calcium ions was reported to be reduced in 
DRG cultures from PAR2 KO mice or in the presence of a TRPV4 antagonist, suggesting the 
requirement of both PAR2 and TRPV4 for CatS-mediated calcium responses in DRGs. This is 
one explanation for the calcium transients we observed in our DRGs following incubation 
with CatS. However, whether functional TRPV4 is expressed on sensory neurons remains 
controversial. Expression of TRPV4 in sensory neurons has been confirmed by reverse 
transcription PCR, immunohistochemistry, and Western blotting, although concerns about 
the specificity of antibodies available for TRPV4 have been raised (Alexander et al., 2013; 
Grant et al., 2007; Kim et al., 2016). Furthermore, even if TRPV4 is expressed in neurons, 
whether it is normally functional is also disputed. Alexander et al. (2013) failed to observe 
calcium fluxes in most DRGs cultured from wild-type or TRPV4 KO mice in response to 
application of the TRPV4 agonist GSK1016790A. It was reported that a small percentage of 
thoracic DRGs cultured from wild-type mice (but not TRPV4 KO mice) did respond to the 
agonist, although a similar percentage of TG neurons from both wild-type and TRPV4 KO 
mice also responded to GSK1016790A, suggesting these calcium fluxes could in fact be an 
artefact or off-target effects. Instead, it is suggested that the role of TRPV4 in hyperalgesia 
and inflammation is not due to the activity of neuronal TRPV4, but instead of non-neuronal 
TRPV4. In support of this, TRPV4 is also expressed in non-neuronal cells, including 
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endothelial cells, and indeed reports of expression of TRPV4 detected during reverse 
transcription PCR and Western blotting of DRGs could be of vascular rather than neuronal 
origin (Hartmannsgruber et al., 2007). An alternative explanation may be that TRPV4 
expressed on neurons is not normally functional, but can become functional following 
sensitisation or under inflammatory conditions. In agreement with this, Poole et al. (2013) 
observed that approximately half of their DRGs that responded to application of trypsin also 
responded to application of GSK1016790A. Because they applied trypsin prior to application 
of GSK1016790A and did not stimulate neurons in the absence of trypsin or any other PAR2 
agonists, it cannot be excluded that TRPV4 was sensitised or primed by activation of PAR2, 
resulting in calcium fluxes to TRPV4 agonists that otherwise would not have been observed. 
Furthermore, differences in basal somatic sensation between wild-type ad TRPV4 KO mice 
have not been reported (Alexander et al., 2013; Grant et al., 2007). In contrast, increased 
sensitivity to noxious pressure is reported in wild-type mice treated with NGF, but not 
TRPV4 KO mice treated with NGF, suggesting activation of TRPV4 is more likely to be 
involved in enhanced excitability in inflammation and pathological conditions such as atopic 
dermatitis (Alexander et al., 2013). 
 
The role of TRP channels in itch (and pain) sensations has been well documented, and these 
channels are reported to be expressed on sensory neurons (Caterina et al., 1997; Nagata et 
al., 2005; Tominaga et al., 1998). They can be activated by a number of different agonists 
and under various conditions. TRPV1 is known to be activated by capsaicin, noxious heat, 
and low pH (Caterina et al., 1997; Tominaga et al., 1998), while agonists of TRPA1 include 
mustard oil, cinnamon oil, cannabinoids, and bradykinin (Bandell et al., 2004; Jordt et al., 
2004). Activation of these receptors results in the opening of the channels forming a pore 
that allows the passage of cations including calcium and sodium, making them suitable for 
investigating in calcium imaging and electrophysiology experiments (Caterina et al., 1997; 
Jordt et al., 2004). The calcium fluxes observed following activation and opening of these 
channels can be prevented by the removal of extracellular calcium from the medium, 
suggesting that most or all of the calcium is derived from the extracellular environment 
(Caterina et al., 1997; Jordt et al., 2004). However, calcium may also be released from 
intracellular stores. Canonical signalling of PAR2 is reported to result in release of calcium 
from intracellular stores via coupling to Gaq and subsequent activation of PLC and 
production of IP3 (Wang et al., 2010; Zhao et al., 2014a), although the exact mechanism of 
calcium release from intracellular stores may vary depending on cell type as it is not 
reported to occur by this mechanism in all cells (Oikawa et al., 2013). In contrast to 
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canonical activation of PAR2, CatS-mediated activation of PAR2 does not mobilise 
intracellular calcium, resulting instead in generation of cAMP (Zhao et al., 2014a). Thus, it is 
likely that the calcium fluxes observed were due to the influx of extracellular calcium, likely 
through TRP channels which are permeable to cations. However, further experiments 
should be performed to investigate the role of both intracellular and extracellular calcium in 
CatS-mediated neuronal responses. 
 
Calcium ions also play a role in the inactivation and desensitisation of TRP channels 
(Caterina et al., 1997; Nagata et al., 2005; Wang et al., 2008). However, the requirement of 
these channels in mediating itch signalling from pruritogens detected by nerve terminals in 
the skin has recently come under dispute. Using skin-nerve preparations, Ru et al., (2017) 
reported that blocking TRP channels with Ruthenium red or using preparations from TRPV1 
or TRPA1 KO mice did not affect responses to various pruritogens applied at the nerve 
terminals, although responses could be reduced in the presence of a chloride channel 
inhibitor. It was proposed that activity of TRP channels in the cell body may be important for 
the behavioural responses to pruritogens, which explains why scratching behaviour in 
response to pruritogens is reduced in TRP KO mice. However, this does not explain why 
calcium transients are observed in DRGs following application of pruritogens, such as we 
observed with CatS, and others have observed with histamine, and how such responses can 
be reduced in cultures from TRP KO animals, unless differences in experimental techniques 
are considered. In the skin-nerve preparations used by Ru et al., (2017), the axons of the 
sensory neurons innervating the skin remain intact, whereas in calcium imaging experiments 
DRGs are cultured and are required to regrow their neurites. Thus, the expression and 
function of receptors and channels such as TRPs in cultured DRGs may not accurately reflect 
their expression and function in the terminals of unaxotimised neurons. Nevertheless, we 
were able to demonstrate the requirement of expression of TRPV1 and TRPA1 in sensory 
neurons for CatS -mediated calcium signals in vitro. 
 
Of all the neurons that responded to CatS, most also responded to the TRPV1 agonist 
capsaicin or the TRPA1 agonist mustard oil. Furthermore, the percentage of cells that 
responded to CatS in calcium imaging experiments was reduced in cultures from TRPV1 KO 
and TRPA1 KO mice. We therefore conclude that cells that respond to CatS are likely to 
belong to the TRPV1 and TRPA1 expressing subpopulation of sensory neurons. This is in 
agreement with previous studies in which a high incidence of co-localisation of PAR2 and 
TRPV1 or TRPA1 in neurons has been reported (Dai et al., 2004; Dai et al., 2007). 
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Furthermore, because the neurons responsible for pruriception are likely to be a subset of 
nociceptors, we would expect neurons that respond to pruritogens such as CatS to express 
TRPV1 and respond to capsaicin (Imamachi et al., 2009). However, one of the limitations of 
our patch-clamping and calcium imaging assays is that it cannot distinguish pruriceptors 
from nociceptors, and whether the neurons are polymodal or specific for conveying itch or 
pain. Thus, although we can conclude that DRGs that respond to CatS are a subset of 
nociceptors, we cannot determine the sensation(s) they are responsible for conveying. In 
fact, because injections of CatS in mice cause both nocifensive wiping and scratching 
behaviours, it is likely that neurons that respond to CatS are involved in conveying both pain 
and itch sensations, as observed in our behavioural studies in mice. Whether the different 
sensations result by activation of different receptors by CatS or by different subsets of cells 
remains to be investigated. 
 
In addition to the neurons that responded to CatS belonging to the TRPV1/TRPA1-expressing 
subpopulation, we also observed that a greater percentage of cells responded to the TRPV1 
agonist capsaicin or the TRPA1 agonist mustard oil if the cells were exposed to CatS first, 
suggesting sensitisation of these channels. Since PAR2 can sensitise TRPV1 and TRPA1, one 
likely explanation is that CatS has cleaved and activated PAR2 in our neuronal cultures, 
which has resulted in sensitisation of TRPV1 and TRPA1, making the cells more likely to 
respond when exposed to capsaicin and mustard oil (Amadesi et al., 2004; Amadesi et al., 
2006; Dai et al., 2004; Dai et al., 2007). Previous studies have investigated the role of PAR2 
activated by trypsin or the synthetic peptide agonist that is produced following cleavage of 
PAR2 by trypsin. In the case of TRPV1, sensitisation was found to occur via PKC and PKA 
phosphorylation of TRPV1, while TRPA1 was found to be sensitised by hydrolysis of PIP2 by 
PLC. However, whether CatS causes sensitisation of TRPV1 and TRPA1 by the same 
mechanisms is not yet known. Indeed, since the mechanisms of sensitisation of TRPV4 by 
PAR2 are different when PAR2 is cleaved by CatS compared with cleavage at the canonical 
site (Zhao et al., 2014a), it would not be surprising if the mechanisms by which TRPV1 and 
TRPA1 became sensitised by PAR2 were also different following cleavage of PAR2 by CatS 
compared with trypsin. Activation of PAR4 has also been reported to cause sensitisation of 
TRPV1 by PKC (Vellani et al., 2010), and because CatS has been reported to cleave PAR4 in 
addition to PAR2, the increase in the percentage of neurons responding to capsaicin 




In DRG neurons cultured from TRPV1 KO mice, a significant reduction in the percentage of 
cells that responded to CatS was observed. This is in agreement with what was observed in 
our behavioural studies, in which CatS-induced itching was significantly reduced in TRPV1 
KO mice compared with wild-type mice. Thus, functional TRPV1 appears to be essential for 
both CatS-mediated calcium responses in neurons in vitro and scratching behaviour in vivo. 
One discrepancy we are unable to explain, however, is the reduction in calcium response of 
cultured DRGs from TRPA1 KO mice to CatS, while no significant reduction in scratching 
behaviour was observed when CatS was injected in TRPA1 KO mice. Although a slight 
reduction in scratching behaviour was noted following injection of CatS into TRPA1 KO mice 
compared with WT mice, this was not significant. In contrast, a significant decrease in the 
percentage of cells that responded to CatS was observed in cultures from TRPA1 KO mice 
compared with wild-type mice. One explanation for this is the difference between in vivo 
behavioural studies and in vitro assays looking at the responses of cells, which may not 
necessarily be the same; in this instance we are assuming that calcium fluxes and activation 
of the cell means transmission of itch signals and subsequent scratching behaviour. 
Compensatory mechanisms may exist in TRPA1 KO mice, such that no obvious defects in 
CatS -mediated scratching are observed. For instance, Petrus et al. (2007) found that CFA-
induced hyperalgesia could be reduced in wild-type mice treated with a TRPA1 inhibitor, 
while mice lacking functional TRPA1 receptors still displayed considerable CFA-induced 
hyperalgesia. Changes in the expression of other TRP channels in DRGs and other cell types 
are thought to be responsible for this, although these have yet to be demonstrated. 
However, a similar compensatory mechanism may result in CatS-induced scratching 
behaviour in TRPA1 KO mice, even in the absence of calcium responses in these DRGs in 
vitro. Furthermore, because TRPV1 and TRPA1 are also reported to be expressed on skin 
keratinocytes and mast cells as well as sensory neurons, it is possible that in behavioural 
studies the presence or absence of these channels on non-neuronal cells could also be 
mediating an indirect effect on CatS-induced scratching in behavioural studies, which would 
not be detected in neuronal calcium imaging experiments (Atoyan et al, 2009; Biro et al., 
1998; Inoue et al., 2002; Oh et al., 2013; Southall et al., 2003). Thus, although CatS did not 
cause calcium responses in neurons cultured from TRPA1 KO mice, itch sensations and 
scratching behaviour could still occur, for instance, via the release of histamine from mast 
cells and sensitisation or compensation of TRPV1 expressed on neurons and other cell types. 
 
To conclude, CatS causes inward currents and increased calcium fluxes in a sub-population 
of murine DRGs. Most of these neurons responded to TRPV1 and TRPA1 agonists, and 
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responses to CatS were reduced in DRGs cultured from TRPV1 and TRPA1 KO mice, 
suggesting these neurons belong to a subset of nociceptors, as would be expected for 
pruriceptors. Furthermore, CatS was able to sensitise these receptors, increasing the 
percentage of neurons that responded to application of either capsaicin or mustard oil. CatS 
is likely to mediate at least some of its effects via PAR2, since calcium fluxes to CatS were 
reduced in the presence of a PAR2 antagonist. However, a number of questions remain 
unanswered, such as whether these responses reflect the signalling of itch or pain 
sensations (or both), the mechanism by which CatS sensitises TRPV1 and TRPA1, and 





























Chapter 4  
Activation of dorsal horn neurons and release of itch-related peptides by intraplantar 
Cathepsin S 
4.1 Introduction 
Activation of primary afferent neurons by pruritogens causes release of neurotransmitters 
and neuropeptides from their central terminals in the dorsal horn of the spinal cord, in turn 
activating interneurons and projection neurons to result in transmission of the itch signal to 
higher centres of the CNS. We have demonstrated that CatS could activate primary sensory 
neurons that are likely pruriceptors belonging to a subset of nociceptors, and that activation 
may occur via PAR2. Activation of PAR2 using trypsin and synthetic agonists has already 
been demonstrated to cause the release of the neuropeptides CGRP and substance P from 
C-fibre terminals (Steinhoff et al., 2000). However, whether CatS-mediated activation of 
primary afferents also causes neurons in the spinal cord itch circuitry to become activated 
had not yet been addressed. 
 
Chapter Objectives 
The aim of this chapter was to test the hypothesis that activation of pruriceptors by CatS in 
the periphery results in the release of NPPB by the central terminals of sensory neurons, in 
turn activating spinal cord dorsal horn neurons. To address this aim, we first examined 
whether intradermal injection of CatS resulted in neuronal activation in the dorsal horn of 
the spinal cord. We then confirmed expression of the itch-related neuropeptides NPPB and 
GRP in the mouse DRG and spinal cord. Next, we investigated whether CatS would cause the 
release of NPPB from primary sensory neurons in DRG culture as well as in the dorsal horn 
following intraplantar injection of the protease. We focused on expression and release of 
NPPB from DRG cells, as there is much evidence of the role of this neuropeptide in the itch 
circuitry and it is likely to be released from the afferents of primary sensory neurons 
following non-histaminergic pruritic stimuli where it would then result in activation of 
neurons in the dorsal horn of the spinal cord, providing a link between CatS-induced 
responses of primary afferent neurons and activation of dorsal horn neurons. As a positive 
control, the expression of CGRP was also investigated as a neuropeptide that is co-






4.2.1 Quantitative polymerase chain reaction (qPCR) 
Dissection of murine DRGs was performed as described in Chapter 3. 30 DRGs were 
removed from each mouse. Total RNA was extracted using Trizol reagent (Ambion, Life 
Technologies, UK) and the PureLink RNA Mini Kit (Ambion, Life Technologies, UK), according 
to the manufacturer's protocol. Total RNA concentration was measured using the NanoDrop 
spectrometer. 1000 ng RNA was used to synthesise first strand DNA using the Superscript 
VILO cDNA Synthesis Kit (Invitrogen, UK) according to the manufacturer’s protocol. 
Expression levels of NPPB and GRP were analysed, using β-actin as a reference transcript. 
Amplification was performed with a LightCycler 480 (Roche) using SYBR Green I Master 
(Roche). The primers used are given in Table 4.1. The instrument was programmed as 
follows: 95˚C for 5 minutes and 45 cycles of 3 steps of 10 seconds each, including denaturing 
at 95˚C, annealing at 60˚C, and primer extension at 72˚C. Samples were run as duplicates, 
with 18S as the housekeeping gene. Samples in which the melting curve had more than one 
peak were excluded from analysis. Data was analysed using LightCycler 480 software 
(version 1.5.1).  The relative gene expression level was calculated according to the 2-ΔCt 
method, where Ct represents the threshold cycle.  
 
Table 4.1: Primers used for NPPB, GRP, and β-actin in qPCR 
Genes Forward Sequence Reverse Sequence Reference 
NPPB GTTTGGGCTGTAACGCACTG CAGAGCTGGGGAAAGAGACC 
Solorzano et al., 
2015 
GRP CCGGTGTCGACAGGCGCAG TCAGCCGCATACAGGGACGG 
Solorzano et al., 
2015 
β-actin GGCTGTATTCCCCTCCATCG CCAGTTGGTAACAATGCCATGT 
Jiang et al., 2017a; 
Veres-Szekely et 
al., 2017 
4.2.2 Enzyme-linked immunoabsorbent assay (ELISA) for natriuretic polypeptide B 
Culture of murine DRGs was performed as described in Chapter 3 with 5,000 – 6,000 cells 
per coverslip. DGRs were cultured overnight followed by stimulation with capsaicin (1 μM, 
Sigma, UK) or DMSO (0.01%, Sigma, UK) in the presence of phosphoramidon (1 µM, Sigma, 
UK), added to prevent potential digestion of NPPB by endogenous endopeptidases, in HEPES 
at pH7.4 (HEPES, 10 mM, Sigma, UK; NaCl, 150 mM, Sigma, UK; KCl, 5 mM, Sigma, UK; MgCl2, 
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1 mM, G Biosciences, USA; CaCl2, 1 mM, Fisher Scientific, UK; glucose, 5.55 mM, Sigma, UK). 
NPPB content in cell media was measured using an ELISA for murine NPPB (Cloud-Clone 
Corp., USA), according to the manufacturer’s protocol. All samples were run in duplicate. 
The optical density of each well was determined at 450 nm wavelength using a FLUOstar 
Omega Spectrophotometer (BMG Labtech, UK). A standard curve of 1.37 pg/ml to 1,000 
pg/ml was generated using a serial dilution of the stock standard provided by the 
manufacturer, and the concentration of NPPB released from the samples into the 
supernatants was determined from the standard curve.  
4.2.3 Immunohistochemical staining 
Following completion of behavioural experiments, mice were anaesthetised with sodium 
pentobarbital (Euthanol, 100 mg/kg body weight) and transcardially perfused with 0.9% 
saline followed by 4% paraformaldehyde in 0.1 M phosphate buffer. Tissues were removed 
and post-fixed for 2 hours in 4% paraformaldehyde at 4°C and cryoprotected in 20% sucrose 
in 0.1 M phosphate buffer for 24 hours at 4°C. Tissues were then frozen in OCT embedding 
medium (VWR, UK) and stored at -80°C. Using a cryostat (Bright Instruments, UK), DRG and 
TG sections (7 μm thick) were cut, while lumbar spinal cord tissues were transversely 
sectioned at 20 μm, and mounted onto 25 mm x 75 mm x 1 mm microscopic glass slides 
(VWR, UK). Slides were stored at -20°C. 
 
Tissue sections were rehydrated in PBS for 10 minutes prior to staining. For staining with 
NPPB, β-III-tubulin, and IB4, antigen retrieval was performed using citrate antigen 
unmasking solution (Vector Laboratories, USA) diluted 1:100 in H2O for 30 minutes at 80˚C, 
followed by blocking in 2% milk for 30 minutes at room temperature. Unless being used for 
co-staining with NPPB, tissues were blocked in 1% BSA + 0.1% NaN3 + 0.2% Triton X blocking 
buffer at room temperature for 1 hour for staining with CGRP. A similar blocking buffer 
comprising 1% BSA + 0.1% Triton X was used to block tissues stained with pERK. Tissues 
were then incubated overnight at room temperature in primary antibody diluted in the 
appropriate blocking buffer, followed by washes and incubation for 2 hours at room 
temperature in secondary antibody diluted in the appropriate blocking buffer (Table 4.2). A 
minimum of three washes in PBST was performed after each antibody incubation. Sections 
were mounted in Vectashield mounting medium with DAPI (Vector Laboratories, USA). A 22 
x 55 mm coverslip (Academy Science, UK) was placed over the slide and sealed with nail 
varnish. Images were taken using a Zeiss Axioplan 2 fluorescent microscope and Axiovision 
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version 4.8.2 software (Zeiss, UK) or a Zeiss LSM 710 confocal microscope (Zeiss, UK). A 
minimum of three tissue sections per animal were acquired. 
 
Table 4.2: Table of primary and secondary antibodies used for immunocytochemistry 
Primary Concentration Secondary Concentration 
Goat anti-NPPB, V-17 




conjugated AlexaFluor 488 
(Molecular Probes, USA) 
1:500 
Sheep-anti-CGRP, CA1137 
(Enzo Life Sciences, USA) 
1:1000 
Donkey-anti-sheep IgG-
conjugated AlexaFluor 546 
(Molecular Probes, USA) 
1:500 
Rabbit-anti-β-III-tubulin, 
ab18207 (Abcam, UK) 
1:2000 
Donkey-anti-rabbit IgG-
conjugated AlexaFluor 546 
(Molecular Probes, USA) 
1:500 
IB4, L2140 (Sigma, UK) 1:100 
Extra-avidin TRITC (Sigma, 
UK) 
1:400 





conjugated AlexaFluor 488 
(Molecular Probes, USA) 
1:1000 
4.2.4 In-situ hybridisation 
NPPB mRNA in DRG sections was labelled using fluorescent in-situ hybridisation. Various 
oligonucleotide sequences were designed from mouse NPPB cDNA (GenBank accession 
number NM_008726) as well as scramble sequences. Sequences were 33 nucleotides in 
length and BLAST searches were performed check whether they could potentially anneal to 
similar sequences. Sequences that did not form dimers and had weak or no secondary 
structures were selected for use. The oligonucleotides in table 4.3 were selected for testing 
and were ordered from Sigma (UK) and diluted to 1 μM before use. Oligonucleotides were 
labelled with biotin-11-dUTP using the biotin 3' end DNA labelling kit (Thermo Scientific, UK) 








Table 4.3: Oligonucleotide probes used for in-situ hybridisation 
NPPB Primers 
Primer Number Sequence Tm CG% 
190 CCTACAACAACTTCAGTGCGTTACAGCCCAAAC 76.1 48.5 
263 GCTTGAGATATGTGTCACCTTGGAATTTTGAGG 74.2 42.4 
377 GAGCTGTCTCTGGGCCATTTCCTCCGACTTTTC 79.9 54.5 
380 CTGTCTCTGGGCCATTTCCTCCGACTTTTCTCT 78.3 51.5 
Scramble Primers 
Primer Number Sequence Tm CG% 
15 CCCAAACCTTCACTCAACATTGTTACCATGTAG 73.1 42.5 
16 ACAAAGAGACTTTAGTCTCCCATTGCCTCTGGA 74.6 45.5 
 
To investigate whether oligoprobes would hybridise to RNA present in tissues, the probes 
were tested on sections that had been treated with RNase (1x, Sigma, UK) at 37°C for 30 
minutes or left untreated. Sections were then dehydrated in 70%, 95%, and 100% ethanol 
and left to dry. Meanwhile, oligoprobes were diluted 1:40 in hybridisation buffer 
(formamide 50%, Sigma, UK; dextran sulfate 10%, Sigma, UK; 0.1% SDS, Sigma, UK; salmon 
sperm DNA, 300 ng/ml, Sigma, UK; saline-sodium citrate (SSC) buffer, 2x, Sigma, UK). The 
final concentration of labelled oligoprobe was 2.5 nM. Oligoprobes were placed on a heat 
block at 65°C for 15 minutes and kept on ice before use. The prepared oligoprobe was 
added to the tissue sections on the slides and an ethanol-treated glass coverslip was 
lowered over each slide to prevent evaporation and loss of the oligoprobe. Slides were then 
incubated overnight at 50°C. The following day, slides were washed in SSC buffer and PBS 
(according to the schematic in Figure 4.1). Avidin-Biotin Complex (ABC) (Vector Laboratories, 
USA) was prepared by diluting according to the manufacturer's protocol, and sections were 
incubated in ABC for 30 minutes at room temperature. Biotinyl tyramide (NEN Life Science, 
UK) was prepared and diluted according to the manufacturer's protocol, with which sections 
were incubated for 10 minutes. Sections were then incubated in Extra-avidin FITC (1:400 
dilution, Sigma, UK) diluted in 0.1% PBS-T for to 2 hours at room temperature. After a final 
set of washes, sections were either mounted in Vectashield mounting medium with DAPI 
and covered with a 22 x 55 mm coverslip, or underwent antibody staining as for above. 
Sections were imaged using a Zeiss Axioplan 2 fluorescent microscope and Axiovision 




Figure 4.1: Schematic of fluorescent in-situ hybridisation staining protocol 
Mouse DRG tissue sections underwent in-situ hybridisation for NPPB using biotin-labelled 
oligoprobes. All solutions, including RNase buffer, phosphate buffered saline (PBS), saline-
sodium citrate (SSC), Avidin-Biotin Complex (ABC), and biotinyl tyramide were prepared using 




4.2.5 Quantification of staining 
 
Sensory ganglia 
For quantifying staining of neurons in sensory ganglia sections, the total number of neurons 
was first obtained by identifying based on their shape and size or β-III-tubulin staining. 
Individual neurons were labelled and a threshold was established for determining whether 
cells were positively stained. The threshold was based on the intensity of staining of the cell 
and a cell was classified as positively stained if the intensity was at least 40 % and 50 % 
greater than the average intensity of negatively-stained cells, for NPPB and CGRP, 
respectively. Intensity was measured using Image J software. Because of high background 
staining in some images, a manual count was also performed for some images with the 
experimental group blinded, in addition to the threshold count. An average value for the 
percentage of positively-stained cells for each animal was calculated. 
 
Spinal cord 
Release of neurotransmitters from the central terminals of primary afferent neurons was 
measured by quantification of staining for neurotransmitters in the spinal cord dorsal horn, 
following a method modified from Lever et al. (2001). Quantitative assessment of 
immunoreactivity (IR) in the spinal cord was performed by determining the intensity of 
fluorescence in laminae I and II of the dorsal horn with the experimental group blinded. 
Three boxes measuring 100 x 100 pixels were spaced equally across the superficial laminae 
of the dorsal horn. Using Axiovision SE64 4.9.1 software (Zeiss, UK), the mean intensity of 
each of the boxes was determined. The background intensity for each image was 
determined using a 100 x 100 pixel box and was subtracted from the intensity values 
obtained. An average value for fluorescence intensity for the superficial dorsal horn was 
then calculated. 
 
Quantitative assessment of immunoreactivity in the spinal cord was also performed by 
determining area of fluorescence in laminae I and II of the dorsal horn with the 
experimental group blinded. This method was performed in two different ways. The first 
involved placing three boxes measuring 100 x 100 pixels equally across the superficial 
laminae of the dorsal horn. Using Image J software, a threshold intensity was set such that 
the immunoreactivity areas were highlighted, while areas that were free from staining 
where not highlighted. This threshold was kept the same for all images analysed for each 
experiment. The percentage of area occupied for in each 100 x 100 pixel box was 
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determined and an average value for fluorescence area for the superficial dorsal horn was 
then calculated. The second method was similar to this but involved outlining the entire 
area of laminae I and II of the doral horn to which a threshold was set to determine areas of 
immunoreactivity. 
4.2.6 Behavioural testing 
 
Thermal hyperalgesia 
Thermal withdrawal thresholds were assessed using the radiant heat (Hargreaves) test. Mice 
were acclimatised in 8 x 5 x 10 cm Perspex cubicles over a glass surface for 60 minutes prior 
to testing. Infrared radiation of 80-100 mWatts/cm2 was applied to the plantar surface of 
the right hindpaw only. Intensity was calibrated to give an average withdrawal response 
after 10 seconds, while a cut-off time of 20 seconds was used to avoid tissue damage. The 




Mechanical withdrawal thresholds were assessed using von Frey filaments (Linton 
Instruments, UK) applied to the plantar surface of the hind paw. Mice were acclimatised in 8 
x 5 x 10 cm cubicles over a wire mesh for 60 minutes before testing. Von Frey filaments 
ranging between 0.008 g and 1 g were applied to the plantar surface of each hind paw until 
the filament bent, and was then held in place for 3 seconds or until the paw was withdrawn. 
Reflexes associated with movement or grooming were excluded. The “up-down” method 
was used to calculate the 50% paw withdrawal threshold (Chaplan et al., 1994). 
Assessments started with the 0.07 g filament. Upon observing a positive withdrawal 
response to application of the filament, the next lower force filament was then applied. In 
contrast, an absence of withdrawal response to application of the filament resulted in 
application of the next higher force filament, up to 1 g. Responses to four subsequent 
filaments were assessed in this way according to the up-down sequence. 
 
Drug administration 
2.5 S murine NGF (Alomone, Isreal) was dissolved in sterile 0.9% saline and 20 µg/100 µl was 
injected subcutaneously into the nape of the neck using a 25 G needle every second day for 
up to 12 days. Thermal hyperalgesia was assessed one hour after injection of NGF or saline 
vehicle. hr-CatS (Medivir, Sweden) was diluted in sterile 0.9% saline and 1 µg/10 µl was 
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injected intraplantar into the right hind paw using a 25 G needle. Mechanical hyperalgesia 
was assessed 30 minutes or 3 hours after injection of CatS or saline vehicle. Capsaicin 
(Sigma, UK) was dissolved in ethanol and Tween-80 and diluted in sterile 0.9% saline. 
Capsaicin (1 µg/10 µl) was injected intraplantar into the right hind paw using a 25 G needle. 
Mechanical hyperalgesia was assessed 30 minutes or 3 hours after injection of capsaicin or 
saline vehicle. 
4.2.7 Statistical analysis 
All data were analysed and graphs were generated using GraphPad Prism 5 (Graphpad 
Software Inc., USA) and are shown as mean ± standard error of the mean (SEM). P≤0.05 was 
set as the level of statistical significance for all experiments. 
 
qPCR results were analysed using a Student’s t-test to compare expression of NPPB with 
that of GRP.  
 
For immunohistochemical and in-situ hybridisation data, statistics was performed on raw 
data. For cell number counts, fluorescence intensity, and fluorescence area measurements, 
average values were obtained for each animal. A mean value for each experimental group 
was obtained and groups were compared with one another using Student’s t-test or one-
way ANOVA followed by Bonferroni post-tests to measure differences between two or more 
groups, respectively.  
 
For the assessment of thermal sensitivity, data was calculated from the averages of three 
readings per mouse and expressed as the average time for paw withdrawal for each group. 
Data were analysed using two-way ANOVA with Bonferroni post-hoc test to compare 
between groups at different time points.  
 
For assessment of mechanical hyperalgesia, data are expressed as the average 50% paw 
withdrawal thresholds (PWT) for both hind paws, calculated using the method as described 
by Dixon, 1980. Data were analysed using one-way ANOVA with Bonferroni post-hoc test to 




4.3.1 Intraplantar injection of Cathepsin S activates cells in the dorsal horn 
Peripheral injection of pruritogens, including histamine and SLIGRL-NH2, has previously been 
demonstrated to activate cells in the dorsal horn (Akiyama et al., 2009b; Akiyama et al., 
2016a; Bell et al., 2016; Jinks et al., 2002; Kiguchi et al., 2016; Nakano et al., 2008; Nojima et 
al., 2003; Zhang et al., 2014). Activation of primary afferent fibres by pruritogens results in 
release of neurotransmitters and neuropeptides from their central terminals, which in turn 
activating cells in the dorsal horn. Activation of these neurons has also been demonstrated 
to be required for scratching behaviours in mice, as preventing activation of these cells 
inhibits transmission of itch signals. For instance, Zhang et al. (2014) reported that 
intrathecal injection of the U0126 (which inhibits phosphorylation of ERK) reduces 
histamine-induced scratching behaviour, suggesting activation of neurons in the dorsal horn 
is required for transmission of itch signals and/or the behavioural scratching responses that 
occur as a consequence of activation of pruriceptors. We therefore performed a preliminary 
study to investigate whether neurons in the dorsal horn responded to intraplantar injection 
of hr-Cathepsin S or capsaicin by expressing pERK. Whilst capsaicin did not result in changes 
in pERK expression, intraplantar CatS was associated with a significant increase in the 
number of cells positive for pERK compared with saline or capsaicin (Figure 4.2). The lack of 
effect of capsaicin is likely because we stained for pERK 30 minutes after injection of 
capsaicin, while peak activation of pERK in the dorsal horn is reported to occur at 2-10 






























Figure 4.2: Injection of Cathepsin S into the hindpaw resulted in an increase in the number 
of pERK positive cells in the ipsilateral side of the dorsal horn of the spinal cord 
Representative image of dorsal horn stained for pERK following injection of saline (A), 
capsaicin (1 μg/10 μl) (B), or CatS (1 μg/10 μl) (C) Scalebar = 100 μm. Quantified data of 
number of pERK-positive cells in the dorsal horn 30 minutes after intraplantar injection of the 
substances indicated (D). n = 3, 4 per group, data are mean ± SEM. * p ≤ 0.05, One-way 
ANOVA followed by Bonferroni post-hoc test. 
4.3.2 Itch-related peptides are expressed in dorsal root ganglia and spinal cord 
To investigate whether activation of dorsal horn neurons following injection of CatS was 
associated with neuropeptides released from primary afferent fibres acting on these 
neurons, we had to confirm expression of these neuropeptides in sensory neurons. GRP and 
NPPB are two neuropeptides that are proposed to be involved in itch. Both have been 
reported to be expressed in DRGs and released from the terminals of primary sensory 
neurons, where they bind to their respective receptors on interneurons located within the 
dorsal horn of the spinal cord (Abdelalim et al., 2016; Goswami et al., 2014; Kiguchi et al., 
2016; Liu et al., 2014b; Mishra and Hoon, 2013; Pitake et al., 2017; Solorzano et al., 2015; 
Sun and Chen, 2007). Using qPCR, we therefore investigated whether mRNAs of these 
neuropeptides were expressed in mouse DRGs. We observed that both NPPB and GRP were 
expressed in DRG tissues (Figure 4.3, Table 4.4). Expression of NPPB was greater than that of 







































Figure 4.3: Expression of NPPB and GRP mRNA in mouse DRG tissues 
Expression of NPPB and GRP mRNA extracted from mouse DRG relative to that of β-actin. n = 
4; 2 replicates per sample, data are mean ± SEM. No significance, unpaired Student’s t-test. 
 
Table 4.4: Ct values for NPPB and GRP expression 
Average Ct values of samples run as duplicates. 
  β-actin NPPB GRP 
Sample 1 18.305 30.595 27.7 
Sample 2 18.01 30.065 28.89 
Sample 3 18.5 25.16 27.49 
Sample 4 20.055 26.435 28.375 
 
Expression of NPPB mRNA was also confirmed in mouse TG and DRG using in-situ 
hybridisation. We first tested different oligoprobes for NPPB in the presence and absence of 
RNase. Of the different oligoprobes tested, probe N263 gave the best results, with 
approximately 11% of cells staining positive for NPPB mRNA and significantly reduced in the 
presence of RNase (Figure 4.4 A – C). The number of cells positive for NPPB mRNA was 
similar to that previously reported in sensory ganglia (Huang et al., 2018; Mishra and Hoon, 
2013). This probe was thus used for all further in-situ hybridisation experiments. Probe 
N380 did stain some cells, but a lower percentage than that stained by the N263 probe 
(Figure 4.4 D – F). The remaining probes did not give reliable staining. The scramble probe 




























































Figure 4.4: Expression and quantification of NPPB mRNA in mouse TG 
Representative image of staining obtained in mouse TG tissue with the N263 probe in the 
presence (A) or absence (B) of RNase, the N380 probe in the presence (D) or absence (E) of 
RNase, or the scramble probe in the presence (G) or absence (H) or RNase. Quantified data 
of the percentage of cells in the TG stained for NPPB mRNA using the N263 (C), N380 probe 
(F), or scramble probe (I) in the presence or absence of RNase, n = 6 – 8, from 4 animals, data 
are mean ± SEM. * p ≤ 0.05, unpaired Student’s t-test. Scalebar = 50 μm. 
 
Although we confirmed expression of NPPB mRNA in murine tissues, we also wanted to be 
able to confirm expression of NPPB peptide. This was achieved using antibody staining. In 
mouse TG, 7.5% of cells stained positive for NPPB peptide (Figure 4.5 A and B). Expression of 
NPPB peptide was also observed in the DRG (Figure 4.5 C) and in laminae I and II of the 
dorsal horn of the spinal cord (Figure 4.5 D). Attempts were made to stain for NPPB in the 
trigeminal nuclei of the brain stem, where the endings of the TGs are located, but this was 
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unsuccessful due to difficulties in locating the nuclei for processing and staining. We 
























Figure 4.5: Expression of NPPB peptide in mouse TG, DRG, and spinal cord 
Representative image of staining for NPPB peptide in mouse TG (A), DRG (C) and spinal cord 
(D) tissues. Scalebar = 50 μm in B and D, 100 μm in D. Quantified data (B) of the percentage 
of cells in the TG stained for NPPB peptide at 1:500 dilution. n = 8, from 4 animals, data are 
mean ± SEM. * p ≤ 0.05, unpaired Student’s t-test. 
 
To compare expression of NPPB mRNA with NPPB peptide, DRGs underwent staining using 
both in-situ hybridisation probes and antibodies. 13% of cells were positive for NPPB mRNA 
and less than 4% were positive for the scramble probe (Figure 4.6 D). 12% of cells were 
positive for NPPB peptide, which was not affected by the presence of the probe used for in-
situ hybridisation (Figure 4.6 E). Of the cells that were positive for NPPB mRNA, about 71% 
were also positive for the NPPB peptide (Figure 4.6 F). More than 86% of the cells that were 
positive for both NPPB mRNA and peptide were small diameter cells with an area of less 



















































































Figure 4.6: Quantification of NPPB mRNA and NPPB peptide in mouse DRG 
A-C. Representative image of staining for NPPB mRNA using the N263 probe (green) and 
NPPB peptide (red) in DRG tissue. Scalebar = 100 μm. Quantified data of the percentage of 
cells in the DRG stained for NPPB mRNA (D), peptide (E), or both NPPB mRNA and peptide 
(F). Area of DRG cells positive for both NPPB mRNA and peptide (G). n = 3, from 3, 4 sections 
per animal, data are mean ± SEM. *** p ≤ 0.001, unpaired Student’s t-test. 
 
To investigate whether neurons that expressed NPPB belonged to the peptidergic 
population of sensory neurons, DRGs were co-stained for NPPB mRNA and CGRP peptide. 
15% of cells were positive for NPPB mRNA and only 5.4% of cells were positive for the 
scramble sequence (Figure 4.7 D). 31-32% of cells were positive for the CGRP peptide, and 
the percentage of cells positive for CGRP peptide was not affected by the in-situ probe used 
(Figure 4.7 E). Of the cells that were positive for NPPB mRNA, 73% were also positive for 
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CGRP peptide (Figure 4.7 F). Almost 90% of the cells that were positive for NPPB mRNA and 


















































































Figure 4.7: Quantification of NPPB mRNA and CGRP peptide in mouse DRG 
A-C. Representative image of staining for NPPB mRNA using the N263 probe (green) and 
CGRP peptide (red) in DRG tissue. Scalebar = 100 μm. Quantified data of the percentage of 
cells in the DRG stained for NPPB mRNA (D), CGRP peptide (E), or both NPPB mRNA and 
CGRP peptide (F). Area of DRG cells positive for both NPPB mRNA and CGRP peptide (G). n = 
3, from 3, 4 sections per animal, data are mean ± SEM. * p ≤ 0.05, unpaired Student’s t-test. 
 
We also investigated whether NPPB is expressed in the terminals of sensory neurons in the 
dorsal horn of the spinal cord, and evaluated whether expression could be up-regulated and 
release of neuropeptide could be determined by a reduction of expression using 
immunohistochemistry. NPPB peptide was detected in the outer laminae of the dorsal horn. 
However, co-staining of NPPB and CGRP peptides proved problematic, with complete co-
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staining observed (Figure 4.8 C), suggesting cross reaction of the antibodies. Staining overall 
appeared to be more widespread than that observed with NPPB alone, and more similar to 
that obtained with CGRP. In contrast, co-staining of NPPB and IB4 revealed hardly any 
overlap of staining (Figure 4.8 F), suggesting that NPPB-positive nerve terminals likely 
comprise a different population of cells to the mainly non-peptidergic IB4-positive terminals. 
 
 
Figure 4.8: Expression of NPPB, CGRP, and IB4 peptides in the spinal cord dorsal horn 
A-C. Representative images of dorsal spinal cord sections stained for NPPB (green) and CGRP 
(red), with co-staining for NPPB and CGRP (yellow). Scalebar = 100 μm. 
D-F. Representative images of dorsal spinal cord sections stained for NPPB (green) and IB4 
(red), with co-staining for NPPB and IB4 (yellow). Scalebar = 100 μm. 
 
Upregulation of NPPB expression 
After confirming expression of NPPB in murine tissues, we examined whether expression of 
NPPB could be increased following treatment with NGF. Previous work has shown that 
systemic injection of NGF results in increased sensitisation to thermal and mechanical 
stimuli (Alexander et al., 2013). In rodent DRG, NGF also causes increased expression of 
neuropeptides such as CGRP and substance P (Verge et al., 1995). We thus sought to 
investigate whether treatment with NGF would result in upregulation of NPPB in mouse 
DRGs, and therefore provide more peptide for our release experiments. As expected, mice 
injected with NGF (2.5S, mouse) exhibited a significant decrease in the response time to 
noxious thermal stimuli compared to those injected with saline, as early as one hour after 
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the first injection. This increased sensitivity to thermal stimuli was maintained for the 
duration of the experiment (Figure 4.9). Treatment with NGF resulted in a significant 
increase in the percentage of DRGs cells positive for NPPB from 9% to nearly 20% (Figure 
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Figure 4.9: NGF-induced thermal hyperalgesia 
The effect of NGF injected subcutaneously into nape of neck of mice 1 hour before testing of 
thermal sensitivity using the Hargreaves tests. n = 4 for both groups, averages of 3 readings 
from each animal, data are mean ± SEM. *** p ≤ 0.001, Two-way ANOVA followed by 


































Figure 4.10: The effect of NGF on the expression of NPPB in DRGs 
Representative image of staining for NPPB peptide in DRG of mouse injected with saline (B) 
or NGF (C). Scalebar = 100 μm. NGF treatment for 2 weeks significantly increased expression 
of NPPB peptide in the DRGs (C). n = 4 for both groups, averages of 3, 4 sections from each 
animal, data are mean ± SEM. ** p ≤ 0.01, unpaired Student’s t-test. 
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NPPB expression was observed in the outer laminae of the dorsal horn of the spinal cord. 
However, no differences in either intensity of staining or percentage of area stained were 
observed in spinal cords from mice injected with either NGF or saline (Figure 4.11). Spinal 
cords were also stained for CGRP peptide as a positive control. No differences in staining 

















































































Figure 4.11: The effect of NGF on the expression of NPPB in the spinal cord 
Representative image of mouse spinal cord dorsal horn stained for NPPB from mouse 
injected with saline (A) or NGF (B). Scalebar = 100 µm. NGF did not alter the expression of 
NPPB protein in the dorsal horn of the spinal cord, as measured by intensity (C) or area (D) 
using 100 x 100 pixel boxes, or the area of laminae I and II that were positively stained for 
NPPB (E). n = 4 for both groups, averages of 3, 4 sections from each animal, data are mean ± 
















































































Figure 4.12: The effect of NGF on the expression of CGRP in the spinal cord 
Representative image of mouse spinal cord dorsal horn stained for CGRP from mouse 
injected with saline (A) or NGF (B). Scalebar = 100 µm. NGF did not alter the expression of 
NPPB protein in the dorsal horn of the spinal cord, as measured by intensity (C) or area (D) 
using 100 x 100 pixel boxes, or the area of laminae I and II that were positively stained for 
CGRP  (E). n = 4 for both groups, averages of 3, 4 sections from each animal, data are mean ± 
SEM. * p ≤ 0.05, unpaired Student’s t-test. 
4.3.3 Release of natriuretic polypeptide B from sensory neurons 
After confirming the expression of NPPB mRNA and peptide in the DRG, we investigated 
whether release of this peptide from DRGs could be detected. A preliminary study was 
performed by measuring the concentration of NPPB released from cultured murine DRGs 
using an ELISA. Cells were incubated for 10 minutes before collection of the supernatant and 
measuring the concentration of NPPB in the supernatant. Cells were incubated twice in 
buffer (baseline 1 and 2), followed by a third incubation period in either DMSO (0.01%) or 
capsaicin (1 µM), followed by two more incubations in buffer (recovery 1 and 2). However, 
no NPPB was detected in the supernatant at any time point (Figure 4.13), suggesting the 
cells did not release NPPB under our stimulating conditions, or the concentration of the 
peptide was below the sensitivity of the assay. However, 1 µM capsaicin has previously been 
found to be a poor stimulator of CGRP release from cultured DRG neurons as measured 
using ELISA, while 100 - 250 nM capsaicin resulted in more robust release of CGRP (Calcott 
et al., 2011; Lu et al., 2017). We therefore cannot exclude the possibility that release of 
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NPPB from our DRG neurons was suboptimal and may have been increased using a different 
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Figure 4.13: The release of NPPB was not detected from cultured DRGs 
Preliminary study investigating NPPB release from DRGs measured by ELISA following 
stimulation with DMSO (A) or capsaicin (B). n=2; 2 wells per condition per mouse, samples 
run in duplicate, data are mean. No statistics performed. 
 
Intraplantar injection of Cathepsin S and release NPPB in the spinal cord 
Once we ascertained that NGF upregulated the expression of NPPB in the DRGs as well as 
CGRP in the spinal cord, we continued to investigate whether CatS could induce release of 
NPPB (and CGRP) by primary afferent fibres in the dorsal horn of the spinal cord.  This was 
achieved by injection of human recombinant CatS (1 μg/10 μl) intraplantar into the hindpaw 
of mice and assessment of peptide expression in the dorsal horn by immunohistochemistry. 
To confirm the effect of CatS, mechanical hyperalgesia was tested at 30 minutes and 3 hours 
after injection using von Frey testing. As expected, mechanical hyperalgesia was detected in 
the ipsilateral paw of mice injected with CatS 30 minutes, but not 3 hours after injection 
(Barclay et al., 2007) (Figure 4.14). Mice injected with saline did not show any mechanical 





























Figure 4.14: Cathepsin S induced mechanical hyperalgesia 
Injection of CatS results in a decrease in paw withdrawal threshold (PWT) 30 minutes after 
injection (A). No changes in PWT are observed 3 hours after injection of CatS (B). n = 3 per 
group, data are mean ± SEM. No significance, One-way ANOVA followed by Bonferroni post-
hoc test.  
 
No changes in staining for NPPB were observed in either the ipsilateral or contralateral sides 
of mice injected with saline or CatS from tissues collected 30 minutes or 3 hours after 
injection (Figure 4.15). Similarly, no changes in staining for CGRP as a positive control were 
observed in either the ipsilateral or contralateral sides of mice injected with saline or CatS 
from tissues collected 30 minutes or 3 hours after injection (Figure 4.16), suggesting that 
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Figure 4.15: No effect of Cathepsin S on staining for NPPB in the spinal cord 
Typical image of mouse spinal cord dorsal horn stained for NPPB, ipsilateral (injected) side 
indicated by asterisk. Scalebar = 100 µm. Injection of CatS 30 minutes (B, E, H) or 3 hours (C, 
F, I) before taking tissues did not alter the expression of NPPB protein in the dorsal horn of 
the spinal cord, as measured by pixel area or intensity using 100 x 100 pixel boxes, or the 
percentage of laminae I and II that were positively stained. No differences in the ratio of 
contralateral:ipsilateral NPPB staining using any of the quantification methods (D, G, J). n = 3 
for all groups, averages of 3, 4 sections from each animal, data are mean ± SEM. No 
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Figure 4.16: No effect of Cathepsin S on staining for CGRP in the spinal cord 
Typical image of mouse spinal cord dorsal horn stained for CGRP, ipsilateral (injected) side 
indicated by asterisk. Scalebar = 100 µm. Injection of CatS 30 minutes (B, E, H) or 3 hours (C, 
F, I) before taking tissues did not affect the expression of CGRP protein in the spinal cord 
dorsal horn, measured by pixel area or intensity using 100 x 100 pixel boxes, or the 
percentage of laminae I and II that were positively stained. No differences in the ratio of 
contralateral:ipsilateral CGRP staining using any of the quantification methods (D, G, J). n = 3 
for all groups, averages of 3, 4 sections from each animal, data are mean ± SEM. No 




Intraplantar CatS induces mechanical hypersensitivity that is associated with increased 
expression of pERK in dorsal horn neurons. Thus, sensory neurons activated by CatS can 
cause neurons in the dorsal horn to respond, likely due to release of neurotransmitters 
and/or neuropeptides from the central terminals of these primary afferent fibres. We also 
detected expression of both NPPB and GRP in the cell bodies of sensory neurons in the DRG. 
In addition to being detected in the DRG, NPPB peptide was found in the dorsal horn of the 
spinal cord, where it appeared to be restricted to fibres in the outer laminae. Furthermore, 
we found that expression of NPPB in DRG could be upregulated following treatment with 
NGF, whilst no changes in the dorsal horn of the spinal cord were observed. While 
intraplantar CatS increases expression of pERK in dorsal horn neurons, we did not find 
evidence of changes in NPPB expression in the dorsal horn. 
 
Peripheral administration of CatS causes activation of cells in the dorsal horn of the spinal 
cord, as measured by an increase in the number of pERK-positive cells. Induction of c-Fos 
and phosphorylation of ERK have both been used as markers for activation of cells following 
noxious stimulation (Gao and Ji, 2009). Expression of c-Fos is increased in the dorsal horn in 
a rat model of chemotherapy-induced neuropathic pain and surgical pain (Kalynovska et al., 
2017; Uchytilova et al., 2015), while phosphorylation of ERK is increased in the lumbar spinal 
cord in an intensity-dependent manner following immersion of the hindpaw in hot water 
and in a mouse model of arthritic pain (Chen et al., 2009; Ji et al., 1999). Injection of 
capsaicin results in an increase in c-Fos activity and phosphorylation of ERK in dorsal horn 
neurons (Akiyama et al., 2016a; Ji et al., 1999; Jinks et al., 2002; Nojima et al., 2003; White 
et al., 2010). We did not find an increase in the number of pERK-positive cells in mice 
injected with capsaicin compared with those injected with saline; however, we collected 
tissues 30 minutes after injection of capsaicin, while peak phosphorylation of ERK in the 
dorsal horn is reported to occur 2 – 10 minutes after injection of capsaicin (Ji et al., 1999; 
White et al., 2010). Thus, it is likely we missed the optimum time for measuring 
phosphorylation of ERK after injection of capsaicin. Staining for c-Fos, which is downstream 
of pERK, may have enabled us to observe activation of dorsal horn neurons by capsaicin at 
this later timepoint. 
 
TRPV1 is required for induction of c-Fos and phosphorylation of ERK, as TRPV1 antagonists 
or desensitisation of TRPV1-expressing peripheral nerves reduces the number of c-Fos 
positive cells (Kalynovska et al., 2017; Uchytilova et al., 2015), while the number of pERK-
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positive cells is reduced in TRPV1 KO mice with arthritic pain (Chen et al., 2009). This 
suggests that activation of dorsal horn neurons, as evidenced by c-Fos and pERK, is required 
for transmission of pain signals.  
 
In addition to activation after peripheral noxious stimulation, activation of cells in the dorsal 
horn is also likely to occur following stimulation of peripheral neurons by pruritogens. 
Intradermal injection of pruritogens including histamine, chloroquine, the PAR2 agonist 
SLIGRL-NH2, and serotonin results in an increase in c-Fos immunoreactivity mainly in dorsal 
horn interneurons (Akiyama et al., 2009b; Akiyama et al., 2016a; Bell et al., 2016; Jinks et al., 
2002; Kiguchi et al., 2016; Nakano et al., 2008; Nojima et al., 2003; Zhang et al., 2014). 
Meanwhile, injection of histamine or a mast cell degranulator is associated with neuronal 
activation in the dorsal horn, with the number of pERK-positive neurons reaching peak at 3 
minutes after injection of histamine (Jiang et al., 2015; Zhang et al., 2014). Most neurons 
positive for pERK, and hence activated following intradermal injection of histamine, are 
excitatory interneurons, with some inhibitory interneurons and projection neurons also 
showing activation following injection of histamine (Jiang et al., 2015). Furthermore, 
preventing activation of cells in the dorsal horn prevents histamine-mediated scratching 
behaviour in mice (Zhang et al., 2014). However, in contrast to histamine, Zhang et al. 
(2014) reported that injection of chloroquine and SLIGRL-NH2 did not result in 
phosphorylation of ERK in the spinal cord, although Bell et al. (2016) reported a significant 
increase in the number of pERK-positive cells in the spinal cords of their mice after injection 
of chloroquine. Whether or not the animals are allowed to scratch at the injected site might 
explain these different observations, as Zhang et al. (2014) allowed their mice to scratch to 
confirm the pruritic effects of their agents, while Bell et al. (2016) prevented their mice from 
scratching through the use of collars. Another reason for this could be that chloroquine and 
SLIGRL-NH2 are not always strong enough to activate pERK but are sufficient for activation of 
c-Fos. It is unlikely that pruritogens activating PAR2 or MrgprC11-expressing neurons does 
not result in phosphorylation of ERK, as injection of SLIGRL-NH2 has already been 
demonstrated to activate cells in the dorsal horn (Nakano et al., 2008) and we observed an 
increase in the number of pERK-positive cells in the dorsal horn of mice 30 minutes after 
injection of CatS, which is reported to activate both receptors. Because the intensity of the 
stimulus affects phosphorylation of ERK (Gao and Ji, 2009; Ji et al., 1999), it is possible that 
CatS is a more potent activator of neurons than chloroquine or SLIGRL-NH2 and thus more 




The observation that intraplantar injection of CatS activates cells in the dorsal horn suggests 
activation of sensory neurons. We presume intradermal injection of CatS into the skin would 
likewise result in activation of neurons in the dorsal horn following activation of sensory 
neurons and release of itch-related peptides from the endings of primary afferent fibres. 
However, intradermal injection of CatS would also result in scratching behaviour, which 
would complicate interpretation of the results as activation of dorsal horn neurons could be 
due to either the release of neurotransmitters and neuropeptides from activated primary 
sensory neurons by the pruritogen, or as a result of scratching at the injected site. In rats 
and mice, intraplantar injection of the PAR2 agonists SLIGRL-NH2 or tryptase results in 
thermal and mechanical hyperalgesia and activation of neurons in the spinal cord as 
indicated by c-Fos (Vergnolle et al., 2001). Because CatS also acts via PAR2 receptors, 
activation of PAR2 expressed on sensory neurons by CatS may also result in similar 
activation of neurons in the dorsal horn. We initially hypothesised that activation of primary 
afferent neurons by CatS would result in the release of NPPB, which in turn may directly 
activate dorsal horn neurons or result in the activation of dorsal horn neurons via the 
release of other neurotransmitters and/or neuropeptides released from interneurons. 
Although these activated dorsal horn neurons are likely to be interneurons (Akiyama et al., 
2016a), it is unlikely they are GRP-expressing interneurons, which tend not to show 
activation indicated by phosphorylation of ERK following injection of pruritogens (Bell et al., 
2016). Thus, it is probable these neurons express the GRP receptor, as these are the other 
main class of interneurons in the spinal itch circuitry that may be activated by pruritogens, 
although interneurons of other itch circuits, such as NMB receptor-expressing interneurons, 
may also be activated. Future experiments characterising these neurons and investigating 
the time-course and dose-dependence of CatS-induced phosphorylation of ERK and c-Fos 
would be of interest to find the optimal conditions for activation of dorsal horn neurons and 
determining which part of the spinal cord itch circuitry they belong to. 
 
When this project was first undertaken, the role of NPPB and GRP in the itch circuitry in the 
spinal cord was only beginning to be elucidated, with some groups arguing the release of 
GRP from the central terminals of primary afferent fibres was responsible for mediating itch 
signals while other groups stressed the importance of NPPB. Hence at the time it was 
necessary for us to confirm for ourselves which of these neuropeptides was likely released 
from primary afferent fibres in response to pruritogens. Several studies have previously 
reported the expression of both NPPB and GRP in the DRG, although expression of GRP is 
usually very low and difficult to detect (Barry et al., 2016; Fleming et al., 2012; Liu et al., 
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2014b; Mishra and Hoon, 2013; Solorzano et al., 2015). However, we observed almost equal 
expression of both NPPB and GRP mRNA in our tissues. Similar to Barry et al. (2016), we 
found that a large cycle number was required for detection of GRP mRNA, with an average 
of 28 or more cycles required before GRP mRNA could be detected. Although this is slightly 
fewer than the number of cycles Barry et al. (2016) reported was required for detection of 
GRP mRNA in their mouse DRG samples, it is still near the limits of accurate detection of 
mRNA using this technique. However, we found that a similar number of cycles was 
required to detect expression of NPPB mRNA, suggesting that expression of NPPB mRNA is 
also low in our tissues. Although we report similar expression of NPPB mRNA relative to β-
actin mRNA as Solorzano et al. (2015), our level of GRP mRNA is much higher than theirs and 
is similar to that for NPPB mRNA. The reason for this discrepancy is unclear, although we 
may have used different primers for β-actin than Solorzano et al. (2015), who did not 
provide the primer sequence they used for β-actin in their paper. Thus, it cannot be ruled 
out that differences in the efficiency of detection of β-actin mRNA contributed to this 
discrepancy. Expression of GRP in the DRG is reported to be increased by 20-fold after 
peripheral nerve injury (Solorzano et al., 2015), where its expression level would then be 
closer to that observed for NPPB. Likewise, an increase in the expression of GRP mRNA in 
the DRG is reported in a mouse model of dry skin itch (Barry et al., 2016). However, we used 
wild-type untreated mice in our experiments, and so expression of GRP would not be 
expected to be increased. Variances in normal the expression of GRP and NPPB mRNA in the 
DRG may exist between individual mice, however, which may explain some of the 
differences observed between our results and others, and indeed between different groups. 
In support of this, Fleming et al. (2012) reported that GRP cDNA could sometimes, but not 
always, be amplified from isolated mouse DRG transcripts. Furthermore, large variances in 
the difference in expression of GRP in the mouse dorsal horn and DRG were observed, 
ranging from a 63 to a 1155 fold-difference. This suggests that, at least for GRP mRNA, the 
expression level varies between individual mice, being at or above the threshold level of 
detection for some mice and being below the threshold level of detection for others.  
 
Expression of NPPB mRNA in the DRG and in the TG was further confirmed using in-situ 
hybridisation, where it was expressed in about 10% of cells, similar to that previously 
reported (Huang et al., 2018; Mishra and Hoon, 2013). To confirm the specificity of our in-
situ hybridisation, DRG sections were co-stained for NPPB mRNA and NPPB peptide using in-
situ hybridisation probes and antibodies, respectively. Around 12% of DRG cells expressed 
NPPB peptide. Moreover, most of the cells that expressed NPPB mRNA were also positive 
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for the peptide. However, there remained a sub-population of neurons that were positive 
for NPPB mRNA but not the peptide. It is possible that not all neurons were detected during 
staining or that some neurons were non-specifically stained. Indeed, it is likely that a few 
cells were non-specifically stained for NPPB peptide, as around 4% of cells were stained with 
the scramble probe during the in-situ hybridisation procedure. Furthermore, not all neurons 
that express the mRNA transcripts necessarily translate them to proteins, thus some cells 
that were positive for the mRNA might not express the protein. 
 
To characterise NPPB-expressing neurons in the DRG, they were co-stained for CGRP 
peptide. Around one third of the cells were positive for CGRP peptide, similar to previous 
reports in rat (Fernihough et al., 2005; McCarthy and Lawson, 1990; Staton et al., 2007), 
guinea pig (Lawson et al., 2002), and mouse (Chen et al., 2008; McCoy et al., 2013). 73% of 
cells that were positive for NPPB mRNA were also positive for CGRP peptide, suggesting that 
most NPPB-expressing neurons in the DRG belong to the peptidergic subpopulation. This is 
further supported by the finding that almost 90% of the cells that were positive for NPPB 
mRNA and CGRP peptide were small to medium-sized cells, in agreement with previous 
observations (Staton et al., 2007). Ideally we would have also investigated co-expression of 
both NPPB and CGRP peptides in the DRG, however, this was not possible due to cross-
reactivity of the antibodies being used. Thus, while we are unable to confirm co-expression 
of NPPB and CGRP peptides in the DRG, it is likely that cells expressing NPPB mRNA make up 
a subpopulation of CGRP-positive cells. There are, however, some cells that express NPPB 
mRNA but not CGRP peptide. Although these cells did not differ in size from those that 
expressed NPPB mRNA and CGRP peptide, they could belong to a different subpopulation of 
neurons in the DRG. For example, using in-situ hybridisation in mouse DRGs, Mishra and 
Hoon (2013) reported that half of their NPPB-expressing cells also expressed NMB, 
suggesting the existence of more than one population of NPPB-expressing neurons in the 
DRG. However, in contrast to our observations, Mishra and Hoon (2013) also found that only 
one quarter of their NPPB-expressing cells expressed CGRP. In contrast, Zhang et al. (2010) 
claimed that in rat 95% of NPPB-positive neurons were positive for CGRP, while nearly 90% 
were also positive for IB4. Li et al. (2016) also found co-expression of NPPB and IB4 in rat 
DRG cells. Furthermore, Zhang et al. (2010) also reported expression of NPPB in half of their 
DRG neurons. Thus, large variations in the number of cells expressing NPPB and the 
subpopulation of neurons in which NPPB-expressing cells are found exists, although species 
differences may contribute to this. We propose that the majority of NPPB-expressing 
neurons in the DRG belong to the peptidergic CGRP-positive population, with around a 
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quarter of NPPB-expressing cells belonging to other subpopulations of small diameter 
neurons. This other population of NPPB-expressing neurons is unlikely to belong to the non-
peptidergic IB4-positive population of neurons however, as hardly any overlap in the 
expression of NPPB peptide and IB4 was observed in our spinal cord sections.  
 
NPPB-expressing sensory neurons have previouy been reported to co-express TRPV1, 
suggesting they do belong to the subset of nociceptors potentially involved in pruritus, as 
well as MrgprA and MrgprC11, suggesting they may belong to non-histaminergic itch 
circuitry (Mishra and Hoon, 2013). In addition to establishing wether our mouse sensory 
neurons also co-express NPPB with TRPV1 and Mrgprs, future experiments should be 
performed to determine whether NPPB-expressing neurons also express PAR2, thereby 
providing additional evidence for a mechanism by which activation of PAR2 by CatS could 
result in release of this neuropeptide. 
 
In addition to being detected in the DRG, NPPB peptide was also found in the dorsal horn of 
the spinal cord, where it appeared restricted to fibres in the outer laminae, similar to 
previous reports (Kiguchi et al., 2016). As mentioned previously, cross-reactivity of the 
antibodies for NPPB and CGRP prevented us from co-staining for NPPB and CGRP peptides, 
and because others have been unable to find expression of NPPB mRNA in the spinal cord it 
was not feasible to attempt in-situ hybridisation for NPPB mRNA in the spinal cord (Mishra 
and Hoon, 2013; Pitake et al., 2017). Previous studies have suggested that NPPB-positive 
fibres in the dorsal horn are likely to be positive for CGRP (Abdelalim et al., 2016). However, 
we note that the staining for NPPB and CGRP obtained by Abdelalim et al. shows an almost 
complete overlap, similar to the staining we obtained when we attempted to co-stain for 
NPPB and CGRP peptides. In particular, we found that when tissues were stained for NPPB 
peptide alone, staining appeared as a thin band mostly restricted to the outer part of lamina 
II, as reported by Kiguchi et al. In contrast, co-staining for NPPB and CGRP peptides revealed 
a complete overlap over a wider area comprising much of lamina I and II. Because they did 
not show any staining of dorsal horn tissues for NBBP alone, we cannot know whether the 
findings of Abdelalim et al. are due to cross-reactivity of the antibodies or whether 
expression of NPPB peptide in the dorsal horn can extend out further than what we have 
observed. Experiments which utilise amplification systems (such as tyramide amplification 
of one of the antibodies) to reduce cross-reactivity or different primary antibodies should be 
performed to address the issue. We can, however, report that staining for NPPB peptide and 
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IB4 does not overlap in the spinal cord, with most of the staining for IB4 occurring 
somewhat deeper in the dorsal horn than that for NPPB. 
 
We also found that expression of NPPB could be upregulated following treatment with NGF, 
as has previously been reported for other neuropeptides. NGF increases the expression of 
neuropeptides such as CGRP and substance P in DRGs in culture compared with neurons 
cultured in the absence of NGF or with other growth factors such as brain-derived 
neurotrophic factor and neurotrophin-3 (Nicol and Vasko, 2007). As well as increasing the 
expression of CGRP in cultured DRG neurons, NGF increases release of CGRP from these 
cells when stimulated with high extracellular potassium or capsaicin (Hingtgen et al., 2006; 
Park et al., 2010). Subcutaneous injection of NGF increases expression of substance P in rat 
DRG, while rats treated with anti-NGF antibodies have decreased NGF content in the DRG 
and spinal cord (Otten et al., 1980). Moreover, in rats subcutaneously injected with NGF, the 
basal and electrically evoked release of substance P and CGRP from the spinal cord is 
increased (Malcangio et al., 1997; Malcangio et al., 2000). Expression of the NGF receptor 
tropomyosin receptor kinase A (TrkA) on small diameter neurons that also express 
neuropeptides suggests that it is the activity of NGF on this receptor that is responsible for 
mediating the effects of NGF. Electrically-evoked release of substance P from spinal cord 
slices is reduced in rats treated systemically with a TrkA antibody (Malcangio et al., 2000), 
supporting a role for TrkA in NGF-mediated increase of neuropeptides from primary afferent 
fibres. However, most sensory neurons that express TrkA also co-express the p75 receptor 
(Nicol and Vasko, 2007). Although the affinity of NGF for p75 is lower than for TrkA, 
increased NGF, as for example is observed during inflammation, could also signal via p75 to 
exert its effects. p75 might also increase the sensitivity of TrkA for NGF, as activation of TrkA 
by NGF is reduced in the presence of a p75 blocking antibody (Barker and Shooter, 1994). 
We found that systemic treatment of NGF for two weeks resulted in a doubling of the 
number of cells in the DRG that were positive for the NPPB peptide, suggesting NGF 
upregulates the expression of NPPB in sensory neurons.  
 
A role for NGF in chronic itch conditions has previously been proposed, with increased 
expression of NGF reported in atopic dermatitis, contact dermatitis, and psoriasis conditions 
(Ikoma et al., 2006). NGF levels are increased in the skin of a mouse model of atopic 
dermatitis characterised by excessive scratching behaviour and development of skin lesions 
(Tanaka and Matsuda, 2005). Skin keratinocytes and dermal fibroblasts were found to 
express NGF, making these cells a likely source of NGF in chronic itch conditions (Tanaka and 
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Matsuda, 2005). NGF affects growth of nerve fibres in the skin, with keratinocytes from 
atopic dermatitis patients capable of increasing neurite outgrowth, especially of CGRP-
positive fibres (Roggenkamp et al., 2012). Moreover, NGF increases expression of CGRP and 
substance P in rat DRGs following injury (Verge et al., 1995). This suggests NGF is involved in 
chronic itch conditions and may exert its effects by altering the growth and expression of 
neuropeptides in sensory neurons innervating the skin. Our finding that expression of NPPB 
in sensory ganglia is increased following NGF treatment is thus not surprising given the role 
of NPPB in pruritus, and is a potential mechanism whereby increased expression of NGF in 
the skin could lead to exacerbation of pruritus. However, future experiments further 
confirming increased expression of NPPB in sensory neurons (for example using qPCR), 
should be performed, and these neurons characterised to investigate whether de novo 
expression of NPPB occurs and whether they belong to the same class of neurons that 
express NPPB under normal conditions. Interestingly, NGF treatment has been found to 
decrease expression of NPPB mRNA in myocardial tissue in a rat model of heart failure (He 
et al., 2012), however, regulation in the expression of NPPB by NGF may be different in 
different tissues. 
 
Although expression of NPPB peptide was increased in sensory ganglia following NGF 
treatment, we were unable to detect changes in the expression of NPPB in the dorsal horn 
of the spinal cord using antibody staining, suggesting an increase in the local synthesis of 
NPPB in the cell body but not its transport or release from primary afferents in the spinal 
cord. Alternatively, upregulation of NPPB does occur from primary afferents in the spinal 
cord but cannot be detected using this method. In contrast, the area of staining for CGRP 
peptide in the dorsal horn is increased following NGF treatment, confirming an increase in 
the expression of this neuropeptide in the spinal cord. However, no differences were 
observed in the intensity of staining for CGRP peptide following NGF treatment. Because 
NGF has previously been shown to increase expression of CGRP and other neuropeptides in 
the DRG (Nicol and Vasko, 2007), it is likely our technique is not sensitive enough to detect 
small changes in expression of peptides in the dorsal horn, which could explain why no 
changes in intensity of staining for CGRP or in the area or intensity for NPPB peptide were 
observed. Thus, while we were unable to demonstrate changes in the expression of NPPB 
peptide in the dorsal horn in response to NGF treatment, we cannot conclude that no such 




Injection of NGF increased sensitivity to thermal stimuli, as previously reported in rodents 
(Alexander et al., 2013; Eskander et al., 2015). This behaviour was apparent as early as one 
hour after the first dose of NGF, as has also been previously reported, and was observed 
after each subsequent injection of NGF (Alexander et al., 2013). NGF has been shown to 
increase expression of TRPV1 proteins in DRG neurons and to sensitise TRPV1 by 
phosphorylation of the Y200 residue on the TRPV1 channel following an increase in 
intracellular calcium, resulting in rapid insertion of TRPV1 into the cell membrane (Ji et al., 
2002; Zhang et al., 2005). This provides a potential explanation for the increased sensitivity 
to thermal stimuli observed in NGF-treated mice. We therefore conclude that our NGF 
treatment was successful in our mice, and that systemic NGF for two weeks increases the 
expression of NPPB peptide in the sensory ganglia, and possibly also CGRP, in the dorsal 
horn. Blocking MAPK activity reduces NGF-mediated increase in CGRP expression in 
neuronal cell cultures, supporting the involvement of MAPK in upregulation of CGRP by 
NGF, likely via regulation of the CGRP promoter (Durham and Russo, 2003; Park et al., 2010; 
Xu and Hall, 2007). NGF-mediated increase in CGRP content is also reduced following over-
expression of a dominant negative Ras in sensory neurons or exposure of neurons to a 
farnesyltransferase inhibitor to reduce Ras activity, while over-expressing a constitutively 
active Ras in sensory neurons increases NGF-mediated increase in CGRP content in these 
cells (Park et al., 2010). This suggests activation of the MAPK and Ras pathways are involved 
in increasing the expression of neuropeptides such as CGRP in response to NGF, and similar 
pathways may also be responsible for NFG-induced upregulation of NPPB in DRG neurons. 
 
Injection of CatS into the hindpaw was not associated with changes in expression of NPPB or 
CGRP in the dorsal horn. This suggests that CatS activation of sensory neurons in the 
periphery is not associated with significant release of these neuropeptides from the central 
terminals of such neurons, as might be interpreted from a decrease in expression in the 
spinal cord. However, we cannot rule out that the techniques and analysis methods used 
were insufficient for detecting these changes, particularly if the changes were small. A more 
sensitive method of measuring the release of neuropeptides from sensory neurons, such as 
ELISA, may have provided more information. However, we were unable to detect the 
presence of NPPB in the supernatant of DRG cells even after stimulation with capsaicin, and 
so did not proceed with using this method to further investigate release of NPPB from cells. 
We therefore are unable to conclude whether CatS affects the expression or release of 




In mice, we confirmed that CatS locally injected in the hindpaw resulted in acute mechanical 
hyperalgesia that resolved by 3 hours. Similar results have previously been reported 
following injection of rat recombinant CatS in rats (Barclay et al., 2007; Clark et al., 2007). 
Lieu et al. (2016) also reported an increase in mechanical sensitivity in mice injected with hr- 
CatS. However, in their mice, increased sensitivity to mechanical stimuli persisted for at 
least 4 hours after injection of CatS. The source of CatS used is unlikely to explain the 
differences in duration of mechanical hyperalgesia compared with our observations, as hr- 
CatS manufactured at Medivir was the source of CatS for both experiments. However, Lieu 
et al. (2016) injected 14 μg of CatS into the hindpaws of their mice, whereas we injected 
only 1 μg of CatS. Thus, the higher dose of CatS injected into their mice could explain the 
persistent hyperalgesia observed by Lieu et al. (2016). In addition to increased sensitivity to 
mechanical stimuli, thermal hyperalgesia and increased paw thickness were also reported 
by Lieu et al. (2016), although the onset of thermal hyperalgesia was slower than that for 
mechanical hyperalgesia, requiring at least 2 hours before the effects could be observed. 
We did not measure paw thickness in our mice following injection of CatS, although no 
obvious changes were noted. CatS-mediated hyperalgesia was reduced when mice were 
pre-treated with the PAR2 antagonist GB88 and in PAR2 KO mice (Lieu et al., 2016), 
suggesting CatS acting on PAR2 is responsible for the increased sensitivity to mechanical 
stimuli that was observed. Interestingly, Lieu et al. (2016) found that GB88 also reduced 
hyperalgesia following injection of trypsin or elastase, suggesting that both canonical and 

















Chapter 5  
General discussion 
 
The main findings of this work are: 
1. Skin keratinocytes express CatS mRNA and the peptide can be released from these 
cells following TRPV4 activation. 
2. Sensory neurons respond to direct application of CatS with inward currents and 
increased intracellular calcium. 
3. CatS-responding neurons are a subset of TRPV1 and TRPA1-expressing neurons and 
expression of these channels is required for CatS-mediated calcium responses. 
4. CatS causes sensitisation of TRPV1 and TRPA1-mediated responses in neurons. 
5. CatS acts via PAR2 to cause calcium responses in sensory neurons. 
6. Peripheral application of CatS activates cells in the dorsal horn. 
7. DRG cells express NPPB, where it is mostly co-expressed with CGRP; however, we 
failed to observe release of peptides after CatS treatment. 
 
Keratinocytes as a potential source of Cathepsin S in pruritus 
Skin keratinocytes are a potential source of several pruritogens that may be involved in 
acute itch as well as chronic itch conditions such as atopic dermatitis. We have 
demonstrated expression if CatS mRNA and release of the protease from cells of the HaCaT 
human keratinocyte cell line, which we propose acts as a pruritogen and is responsible for 
itch sensations. Whether CatS released from keratinocytes could act as a pruritogen had not 
been addressed previously. In mice, over-expression of CatS in several tissues, including the 
skin, results in atopic dermatitis-like conditions (Kim et al., 2012), however whether CatS 
was released from keratinocytes and was directly responsible for activation of sensory 
neurons to transmit itch signals was not known, although our above observations combined 
with our finding that CatS activates sensory neurons in vitro supports this concept. 
Additional experiments in which CatS released from cultured keratinocytes is used to 
activate sensory neurons would further support this hypothesis, although other pruritogens 
and sensitising agents may additionally be released from keratinocytes and may also be 
involved. 
 
Our findings and that of others suggest keratinocytes do not normally express CatS protein, 
which suggests CatS is not likely to be involved in acute itch (Kim et al., 2012; Schonefuss et 
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al., 2010). However, expression can be increased under certain conditions. In support of 
this, we observed an increase in Cathepsin mRNA in HaCaTs following incubation with LPS or 
the Th2 cytokines IL-4 and IL-13, while others have reported an increase of the protein in 
HaCaTs following incubation with IFNγ and TNFα, as well as in psoriatic keratinocytes 
(Ainscough et al., 2017; Schonefuss et al., 2010). This suggests expression of CatS could be 
increased in several chronic itch conditions, where it may be responsible for itch in these 
conditions, although the mechanism of increased expression of CatS is likely to differ in 
different conditions. In addition, the mechanisms by which different mediators result in an 
increase in the expression of CatS in keratinocytes has not been explored. IL-4 and IL-13 
have previously been demonstrated to alter expression of several genes in human 
keratinocytes, including increased expression of chemokines such as CCL3, CCL4, CCL26 and 
cytokines including IL-6 and IL-8, and decreased expression of genes involved in cell 
adhesion and barrier function such as fibronectin, filaggrin, loricrin, involucrin, and several 
keratins (Omori-Miyake et al., 2014; Serezani et al., 2017). IL-4 and IL-13 induce activation of 
STAT-6, which translocates to the nucleus where it affects transcription of several genes 
(Goenka and Kaplan, 2011; Serezani et al., 2017). Moreover, STAT-6 promotes the 
production of IgE in B cells and the differentiation of Th2 cells, contributing to the 
phenotype of atopic dermatitis and resulting in a positive feedback cycle with the release of 
more Th2 cytokines (Goenka and Kaplan, 2011). Activation of STAT-6 by IL-4 and IL-13 may 
also affect transcription of CatS in keratinocytes, and future experiments in which 
keratinocytes incubated in IL-4 and IL-13 in the presence of a STAT-6 inhibitor would confirm 
this. IL-13 has previously been reported to induce expression of CatS in lung tissues via 
STAT-6 (Lee et al., 2006; Zheng et al., 2000), and may similarly do so in skin keratinocytes, 
along with IL-4. 
 
Although CatS mRNA was increased following incubation of HaCaTs in IL-4 and IL-13, neither 
intracellular CatS activity nor activity of CatS in the supernatant was found to be increased, 
suggesting there was no increase in protein following these treatments. However, due to 
time contstraints, neither Western blotting nor immunostaining for CatS peptide had been 
performed to check whether protein levels could be increased following treatment with 
these cytokines, which would have enabled us to determine whether IL-4 and IL-13 are 
capable of increasing protein as well as mRNA levels. In contrast, IL-4 and IL-13 have 
previously been shown to increase both expression and release of CatS and other cathepsins 
from bone marrow-derived macrophages (Yan et al., 2016). It is possible additional 
mediators are required for increased production and release of CatS protein from 
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keratinocytes. Furthermore, despite expressing the P2X7 and TLR4 receptors for high 
concentration ATP and LPS, respectively, we could not detect release of CatS from HaCaTs 
following incubation with LPS and ATP, even though this has been reported to cause release 
of from other cell types such as microglia (Clark et al., 2010). This suggests the mechanism 
of CatS release is different in keratinocytes than for microglia. Moreover, release of CatS 
and other pruritogens from keratinocytes may be different under inflammatory conditions 
than in normal healthy skin. To test this possibility, we also measured release of CatS 
following incubation in Th2 cytokines as well as LPS and ATP, although no CatS activity was 
detected. However, because we were also unable to detect an increase in the transcription 
of genes used as markers for atopic dermatitis following incubation in IL-4 and IL-13, we 
cannot rule out that our cells were not optimally stimulated to release CatS. Further 
experiments in which the concentration and duration of incubation in these cytokines is 
required to determine the optimal conditions for modelling atopic dermatitis and release of 
CatS from these cells. 
 
In addition to expression receptors for LPS and ATP, we also noted that HaCaTs express 
TRPV4. TRPV4 is activated by osmotic pressure, innocuous heat, and ultraviolet B radiation 
(Moore et al., 2013; Nilius et al., 2003; White et al., 2016). Activation of this channel has also 
been shown to result in scratching behaviour in mice (Chen et al., 2016). In light of this, we 
investigated whether stimulation of this receptor would result in the release of CatS from 
HaCaTs. Indeed, incubation of HaCaTs in the TRPV4 agonist GSK1016790A was sufficient to 
cause release of CatS, although specificity of the agonist for TRPV4 still needs to be 
confirmed using a TRPV4-specific antagonist. Nevertheless, this suggests CatS could be the 
pruritogen responsible for the TRPV4-induced acute scratching behaviour recently reported 
in mice (Chen et al., 2016). However, activation of TRPV4 in keratinocytes increases 
expression of endothelin-1, which has also been shown to be a pruritogen (McQueen et al., 
2007; Moore et al., 2013; Trentin et al., 2006). Thus, activation of TRPV4 may result in the 
release of several pruritogens, including CatS, that activate pruriceptors in the skin, which 
must be taken into consideration when investigating TRPV4-mediated pruritus. Because we 
did not measure release of endothelin-1 or other substances following activation of 
keratinocyte TRPV4 channels, we cannot exclude the release and involvement of other 
pruritogens. 
 
In the context of chronic itch, one possible scenario is that keratinocytes continually release 
CatS, which may then act as a pruritogen to result in constant transmission of itch signals. 
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This continual release of CatS may or may not be due to continued activation of TRPV4 on 
keratinocytes. In atopic dermatitis, enhanced activity of TRPV4 may occur as a result of 
increased water loss and the development of dry skin resulting in changes in osmolarity. 
Changes in skin pH may also result in activation of TRPV4. The pH of the corneal layer of the 
epidermis is increased in atopic dermatitis and acidic pH has been reported to inhibit TRPV4-
mediated calcium responses in mouse esophageal epithelial cells (Rippke et al., 2004; 
Shikano et al., 2011), suggesting reduced inhibition of TRPV4 on keratinocytes may be 
responsible for increased release of CatS and other pruritogens in atopic dermatitis. 
However, other groups have reported that TRPV4 channels expressed in Chinese hamster 
ovary cells are opened by a decrease in pH (Suzuki et al., 2003). Although we performed the 
CatS activity assays from the HaCaT cell lysates at both pH7 and pH5 to investigate the 
possibility that other proteases may have been cleaving the substrate used in the assay, the 
release assays were performed only at pH7 to ensure specific activity of CatS on the 
substrate. Performing the release assay at pH5 might allow us to determine if TRPV4 opens 
in response to a decrease in pH and hence if there is an increase in CatS release, or if low pH 
reduces opening of the channel and reduces release of CatS. However, any increases in 
activity observed at low pH may also be due to increased activity of CatS at this pH or the 
activity of other proteases on the substrate; therefore other methods of measuring activity 
of TRPV4 and release of CatS from keratinocytes at various pH levels would need to be 
utilised. In any event, because CatS retains activity at neutral pH, it is a good candidate 
pruritogen for the increased skin pH in atopic dermatitis, where other proteases may lose 
activity. 
 
Increased release of other pruritogens such as the kallikreins and TSLP from keratinocytes, 
IL-31 from mast cells and T cells, and histamine and tryptase from mast cells may also 
contribute to enhanced transmission of itch in chronic itch conditions (Andoh et al., 2015; 
Che et al., 2018; Dillon et al., 2004; Kawakami et al., 2009; Niyonsaba et al., 2010; Wilson et 
al., 2013). An alternative possibility is that release of pruritogens from keratinocytes and 
other cells is not increased in chronic itch conditions, but instead neurons become sensitised 
due to release of prostaglandins, bradykinin, and other mediators (Stander et al., 2003). As 
well as being a pruritogen, CatS increases sensitivity of neurons by sensitisation of TRP 
channels (Amadesi et al., 2004; Amadesi et al., 2006; Dai et al., 2004; Dai et al., 2007), 
thereby providing an additional mechanism by which CatS released from skin keratinocytes 
could result in enhanced transmission of itch signals. Finally, increased sprouting of nerve 
fibres in the skin has been reported in chronic itch conditions (Tobin et al., 1992; Tominaga 
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et al., 2009; Urashima and Mihara, 1998), and this may result in increased ability to detect 
and respond to pruritogens, regardless of whether there is an increase in the release of 
pruritogens and mediators that cause sensitisation of neurons. 
 
Activation of sensory neurons by Cathepsin S occurs via PAR2 and requires TEPV1 and 
TRPA1 
CatS, released from keratinocytes, may directly activate the endings of sensory neurons in 
the skin to result in transmission of itch signals. Using patch clamping and calcium imaging 
techniques, we have shown that sensory neurons in vitro can respond to application of CatS. 
The PAR2 antagonist FSLLRY-NH2 reduced CatS-induced calcium responses in neurons, 
supporting the notion that CatS cleaving PAR2 activates the cells, in agreement with 
previous observations (Lieu et al., 2016; Zhao et al., 2014a). It has also been reported that 
CatS cleaves PAR4 and MrgprC11 (Reddy et al., 2010; Reddy and Lerner 2010; Reddy et al., 
2015). Although we found that inhibiting activation of PAR2 alone was sufficient to prevent 
CatS-induced calcium responses, activation of PAR4 and/or MrgprC11 may also contribute 
to these responses in neurons. Indeed, preventing activation of any of these receptors may 
be sufficient to prevent CatS-induced activation of the cell and/or scratching behaviour. 
However, in a recent study by Reddy et al. (2015), calcium responses to CatS were observed 
in DRG cells cultured from PAR2 KO mice, although it should be noted they used a much 
greater concentration of CatS in their assays than we used, which may result in non-specific 
cleavage of receptors and non-physiologically relevant responses. It would therefore be of 
interest to determine the most physiologically relevant concentration of CatS to use and to 
examine whether CatS-mediated calcium responses in DRGs are still reduced in the 
presence of this concentration of CatS and the PAR2 antagonist or in DRG cultures from 
PAR2 KO mice. Furthermore, it remains to be explored whether sensory neurons in vivo 
respond directly to peripheral application of CatS and to link this to itch sensations in 
humans and scratching behaviour in mice. 
 
We noted that sensory neurons that responded with calcium fluxes following application of 
CatS were also likely to respond to agonists of TRPV1 or TRPA1, suggesting CatS-responding 
neurons belong to a subpopulation of TRPV1 and/or TRPA1-expressing cells. This is in 
agreement with what has been reported for other non-histaminergic pruritogens such as 
chloroquine and in particular members of the papain superfamily of cysteine proteases such 
as mucunain (Bautista et al., 2014; Ross, 2011; Wilson et al., 2011), and supports the role of 
CatS as a pruritogen of non-histaminergic itch. If CatS is the pruritogen or one of the 
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pruritogens responsible for increased transmission of itch signals in conditions such as 
atopic dermatitis, then this could explain why anti-histamines are ineffective in treating the 
disease.  Moreover, not only do CatS-responding cells belong to a subpopulation of TRPV1 
and/or TRPA1-expressing neurons, but expression of both receptors is required for CatS-
induced calcium responses, as demonstrated by the finding that when CatS was applied to 
DRG cells cultured from TRPV1 KO or TRPA1 KO mice, the percentage of cells responding to 
CatS was reduced to baseline. Preliminary behavioural experiments performed by our group 
found that CatS-mediated scratching behaviour was significantly reduced in TRPV1 KO mice 
compared with wild-type mice, and our calcium imaging experiments in DRGs from TRPV1 
KO mice support the role of TRPV1 in CatS-mediated responses. In contrast, the observation 
that CatS-mediated scratching behaviour was only slightly reduced in TRPA1 KO mice and 
that this reduction was not significant compared with scratching behaviour in wild-type 
mice is at odds with our finding that CatS-mediated calcium responses were prevented in 
DRG cultures from TRPA1 KO mice. If, however, CatS cleaves other receptors such as 
MrgprC11 (Reddy et al., 2015), then it would be expected that expression of functional 
TRPA1 would be required for CatS-mediated signalling and scratching behaviour, as 
MrgprC11 signals though this channel (Wilson et al., 2011). Thus, the involvement of TRPA1 
in CatS-induced calcium responses in neurons also agrees with the notion that CatS signals 
via MrgprC11.  
 
Similarly, the proposed cleavage of PAR4 by CatS is also likely to require signalling via both 
TRPV1 and TRPA1 channels, as PAR4-induced scratching behaviour is reduced when mice 
are pre-treated with TRPV1 or TRPA1 antagonists (Patricio et al., 2015). However, as with 
our observations in mice, Patricio et al. reported that PAR4-induced scratching behaviour 
was reduced in TRPV1 KO mice but not in TRPA1 KO mice, which the authors suggested was 
due to compensatory mechanisms in TRPA1 mice such as increased expression of other TRP 
channels, which could also explain our observation that CatS-induced scratching behaviour 
was not reduced in TRPA1 KO mice. As with PAR2, PAR4 has also been shown to sensitise 
TRPV1 channels in neurons (Vellani et al., 2010). Thus, one possible scenario is that CatS 
cleaves multiple receptors to signal via both TRPV1 and TRPA1, with TRPV1 being crucial for 
scratching behaviours and hence presumably itch sensations, while activation of TRPA1 may 
contribute additionally but is dispensable for scratching behaviour and can be compensated 






Figure5.1: Activation of receptors and sensitisation of TRP channels by Cathepsin S 
 
As well as responding to application of CatS, we found an increase in the number of sensory 
neurons that responded to TRPV1 and TRPA1 agonists when the cells were exposed to CatS 
before exposure to these agonists, suggestive of sensitisation of these TRP channels by CatS. 
This observation is not surprising given that activation of PAR2 has previously been shown 
to sensitise TRPV1 and TRPA1 channels (Amadesi et al., 2004; Amadesi et al., 2006; Dai et 
al., 2004; Dai et al., 2007), and the ability of CatS to cleave and activate PAR2 (Elmariah et 
al., 2014; Reddy et al., 2010; Zhao et al., 2014a). Sensitisation of neurons to TRPV1 and 
TRPA1 agonists increases the likelihood that these cells will respond and could be an 
additional mechanism by which CatS causes calcium responses in neurons. As far as we are 
aware, this is the first time it has been demonstrated that CatS sensitises neuronally-
expressed TRPV1 and TRPA1 channels in vitro. We hypothesise that CatS cleaves neuronal 
PAR2 to sensitise TRPV1 and TRPA1 channels similar to that previously reported for PAR2-
mediated sensitisation of TRPV1 and TRPA1 (Figure 5.1).  
 
Activation of dorsal horn neurons by Cathepsin S 
Once activated by pruritogens, sensory neurons release neurotransmitters and 
neuropeptides from their terminals in the dorsal horn of the spinal cord, in turn activating 
cells involved in the spinal cord itch circuitry. We proposed that activation of sensory 
neurons by CatS would result in the release of NPPB from their central terminals, although, 
in preliminary experiments using an ELISA, we were unable to detect NPPB released into the 
supernatant of DRG cell cultures following incubation with capsaicin. However, NPPB has 
recently been demonstrated to be released from DRG cells in culture following incubation 
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with the pruritogen IL-31 using an ELISA, confirming the ability of these cells to release NPPB 
and detect it using this technique (Meng et al., 2018; Pitake et al., 2018). We therefore 
cannot rule out that DRG neurons do not release NPPB following incubation with capsaicin 
or pruritogens such as CatS. We could, however, confirm expression of both NPPB mRNA 
and peptide in DRG neurons using qPCR, in-situ hybridisation, and immunostaining 
techniques, as has previously been reported (Li et al., 2016a; Mishra and Hoon, 2013; Pitake 
et al., 2017; Pitake et al., 2018; Solorzano et al., 2015; Zhang et al., 2010).  
 
We also detected expression of NPPB in the outer laminae of the dorsal horn of the spinal 
cord, supporting the notion that this neuropeptide may be released from the endings of 
sensory neurons. This prompted us to measure release of NPPB in the spinal cord. Using a 
similar technique previously employed by Lever et al. (2001) to measure release of BDNF 
from the terminals of sensory neurons in the dorsal horn, we performed immunostaining of 
dorsal horn sections to measure release of NPPB following intraplantar injection of CatS into 
the hindpaw. Although intraplantar injection of CatS resulted in mechanical hyperalgesia, 
confirming successful injection of the protease, no changes in staining for NPPB were 
observed between the ipsilateral and contralateral sides of animals injected with CatS or 
saline. Because NPPB is co-expressed with and likely to be released with other peptides such 
as CGRP (Meng et al., 2018; Mishra and Hoon, 2013), we also stained for CGRP to measure 
its release as a control, but likewise found no differences in staining between the ipsilateral 
and contralateral sides of CatS or saline-injected animals. Although this suggests NPPB and 
CGRP are not released from the terminals of sensory neurons following their activation by 
CatS, more probable is that our technique was not sensitive enough to be able to detect 
small differences in the release of these neuropeptides. Alternatively, neuropeptides other 
than NPPB might be released from primary afferent fibres in response to activation by CatS. 
For example, some DRG neurons have been reported to express GRP (Barry et al., 2016). We 
also found some expression of GRP mRNA in our DRG tissues, and this might be the 
neuropeptide that is released by neurons when they are activated by CatS. NMB is another 
neuropeptide proposed to be involved in itch and is expressed by DRGs, and along with CatS 
is reported to be upregulated in a canine model of atopic dermatitis (Olivry et al., 2016). The 
release of other neuropeptides such as GRP and NMB from the terminals of primary 
afferents following activation by CatS remains to be investigated. 
 
While we did not find evidence of release of neuropeptides, we did find an increase in the 
number of cells in the dorsal horn that were activated following intraplantar injection of 
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CatS compared with injection of saline. This suggests neuropeptides and/or 
neurotransmitters are released from primary afferent terminals in response to CatS, which 
in turn activate cells in the dorsal horn. Whether these cells are interneurons of the itch 
pathway or projection neurons has not yet been explored, although might be confirmed by 
co-staining, for instance for the NPPB receptor NPRA. Because we only stained for 
phosphoERK at one time point after injection of CatS, it is possible that even greater 
activation of neurons in the dorsal horn may be observed at different timepoints, as has 
been observed with capsaicin (Ji et al., 1999), although the number of activated cells we 
observed was considerably greater than that for saline-injected animals. As already 
mentioned, we likely missed the optimum timepoint for measuring activation of cells in the 
spinal cord following injection of capsaicin and we did not perform staining for downstream 
activation of c-Fos. However, it would be interesting to compare optimum activation of 
dorsal horn neurons in the spinal cord following peripheral injection of CatS and capsaicin, 
as well as other pruritogens, and determine if the same neurons are activated. It was 
recently reported that release of NPPB from the peripheral endings of sensory neurons 
resulted in activation of cultured human keratinocytes and the release of cytokines such as 
IL-17A from these cells (Meng et al., 2018). NPPB released from the central terminals of 
primary afferents could also result in similar activation of cells in the dorsal horn of the 
spinal cord. It is therefore possible that activation of sensory neurons by CatS has caused 
the release of NPPB from their central terminals resulting in activation of neurons in the 
dorsal horn. 
 
The main drawback with our observations in the dorsal horn of the spinal cord is that they 
relate to the activities of CatS as an algogen rather than a pruritogen. Previous work in our 
lab has demonstrated CatS acts as both an algogen and a pruritogen when injected into 
mice, suggesting it activates both nociceptors and pruriceptors, or neurons that transmit 
both nociceptive and pruriceptive signals. Whether CatS injected intradermally into the 
hairy skin of the cheek results in activation of the same populations of neurons as CatS 
injected intraplantar into the glabrous skin of the hindpaw remains to be investigated. 
Different types of skin are innervated by different types of neurons and to different extents. 
For example, Cain et al. (2001) reported that neurons innervating the glabrous skin of mice 
had a greater threshold to mechanical stimuli and a lower threshold to noxious heat 
compared with neurons innervating hairy skin, while Boada et al. (2010) found that neurons 
innervating the glabrous skin of rats comprised a higher proportion of high-threshold 
mechanosensitive nociceptors and a faster conduction velocity of fast-conducting 
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nociceptors compared with those innervating hairy skin. Nevertheless, we have 
demonstrated that CatS can both activate sensory neurons and cells in the spinal cord dorsal 
horn, making it a candidate pruritogen for the release of neuropeptides involved in itch 
signalling in the dorsal horn.  
 
Conclusion 
To conclude, we propose the following pathway of CatS -induced itch (Figure 5.2), in which 
CatS released from skin keratinocytes, for example following activation of TRPV4 and 
subsequent influx of calcium, cleaves receptors such as PAR2 expressed on the endings of 
sensory neurons in the skin. This results in sensitisation of TRPV1 and TRPA1 channels, 
causing an influx of sodium and calcium ions into the cells and the opening of voltage-gated 
channels to result in propagation of action potentials. The terminals of these primary 
afferents likely release neuropeptides such as NPPB, which then binds to its receptor on 
interneurons in the dorsal horn that in turn release GRP. The itch signal then continues 
along the spinaothalamic tract to the thalamus where it is relayed to other brain centres 
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